iPS Cells for Modelling and Treatment of Human Diseases by unknown
Printed Edition of the Special Issue Published in 
Journal of Clinical Medicine
iPS Cells for Modelling and




Michael J. Edel (Ed.) 
 
 
iPS Cells for Modelling and  






















This book is a reprint of the special issue that appeared in the online open access journal 





Michael J. Edel  
Departament de Ciències Fisiològiques I 
Facultat de Medicina 
Universitat de Barcelona 
Spain  
The University of Western Australia 



















1. Edition 2015 
 




ISBN 978-3-03842-121-4 (PDF) 





© 2015 by the authors; licensee MDPI, Basel, Switzerland. All articles in this volume are 
Open Access distributed under the Creative Commons Attribution 4.0 license 
(http://creativecommons.org/licenses/by/4.0/), which allows users to download, copy and 
build upon published articles even for commercial purposes, as long as the author and 
publisher are properly credited, which ensures maximum dissemination and a wider impact of 
our publications. However, the dissemination and distribution of copies of this book as a 
whole is restricted to MDPI, Basel, Switzerland.  
III
Table of Contents 
List of Contributors ............................................................................................................ VII 
About the Guest Editor ....................................................................................................... XII 
Preface .............................................................................................................................. XIII 
Chapter 1: Neuronal 
Roger Torrent, Francesca de Angelis Rigotti, Patrizia Dell’Era, Maurizio Memo, 
Angel Raya and Antonella Consiglio
Using iPS Cells toward the Understanding of Parkinson’s Disease
Reprinted from: J. Clin. Med. 2015, 4(4), 548-566 
http://www.mdpi.com/2077-0383/4/4/548 .............................................................................. 1
Dmitry A. Ovchinnikov and Ernst J. Wolvetang
Opportunities and Limitations of Modelling Alzheimer’s Disease with Induced 
Pluripotent Stem Cells
Reprinted from: J. Clin. Med. 2014, 3(4), 1357-1372 
http://www.mdpi.com/2077-0383/3/4/1357 .......................................................................... 21 
Kristine Freude, Carlota Pires, Poul Hyttel and Vanessa Jane Hall  
Induced Pluripotent Stem Cells Derived from Alzheimer’s Disease Patients: The Promise, 
the Hope and the Path Ahead
Reprinted from: J. Clin. Med. 2014, 3(4), 1402-1436
http://www.mdpi.com/2077-0383/3/4/1402 ..........................................................................36
Irene Faravelli, Emanuele Frattini, Agnese Ramirez, Giulia Stuppia, Monica Nizzardo 
and Stefania Corti  
iPSC-based Models to Unravel Key Pathogenetic Processes underlying Motor Neuron 
Diseases Development
Reprinted from: J. Clin. Med. 2014, 3(4), 1124-1145
http://www.mdpi.com/2077-0383/3/4/1124 .......................................................................... 68 
IV
Chapter 2: Cardiac 
Alexis Bosman, Michael J. Edel, Gillian Blue, Rodney J. Dilley, Richard P. Harvey and 
David S. Winlaw 
Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
Reprinted from: J. Clin. Med. 2015, 4(4), 768-781 
http://www.mdpi.com/2077-0383/4/4/768 ............................................................................89
Stephanie Friedrichs, Daniela Malan, Yvonne Voss and Philipp Sasse  
Scalable Electrophysiological Investigation of iPS Cell Derived Cardiomyocytes Obtained by 
a Lentiviral Purification Strategy 
Reprinted from: J. Clin. Med. 2015, 4(1), 102-123
http://www.mdpi.com/2077-0383/4/1/102 ..........................................................................103
Kwong-Man Ng, Cheuk-Yiu Law and Hung-Fat Tse  
Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent 
Stem Cells
Reprinted from: J. Clin. Med. 2014, 3(4), 1105-1123
http://www.mdpi.com/2077-0383/3/4/1105 ........................................................................124
Chapter 3: Eye 
Fred Kuanfu Chen, Samuel McLenachan, Michael Edel, Lyndon Da Cruz, Peter Coffey 
and David A. Mackey  
iPS Cells for Modelling and Treatment of Retinal Diseases
Reprinted from: J. Clin. Med. 2014, 3(4), 1511-1541
http://www.mdpi.com/2077-0383/3/4/1511 ........................................................................ 145 
Huy V. Nguyen, Yao Li and Stephen H. Tsang 
Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases
Reprinted from: J. Clin. Med. 2015, 4(4), 567-578
http://www.mdpi.com/2077-0383/4/4/567 ..........................................................................174
Ricardo P. Casaroli-Marano, Núria Nieto-Nicolau, Eva M. Martínez-Conesa,
Michael Edel and Ana B. Álvarez-Palomo  
Potential role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the 
Ocular Surface
Reprinted from: J. Clin. Med. 2015, 4(2), 318-342 
http://www.mdpi.com/2077-0383/4/2/318 .......................................................................... 186
V 
Chapter 4: Spinal Cord Injury 
Mohamad Khazaei, Ahad M. Siddiqui and Michael G. Fehlings  
The Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: 
Opportunities and Challenges 
Reprinted from: J. Clin. Med. 2015, 4(1), 37-65 
http://www.mdpi.com/2077-0383/4/1/37 ............................................................................ 213
Stuart I. Hodgetts, Michael J. Edel and Alan R. Harvey  
The State of Play with iPSCs and Spinal Cord Injury Models 
Reprinted from: J. Clin. Med. 2015, 4(1), 193-203
http://www.mdpi.com/2077-0383/4/1/193 ..........................................................................243
Chapter 5: Liver 
Yue Yu, Xuehao Wang and Scott Nyberg  
Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment
Reprinted from: J. Clin. Med. 2014, 3(3), 997-1017
http://www.mdpi.com/2077-0383/3/3/997 .......................................................................... 257
Chapter 6: Muscle 
Isart Roca, Jordi Requena, Michael J. Edel and Ana Belén Alvarez-Palomo  
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
Reprinted from: J. Clin. Med. 2015, 4(2), 243-259
http://www.mdpi.com/2077-0383/4/2/243 ..........................................................................281
Chapter 7: Bone 
I-Ping Chen  
The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast 
Defects in Rare Genetic Bone Disorders
Reprinted from: J. Clin. Med. 2014, 3(4), 1490-1510
http://www.mdpi.com/2077-0383/3/4/1490 ........................................................................ 299 
VI
Chapter 8: Germ Cells 
Tetsuya Ishii 
Human iPS Cell-derived Germ Cells: Current Status and Clinical Potential
Reprinted from: J. Clin. Med. 2014, 3(4), 1064-1083 
http://www.mdpi.com/2077-0383/3/4/1064 ........................................................................321
Chapter 9: Genetic Disorders 
Tomer Halevy and Achia Urbach
Comparing ESC and iPSC—Based Models for Human Genetic Disorders
Reprinted from: J. Clin. Med. 2014, 3(4), 1146-1162
http://www.mdpi.com/2077-0383/3/4/1146 ........................................................................ 343 
Shin Kawamata, Hoshimi Kanemura, Noriko Sakai, Masayo Takahashi and  
Masahiro J. Go  
Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell 
Products
Reprinted from: J. Clin. Med. 2015, 4(1), 159-171
http://www.mdpi.com/2077-0383/4/1/159 ..........................................................................359
Youssef Hibaoui and Anis Feki  
Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced 
Pluripotent Stem Cells
Reprinted from: J. Clin. Med. 2015, 4(4), 696-714 
http://www.mdpi.com/2077-0383/4/4/696 ..........................................................................371
Chapter 10: Immune Response 
Meilyn Hew, Kevin O'Connor, Michael J. Edel, Michaela Lucas
The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases
Reprinted from: J. Clin. Med. 2015, 4(6), 1193-1206
http://www.mdpi.com/2077-0383/4/6/1193 ........................................................................ 393 
VII 
List of Contributors 
Ana Belén Alvarez-Palomo: Control of Pluripotency Laboratory, Department of 
Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, 
Casanova 143, 08036, Barcelona, Spain
Gillian Blue: Heart Centre for Children, The Children's Hospital at Westmead, Westmead 
NSW 2145, Australia; Sydney Medical School, University of Sydney, Sydney NSW 2006, 
Australia
Alexis Bosman: Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 
Liverpool St., Darlinghurst NSW 2010, Australia; St. Vincent's Clinical School and School of 
Biotechnology and Biomolecular Sciences,  University of New South Wales, Kensington 
NSW 2052, Australia 
Ricardo P. Casaroli-Marano: Department of Surgery, School of Medicine and Hospital 
Clínic de Barcelona (IDIBAPS), University of Barcelona, Calle Sabino de Arana 1 (2nd 
floor), E-08028 Barcelona, Spain; CellTec-UB and the Clinic Foundation for Biomedical 
Research (FCRB), University of Barcelona,  Avda. Diagonal 643, E-08028 Barcelona, Spain; 
Tissue Bank of BST (GenCat), Calle Dr Antoni Pujadas 42, SSMM Sant Joan de Déu, Edifici 
Pujadas, E-08830 Sant Boi de Llobregat, Spain 
Fred Kuanfu Chen: Centre for Ophthalmology and Visual Science (Incorporating Lions Eye 
Institute), The University of Western Australia, Perth WA 6009, Australia; Ophthalmology 
Department, Royal Perth Hospital, Perth WA 6009, Australia 
I-Ping Chen: Department of Oral Health and Diagnostic Sciences, University of Connecticut 
Health Center,  263 Farmington Avenue, Farmington, CT 06030, USA 
Peter Coffey: Division of Cellular Therapy, Institute of Ophthalmology, University College 
of London, London EC1V 9EL, UK 
Antonella Consiglio: Institute for Biomedicine of the University of Barcelona (IBUB), 
Barcelona Science Park, Barcelona 08028, Spain; Department of Molecular and Translational 
Medicine, Fibroblast Reprogramming Unit, University of Brescia, Brescia 25123, Italy 
Stefania Corti: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology 
and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Foundation 
Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, Italy 
Lyndon Da Cruz: Department of Vitreoretinal Surgery, Moorfields Eye Hospital, London 
EC1V 2PD, UK; Division of Cellular Therapy, Institute of Ophthalmology, University 
College of London, London EC1V 9EL, UK 
Francesca de Angelis Rigotti: Institute for Biomedicine of the University of Barcelona 
(IBUB), Barcelona Science Park, Barcelona 08028, Spain 
Patrizia Dell’Era: Department of Molecular and Translational Medicine, Fibroblast 
Reprogramming Unit, University of Brescia, Brescia 25123, Italy 
VIII 
Rodney J. Dilley: Ear Science Institute Australia, Centre for Cell Therapy and Regenerative 
Medicine and School of Surgery, University of Western Australia, Nedlands WA 6009, 
Australia 
Michael J. Edel: Control of Pluripotency Laboratory, Department of Physiological Sciences 
I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 
08036, Spain; Developmental and Stem Cell Biology, Victor Chang Cardiac Research 
Institute, Sydney NSW 2145, Australia; Faculty of Medicine, Westmead Children's Hospital, 
Division of Paediatrics and Child Health, University of Sydney Medical School, Sydney 
NSW 2145, Australia; School of Anatomy, Physiology and Human Biology, and the Harry 
Perkins Institute for Medical Research (CCTRM), The University of Western Australia, 
Western Australia 6009 
Irene Faravelli: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology 
and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Foundation 
Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, Italy 
Michael G. Fehlings: Department of Genetics and Development, Toronto Western Research 
Institute,  University Health Network, Toronto, M5T 2S8, ON, Canada; Department of 
Surgery, University of Toronto, Toronto, M5T 1P5, ON, Canada; Institute of Medical 
Sciences, University of Toronto, Toronto, M5S 1A8, ON, Canada 
Anis Feki: Department of Obstetrics and Gynecology, Cantonal Hospital of Fribourg,  
Chemin des Pensionnats 2-6, 1708 Fribourg, Switzerland 
Emanuele Frattini: Dino Ferrari Centre, Neuroscience Section, Department of 
Pathophysiology and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS 
Foundation Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, 
Italy
Kristine Freude: Department of Veterinary Clinical and Animal Sciences, Faculty of Health 
and Medical Sciences, University of Copenhagen, Gronnegaardsvej 7, Frederiksberg C DK-
1870, Denmark 
Stephanie Friedrichs: Institute of Physiology I, Life and Brain Center, University of Bonn, 
Bonn 53127, Germany 
Masahiro J. Go: Research and Development Center for Cell Therapy, Foundation for 
Biomedical Research and Innovation, TRI#308 1-5-4, Minatojima-Minamimachi, Chuo-ku, 
Kobe 650-0047, Japan 
Tomer Halevy: Stem Cell Unit, Department of Genetics, Institute of Life Sciences, The 
Hebrew University of Jerusalem, Jerusalem 91904, Israel 
Vanessa Jane Hall: Department of Veterinary Clinical and Animal Sciences, Faculty of 
Health and Medical Sciences, University of Copenhagen, Gronnegaardsvej 7, Frederiksberg C 
DK-1870, Denmark 
Alan R. Harvey: School of Anatomy, Physiology and Human Biology, The University of 
Western Australia, Crawley, Western Australia 6009, Australia 
Richard P. Harvey: Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 
Liverpool St., Darlinghurst NSW 2010, Australia; St. Vincent's Clinical School and School of 
Biotechnology and Biomolecular Sciences,  University of New South Wales, Kensington 
NSW 2052, Australia 
IX
Meilyn Hew: Department of Clinical Immunology, Pathwest Laboratory Medicine, Queen 
Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia 
Youssef Hibaoui: Department of Genetic Medicine and Development, University of Geneva 
Medical School and Geneva University Hospitals, 1 Rue Michel-Servet, CH-1211 Geneva, 
Switzerland 
Stuart I. Hodgetts: School of Anatomy, Physiology and Human Biology, The University of 
Western Australia, Crawley, Western Australia 6009, Australia 
Poul Hyttel: Department of Veterinary Clinical and Animal Sciences, Faculty of Health and 
Medical Sciences, University of Copenhagen, Gronnegaardsvej 7, Frederiksberg C DK-1870, 
Denmark 
Tetsuya Ishii: Office of Health and Safety, Hokkaido University, Sapporo 060-0808, Japan 
Hoshimi Kanemura: Research and Development Center for Cell Therapy, Foundation for 
Biomedical Research and Innovation, TRI#308 1-5-4, Minatojima-Minamimachi, Chuo-ku, 
Kobe 650-0047, Japan; Laboratory for Retinal Regeneration, RIKEN Center for 
Developmental Biology, 2-2-3, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan 
Shin Kawamata: Research and Development Center for Cell Therapy, Foundation for
Biomedical Research and Innovation, TRI#308 1-5-4, Minatojima-Minamimachi, Chuo-ku, 
Kobe 650-0047, Japan 
Mohamad Khazaei: Department of Genetics and Development, Toronto Western Research 
Institute,  University Health Network, Toronto, M5T 2S8, ON, Canada 
Cheuk-Yiu Law: Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen 
Mary Hospital,  the University of Hong Kong, Hong Kong SAR, China; Research Center of 
Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University 
of Hong Kong, Hong Kong SAR, China 
Yao Li: Department of Ophthalmology, Columbia University, 635 W 165th St, New York, 
NY 10032, USA 
Michaela Lucas: Department of Clinical Immunology, Pathwest Laboratory Medicine, 
Queen Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia; School of 
Medicine and Pharmacology and School of Pathology and Laboratory Medicine, The 
University of Western Australia, Harry Perkins Institute of Medical Research, Perth, 6009, 
Western Australia, Australia; Institute for Immunology and Infectious Diseases, Murdoch 
University, Perth, 6150,  Western Australia 
David A. Mackey: Centre for Ophthalmology and Visual Science (Incorporating Lions Eye 
Institute), The University of Western Australia, Perth WA 6009, Australia
Daniela Malan: Institute of Physiology I, Life and Brain Center, University of Bonn, Bonn 
53127, Germany
Eva M. Martínez-Conesa: Tissue Bank of BST (GenCat), Calle Dr Antoni Pujadas 42, 
SSMM Sant Joan de Déu, Edifici Pujadas, E-08830 Sant Boi de Llobregat, Spain
Samuel McLenachan: Centre for Ophthalmology and Visual Science (Incorporating Lions 
Eye Institute), The University of Western Australia, Perth WA 6009, Australia
Maurizio Memo: Department of Molecular and Translational Medicine, Fibroblast 
Reprogramming Unit, University of Brescia, Brescia 25123, Italy 
X 
Kwong-Man Ng: Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen 
Mary Hospital,  the University of Hong Kong, Hong Kong SAR, China; Research Center of 
Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University 
of Hong Kong, Hong Kong SAR, China 
Huy V. Nguyen: College of Physicians and Surgeons, Columbia University, 100 Haven Ave, 
Apt 14B, New York, NY 10032, USA 
Núria Nieto-Nicolau: CellTec-UB and the Clinic Foundation for Biomedical Research 
(FCRB), University of Barcelona,  Avda. Diagonal 643, E-08028 Barcelona, Spain 
Monica Nizzardo: Dino Ferrari Centre, Neuroscience Section, Department of 
Pathophysiology and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS 
Foundation Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, 
Italy 
Scott Nyberg: Division of Experimental Surgery, Mayo Clinic College of Medicine, 
Rochester, MN 55905, USA 
Kevin O'Connor: Department of Clinical Immunology, Royal Perth Hospital, Perth 6000, 
Western Australia, Australia 
Dmitry A. Ovchinnikov: Stem Cell Engineering Group, Australian Institute for 
Bioengineering and Nanotechnology,  The University of Queensland, St. Lucia 4072, 
Australia 
Carlota Pires: Department of Veterinary Clinical and Animal Sciences, Faculty of Health 
and Medical Sciences, University of Copenhagen, Gronnegaardsvej 7, Frederiksberg C DK-
1870, Denmark 
Agnese Ramirez: Dino Ferrari Centre, Neuroscience Section, Department of 
Pathophysiology and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS 
Foundation Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, 
Italy 
Angel Raya: Control of Stem Cell Potency Group, Institute for Bioengineering of Catalonia 
(IBEC), Barcelona 08028, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 
Barcelona 08010, Spain; Center for Networked Biomedical Research on Bioengineering, 
Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain; Center of 
Regenerative Medicine in Barcelona, Dr. Aiguader 88, Barcelona 08003, Spain 
Jordi Requena: Control of Pluripotency Laboratory, Department of Physiological Sciences I, 
Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, 
Barcelona, Spain 
Isart Roca: Control of Pluripotency Laboratory, Department of Physiological Sciences I, 
Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, 
Barcelona, Spain 
Noriko Sakai: Laboratory for Retinal Regeneration, RIKEN Center for Developmental 
Biology, 2-2-3, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan 
Philipp Sasse: Institute of Physiology I, Life and Brain Center, University of Bonn, Bonn 
53127, Germany 
Ahad M. Siddiqui: Department of Genetics and Development, Toronto Western Research 
Institute,  University Health Network, Toronto, M5T 2S8, ON, Canada 
XI 
Giulia Stuppia: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology 
and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Foundation 
Ca'Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, Italy 
Masayo Takahashi: Laboratory for Retinal Regeneration, RIKEN Center for Developmental 
Biology, 2-2-3, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan 
Roger Torrent: Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona 
Science Park, Barcelona 08028, Spain 
Stephen H. Tsang: Department of Ophthalmology, Columbia University, 635 W 165th St, 
New York, NY 10032, USA 
Hung-Fat Tse: Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen 
Mary Hospital,  the University of Hong Kong, Hong Kong SAR, China; Research Center of 
Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University 
of Hong Kong, Hong Kong SAR, China; Hong Kong-Guangdong Joint Laboratory on Stem 
Cell and Regenerative Medicine, the University of Hong Kong and Guangzhou Institutes of 
Biomedicine and Health, Hong Kong SAR, China; Shenzhen Institutes of Research and 
Innovation, the University of Hong Kong,  Hong Kong SAR, China 
Achia Urbach: Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University,  
Ramat Gan 5290002, Israel 
Yvonne Voss: Institute of Physiology I, Life and Brain Center, University of Bonn, Bonn 
53127, Germany; Physical Chemistry I, University of Siegen, Siegen 57076, Germany 
Xuehao Wang: Key Laboratory of Living Donor Liver Transplantation, Ministry of Public 
Health, Nanjing, Jiangsu Province 210029, China; Liver Transplantation Center, The First 
Affiliated Hospital of Nanjing Medical University,  Nanjing, Jiangsu Province 210029, China 
David S. Winlaw: Heart Centre for Children, The Children's Hospital at Westmead, 
Westmead NSW 2145, Australia; Sydney Medical School, University of Sydney, Sydney 
NSW 2006, Australia 
Ernst J. Wolvetang: Stem Cell Engineering Group, Australian Institute for Bioengineering 
and Nanotechnology,  The University of Queensland, St. Lucia 4072, Australia 
Yue Yu: Key Laboratory of Living Donor Liver Transplantation, Ministry of Public Health, 
Nanjing, Jiangsu Province 210029, China; Liver Transplantation Center, The First Affiliated 
Hospital of Nanjing Medical University,  Nanjing, Jiangsu Province 210029, China 
 
XII 
About the Guest Editor 
Dr. Michael Edel has specialised his university studies in the basic and fundamental 
principles of Anatomy, Embryology and Human Physiology, completing his PhD in 
Pathology in 2000 at the University of Western Australia, Perth, Australia. He moved to 
Barcelona in 2004, and works with his wife, Dr. Ana Belen Alvarez Palomo, to develop new 
clinical grade cell reprogramming technology to make stem cells to study and treat human 
disease.  
He is currently a Group Leader/Ramon y Cajal Investigator and accredited Associate 
Professor, based at the University of Barcelona, Faculty of Medicine. He is a senior researcher 
in the field of IPSCs, hESC, gene regulation, epigenetics, cell cycle, direct cell 
reprogramming to neurons, lung or cardiac muscle cells for the use of such cells as a cell 
replacement therapy. He has 46 publications to date, a book on the state of the art of iPSC 
technology (Journal of Clinical Medicine, 2015), he is an Editorial Board Member for the 
Journal of Clinical Medicine, ten years post-doctoral experience and five years as a group 
leader. He is affiliated as a Senior Research Fellow at the University of Western Australia, 
Centre for Cell Therapy and Regenerative Medicine (CCTRM), School of Medicine and 
Pharmacology, as well as at the University of Sydney, Faculty of Medicine, and Visiting 
International Research Fellow at the Victor Chang Cardiac Research Institute, Sydney, 
Australia.   
Dr. Edel has a number of current research project grants as chief investigator to develop new 
clinical grade stem cell technology, including a University of Western Australia near miss 
grant to develop a project on bioengineering cardiac muscle from iPSC to treat heart disease. 
He has been invited as a guest speaker as part of the distinguished faculty or co-chair for over 
20 congresses the past ten years.  For more information see his Lab Web 




The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has 
moved very quickly, from bench to bedside in just eight years since its first discovery in 
humans. The best example of this is the RIKEN clinical trial this year in Japan, which will use 
iPSC-derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). 
This is the first human disease to be tested for regeneration and repair by iPSC-derived cells 
and others will follow in the near future.  
Currently, there is an intense worldwide research effort to bring stem cell technology to the 
clinic for application to treat human diseases and pathologies. Human tissue diseases, 
including those of the lung, heart, brain, spinal cord, and muscle, drive organ bioengineering 
to the forefront of technology concerning cell replacement therapy. Given the critical mass of 
research and translational work being performed, iPSCs may very well be the cell type of 
choice for regenerative medicine in the future.  
Basic science questions, such as efficient differentiation protocols to the correct cell type for 
regenerating human tissues, the immune response of iPSC replacement therapy, gene editing 
for disease modeling and genetic stability of iPSC-derived cells, are currently being 
investigated for future clinical applications. New methodologies to change cell fate are being 
developed. The field of direct cell reprogramming is also gaining momentum with over five 
different cell types generated to date including central nervous system cells, spinal motor 
neurons, RPE cells, pericytes, monocytes and hepatocytes. As this field develops, new 
applications not previously thought possible before will open up to take advantage to treat 
human diseases and conditions. 
Please join us in presenting this Special Issue on the state of the art research currently being 
performed worldwide to bring iPSC to the clinic so as to help understand and treat various 
human diseases. It is my pleasure to thank the authors and reviewers for contributing to this 
special issue and am sure it will become an excellent reference text for iPSC research 
covering ten different human disease/conditions. 
Dr. Michael J. Edel 
Guest Editor 
Editorial Board Member 
University of Barcelona: michaeledel@ub.edu 
University of Western Australia: Michael.edel@uwa.edu.au
















Using iPS Cells toward the Understanding of  
Parkinson’s Disease 
Roger Torrent, Francesca De Angelis Rigotti, Patrizia Dell’Era, Maurizio Memo,  
Angel Raya and Antonella Consiglio 
Abstract: Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) represents 
an efficient tool for in vitro modeling of human brain diseases and provides an innovative opportunity 
in the identification of new therapeutic drugs. Patient-specific iPSC can be differentiated into 
disease-relevant cell types, including neurons, carrying the genetic background of the donor and 
enabling de novo generation of human models of genetically complex disorders. Parkinson’s disease 
(PD) is the second most common age-related progressive neurodegenerative disease, which is mainly 
characterized by nigrostriatal dopaminergic (DA) neuron degeneration and synaptic dysfunction. 
Recently, the generation of disease-specific iPSC from patients suffering from PD has unveiled a 
recapitulation of disease-related cell phenotypes, such as abnormal -synuclein accumulation and 
alterations in autophagy machinery. The use of patient-specific iPSC has a remarkable potential to 
uncover novel insights of the disease pathogenesis, which in turn will open new avenues for clinical 
intervention. This review explores the current Parkinson’s disease iPSC-based models highlighting 
their role in the discovery of new drugs, as well as discussing the most challenging limitations 
iPSC-models face today. 
Reprinted from J. Clin. Med. Cite as: Torrent, R.; De Angelis Rigotti, F.; Dell’Era, P.; Memo, M.; 
Raya, A.; Consiglio, A. Using iPS Cells toward the Understanding of Parkinson’s Disease.  
J. Clin. Med. 2015, 4, 548–566. 
1. Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world after 
Alzheimer’s disease (AD), affecting 2% of the population over the age of 60. The mean duration of 
the disease from the time of diagnosis to death is approximately 15 years, with a mortality ratio of  
2 to 1 in the affected subjects [1]. 
PD is characterized by debilitating motor deficits, such as tremor, limb rigidity and slowness  
of movements (bradykinesia) although non-motor features, such as hyposmia, cognitive decline, 
depression, and disturbed sleep are also present in later stages of the disease [1–3]. Neuropathologically, 
these motor deficits are caused by the progressive preferential loss of striatal-projecting neurons of 
the substantia nigra pars compacta; more specifically a subtype of dopaminergic neurons (DAn) 
patterned for the ventral midbrain (vmDAn). Neuronal loss is typically accompanied by the presence 
of intra-cytoplasmic ubiquitin-positive inclusions in surviving neurons. These structures are known 
as Lewy bodies and Lewy neurites and they are mainly composed of the neuronal protein -synuclein 
( -syn). These protein inclusions are not only found throughout the brain but also outside of the 
CNS. Moreover, microglial activation and an increase in astroglia and lymphocyte infiltration also occur 




Approximately 90%–95% of all PD cases are sporadic with no family history. Although disease 
onset and age are highly correlated, PD occurs when complex mechanisms such as mitochondrial 
activity, autophagy or degradation via proteasome are dysregulated by environmental influence or 
PD-specific mutation susceptibility [5]. 
Studies of rare large families showing classical Mendelian inherited PD have allowed for the 
identification of 11 genes out of 16 identified disease loci. They include dominant mutations in  
Leucine-rich repeat kinase 2 (LRRK2), recessive mutations in Parkin (coded by PARK2) and  
PTEN-induced putative kinase (PINK1) [6], as well as both rare dominant mutations and multiplications 
in the gene encoding -synuclein (SNCA). 
Current treatment for PD is limited to targeting only the symptoms of the disease and does not 
cure or delay disease progression. Therefore, the identification of new and more effective drugs to 
slow down, stop and even reverse PD is critical. This limited symptomatic treatment is due to the 
lack of clear understanding of the underlying mechanisms affected during PD. Using patient-specific 
iPSC-based models to recapitulate the disease from start to finish delivers a more detailed picture of 
the mechanisms involved in the progression of Parkinson’s disease and will aid in the discovery of 
disease-targeted therapies in the future. 
2. Models of Parkinson’s Disease 
Despite advances in the identification of genes and proteins involved in PD, there are still gaps in 
our understanding of the underlying mechanisms involved [7,8]. The lack of PD models fully 
representing the complex mechanisms involved in disease progression, as well as the near impossible 
task of extracting live neurons from patients has proven the investigation of PD difficult [8].  
In general, genetic mouse models do not represent the pathophysiological neurodegeneration and 
protein aggregation pattern observed in PD patients [9,10], and are thus limited [11,12]. On the other 
hand, PD animal models of administration of neurotoxins systemically or locally have successfully 
replicated DAn neurodegeneration, however they fail to recapitulate the degeneration in a slow and 
progressive manner, nor the formation of Lewy body-like inclusions which occur in PD human 
pathology [13]. 
Although the cellular models of PD, mostly based on human neuronal tumor cell lines, have 
provided helpful insights into alterations in specific subcellular components (such as proteasome, 
lysosome and mitochondrion), the relevance of these findings for PD pathogenesis is not always 
immediate. These models do not, however, investigate the defective mechanisms within the 
predominantly affected cell in PD, the DAn [14]. In addition, all studies involving human tissue have 
been performed with post-mortem samples, which can only allow for a limited analysis. 
The recent discovery of cellular reprogramming to generate induced pluripotent stem cells (iPSC) 
from patient somatic cells offers a remarkable opportunity to generate disease-specific iPSC [15], 
and to reproduce at a cellular and molecular level the mechanisms involved in disease progression. 
The use of iPSC offers not only the possibility of addressing important questions such as the 
functional relevance of the molecular findings, the contribution of individual genetic variations, 
patient-specific response to specific interventions, but also helps to recapitulate the prolonged 





Figure 1. Generation and use of iPSC modelling in PD. Somatic cells from a diseased 
patient are isolated and then reprogrammed to a pluripotent state (iPSCs). iPSCs can be 
maintained in culture or induced to differentiate along tissue- and cell-type specific 
pathways. Differentiated cells can be used to elucidate disease mechanism pathways, as 
well as for the development of novel therapies. 
3. Generation of PD-Specific iPSCs 
In recent years, neurodegenerative disease research has quickly advanced with the help of stem 
cell technology reprogramming somatic cells, such as fibroblasts, into induced pluripotent stem cells  
(iPSC) [15]. Human iPSC share many characteristics with human embryonic stem cells (hESC), 
including similarities in their morphologies, gene expression profiles, self-renewal ability, and 
capacity to differentiate into cell types of the three embryonic germ layers in vitro and in vivo [16]. 
An important advantage of induced cell reprogramming is represented by the possibility of 
generating iPSC from patients showing sporadic or familial forms of the disease. These in vitro 
models are composed of cells that carry the patients’ genetic variants, some known and others not, 
that are key to the contribution of disease onset and progression. Moreover, given that iPSC can be 
further differentiated into neurons, this technology potentially provides, for the first time, an 
unlimited source of native phenotypes of cells specifically involved in the process related to neuronal 
death in neurodegeneration in vitro. 
One issue found in modeling PD with the use of iPSC is to correctly reproduce its late-onset 
characteristics, since aging is a crucial risk factor. Indeed, at first it was unclear whether 
disease-specific features of neurodegenerative disorders that usually progressively appear over 
several years were reproducible in vitro over a period of only a few days to a few months. As a 
consequence, iPSC were initially used to model neurodevelopmental phenotypes and a variety of 
monogenic early-onset diseases [17–24]. However, studies using iPSC derived from patients with 
monogenic and sporadic forms of PD have illustrated these key features of PD pathophysiology, as a 
late-onset neurodegenerative disorder, after differentiating these iPSC into dopaminergic neurons. 
Moreover, several inducible factors that cause cell stress, such as mitochondrial toxins [25], growth 




premature aging) [26], have also been used to accelerate and reproduce the phenotypes found during 
disease progression. 
In this review, the recent work on iPSC-based PD modeling for both sporadic and familial cases 
will be discussed, as well as how iPSC-based studies are helping in the advancement of novel drug 
discoveries. These studies give insight for the fundsamental understanding of PD pathogenesis, 
which is critical for the development of new treatments. 
4. Modeling Sporadic and Familial PD Using iPSC 
Over the last few years, several studies have reported the generation of iPSC from patients 
suffering from sporadic and genetic forms of PD (Table 1). The first group generated PD-specific 
iPSC from a sporadic PD patient in 2008 [27]. Over the following year, the Jaenisch’s group was able 
to demonstrate that iPSC derived from PD patients were able to differentiate towards DAn, however, 
no characteristic signs of progressive neurodegeneration or disease-related phenotypes were 
observed in those cells [28]. The Jaenisch group generated gene-free iPSC lines from skin fibroblasts 
of five idiopathic PD patients. Using in vivo experiments, they showed that PD-specific 
iPSC-derived DAn were able to survive and engraft in the rodent striatum for at least 12 weeks.  
A small number of these cells co-expressed tyrosine hydroxylase (TH) and G-protein-gated inwardly 
rectifying K+ channel subunit (GIRK2), which are the hallmark characteristics of vmDAn. 
Remarkably, injection of these iPSC-derived DAn into the brains of 6-OHDA-lesioned rats resulted 
in motor symptoms improvement [29]. 
Many laboratories have now successfully recapitulated in vitro some of the characteristics of PD, 
using iPSC as a model compared to the aforementioned studies in which no signs of Parkinson’s 
disease were observed. However, given that PD is a progressive aging disease that affects several 
cellular mechanisms involving different cell types, each iPSC model highlights only some 
PD-associated characteristics. Nevertheless, each one of these models has helped to understand some 
of the fundamental underlying mechanisms as a proof-of-concept. In the last few years, iPSC-model 
reliability has rapidly improved and has paved the way for the discovery of new complex biomolecular 
interactions in the pathogenesis of PD. Thus, iPSC modeling has shown to be promising as a tool for 






Recently, iPSC-derived DA neurons carrying a triplication of SNCA, the coding gene for -syn 
protein, have been generated [30,31]. These cells showed enhanced -syn mRNA and protein  
levels [30] and increased cell death vulnerability when exposed to oxidative-stress inducers [31]. 
Using an iPSC model based on the rare missense A53T SNCA mutation, Chung et al. observed early 
pathogenic phenotype in patient-derived neurons, compared to isogenic gene-corrected controls.  
In particular, they observed a connection between nitrosative and ER stress in the context of -syn 
toxicity. Interestingly, the levels of CHOP (CCAAT enhancer binding protein homologous protein), 
a component of ER stress-induced apoptosis, did not change, indicating that in this model cellular 
pathology was still at an early stage [32]. iPSC-derived DAn, carrying the A53T SNCA mutation, 
also showed -syn aggregation, altered mitochondrial machinery, thus enhancing basal ROS/RNS 




transcription factor MEF2 and its consequent inhibition, reducing the expression of the mitochondrial 
master regulator PGC1  and genes that are important for the development and survival of  
A9 DAn [43]. Interestingly, Ryan et al., postulated that the MEF2-PGC1  pathway contributes to the 
appearance of late-onset phenotypes in PD due to the complex interaction between environmental 
factors and gene expression. Indeed, when PD-associated pesticides were added below EPA-accepted 
levels, this was enough to exacerbate oxidative/nitrosative stress, inhibiting MEF2-PGC1  and 
inducing apoptosis, a late-onset phenotype [25]. 
Interestingly, -syn is one of the main pathological readouts for many of the sporadic and  
familial PD cases that are not related with mutations in SNCA [44]. For example, the clinical  
link between the lysosomal storage disorder Gaucher disease (GD) and PD appears to be based on  
the fact that mutations in acid GBA1 gene, which causes GD, contributes to the pathogenesis of 
synucleinopathies [33,34]. GBA1 encodes the lysosomal enzyme -Glucocerebrocidase (GCase), 
which cleaves the -glucosyl linkage of GlcCer. Functional loss of GCase activity in iPSC-derived 
neurons has been associated with compromised lysosomal protein degradation, which in turn induces 
-syn accumulation, resulting in neurotoxicity through aggregation-dependent mechanisms [33].  
In addition, iPSC-derived neurons carrying the heterozygous mutation in GBA1 also have shown 
increased levels of GlcCer, changes in the autophagic/lysosomal system and calcium homeostasis, 
which may cause a selective threat to DA neurons in PD [34]. 
Similarly to mutations in GBA1, mutations in PINK1 and PARK2 are also associated with early 
onset recessive forms of familial PD [45]. Both proteins, PINK1 and Parkin, are involved in the 
clearance of mitochondrial damage. Therefore their mutations cause a PD characterized by 
mitochondrial stress as main feature [46–48]. Under physiological conditions, Parkin, which is 
localized in the cytoplasm, is translocated to damaged mitochondria in a PINK-dependent manner 
triggering mitophagy [49]. This has been confirmed in iPSC-derived DA neurons carrying a 
mutation in PINK1. In these cells, Parkin recruitment to mitochondria was impaired and only 
over-expression of WT PINK1 was able to rescue the function [37]. On the other hand, iPSC models 
for mutation in PARK2 revealed an increase of oxidative stress. Jiang and colleagues showed that 
iPSC from patients carrying mutations in PARK2 enhanced the transcription of monoamine oxidase, 
the spontaneous release of dopamine and significantly decreased dopamine uptake, increasing 
susceptibility to reactive oxygen species [35]. Although the incremented oxidative stress has been 
confirmed in a parallel study, in this study no difference in monoamine oxidase was observed [36]. 
On the contrary, the oxidative stress was accompanied by a compensation mechanism that involved 
the activation of the reducing Nrf2A pathway [36]. 
Mutations in LRRK2 have been one of the most studied mutations in PD, not only because they are 
the most common cause of familial PD, but also because clinical symptoms of LRRK2-PD are similar 
to those of idiopathic PD [50]. The most common mutation is the G2019S, which results in  
hyper-activity of the LRRK2 kinase domain. Although penetrance of this gene has shown to be 
variable between individuals’ age, iPSC model of a G2019S LRRK2-PD has recapitulated 
characteristic features of PD, such as accumulation of -syn, increase in genes responsible for 
oxidative stress and enhanced susceptibility to hydrogen peroxide, which is displayed through 




-syn were found to be increased in neurons from LRRK2-iPSC, when compared to those 
differentiated from control iPSC or hESC. 
Our group has generated iPSC lines from seven patients with idiopathic PD and four patients 
carrying G2019S mutation in the LRRK2 gene [40]. We observed morphological alterations in 
PD-derived iPSC vmDAn (fewer and shorter neurites) as well as an increase in the number of 
apoptotic neurons over a long-time culture (2.5 months). Moreover, we found an accumulation of 
-syn in LRRK2-iPSC derived DAn after a 30 days culture. 
Sporadic forms of PD are not as well defined, given that they may be caused by several genetic 
variants, as well as a strong environmental effect. However, our study revealed that DAn, which 
were derived from idiopathic PD patients, also showed an increased susceptibility to degeneration  
in vitro after long-term culture [40]. 
Importantly, the appearance of the neurodegenerative phenotypes in differentiated DAn from 
either idiopathic or LRRK2-associated PD was shown to be the consequence, at least in part, of 
impaired autophagy. Blockade of autophagy by lysosomal inhibition showed a specific reduction in 
autophagic flux by LC3-II immunoblotting, suggesting that the clearance of autophagosomes was 
compromised [40]. Proteins may also enter the autophagic process directly at the lysosome level, via 
chaperone-mediated autophagy (CMA). Increased co-localization of -syn with LAMP2A puncta in 
iPSC-derived LRRK2 DAn, revealed a compromised degradation of -syn by CMA [41]. Although 
both wild-type and mutant LRRK2 inhibit CMA, G2019S LRRK2 protein was more resistant to  
the CMA-mediated degradation, resulting in -syn accumulation [41]. Furthermore, the same 
phenotype was induced by over-expression of wild-type or G2019S LRRK2 in control iPSC-derived 
cultures [40] and rescued by LRRK2 inhibition [42]. Indeed, iPSC-derived DAn cultures from 
isogenic G2019S LRRK2 lines (mutation being the sole experimental variable) exhibited an 
increased mutant-specific apoptosis and decreased neurite outgrowth, as well as alterations in the 
expression of several pERK (phosphorylated ERK) controlled genes, all of which could be rescued 
by the inhibition of LRRK2 [42]. Moreover, the genetic correction of LRRK2 mutation resulted in 
the phenotypic rescue of differentiated neurons with improved neurite length to levels comparable to 
those of controls. 
5. Patient-Derived Stem Cells Could Improve Drug Research for PD 
An important goal of humanized stem cell-based PD model systems is the screening of potential 
new drugs that could affect the neurodegenerative process at several levels during its development in 
specifically affected human cells. Moreover, the availability of such patient-specific stem cell-based 
model systems could help identifying new pharmacological strategies for the design of personalized 
therapies. Recently, iPSC-derived forebrain neurons have been used as a platform to screen 
disease-modifying drugs, highlighting the possibilities of iPSC technology as an in vitro cell-based 
assay system for AD research [51]. A recent study has also taken a significant leap towards 
personalized medicine for PD patients, by investigating signs of the disease in patient-specific 
iPSC-derived neurons and testing how the cells respond to drug treatments [38]. The study showed 
that neurons derived from PD patients carrying mutations in the PINK1 or LRRK2 genes display 




vulnerability to oxidative stress. However, they found that oxygen consumption rates were lower in 
cells with mutations in LRRK2 and higher in cells with the mutations in PINK1. Notably, they were 
able to rescue the phenotype caused by toxins to which the cells were exposed to with various drug 
treatments, including the antioxidant coenzyme Q10 and rapamycin. Most importantly, the response 
of iPSC-derived neurons was different depending on the type of familial PD, since drugs that 
prevented damage to neurons with mutations in LRRK2, did not protect neurons with mutations in 
PINK1 [38]. 
In addition, Ryan and colleagues performed a high-throughput screening (HTS) to identify 
molecules that are capable of protecting DAn from the toxic effect of PD-associated pesticides.  
They observed that the MEF2-PGC1  pathway contributes to the late-onset PD phenotypes due to 
the interaction between environmental factors and gene expression [25]. They performed HTS for 
small molecules capable of targeting the MEF2-PGC1  pathway and they identify isoxazole as  
new potential therapeutic drug. Isoxazole, not only drove the expression of both MEF2 and PGC1 , 
but also protected A53T DAn from pesticide-induced apoptosis [25]. 
Chung and colleagues investigated yeast and iPSC PD models in parallel to discover and reverse 
phenotypic responses to -syn. In conjunction to what was previously reported, they showed a 
connection between -syn toxicity, accumulation of NO and ER stress [32]. With these results, they 
took a step further by screening for possible -syn toxicity suppressors in their iPSC model, to 
compare with their previous yeast screenings [52–54]. In particular they showed that the ubiquitin 
ligase Nedd4 and its chemical activator NAB2 [53] are able to rescue the -syn toxicity in 
patient-derived neurons [32], opening a door to a new potential drug treatment. 
These results encourage the use of iPSC technology as a tool to discover potential therapeutic 
drugs. However, concluding for what recent studies have unveiled up until now focusing only on 
genetic forms of PD, it remains to be determined whether this advanced technology can be used also 
in sporadic patients with uncertain genetic cause of the disease. 
6. Limitations of Using iPSC in Disease Modeling: From Overall Neurodegeneration to the 
Detailed Mechanisms Involved 
6.1. Reprogramming and Epigenetic Signatures 
Reprogramming increases cell variability due to the introduction of mutations in the genomic 
DNA [55] and the insertion of exogenous reprogramming genes. Moreover reprogrammed cells 
maintain a residual DNA methylation signature characteristic of the somatic tissue of origin [56–59] 
affecting also gene expression [60]. These issues can affect the predisposition of a given line to 
differentiate into particular cell type independently of the patient’s genotype, and will abrogate the 
possibility of using these lines for cell therapy treatment in the future. To decrease the impact of these 
technical limitations, more than one clone for each iPSC line is usually analyzed. However, the use 
of integrating methods, such as lenti- and retro-virus infection for gene transduction, not only 
increases cell variability, but also maintains residual expression of exogenous reprogramming genes 
that is only partially lost through cell passaging. The residual expression of reprogramming genes 




expression of reprogramming genes. Indeed, the reprogramming process by which a somatic cell 
acquires pluripotent potential is not a genetic transformation, but an epigenomic one [61], therefore 
only a transient expression of reprogramming genes needs to be activated. Alternative methods to the 
retro- or lenti-viral infection, have been recently adopted. These include the use of non-integrating 
viral vectors such as Sendai virus [62], episomal vectors [63], protein transduction [64], or 
transfection of modified mRNA transcripts [65]. These methods of reprogramming are relevant in 
the context of any future clinical applications of iPSCs in the field of transplantable replacement  
cell therapies. 
As aforementioned, one of the major concerns in iPSC modeling through the reprogramming of 
somatic cells into iPSCs has been that of resetting the identity of these cells back to an embryonic 
stage, therefore having to consider the generated iPSC-derived neurons as fetal neurons. Given the 
slow progression of neurodegenerative diseases, the idea of modeling this type of disease in a dish 
has been highly doubted. However, despite the typical late-onset of PD, the key cellular and 
molecular pathological mechanisms may have started before the onset of the disease. Therefore, -syn 
accumulation, autophagic clearance and mitochondrial dysfunctions, among other pathological 
mechanisms afforested, could have been active in the early stages of the disease. The cumulative 
effect of these abnormalities along with the effect of environmental influence, have been shown to 
progressively encourage neurodegeneration [25]. In addition the use of cell stressors and inducible 
aging [26] also have shown the possibility of accelerating the appearance of diseased phenotypes in  
a dish. 
6.2. Reliable Control Lines and Gene-Editing 
Comparative studies require an appropriate control that accounts for differences between lines 
due only to the genotypic background that exists between individuals. This is especially crucial in 
diseases whose causative mutations do not have a high penetrance. For example, when complex 
diseases, such as PD, are modeled with patient- and healthy donor-derived iPSC, the patient iPSC 
tend to show subtle phenotypes that can be masked by genetic background effects [66]. For this 
reason, it is imperative to remove the excess genetic variation between iPSC clones and controls, to 
ensure a more reliable comparative analysis. Given that to obtain iPSC from unaffected siblings or 
parental controls is not often possible, a solution is to generate isogenic controls directly from the 
patient iPSCs. In the last years, several research groups have used this approach to correct known 
mutations [25,26,32,34,42,67], or even utilizing the introduction of the same mutation in control 
iPSC lines to see the effect of just the mutation itself [42,67]. For this reason, isogenic controls  
have claimed to be crucial when it comes to assess the impact of any mutation on specific  
cellular processes. Therefore, editing technologies based on Zinc Fingers Nucleases, TALENs or  
CRISPR [68], have become indispensable tools in developing comparative studies in iPSC models, 





6.3. Cell Differentiation and Sorting 
The efficacy of Parkinson’s disease iPSC models depends highly on their ability to correctly 
differentiate neurons into the specific cell type that is affected by the disease (in this case A9 
dopaminergic neuronal subtype). Indeed this is critical in order to recapitulate disease features  
in vitro and observe comparative differences between diseased and healthy control lines. Neuronal 
differentiation of iPSC into DA neurons is not only subjected to high variability of efficiency, 
depending on the techniques used in a laboratory, but also on the specific ability of each iPSC line. 
For example, by comparing the studies reported in this review, the percentage of DA neurons 
compared to the total number of cells varies depending on each cell line, differentiation method and 
even laboratory group (Table 1). Throughout the field, groups encountered problems in yielding a 
high percentage of DA neurons within the differentiated population. Therefore, although a number of 
results are based on the disease phenotype through the identification of TH positive cells by 
immunocytochemistry, protein immunoblots in which all cell populations are considered skews the 
data. More specifically, the levels of affected protein in the few TH positive cells may be diluted and 
missed when mixed with the whole population of differentiate cells when analyzed. Interpretation of 
these results have been, thus, controversial, especially in the cases in which PD iPSC-derived models 
have low yield in DA differentiation, which probably cannot go beyond the gross neurodegeneration 
mechanisms that they have observed. Thus, delving deep inside the biomolecular pathways affected 
in PD will require a more fine-tuned differentiation protocol that allows the enrichment of the cell 
type of interest. To achieve this, a novel floor-plate-based strategy described by Kriks and colleagues 
has become the gold standard in the generation of human A9 vmDA neurons for both transplantation 
and research purposes [69]. The protocol is based on the concurrent inhibition of two parallel 
SMAD/TGF-  (transforming growth factor- ) superfamily-signaling pathways, which during CNS 
development induce no-neuronal fates such as endoderm or mesoderm. This inhibition directs the 
cell culture to a predetermined neural progenitor fate with an efficiency of at least 80% of PAX6+ 
neural cells among total cells [70]. Differentiation of these neuronal stem cells into mature vmDAn is 
then instructed through the molecular guidance of Sonic Hedgehog (SHH), FGF8 and more 
importantly Wnt signaling pathway induction, which enhances expression of the transcription factors 
FOXA2 and LMX1A [71,72]. The final step of neuronal maturation is achieved through the use of a 
cocktail of neurotrophic factors, including BDNF, GDNF, TGF 3, dbcAMP, and ascorbic acid 
(Figure 2). Interestingly, the most recent papers reviewed here have started to implement the A9 
vmDAn enrichment protocol [25,26,34] with the addition of isogenic-corrected controls [25,34]. 
Moreover, Schöndorf and colleagues improved the Kriks differentiation protocol thanks to the use of 
a cell sorting method (Fluorescence-activated cell sorting), which allowed for a 6.1-fold enrichment 
of the neuronal population. This step of sorting was necessary to assess reliable biomolecular 
changes that could not have been assessed with an unsorted heterogenic population [34]. 
On the other hand, to unveil the mechanisms behind pathophysiological processes such as 
neuroinflammation, the investigation of all cells responsible for the maintenance of CNS 
homeostasis, such as astrocytes and microglia, is crucial. Nevertheless, the study of a more isolated 





Figure 2. Schematic summary of the novel floor-plate A9 vmDAn differentiation 
protocol by Kriks [69]. The first stage illustrates floor-plate induction [70], with the 
appropriate modification in order to reach a more specialized A9 midbrain DA neuronal 
identity. Exposure to LDN (LDN193189) and SB (SB431542) triggers the Dual-SMAD 
inhibition. Purmorphamine (Pur), which activates Sonic Hedgehog (SHH) signaling, 
together with SHH and FGF8 is not sufficient to trigger a selective enrichment of 
midbrain DA precursors. However, SHH/Pur/FGF8 in combination with exposure to 
CHIR99021 (a potent GSK3  inhibitor known to strongly activate WNT signaling) 
allows for a complete enrichment of DA precursors with A9 midbrain identity, by 
inducing the expression of FOXA2 and LMX1A. Neural differentiation and maturation 
is achieved through the use of a cocktail of neurotrophic factors BAGCT (BDNF + 
ascorbic acid + GDNF + dbcAMP + TGF 3). 
7. Conclusions and Challenges 
PD is a progressive neurodegenerative disease resulting in the gradual loss of vmDA neurons, as 
well as cytoplasmic inclusions called Lewy Bodies. The exact mechanisms leading to vmDA 
neuronal death in PD are still unclear, although pathogenic protein aggregation of -synuclein, 
mitochondrial dysfunction, oxidative and nitrosative stress, or altered autophagy have been proposed 
as mechanisms that contribute to this devastating neurodegenerative process. The generation of 
reliable iPSC-based models for late-onset neurodegenerative disorders, in which the etiology is yet to 
be uncovered, has proven to be difficult to overcome. However, recent advances in the field have 
demonstrated the feasibility of developing experimental models of PD based on iPSC from patients 
of both genetic and idiopathic forms of PD that recapitulate the key features of the disease.  
The successful generation of these genetic and idiopathic PD models has opened the door bringing to 
light some of the crucial pathogenic mechanisms responsible for the initiation and progression of PD, 
as well as aid in the development of novel drugs that may prevent or rescue neurodegeneration in PD. 
Recent findings in the field have moved far beyond the proof-of-principle stage, and have started to 
optimize and standardize these models for the discovery of new aspects of disease biology and new 
targets for therapeutic intervention. The use of isogenic-corrected controls, more reliable 
differentiation protocols [25,26,34] and efficient cell-sorting methods [34], have strongly validated 




neuroscience, the opportunity and challenge to combine patient-derived disease-specific stem cells 
with drug screening technologies with the aim of finding new therapies is now a possibility.  
In addition, the combination of establishing optimal neuronal differentiation protocols of iPSC 
using genetic reporters, together with software analysis algorithms, allows for the possibility of 
automatically tracking each cell over time and to assess any feature of interest, thus providing this 
system with a powerful tool in drug discovery in the near future. 
Moreover, by studying symptomatic and asymptomatic mutation carriers, iPSC technology 
could also provide a unique opportunity for identifying putative gene-linked PD biomarkers in 
pre-symptomatic individuals, opening a new novel window for the early diagnosis and 
individualized treatment in the preclinical phase of the disease. 
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Opportunities and Limitations of Modelling Alzheimer’s 
Disease with Induced Pluripotent Stem Cells 
Dmitry A. Ovchinnikov and Ernst J. Wolvetang 
Abstract: Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has opened 
the way for patient-specific disease modelling. Following their differentiation into neuronal cell 
types, iPSC have enabled the investigation of human neurodegenerative diseases, such as 
Alzheimer’s disease (AD). While human iPSCs certainly provide great opportunities to repeatedly 
interrogate specific human brain cell types of individuals with familial and sporadic forms of the 
disease, the complex aetiology and timescale over which AD develops in humans poses particular 
challenges to iPSC-based AD models. Here, we discuss the current state-of-play in the context of 
these and other iPSC model-related challenges and elaborate on likely future developments in this 
field of research. 
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1. Opportunities and Limitations of Modelling Alzheimer’s Disease with Induced Pluripotent  
Stem Cells 
The ability to generate patient-specific induced pluripotent stem cells (iPSCs) through 
reprogramming of somatic cells and, following their differentiation into neuronal cell types,  
investigate the aetiology of human neurodegenerative diseases, such as Alzheimer’s disease (AD),  
has created much excitement about this new in vitro disease modelling paradigm. While human 
iPSCs certainly provide great opportunities to repeatedly interrogate specific human brain cell types 
of individuals with familial and sporadic forms of the disease, the complex aetiology and timescale 
over which AD develops in humans poses particular challenges to iPSC-based AD models. Here, we 
discuss the current state-of-play in the context of these and other iPSC model-related challenges and 
elaborate on likely future developments in this field of research. 
2. iPSCs as a Model System 
Following the ground-breaking work by Takahashi, Yamanaka and others [1], the concept of 
personalized disease modelling with induced pluripotent stem cells, generated from a patient’s own 
somatic tissues, is now firmly established (e.g., see [2–6]). While larger cohorts of iPSCs from 
various diseases are being generated worldwide through various consortia, industry or iPSC banks, a 
survey of the literature indicates that the vast majority of studies are limited to the comparison of a 
few disease and control samples (Table 1). While this in no way invalidates the data obtained thus 
far, there is evidence that iPSCs, even from the same individual, can vary in terms of both DNA 
mutation load [7], gene expression [8] and epigenetic signatures [9–15], often resulting in 




however, report no or only a few differences in gene expression between different hESC and  
iPSC lines [17–19]. Some of the variability appears to be driven by the method chosen to reprogram 
the somatic cells, with non-integrating methods showing the least variability [20–22], allelic 
variation [23,24], the age and type of cells used for reprogramming [25] and the culture time and 
method used to expand iPSC following establishment [26]. Rarely, researchers have shown, 
however, that three independent clonal iPSC lines from multiple patients with the same disease 
statistically differ from controls and that this does not change with increased passage number.  
Given what we now know about the erosion of imprinting at affected loci, as well as the  
variability (and erosion) of X-chromosome inactivation [27,28], parameters that can profoundly affect 
neurally-differentiated cell types, these are important factors to consider when embarking on or 
interpreting iPSC disease modelling studies. Similarly, the issue of choosing the appropriate controls 
for comparative studies of human samples is not a trivial one. While unaffected sibling or parental 
control samples are preferable, these are not always available or come from family members of 
different age or gender and different genetic make-up. We predict that with time, there is likely to be 
an increasing demand for the isogenic gene-corrected controls (if the mutation is known [4]) or 
verification of the causality of single or compounded disease-associated alleles through the 
introduction of such mutations into control (“disease-unaffected”) iPSC lines through genome 
editing technologies (e.g., using CRISPRs (Clustered Regularly Interspaced Short Palindromic 
Repeats) or TALENs (Transcription Activator-Like Nucleases) [29,30]), thereby reducing the need 
for very large (and costly) disease and patient-specific iPSC cohorts. 
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3. Making the Right Cell Type 
AD is characterized by progressive dementia accompanied by the occurrence of neuritic plaques 
(NP), mainly comprised of extracellular deposits of amyloid beta (A ) protein and neurofibrillary 
tangles (NFT), consisting of intracellularly-aggregated hyperphosphorylated tau protein [38].  
With the exception of familial forms of the disease, constituting approximately 2%–5% of disease 
burden, the vast majority of clinically seen AD is the sporadic form of the disease, and despite many 
decades of research, its aetiology remains largely enigmatic. Sporadic AD can vary in its time of 
onset, severity and clinical read-outs and may in fact encompass multiple AD-like diseases with 
distinct aetiologies. Glutamatergic and basal forebrain cholinergic neurons in the cerebral cortex and 
the hippocampus are thought to be cells that are affected at early stages and lost during AD 
pathogenesis, with further loss of GABAergic and other neuronal cell types during the advanced 
stages of the disease [39]. These AD tell-tale signs further appear to be invariably associated with, and 
perhaps driven by, astrocyte and microglial activation, as well as changes in local vasculature [40]. 
Given that AD development is clearly a gradual process involving the interaction of multiple cell 
types in a complex three-dimensional milieu and typically first observed in specific regions of the 
ageing brain, what is the correct iPSC-derived cell type that will most faithfully model AD in vitro 
(Figure 1)? Thus far, most iPSC-AD modelling studies have employed either embryoid body/ 
neurosphere or small molecule-based neuronal differentiation protocols that are known to generate 
mainly glutamatergic cortical forebrain neurons [32–34,41–43]. In terms of gene and neuronal 
marker expression, these largely cortical neuronal cultures at 4–9 weeks still consist of a mixture of 
different cell types of variable maturity levels, most closely resembling early human foetal neurons 
(a conclusion largely based on gene expression and functional analyses of their action potentials and 
calcium-handling ability). Despite these facts, and perhaps as a testament to the robustness and 
expressivity of certain AD phenotypes, increased A 42 amyloid production and tau-phosphorylation 
changes have been observed in such cultures. There is a clear need, however, to develop protocols 
that will allow the generation of specific and relevant cell types (e.g., basal forebrain cholinergic 
neurons) and purify such neurons away from differently patterned neuronal cell types if we are to 
decipher the gene-regulatory networks involved in disease initiation. There is a similar need for the 
development of protocols that will mimic or accelerate the maturation and “ageing” processes of 
such neurons in vitro. Researchers have started to explore this concept through subjecting neural 
cells to prolonged culture [44], the transient delivery of progerin [45], telomere shortening [46], 
chronic exposure to oxidative stress [47], DNA damaging agents [48] or proteasome inhibitors [49,50]. 
Similarly, the field has started to embrace the concept that AD is not a solely neuron-driven disease, 
but involves an interaction between neurons and astrocytes [51] (and likely microglia [52] and the 
local microvasculature [40]) that, while initially beneficial, upon reaching a certain threshold, 
becomes deleterious to neuronal function and survival [53]. Even though it is difficult to envisage 
that we will be able to artificially recreate such a complex, three-dimensional tissue as the human 
brain at this stage, iPSC technology is well suited to study paracrine interactions in the dish [54,55], 
particularly since astrocytes can be readily isolated from control or AD neuronal cultures using flow 




Experiments of this type recently identified astrocytes as an important contributor to 
neuro-degeneration in Down syndrome iPSC-derived neuronal cultures, a condition that displays  
AD with a 100% penetrance [56]. Adding microglia, the third cell type of the AD pathogenesis 
“triad”, to such an in vitro model is now achievable. While differentiation of microglia from mouse 
pluripotent stem cells is achievable [57–59], the generation of this yolk sack haematopoiesis-derived 
macrophage cell type [60] from human pluripotent stem cells has thus far not been reported.  
The biggest advantage of any iPSC-based AD modelling exercise will remain the ability to gene-edit 
the cells by the introduction of the specific mutations or transgenes and corroborate the causality of 
newly-discovered cell-cell or gene-gene interactions. Combining such an approach with single-cell 
sequencing technology may be the key to uncovering whether increasing cellular heterogeneity, 
occurring over time, and possibly induced by normal neuronal activity, is a contributing factor in  
AD pathogenesis. 
Figure 1. Modelling Alzheimer disease with iPSC-derived cell types has the potential to 
reveal cell-cell and paracrine signalling events underlying disease aetiology. 
 
4. AD Phenotypes Which Can be Reliably Modelled in Vitro 
There appears to be forming an increasing consensus that AD-like pathological changes involve 
early alterations in phosphorylation of the neuronal protein, tau, and its aggregation into neurofibrillary 
tangles (NFTs), followed and exacerbated by beta-amyloid toxicity and plaque formation [61–63].  
In AD patients, cognitive decline correlates closely with the decreased thickness of cortical layers in 




AD iPSC-derived neurons to cell survival assays before and after noxious stimuli, such as oxidative 
stress, appears sensible and is, thus, commonly used [66]. A correlate that closely matches the 
cognitive decline in AD is the occurrence of NFTs, rather than beta-amyloid plaques [67]. 
Determining the level of the microtubule-associated protein, tau, the main constituent of NFT,  
and the prevalence and subcellular localisation of its different phosphorylated forms would  
therefore seem essential, since tau appears to act as a key mediator or enabler of both A - and 
apoE4-dependent AD pathogenesis. In one study [34], the expression of tau or phospho-tau isoforms 
was not observed, whereas others [41] did observe this in familial and one sporadic 
AD-iPSC-derived neurons [31]. Measuring the activity and phosphorylation status of GSK3 , one of 
the key kinases involved in tau-phosphorylation [68], is also commonly a part of the analysis [69]. 
Although it has become clear that the role of -amyloid in AD pathogenesis is much more complex 
than was initially appreciated, with perhaps early neuro-protective roles for APP and clear 
neuro-degenerative effects of aggregated processed forms, such as A 42 during later stages, 
measurements of the expression of APP and its processed forms remains a highly relevant parameter 
to examine. Indeed, elevated levels of extracellular A 42, as well as the presence of intracellular 
aggregates have been reported in iPSC-based models of AD [32]. There is further increasing 
evidence that APP and -amyloid are linked to enlargement and altered localisation of early 
endosomal compartments marked by RAB5, and this has indeed been reported in AD iPSC-derived 
neurons [41]. Both tau and -amyloid have been linked to a loss of dendritic spines and synapses  
in mice and humans, and this is another parameter that closely matches the cognitive decline in  
AD [70]. While these can be readily measured in neurons generated in vitro from AD-iPSCs, this 
approach has so far been under-used, perhaps owing to the fact that identification and binning of 
different neuronal subtypes is still difficult to achieve. Notably, there is evidence in mouse models  
of AD that synapto-dendritic degeneration is often preceded by an aberrant neuronal network  
activity [71,72], suggesting that inappropriate synaptic wiring or network stimulation may be an 
early contributor to AD pathogenesis. While rabies virus-based synaptic connectivity assays have 
been used to good effect in iPSC models of schizophrenia [73] and neuronal connectivity in the dish 
can be readily assessed through dye injection (Figure 2, [74]), these have thus far not been used to 
any extent in iPSC-based AD research. Given emerging evidence that neuronal activity may stimulate 
retrotransposon mobility [75], induce double-stranded DNA breaks [76], elicit epigenetic changes in 
neurons [77–82] and trigger the expression of activity-dependent long non-coding RNAs  






Figure 2. A Day 70 neuronal culture from control iPSCs, imaged 30 min after one  
cell was micro-injected with NeuroBiotin™ and detected using Streptavidin-Cy3, 
reveals the highly interconnected nature of neurons and astrocytes generated in vitro. 
Image courtesy of Patrick Fortuna and Refik Kanjhan (University of Queensland, 
Brisbane, Australia). 
 
5. Down Syndrome iPSC as a Model for AD 
All individuals with Down syndrome develop an early-onset AD. An obvious candidate gene for 
this phenomenon is APP (amyloid precursor protein), which resides on chromosome 21. Although 
increased APP gene dosage can certainly be a major driver of AD, as indicated by the fact that 
families with APP gene duplications develop early onset AD [86–88] and the lack of discernible AD 
pathology in partial trisomy 21 patients lacking the gene [89], this does not mean that other HSA21 
genes do not contribute to AD in DS. Indeed, mouse models and clinical data clearly indicate 
important AD enhancing roles for the DYRK1A kinase (because of its ability to directly 
phosphorylate tau, APP and RCAN1) [90–92], RCAN1 (a calcium regulated phosphatase able to 
increase tau-phosphorylation through inhibition of the phosphatase calcineurin and to regulate 
vesicle fusion kinetics) [93,94], ETS2 (a transcription factor upregulated by oxidative stress that 
transactivates APP) [95–97] and BACE2 (a non-amyloidogenic -secretase) [98–100]. 
Since the genetic defect in Down syndrome is known (trisomy 21), iPSCs from DS individuals 
present an attractive model to test hypotheses of AD pathogenesis. Indeed, we and others have shown 
that neuronally-differentiated DS iPSCs exhibit a number of phenotypes akin to AD, including: 
Increased neuronal cell death that can be rescued by anti-oxidants, reduced neurite extension  
numbers [66], reduced synapse formation, increased A 42 production and hyperphosphorylated  
tau [42]. DS iPSCs subjected to neural differentiation also show enhanced gliogenesis, generating 
astrocytes that exhibit an activated phenotype and increased ROS production levels, upregulation of 
iNOS, yet reduced expression of NFE2L2, TSP-1 and TSP-2, consistent with the reduced 
neuroprotective and neurotrophic ability of such astrocytes [56]. It is therefore evident that DS 




to isolate isogenic euploid iPSC from reprogrammed DS fibroblast cultures, providing the ideal 
isogenic controls needed for gene regulatory network analysis. Advanced genome interrogation 
tools, such as CRISPR, can now be used to delete specific genes or gene cohorts on chromosome 21, 
and delivery of XIST to HSA21 has already been used to epigenetically silence the supernumerary 
trisomy 21 genes [101]. We anticipate that such genome modifying technologies in iPSC will rapidly 
provide novel insights into the cell-autonomous and non-cell autonomous processes underlying AD 
pathogenesis in DS. This will be of great relevance to understanding the bases of the sporadic AD in 
the general population. The time is now ripe for testing the effect of susceptibility loci identified 
through GWAS studies, such as ApoE 4 allele PICALM, BIN1, SORL1, clusterin/ApoJ and  
CR1 [102] using, for example, CRISPR technology in iPSC models of AD disease and testing their 
contribution to in vitro-assessable phenotypes. 
6. Drug Screening Utilizing AD iPSC-Derived Cell Types 
AD iPSC-derived neurons are currently being used to screen for drugs that could be of potential 
benefit to patients. Encouragingly, compounds that inhibit gamma-secretase activity were effective 
at reducing beta-amyloid production in AD iPSC-derived neuronal cultures. Non-steroidal 
anti-inflammatory drugs, such as sulindac sulphide, show effectiveness in presenilin 1-overexpressing 
cells, albeit not for the L166P mutant [43]. Similarly, minocycline was able to normalize the 
pathological phenotypes of DS astroglia [56], emerging as a promising drug candidate for 
DS-associated AD and possibly familial AD, as well. In order to enable the high-throughput 
capability required for screening large chemical libraries, the field will need to address the issue of 
identifying, generating and culturing the correct cell types (discussed above), make informed choices 
about what cellular readout will be most informative in terms of preventing early AD changes in the 
brain and consider the fact that a combination of drugs will affect multiple cell types that are 
functionally inter-linked to the disease process, providing challenges to image analysis and culture 
platforms alike. A recent study by Choi et al. [37] demonstrated that the generation of 
three-dimensional cultures of familial AD-recapitulating human neurons was essential and sufficient 
to reproduce some aspects of the AD phenotype, such as extracellular amyloid-  plaque and 
neurofibrillary tangle formation. While the study did not utilize the iPS cells per se, the multipotent 
neural progenitor cell line used closely resembles neural progenitor cells generated during standard 
neural iPS differentiation [66]. 
7. Conclusions 
Although it is still a relatively young field of research, the iPSC-based disease modelling of AD 
has made great progress in a short time, and it is anticipated that, as more AD researchers come to 
appreciate both the value and limitations of this platform, exciting new discoveries that will 
ultimately benefit dementia patients are likely to be forthcoming. Recent advances in footprint-free 
iPSC generation, single cell and epigenome analysis technology and the ability to introduce or 
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Induced Plursipotent Stem Cells Derived from Alzheimer’s 
Disease Patients: The Promise, the Hope and the Path Ahead 
Kristine Freude, Carlota Pires, Poul Hyttel and Vanessa Jane Hall 
Abstract: The future hope of generated induced pluripotent stem cells (iPS cells) from Alzheimer’s 
disease patients is multifold. Firstly, they may help to uncover novel mechanisms of the disease, 
which could lead to the development of new and unprecedented drugs for patients and secondly, they 
could also be directly used for screening and testing of potential new compounds for drug discovery. 
In addition, in the case of familial known mutations, these cells could be targeted by use of advanced  
gene-editing techniques to correct the mutation and be used for future cell transplantation therapies. 
This review summarizes the work so far in regards to production and characterization of iPS cell 
lines from both sporadic and familial Alzheimer’s patients and from other iPS cell lines that may help 
to model the disease. It provides a detailed comparison between published reports and states the 
present hurdles we face with this new technology. The promise of new gene-editing techniques and 
accelerated aging models also aim to move this field further by providing better control cell lines for 
comparisons and potentially better phenotypes, respectively. 
Reprinted from J. Clin. Med. Cite as: Freude, K.; Pires, C.; Hyttel, P.; Hall, V.J. Induced 
Pluripotent Stem Cells Derived from Alzheimer’s Disease Patients: The Promise, the Hope and the 
Path Ahead. J. Clin. Med. 2014, 3, 1402–1436. 
1. Introduction 
Alzheimer’s disease (AD) is an incurable age-associated disorder characterized by progressive 
neurodegeneration and is the most common type of dementia, currently affecting 35.6 million people 
worldwide, which is a figure that is expected to triple by 2050 [1]. The majority of cases have  
a development of late-onset symptoms (after the age of ~65), which include personality/behaviour 
changes and memory deficits, hindering general, everyday activities [2]. This late-onset form is most 
often the sporadic form of AD (SAD), whereby increasing age is the greatest risk factor, but may also 
be associated with unknown environmental exposures, or a family history of AD. Mutations in the 
polymorphic apolipoprotein E (APOE) gene are known to increase the risk in developing late-onset 
AD and it is further believed that this complex disease involves other susceptibility genes and/or 
spontaneous mutations in unknown genes [3–5]. Genetic factors account for approximately 80% of 
the risk for AD, and genome-wide association studies (GWAS) have identified several candidate 
genes besides APOE that may be associated with late-onset disease, including ABCA7, BIN1, CD33, 
CLU, CR1, CD2AP, EPHA1, MS4A6A-MS4A4E, PICALM, HLA-DRB5-DRB1, SORL1, FERMT2, 
CASS4, PTK2B, amongst others [6–10]. However, these susceptibility loci explain only around half 
of the total genetic variance and extensive further analyses are still necessary to characterize these 
candidate genes and elucidate their association with AD risk. Less than 5% of AD patients manifest 
symptoms at an earlier stage (before the age of 65), i.e., familial AD (FAD), which is linked to 




(PSEN1) and presenilin 2 (PSEN2) [11]. PSEN1 accounts for the majority of FAD cases, whereas, 
PSEN2 and APP mutations are rarer and some FAD cases are not caused by mutations on any of 
these genes [12]. In this review, we provide an overview of the current status in the development of 
patient-specific induced pluripotent stem (iPS) cells derived from AD patients and how these cells 
may help sufferers of the disease, with respect to basic research findings, drug discovery and other 
treatments that may prospectively benefit the patients. 
2. AD Pathology and Progression 
The pathophysiology of the disease is not well understood and considering the prevalence and 
poor prognosis of AD, there has been a research priority in developing disease models for studying 
pathogenicity and to aid in development of therapeutic approaches. The difficulty in accessing brain 
samples from patients, along with the fact that only post-mortem brain analysis allows a definite AD 
diagnosis, makes iPS cells technology highly relevant in this context. That is, these cells, which are 
produced from directly reprogrammed AD patient somatic cells (e.g., dermal fibroblasts) into 
neuronal cells [13], will help us gain access to the disease in a dish, which would be much easier  
to study. 
Two pathological hallmarks are known to occur in the patient’s brain, however, it remains unclear 
which of these appear first and/or is mainly responsible for the disease’s progress [11,14].  
One hallmark is the development of senile neuritic plaques, composed of extracellular accumulation 
of Amyloid-  (A ). These are formed from the extracellular deposition of A  monomers, which 
aggregate as amyloid fibrils outside of the neurons. There is much evidence to support the Amyloid 
hypothesis, which suggests these plaques are largely responsible for extensive synaptic loss and 
neuronal death in the disease [15,16]. Tauopathy, the second hallmark, refers to intracellular 
neurofibrillary tangles (NFTs) of hyperphosphorylated cytoskeletal protein tau, which are known to 
destabilize axonal microtubules and lead to cell loss [17]. These tangles are also considered by many 
to be the leading cause of the disease and which is described as the tau hypothesis. Both the Amyloid 
hypothesis and the tau hypothesis remain leading contenders for the underlying cause of the disease. 
Staging of AD progression based on cortical neurofibrillary changes and increased expression  
of abnormal tau on postmortem brains reveal that Stage I (asymptomatic) initiates first in the 
periallococortical transentorhinal region of the temporal mesocortex located on the medial surface of  
the rhinal or collateral sulcus [18]. Stage II (asymptomatic) is evident to have spread to the layer 
pre-  or layer II of the entorhinal region and even deeper into the transentorhinal region. In stage III, 
lesions have progressed into the hippocampus, the layers pre-  and pri-  of the deep entorhinal 
layers, the temporal mesocortex and the high order sensory association areas of the temporal 
neocortex. In stage IV, the Ammon’s horn, the insular cortex and the medial temporal gyrus become 
affected [18]. Stage V is characterized by progression of lesions into the superior temporal gyrus and 
slightly affecting the premotor and first order sensory association areas of the neocortex [18].  
The peristriatic region and parastriate area of the occipital lobe are also affected. The final stage VI 
ultimately resulting in death, is characterized by progression to the parastriate area and Brodman area 




As a consequence, varying neural cells are affected, including, glia and neurons, such as  
pyramidal neurons, interneurons and specific neurons such as basal forebrain cholinergic neurons 
(BFCNs) [18–24]. In addition, extensive inflammation, glycation defects, deficiencies in the cell 
cycle in primary neurons, oxidative stress and endoplasmic reticulum stress-induced apoptosis have 
also been implicated in the disease [25–33]. 
3. Requirement for Further Basic Research into the Disease 
With the difficulties in obtaining patient brain samples and a lack of adequate animal models of  
the disease, AD research is considerably hampered. Since discovering genetic mutations within 
FAD, several transgenic animal models (mostly rodent) containing single mutations (in PSEN, APP 
and tau) have been made [34–37]. These models have explained, to some extent, the pathogenicity of 
soluble A  oligomers and the connection between amyloidopathy and tauopathy, but failed to 
recapitulate the complete pathology observed in humans. For example, the transgenic AD mouse 
model (the PDAPP mouse), which overexpresses human APP containing the Indiana mutation 
(V717F) [34], has senile plaques, age-related A  accumulation and synaptic loss, however fails to 
show the presence of NFTs. Hsiao and colleagues developed the most studied AD transgenic model 
(Tg2576 mice), which overexpresses the human APP transgene containing the Swedish mutation 
(K670N/M671L) [35]. These mice also show age-related A  deposition, an increased A 1-42/ 
A 1-40 soluble ratio, plus senile plaques, however, fail to show any neuronal loss [38]. Several other 
transgenic models have since been generated [39–42] and A  deposits and cognitive decline were 
widely reported in these models, but not NFTs or neuronal loss. The crossing of lines or production 
of double, triple or multiple mutations appear to mimic AD pathology even better, including in some 
cases, NFT-like lesions and neuronal death [43–47]. Unfortunately, the use of this multiple 
gene-strategy to induce widespread pathological features in the rodent differs considerably to 
familial human AD patients, which carry only single mutations. Furthermore, the use of these rodent 
models for pharmacological testing and evaluation of candidate drug targets has not led to the 
development of many successful drugs to date [48,49]. Staggeringly, it has been reported that 
hundreds of candidate drugs have failed during drug development [50] and it may simply be that  
our animal models are currently not optimal for either drug discovery or drug testing [49]. Emerging 
research indicates that in vitro human cell models of the disease may serve as more suitable models 
for recapitulating both the amyloid and tau hallmarks of the disease. One recent paper has reported 
that human neural progenitors cultured in vitro in 3D overexpressing either or both human APP and 
PSEN1 genes containing FAD mutations could display both increased A 40 and A 42 expression, 
increased extracellular A  deposits, increased insoluble A  and increased phosphorylated tau (p-tau) 
in a proportion of differentiated neurons. Such evidence definitely helps to pave the way for future 
research into disease modeling using human-based cell culture systems. 
Currently, there is no cure for AD or available drugs for the disease that can prevent progression  
long-term. Healthcare systems are over-loaded with dementia patients, which costs the society 
globally, around $604 billion (US dollars, 2010), making the disease a heavy economic burden on 
society [1]. With the ever-increasing age of the population and lack of highly successful clinical 




slight improvement and delay in clinical onset of the disease within patients would have a great 
economic and social impact [51]. Reliable biomarkers are also very much needed since they allow 
for the in vivo detection of AD pathology in “normal” asymptomatic individuals [51]. Imaging 
technologies (i.e., PET scans) and cerebrospinal fluid biomarkers have been developed and can 
detect certain indications of AD pathology in humans, but their predictive capacity at an individual 
level is still not reliable [11]. Moreover, these tests have been mainly used in a research environment 
and the question of whether they should be applied widely in clinics is still debatable, due to the lack 
of adequate testing in preclinical and clinical trials [11]. 
4. Hope in Modeling Alzheimer’s Disease Using Patient-Specific Induced  
Pluripotent Stem Cells 
The development of iPS cells emerged in 2006, when mouse fibroblasts were successfully 
reprogrammed into pluripotent stem cells by retroviral-delivery of four transcription factors (Oct3/4, 
Sox2, c-Myc and Klf4), which activated an endogenous pluripotent state in somatic cells [52]. These 
iPS cells resembled embryonic stem cells (ESCs) [53], both in their expression profile, their ability to 
grow indefinitely and their ability to differentiate into all cell lineages of the body, including 
ectoderm, mesoderm and endoderm [52]. These cells have the potential to contribute to chimeras and 
to be transmitted through these chimeras into the germline, further proving their pluripotency [54]. 
The same and similar sets of factors were then applied to adult human fibroblasts [55–57]. It is 
reported these cells truthfully mimic human ESCs, however the reprogramming process is thought to 
induce some disparity at both the genetic and epigenetic levels [58–61]. Viral-delivery methods have 
shown good efficiency but also result in random integration of the transgenes into the genome, 
potentially leading to insertional mutagenesis and tumorigenicity, therefore restricting its use for 
future potential clinical trials [62]. More recently, integration-free reprogramming systems, 
including episomal plasmids containing the reprogramming factors, Sendai virus, direct mRNA, 
protein and small molecules, have all been successfully used for generation of potentially 
transgene-free human iPS cells [56,63–65]. Moreover, xeno- and feeder-free culture methods have 
also helped to decrease variability between lines generated [66,67]. In addition, other cell types from 
patients have been successfully and safely used for reprogramming. As an alternate to dermal skin 
fibroblasts (acquired from surgical skin biopsies), peripheral blood mononuclear cells (PBMCs) 
(which are easy to harvest from routine peripheral blood samples) have been used to isolate T cells 
and generate human iPS cells [68,69]. One advantage is that the reprogramming of these cells can 
also be done quickly, with no need for prior expansion. These protocols therefore facilitate the 
production of human iPS cells from human somatic cells with minimal invasiveness. Together, these 
mentioned advances in production of human iPS cells might allow research to fulfill the restricted 
guidelines of Good Manufacturing Practices (GMPs) for the development of clinically-approved iPS 





5. Therapeutic Benefits 
The discovery of iPS cells is groundbreaking, as it means that patient-specific cell lines can be 
established easily. Contrary to human iPS cells, human ESCs have been surrounded by ethical 
controversy due to the use of human embryos, which is a serious problem in terms of sample 
availability and public acceptance [71]. Human iPS cells are also clinically advantageous since the 
use of autologous tissue ideally surpasses the patient’s immune rejection, contrary to the allogeneic 
barriers of human ESCs [72]. Therapeutic cloning also allows the generation of pluripotent stem 
cells that are genetically similar to patients, however this requires the destruction of donor eggs or 
embryos and still has several technical issues [73,74]. Moreover, considering the unavailability of  
in vitro human disease models, human iPS cells could help to provide large numbers of 
patient-specific neuronal cells for research and clinical objectives. Pairing of both human iPS cell 
technology and advances in genome-editing technologies may also provide more robust findings 
since isogenic cell lines could lead to the replacement of age- and sex-matched controls [75–78]. 
Experimentally, this would allow for more phenotypic findings attributed to the genetic difference 
causing the disease, which would not be influenced by individual epigenetic differences [79]. 
Moreover, disease and population heterogeneity can also be diminished due to singular-patient origin 
of human iPS cells. 
Regenerative medicine, including testing of transplantation of cells into live tissues and organs is 
ongoing for AD models of rodents, such as neural progenitor cells (NPCs) [80–86] and mesenchymal 
stem cells [87–89], but remains restricted in relation to transplantation of ESC or iPS-derived neural 
cells [80,90]. Some research, however, does suggest that implanted cells do not survive and that the 
beneficial effect may likely come from their secretion of BDNF (brain-derived neurotrophic factor) 
and GDNF (glial cell-derived neurotrophic factor) [82]. Due to improved immunocompatibility in 
the use of autologous iPS cells, there is considerable hope that differentiated progeny of 
patient-specific iPS cells may be favorable for transplantation. 
In addition, human iPS cells are already being used for drug development and screening in various 
diseases [91] to identify new and superior targets relevant for production of new drugs. In the future,  
it may even be possible to provide patient-customized cell screens from the iPS-derived cells to 
screen a panel of drugs in order to identify the most beneficial treatment plan for each individual 
patient [92]. This could have significant impact in treating this disease where patient variability is 
wide in response to certain drugs [93]. The development of patient-specific iPS cells may also help 
researchers to identify new mechanisms/biomarkers which may help lead to earlier diagnoses of the 
disease [94] as it is possible to culture early neurons or NPCs which may have underlying deficits 
related to the disease. It is also believed that earlier intervention is a key factor for a successful 
therapeutic strategy and an earlier diagnosis would be of extreme benefit to patients, as the initial 
stages of the disease could be treated whilst the patients are still early symptomatic [51]. It is crucial 
for clinical trials to target these early symptomatic patients, therefore facilitating therapeutic 
procedures to succeed in delaying, stopping or even preventing the cognitive decline [51].  
We summarize the implications patient-specific iPS cells have on basic research as well as 




Figure 1. Schematic illustration of the use of induced pluripotent stem (iPS) cells in 
relation to Alzheimer’s disease (AD). (A) iPS cells are derived from a skin biopsy from 
an AD patient and differentiated into neural progenitor cells and neurons; (B) In familial 
cases, the disease-causing mutation can be corrected by gene-editing of the iPS cells, and 
neural progenitor cells and neurons can be used for research and drug screening; (C) The 
patients can in the long run benefit from these activities by cell therapy, better diagnostic 
procedures, customized treatments and novel medical approaches. 
 
6. Induced Pluripotent Stem Cells and Neural Cell Derivatives Have Been Produced from 
Several AD Patients 
The discovery of iPS cells paved the way to model diseases by using patient-specific cells which 
can then be differentiated into disease relevant cell types. However, despite this breakthrough, there 
have been surprisingly only a handful of studies published on Alzheimer’s disease [95–102,103]. 
Induced pluripotent stem cells have now been derived from both familial and sporadic patients and 
these iPS cells have been differentiated into varying neurons and glia, which have been studied in 
respect to specific AD pathology. Here, we summarize the types of cells analyzed and the extent of 




include, duplication or mutations of APP, mutations of PSEN1 and PSEN2, in the case of familial  
AD [96–99,101,102] and mutations in APOE3/E4 resulting in both early sporadic and late sporadic 
forms of the disease [95]. It should be stated that in the case of one study [98], the APP (E693 ) 
mutation background (which is responsible for Alzheimer-type dementia [104]) showed no evident 
tau pathology and lack of fibrilization of A  peptides. Therefore not all hallmark pathologies would 
be anticipated in the iPSC-derived neurons. We also include a study where a Down-syndrome iPS 
cell line was used to model features of AD [100], since it could clearly model varying pathological 
features of the disease. 
In each article, different types of neural cells have been analyzed, which have been derived using 
various differentiation protocols (see overview of protocols in Table 2). Cortical neurons have been 
studied by both Shi and colleagues and Kondo and colleagues [98,100]. Forebrain neurons have been 
studied by Muratore and colleagues [103]. Astrocytes (GFAP+) have also been studied by Kondo 
and colleagues [98] and basal forebrain cholinergic neurons (BFCNs) have been studied by Duan and 
colleagues [95]. GABAergic neurons have been studied by Koch and colleagues [97], whereas, more 
less-defined neurons ( IIITubulin+/MAP2+) have been studied by Israel and colleagues, Yagi and 
colleagues, Liu and colleagues and Sproul and colleagues [96,99,101,102]. Whilst some protocols  
used FACS to sort and purify the neural cell populations (e.g., sorting of CD24+CD184 CD44   
neurons [96,101] and Lhx8+/Gbx1+ neurons [95]), it is without doubt that all the final cell 
populations analyzed had some degree of cell heterogeneity, as often observed by the percentages of 
positive cells stated. Three particular articles performed extensive characterization of the types of 
neurons generated. In the case of the generation of BFCNs, immunocytochemistry confirmed their 
mature features, since a large proportion expressed ChAT and VaChT, and all were found to be HB9 


















Electrophysiological recordings also confirmed these cells to express tetrodotoxin sensitive  
voltage-activated currents and have active voltage-gated calcium channels. Together, this gave very 
convincing evidence for functional BFCNs with a relatively high purity. Israel and colleagues also 
performed extensive characterization of their neurons, including electrophysiological recordings. 
However, although 90% of the neurons were IIITubulin+/MAP2+, the specific types of neurons 
produced remain unclear, with only 15% of neurons expressing VGluT1 and 8% expressing GABA.  
In the case of the cortical neurons generated by Shi and colleagues, these were found to include 
populations of both early and late born cortical neurons. These also formed functional synapses and 
expressed the glutamatergic marker PSD95 [100]. 
7. Modeling Impaired APP Processing from Patient-Specific Induced Pluripotent Stem Cells 
Reveals Considerable Variability 
Varying AD pathologies were analyzed in these articles and all articles had in common an 
analysis of extracellular A . Although some studies were unable to detect A 42 (as levels were 
below the detectable limits of the ELISA), it was striking to see how variable levels of A 40 were in 
the patient lines in comparison to the control/healthy cells. The familial lines carrying the APP 




change in A 40 levels [96], and decreased A 40 was reported in at least three other familial lines 
carrying either a mutation in APP or PSEN1 [97,98]. Furthermore, increased A 42 was only reported 
in approximately one third of the patients [95,98,101,103]. Increased A 42:40 was noted in several 
familial PSEN1 and two familial APP(V717I) patient-derived neurons and it was apparent in at least 
two studies, that this elevation was due to increased A 42 [101–103]. The variation in observed 
secreted A  products may be dependent on the neuronal subtype analyzed, as elevated A 42 was 
observed in three of the five patients, where BFCNs were analyzed [95] and in both APP (V717I) 
patients, where forebrain neurons were produced [103]. In addition, increased A 42 was also 
observed in one AD patient, where cortical neurons were analyzed [98]. It was only the 
Down-syndrome-derived cortical neurons that displayed both increased secreted A 40 and A 42 
levels [100]. In addition, in the same study, the increased A 42 was only detectable in neuron 
cultures that were older than 70 days and in APP (V717I)-derived neurons differentiated for 40–50 
days, an increase in A 42 was also detectable [103]. Interestingly, in the case of PSEN1 (E280A) a 
screening of young pre-symptomatic carriers showed increased levels of A 42 in both plasma and 
CSF [105]. These studies therefore report a wide range of results for both A 40 and A 42 and may 
suggest that it could be necessary to have long-term culture protocols in order to see potentially 
relevant phenotypes. In the case of AD patients, we also know that a variation in expression levels of 
short A  peptides exists. For example, A 42 levels have been reported to be reduced in cerebral 
spinal fluid of patients compared to controls [106,107], whereas another study reported both 
increased and decreased A 42 in AD patients carrying PSEN mutations and decreased A 40 in the 
AD patient’s cerebral spinal fluids [108]. It was also interesting to see that the APP (V717I) iPS 
cell-derived neurons had an increase in A 38 [103]. Thus, it may be important for future studies on 
AD-derived iPS cells to perform long-term neuronal cultures and compare these directly to the A  
levels in the original patient. 
The evaluation for the presence of A  oligomers has been performed in only one study to date. 
Kondo and colleagues could detect the positive expression of the A  oligomer marker, NU1 and 
expression of the low weight oligomer marker, 11A1, in their cortical neurons, specifically localized 
as puncta throughout the neurons from both a familial APP and sporadic AD patient [98]. This was 
also the case for astrocytes generated from the same backgrounds. However, A  oligomers were not 
observed in another line, which had increased extracellular A 42:A 40. Postulation for this 
difference was made by the authors to support a hypothesis that AD may be classified as displaying 
either an extracellular or an intracellular phenotype. 
APP processing was also studied in the AD iPS cell-derived cells by evaluating the effects that  
-secretase or -secretase inhibitors had on the cultured cells. In general, most studies reported a  
decrease of A 40 or A 42 following treatment of the cells with a -secretase or -secretase  
inhibitor [95–97,99–101]. One study also reported that a -secretase inhibitor decreased the 
production of APPs  [103]. As an exception, two sporadic background iPS cell lines were reported to 
have increased A 40 levels following treatment with -secretase inhibitors [95]. The authors claimed 
that this may reflect the potential differences in APP processing in early onset disease vs. late onset 
disease as these two lines were derived from patients exhibiting early onset AD, or alternately, it may 




8. Tau Processing, Cell Death and Oxidative Stress in iPS Cell Lines Modeling AD 
Levels of total and p-tau have been studied in only four of the reports to date. In one study, 
increased p-tau (Thr231) was reported in IIITubulin+/MAP2+ neurons in two familial AD-iPS 
carrying APP duplications and one sporadic AD-iPS cell line, however, this was not observed in a 
second sporadic AD-iPSC line when compared to control cells [96]. A second study has shown that  
Down-syndrome iPS cell-derived cortical neurons re-localized p-tau (Ser202 and Thr205) to the 
dendrites and cell bodies, which was not observed in the control cortical neurons, where diffuse 
staining was only observed in the axons [100]. Furthermore, this study showed that these neurons 
also secreted higher levels of total tau and p-tau (pSer396 and pThr231) over a 48 h period compared to 
the control neurons. Another study has reported both increased total tau and p-tau (Ser262), however the 
increase in pSer262 was only detectable in iPS cell-derived neurons differentiated for 100 days [103]. 
The final study revealed that no abnormal tau protein accumulation could be detected, or led to the 
production of tangles in two PSEN1-iPS cell neurons [99]. Interestingly, the tau pathology was noted 
in cells obtained from patients carrying mutations in the APP gene and not in the patient cells 
carrying PSEN1 mutations. However, given the limited numbers of studies analyzing p-tau, it may 
be difficult to conclude anything from this outcome. Again, it may be important that longer-term 
cultured cells are studied for such pathology as the latter study of p-tau on PSEN1-iPS was 
performed on neurons that were only 2 weeks old. 
Cell death has only been reported in one study, namely in the Down-syndrome iPS cell-derived 
cortical neurons [100]. Cell death in the neurons was reportedly two-fold higher compared to the 
control neurons and was considered to be due to the secretion of tau into the medium. It was 
interesting to observe that despite some studies reporting increased levels of the toxic A  peptide 
A 42, this did not lead to increased cell death. In one study, a test on increased susceptibility to cell 
death by use of glutamate-induced excitation was performed on early sporadic AD iPS cell-derived 
BFCNs which had increased A 42 revealing that increased susceptibility could be seen, however this 
was also observed in a late sporadic AD iPS cell line which did not have elevated A 42 [95], 
meaning that the levels of increased A 42 alone could not be the primary reason for this 
susceptibility to cell death. 
AD-iPS cell models may also be useful for studying oxidative stress. Whilst reports remain 
limited to date, one report showed that both familial and sporadic AD-iPS lines had increased levels 
of oxidative stress genes [98]. Elevated reactive oxygen species (ROS) was also detected both in the 
analyzed cortical neurons and astrocytes that were generated. Further research is clearly needed to 
further investigate the role of oxidative stress in these cell types compared to other AD in vitro  
cell models. 
9. Hunting for New Genes of Interest in AD 
It is apparent, that with current global gene/protein/lipid expression profiling technologies, human 
cells models of disease could be used to identify potentially new mechanisms. One recent study 
performed gene expression profiling (GEP) on immature neurons carrying PSEN1 FAD mutations 




genes were validated and three upregulated genes, namely NLRP2, ASB9 and NDP were investigated 
further by analyzing publically available GEPs performed on AD hippocampus and cDNA from the 
temporal pole of AD patients. NLRP2, a gene involved in inflammation was actually found to be 
downregulated in human AD temporal pole and no significant difference determined in the AD 
hippocampus. The gene ASB9, an ubiquitin ligase, was found to be upregulated in some AD patient 
temporal lobes, but not in the hippocampi. Finally, NDP, a gene thought to play an important role in 
CNS development was actually found to be significantly decreased in the AD patient hippocampi. 
Together, this study highlights that new genes can be discovered that could be used to pursue new 
mechanisms related to the disease, however, validation in the human brain is still an important and 
necessary measure to confirm the in vitro cell model findings. 
10. Current Use of AD-Modeling Stem Cells for Compound Screening and Drug Testing 
Only a rare cohort of studies has applied the use of stem cells derived from AD models to screen 
for novel compounds of interest or for testing recently identified drugs. These, to date, remain mostly 
restricted to mouse studies and primarily involve ESCs [109] although one study has used a non-AD 
human iPS cell model that is sensitive to A  aggregation for such purposes [110]. In one promising 
mouse study, ESCs were differentiated from a mouse model of AD (Tg2576) into an enriched  
population of pyramidal neurons and were subjected to a small molecule library to detect for 
inhibitors of A 40 [109]. Four candidate inhibitors were detected to induce over a 40% reduction in 
A 40 levels compared to controls, which included amiridine, icariin, phenelzine and progesterone. 
In the human study, healthy iPS cells were differentiated into forebrain neurons and subjected to an 
A 1-42 toxicity assay. These cells were then used to screen a GSK proprietary compound library for 
improvement in cell viability, which resulted in 19 hits, including a Cdk2 inhibitor. This field no doubt 
will grow in the coming years and will encompass AD-derived iPS cell lines which will help not only 
to discover new compounds of interest, but could also pave the way for patient-specific therapies. 
11. Production of AD Isogenic Controls for Potential Gene/Cell Therapy 
With the new revolution in gene editing, research has approached a new frontier for the generation 
of patient-specific cell therapies by correcting the patient’s diseased cells. This of course remains 
relevant for familial cases of AD and cases of known and diagnosed mutations. New techniques in 
genome-editing have been developed, which can be used to repair the particular disease causing 
mutation in a relatively simple manner by using transcription activator-like factor nucleases 
(TALENs), which are artificially produced restriction enzymes that specifically detect and bind to a 
desired nucleotide sequence in the genome and which initiate a double stranded break in the DNA. 
Homologous DNA fragments with the correct sequence need to be provided, so the cells can use 
these as a template to generate the correct sequence and thereby replacing the mutation. This method 
facilitates the generation of isogenic controls and control cell lines, which are absolutely identical to 
the patient iPS cells except for the repaired disease-causing mutation. Another such method is 
facilitated by clustered regularly interspaced short palindromic repeats (CRISPRs). This method is 




mutations in specific cell types has recently been performed and has even resulted in the correction of 
the disease in new progeny (in mice) when targeted in oocytes [111–117]. Some of these involve 
correction of frame-shifts [116], but it may also be possible to correct for single base pair mutations. 
One of the considered benefits of TALENs and CRISPRs is that there may be no residual ectopic 
sequences at the site of correction, although this depends on the strategy used for selecting for 
targeted clones, which may involve insertion of a selectable cassette. One potential drawback with 
this strategy is the potential to induce off-targeting genetic changes to other genomic sites that have 
either a similar or the same genetic sequence as that of the targeted sequence. The potential of 
targeting these other sites of course may lead to potential alteration in other genes throughout the 
genome. Such off-targeting has been observed in a handful of these studies [112,115,117], and 
therefore improvements in the design of the TALENs and CRISPRs for only the desired recognition 
target site may be needed before the next step to clinical transplantation is taken. To date, there is no 
literature on successful correction of an AD phenotype using either of these technologies; however, 
this area will no doubt be the focus of the next generation of research. Not only will it be important 
for the generation of healthy patient-specific cells that could be potentially transplanted, but 
corrected cell lines will form the ideal control cells needed for a more accurate interpretation of the 
AD phenotype in the diseased cells, due to the variation observed both between patients, but also 
between healthy age-matched controls. 
12. Current General Limitations of Use of iPS Cells for Disease Modeling 
There are several general limitations regarding the generation of iPS cells and differentiation into 
specific cellular subtypes, which are challenging and not very well understood. General limitations 
are caused by the limited understanding of the nature of iPS cells themselves and by their 
differentiation potential. In particular, the differentiation into a defined neural cell population is 
currently quite challenging. This is mainly because the developmentally relevant proteins and 
transcription factors, which are needed to mimic differentiation into a specific neural cell type, are 
not yet fully understood. 
One general problem of using patient-specific iPS cells is the different epigenetic make-up and 
exposure to diverse environmental conditions every individual is facing. These differences have 
implications on comparative studies involving different patient-specific iPS cells, even between 
patients carrying the same pathological mutation. Despite these inter-patient differences, it has also 
been described that the reprogramming event itself can result in significant clone-to-clone variations, 
resulting in non-desired experimental background noise and even generation of non-disease related 
artifacts [118]. Currently, most studies involving the generation of patient-specific iPS cells involve 
the use of age- and gender-matched controls, which results in comparing epigenetically mismatched 
iPS cells. Isogenic controls generated via TALEN or CRISPR gene editing will be much more ideal 
for the study of disease-related cellular phenotypes and for pharmacological screens, which would 
help overcome this limitation. 
Another general challenge is that only some of the aspects of a differentiated, aged cell can be 
restored to the state of pluripotency following reprogramming. Some of these may include an 




pertaining to the original cell persist following reprogramming, such as acquired mutations, DNA 
damage, epigenetic changes and protein aggregation [121–123]. To date, it is still unclear what effect 
this has on the overall reprogramming efficiency and subsequent differentiation of iPS cells into the 
desired mature cell types. Moreover, iPS cells seem to retain an epigenetic memory, which makes 
them preferentially differentiate into their tissue of origin [124]. 
13. Hurdles Needed to be Overcome in Order to Recapitulate AD Faithfully in a Dish 
One hurdle that needs to be overcome in order to accurately mimic the disease in vitro is the 
ability to produce the most relevant neurons for study. In order to develop in vitro models that can be 
used to screen for novel compounds for possible future treatments, it may be important to focus on 
areas of the brain that are affected earliest, and attempt to model the disease even before the 
symptoms first arise. One hope may be that iPS cells may be able to recapitulate earlier stages of the 
disease. Since Alzheimer’s disease pathology can first be detected in the entorhinal cortex, it might 
therefore be of interest to focus on differentiation of iPS cells into cell types affected in this area  
of the brain, namely pyramidal neurons with glutamate excitation and the varying GABAergic 
interneurons. It appears that it is the long projection neurons that are most vulnerable to  
developing pathology [18]. Short-axon projection cells such as spiny stellate cells apparently resist 
the pathology [18]. Short-axon local circuit cells also avoid pathology with the exception of the 
axo-axonic cells. It is particularly interesting that the vulnerable neurons are either un-myelinated or 
have only a thin sheath of myelin, as for e.g. heavily myelinated Betz cells and Meynert pyramidal 
cells also resist the pathology [18]. It may even be possible in the future to treat pre-symptomatic 
patients by large-scale screenings of the population. This would of course require earlier diagnostic 
tools for the disease for patients, which are still in general lacking, but of which several efforts are 
being undertaken [125–128]. In the case of the hippocampus, it is the CA1 neurons from the temporal 
medial lobe that are heavily affected by the disease, and ideally cross-comparisons with in vitro 
produced CA3 neurons, which are not affected as severely as the CA1 neurons would be ideal, 
however recapitulating these neurons in vitro is no easy task. In the CA1 region, which includes 
pyramidal neurons of at least three subtypes, there is also the supportive GABAergic interneuron 
population of which at least 20 different types are known [129]. Calretinin positive interneurons  
and somatostatin/parvalbumin positive interneurons (bistratified interneurons) in the CA1 are  
both affected in earlier stages of the disease [20]. In order to develop such protocols, a better 
understanding of the development of these neurons in vivo is required in order to mimic this process 
ex vivo. In the case of cortical pyramidal neurons, these are produced from progenitors located in the 
neocortical germinal zone in the dorsolateral wall of the telencephalon [130]. One recent report has 
shown the successful generation of cortical pyramidal neurons from both human ESC and iPS cells, 
which could successfully innervate the mouse brain [131], indicating there may be a strong future for 
developing efficient protocols for these cell types. In the case of the interneurons, these are generated 
in the ventral telencephalon and migrate to the neocortex [130]. Furthermore, although some markers 
can be used to distinguish pyramidal neurons from interneurons [129], additional markers of these 
neurons, in particularly, surface-specific markers are needed in order to improve selection and 




several neuronal subtypes as mentioned above, most differentiation protocols focus on the derivation 
of specific neural subtypes, which are mostly affected by the disease. These current protocols achieve 
in some cases good enrichment of a certain neural subpopulation (see Table 2). Despite the varying 
outcomes of different protocols there is also the problem of different results from the different iPS 
cell clones from the same patient cell line. Furthermore, neural differentiation is a complex scenario, 
which is dependent on internal and external morphogenic cues, gene expression and transcription 
factor activity in a spatio-temporal manner [132]. 
Another significant hurdle is overcoming the lack of knowledge of the types of cells that are 
currently being used for analyses. Heterogeneity itself may not be a problem, if we can re-create the 
same heterogeneity observed in the specific regions of the brain affected. However, several different 
approaches and protocols currently exist for differentiation of ESC and iPS cells into cortical  
neurons [100], BFCNs [95], other neurons like dopaminergic neurons mostly affected in Parkinson’s 
disease [133] and astrocytes [134,135]. Some of these differentiation protocols may show variation 
in differentiation efficiency between cell lines, but even from experiment to experiment using the 
same clone but at different time points [136]. 
Many of the differentiation protocols in the AD iPS cell papers to date have produced neurons 
which are IIITubulin+ and MAP2+ [95–97,99,101] using neuronal induction factors, such as, 
BDNF, GDNF, N2 and B27 (see Table 2). Although it is promising to see phenotypic hallmarks of 
AD recapitulated at a cellular level using these differentiation protocols, there remain variations in 
the phenotypes created. This may be due to the differences in timing of differentiation, some degree 
of cell heterogeneity and the lack of clear understanding of the types of neurons generated. It 
therefore remains difficult to make a direct comparison of the conducted approaches and analyses of 
AD iPS cells. For example, it might well be possible that the observed elevated expression of 
stress-related genes and ROS as well as the formation of A  oligomers found in the SATB2+ and 
TBR1+ neurons is only observable in this specific sub-population and not detectable in other 
IIITubulin+ and MAP2+ neurons. 
In conclusion, there are many differences amongst the final neural cell population generated  
by the differentiation protocols, as well as in the final composition of neural subtypes generated.  
The reproducible detection of an AD related phenotype is very much dependent on the generation of 
predictable and fully matured brain region-specific neurons. Therefore, it would be relevant to 
combine the phenotypic observations so far gathered and routinely check all AD iPS cell models for 
the presence or absence of all of these disease hallmarks. 
Even though tremendous advances have been made in the generation of AD iPS cells and 
subsequent differentiation into cortical neurons, other neurons and glia, the analysis of the cellular 
disease phenotype is still the most challenging aspect of this cellular model of AD. One of the most 
profound problems is the lack of reliable reproducibility of the differentiation protocols and the 
clonal variation even amongst iPS cell clones from the same patient, which could be responsible for 
the varying outcomes in the results. One explanation could be the incomplete reset of the cellular 
epigenetic landscape to the pluripotent state and current limitations of differentiation protocols, 
which fail to produce functional and specific neuronal subtypes. This could possibly be contributing 




One of the sporadic AD iPS cell lines showed no phenotype whatsoever, which could mean that there 
are either unknown phenotypic hallmarks related to AD, or simply, in this case, the neurons were not 
matured enough to display a disease phenotype. The lack of mature neuronal differentiation is 
supported by the findings that another APP related mutation (APPV717I) showed a marked increase 
in A 42 levels, which increased during the course of the differentiation protocol. A comparative 
analysis of APP and APP cleavage products starting from day 9 until day 100 clearly showed that a 
significant increase of A 42 was not detectable before day 40 during the terminal differentiation 
protocol [103]. These two approaches underline the necessity of optimized differentiation protocols 
in terms of duration and timepoint of analyses of the disease phenotype. Another plausible 
explanation for the absence of a cellular SAD phenotype could be due to altered A  clearance in the 
patients. It has been shown by several groups that astrocytes may contribute to the A  clearance by 
restricting the inflammatory response in the brain [137,138]. Interestingly, APOE4, which is a risk 
factor for SAD, is expressed in astrocytes implying an important functional role of these cells in the 
neurodegenerative progression in the patients [139]. Microglia certainly also play an important role 
in A  clearance [140]. These cell types and their impact in AD in vitro systems remain largely 
unexplored. Nevertheless, it was also possible to observe an increase in phosphorylation of tau 
(Thr231) and an increase in GSK3 beta activity, in the two APP duplication iPS cell models and in one 
of the sporadic AD iPS cell models [96]. The use of more defined neural subtypes could be more 
beneficial in dissecting the underlying causes of AD progression. These are also encouraging 
findings for validation in using these cellular models to identify cellular changes in AD. Different 
groups have reported the production of AD iPS cells and used different approaches to perform neural 
differentiation and analyses of these cells. This makes it difficult to establish a common cellular 
phenotype to set as a baseline for AD iPS cell models. However, this is very necessary in order  
to ensure that a lack of phenotype or a novel phenotype is not caused by insufficient neural  
subtype differentiation. 
Overcoming the variation in the AD pathologies of analyzed AD-iPS-derived neural cells is 
important. Whether this variation is reflective of patient variability or cell line variability remains 
unclear. However, one way to overcome this problem would be to make sure at least three clones of 
each patient are produced, and that these produced identical phenotypes. It may also be important to 
have patient medical history that can verify pathology observed when first analyzing results. It is 
evident that not all iPS cell clones recapitulate results, and those that do not should be discarded or 
eliminated from analyses and interpretation. It is also clear that our lack of understanding of the cell 
types that are being analyzed could impede dramatically on our results and interpretations of them. 
This is a difficult task to overcome, as the complexity of the brain is colossal. It requires significant 
years of basic research into identifying the development cues of the neurons and neural cells of 
interest for the disease. Although, a recent promising study has revealed that 3D brain structures can 
be recreated in vitro from differentiated human embryonic stem cells [141], revealing that it may be 





14. Future Induction of an AD Phenotype Using Components that Introduce Cellular Stress 
Issues in resetting the biological clock during reprogramming could quite possibly explain the 
difficulties observed in obtaining ideal phenotypes in some AD iPS cell models. This does not come 
as a surprise since AD is a disease in which not only the malfunction of AD related genes, but also the 
aging of cells, as well as the whole organism is involved. This potentially makes the fundamental use 
of in vitro AD iPS cell systems questionable. However, some research groups have started to use 
cellular stresses to provoke accelerated aging in in vitro produced neural cells and have even 
introduced systems, which overexpress genes related to premature aging. This could lead to the 
development of shorter differentiation protocols, which would be of extreme benefit both for 
researchers and for the eventual benefits for patients. 
In one study, it was possible to alleviate A  oligomer-induced cellular stress using docosahexaenoic 
acid (DHA) in neurons derived from iPS cells [98]. Since it is known that oxidative stress is a key 
hallmark of Alzheimer’s disease and accelerates the diseases progression [142], ROS could be useful 
in triggering a disease phenotype in SAD iPS cell-derived neurons where no disease phenotype is 
observable or to accelerate the cellular disease and aging process itself. Mitochondria generate 
energy via oxidative phosphorylation and ROS is the byproduct for this energy generation.  
This observation led to the free radical hypothesis of ageing, which makes ROS species responsible 
for accumulative cellular damage over lifetime [143]. Currently, aerobic metabolism and the 
corresponding generation of ROS is still the most widely accepted cause of ageing, but little is 
known about the intracellular targets of ROS and how oxygen manipulation of these influences 
lifespan [144]. Another widely used ROS species is hydrogen peroxide (H2O2), which belongs to the 
exogenous ROS species, causing mostly DNA damage and which induced an apoptotic cellular 
response at high doses. The usage of this kind of stressor has therefore a lasting effect due to the 
DNA damage; however, it is not clear if these mutations directly cause a phenotype. On the other 
hand, a recent study showed that exposure of rat NPCs to H2O2 may actually be beneficial and induce 
neurogenesis [145], which is in contrast to the proposed damaging effect H2O2. This report also 
showed that low dosages of H2O2 induced proliferation of rat NPC cells, and even modified their 
differentiation potential towards an oligodendrocyte fate. This is a particularly interesting aspect 
since inflammation processes in the brain caused by H2O2 have been reported [146]. Unfortunately, 
the preferred differentiated neural subtype by low dosage exposure to H2O2 are oligodendrocytes, 
which would not be useful in replacing the degenerated pyramidal, cortical or cholinergic neurons, 
which are mostly affected by neurodegeneration in AD. Another technique, which is widely used to 
stress cells, includes serum starvation (which in the case of neural cells involves withdrawal of B27). 
This has been shown to robustly induce autophagy and neural death [147] and therefore a reduction 
of B27 in the neural media could be used to mimic stress and induce autophagy. Currently, none of 
the AD iPS cell published studies have used ROS species or serum starvation to provoke a more 





15. Induction of an AD Phenotype by Manipulating the Gene Expression of Age  
Inducing Genes 
Another possible approach to mimic ageing in a dish could be to activate or repress key regulatory 
genes involved in the ageing process. A recent report revealed that overexpression of progerin 
(which when occurs in humans, causes Hutchinson-Gilford progeria) in an iPS cell model of 
Parkinson’s disease resulted in an accelerated aged phenotype [148]. This cell model revealed 
pronounced dendritic degeneration, progressive loss of tyrosine hydroxylase expression, enlarged 
mitochondria and Lewy-body-precursor inclusions, which are indicative to the fact that the induced 
ageing was successful. 
Other strategies to induce accelerated aging could involve RNAi-mediated knockdown of 
relevant targets such as sirtuin 1 (SIRT1), repressor element 1-silencing transcription factor (REST) 
or vacuolar protein sorting 41 (VPS41). Further genes of interest have been identified in C. elegans, 
which are also involved in autophagy lysosomal trafficking and shown to convey neuroprotective 
features. Amongst these are autophagy related 7 (ATG7) and PDZ domain containing  
family, member 1 (GIPC) [149]. SIRT1 has been shown to be involved in healthy ageing and 
longevity [150,151] and appears to be neuroprotective in AD [152]. Moreover, REST induces the 
expression of stress response genes and is neuroprotective [153]. VPS41 is involved in lysosomal 
trafficking and overexpression of this protein has been shown to enhance clearance of misfolded 
alpha synuclein [154]. A knockdown of VPS41 appears to hinder the lysosomal complex function 
and formation and accelerate accumulation of toxic misfolded proteins including A . In particular, 
genes involved in autophagy could be of interest since the clearing of misfolded A  is believed to 
occur via autophagy and a downregulation or ablation of genes in this pathway could induce ageing 
as well as enhance the AD phenotype related to autophagy. Other studies have implied an important 
role for Beclin1 in autophagy and even APP processing [155], which makes this gene an interesting 
target as well. Clearly a systematic knockdown approach via RNAi targeting components of the 
autophagy and lysosomal pathways would be an amenable approach for identifying suitable targets 
that could induce ageing and accelerate the cellular pathology of AD iPS cell-derived neurons. 
16. Conclusions and Future Perspectives 
There are obviously still some hurdles that need to be overcome before science can faithfully 
recapitulate AD in a dish using iPS cells that might provide benefit to AD patients. It also remains to 
be seen if cell therapy by transplantation of AD-corrected iPS-derived neural cells could be of benefit 
to patients, by assessing integration of grafts into the brain and/or other related effects such as 
inflammation, or if AD-iPS derived disease models could help to deliver new and more advanced 
therapies to the patients. It is clear from the studies performed so far that more research is required. In 
keeping perspective, this research is aimed for the development of new and better medicines that can 
treat the disease long-term, rather than medicines that apply temporary brakes on it, and ultimately 
we are searching for a cure, which may totally alleviate the disease. The benefits to the community 
both at a societal level, but also at an economical level, are tremendous and would positively benefit 




What is evident, however, is that there is a clear step towards translational medicine for 
pluripotent stem cells, and in particular for treatment of disease. This is most striking in the case of 
other neurodegenerative disease such as Parkinson’s disease [156,157]. Ultimately, human iPS cells 
will help to contribute detailed knowledge on AD mechanisms and might even lead to breakthroughs 
that could allow clinicians to develop earlier diagnoses, or be used for patient individualized 
medication and potentially for future cell transplantations. In considering how far we have come with 
the advancement of iPS technologies, and in the few years since the implementation of the 
technology, it is likely that the path ahead will unveil potentially significant advances in the 
treatment of the disease. 
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iPSC-Based Models to Unravel Key Pathogenetic Processes 
Underlying Motor Neuron Disease Development 
Irene Faravelli, Emanuele Frattini, Agnese Ramirez, Giulia Stuppia, Monica Nizzardo and 
Stefania Corti 
Abstract: Motor neuron diseases (MNDs) are neuromuscular disorders affecting rather exclusively 
upper motor neurons (UMNs) and/or lower motor neurons (LMNs). The clinical phenotype is 
characterized by muscular weakness and atrophy leading to paralysis and almost invariably death 
due to respiratory failure. Adult MNDs include sporadic and familial amyotrophic lateral sclerosis 
(sALS-fALS), while the most common infantile MND is represented by spinal muscular atrophy 
(SMA). No effective treatment is ccurrently available for MNDs, as for the vast majority of 
neurodegenerative disorders, and cures are limited to supportive care and symptom relief. The lack 
of a deep understanding of MND pathogenesis accounts for the difficulties in finding a cure, 
together with the scarcity of reliable in vitro models. Recent progresses in stem cell field, in 
particular in the generation of induced Pluripotent Stem Cells (iPSCs) has made possible for the 
first time obtaining substantial amounts of human cells to recapitulate in vitro some of the key 
pathogenetic processes underlying MNDs. In the present review, recently published studies 
involving the use of iPSCs to unravel aspects of ALS and SMA pathogenesis are discussed with an 
overview of their implications in the process of finding a cure for these still orphan disorders. 
Reprinted from J. Clin. Med. Cite as: Faravelli, I.; Frattini, E.; Ramirez, A.; Stuppia, G.;  
Nizzardo, M.; Corti, S. iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying 
Motor Neuron Disease Development. J. Clin. Med. 2014, 3, 1124–1145. 
1. Introduction 
Motor Neuron Diseases (MNDs) are incurable neurological disorders characterized by the 
progressive loss of pyramidal cells in the primary motor cortex (upper motor neurons, UMNs) and/or 
cells in the anterior horns of the spinal cord and their homologues in the motor nuclei of the 
brainstem (lower motor neurons, LMNs). Concerning their epidemiology, the prevalence of MNDs 
accounts for about 5–7 cases in every 100,000 people, with an annual incidence of approximately 
two new cases per 100,000 people [1]. MNDs are not equally distributed between genders, being 
more common in males, with a male to female ratio of 2:1 [1]. There is a great variability in life 
expectancy of patients affected by MNDs, for reasons that remain unknown for the most part: death 
usually occurs within 3–5 years after the onset of symptoms (such as for amyotrophic lateral 
sclerosis—ALS), but cases with either a slower (i.e., spinobulbar muscular atrophy—SBMA) or a 
more rapid course have been described (i.e., spinal muscular atrophy—SMA type 1) [2]. 
The biological substrate of MNDs is responsible for the extremely disabling clinical phenotype, 
characterized by progressive weakness with muscle wasting, eventually leading to paralysis and 
death, mostly secondary to respiratory insufficiency [3]. No effective therapy is currently available 




MNDs highly impact on patients’ quality of life: they are usually dependent on the use of respiratory 
aids and wheelchairs, requiring 24-h assistance [4]. 
MNDs are usually differentiated relating to the subset of motor neurons that are mainly involved 
in the disease course. Upper motor neurons are especially affected in primary lateral sclerosis (PLS) 
and hereditary spastic paraplegias (HSP). On the other hand, SMA, progressive muscular atrophy 
(PMA), SBMA and hereditary motor neuropathies (HMNs) involve mainly lower motor neurons. 
ALS is the most common adult form of MND, characterized by the simultaneous degeneration of 
UMNs and LMNs. ALS can be divided into a sporadic form (sALS), representing 90%–95% of all 
cases, and a familial form (fALS), accounting for the remaining 5%–10% of cases [5]. It is well 
accepted that genetic factors play a determinant role also in the sporadic ALS cases [6]. The sporadic 
form presents a rather uniform distribution in Western countries: in Europe and North America, the  
incidence is 1.5–2.7 cases per 100,000 persons every year [5], with a prevalence of 2.7–7.4 cases per 
100,000 persons [7]. The incidence increases considerably every decade of life, reaching a peak at  
74 years of age, and then progressively decreases [8]. The lifetime risk to develop ALS is 1:350 for 
males and 1:400 for females [9]. The age of onset is around 50–60 years, and the mean survival of 
ALS patients is 2–3 years after the diagnosis. 5%–10% of patients affected by ALS have a familial 
history of MNDs (fALS), in most cases presenting a mendelian autosomal dominant pattern of 
inheritance [6]. The clinical phenotype of fALS is usually considered indistinguishable from sALS. 
Nevertheless, fALS is characterized by an equal male to female ratio, a more precocious age of onset 
and, oftentimes, a longer life expectancy. At present, more than 16 loci have been associated with 
ALS or other atypical forms of MNDs, and two loci have been associated to ALS with frontotemporal 
dementia (ALS-FTD) [6]. In about 60% of fALS patients, a causative gene can be identified. 
Mutations of C9ORF72 are found in 40% of cases, followed by mutations of superoxide dismutase-1 
(SOD1) (20% of cases), TARDBP (4% of cases), FUS (4% of cases) and other genes [10]. 
The group of SMAs comprises a series of LMN disorders characterized by extreme heterogeneity 
in both clinical presentation and genetic condition. 
The most prevalent forms of SMAs go under the name of “Proximal Spinal Muscular Atrophy”, 
often referred to simply as “SMA”, and are caused by genetic mutations on chromosome 5q (hence  
the term “5q-SMA”). SMA is the most common MND during childhood: with an incidence of  
1:6000–1:10,000 live births and a carrier frequency of 1:40–1:60, it is the leading genetic cause of 
infantile mortality [11,12]. SMA selectively affects LMNs, being characterized by the degeneration of 
alpha MNs in the ventral horns of the spinal cord and MNs in the motor nuclei of cranial nerves in the 
brainstem. SMA patients exhibit a progressive and symmetric involvement of various muscle 
groups, which present hypotonic, hyposthenic and atrophic, with a preferential distribution in the 
proximal compartments of the lower limb. Based on the degree of severity of the disease, different 
forms of SMA can be identified (types I–IV). Children with type I SMA, the most severe and 
common form, are affected at birth or, at the latest, by the age of 6 months, thus never becoming able 
to sit [13]. The other types of SMA present a progressively milder phenotype. Life expectancy is 
extremely variable in the spectrum of the different forms of the disease, ranging from less than  
2 years of age in type I, to an unaffected lifespan in type IV. The genetic condition accounting for the 




mapped in 5q11.2–q13.3 [14]. In the human genome, two almost identical copies of SMN are 
localized on chromosome 5q13: the telomeric SMN1 gene and its inverted centromeric homologue 
SMN2. SMN2 only differs from SMN1 for five base pair changes, of which a C to T substitution at  
+6 of exon 7 (c.840C > T) is the only nucleotide change in the coding region [15]. This is localized in 
an exonic splicing enhancer, thus causing an alternative splicing of pre-mRNA of SMN2 that 
excludes exon 7 from the majority of SMN2 transcripts. The result is the production of 10%–50% of 
the full-length functional protein and 50%–90% of a truncated, non-functional and unstable 
transcript (SMN 7) [16]. All individuals affected by SMA retain a variable number of copies of 
SMN2, which correlates to the severity of the disease. The exact functions of the SMN protein, as 
much as the reasons accounting for the disruption of MNs in SMA, are yet to be fully disclosed. 
Further, less common forms of SMAs recognize defects in genes other than SMN1 and  
present with early denervation weakness, but different clinical symptoms than those stated above, 
including joint contractures (infantile SMA with arthrogryposis—XL-SMA), distal rather  
than proximal weakness (distal SMA or HMNs), diaphragmatic paralysis (SMA with  
respiratory distress 1—SMARD1), and pontocerebellar degeneration (SMA with pontocerebellar 
hypoplasia—SMA-PCH) [17,18]. 
The inaccessibility to the cell type of interest majorly involved in MNDs and the lack of 
established models for the elucidation of pathogenetic mechanisms underlying such disorders 
represent a fundamental obstacle for progresses to be made in the field of therapies development.  
In order to resolve these issues and make durable discoveries, new strategies should be taken into 
account. In this respect, stem cell technology may represent a valuable solution. 
Induced pluripotent stem cells (iPSCs) are originated from patients’ differentiated cells 
(oftentimes fibroblasts) through the use of reprogramming factors, first identified by Yamanaka in 
2006 [19]. IPSCs are able to differentiate towards cell types of the three germ layers in vitro and give 
rise to teratomas in vivo. They can be identified with stem cell markers and resemble embryonic stem 
cells (ESCs) both in morphology and behaviour, but they are not burdened by ethical concerns [20]. 
IPSCs are patients’ specific cells, thus avoiding more likely immunoreactions if transplantation 
strategies were taken into account. Moreover, iPSCs can be produced in substantial amounts, 
providing an optimal cell source for regenerative therapeutic approaches. The possibility of 
differentiating iPSCs towards any cell type of interest represents a great advantage in the context of 
MNDs, which affect MNs rather selectively [21]. Indeed, in recent years, protocols for the 
differentiation of iPSCs towards MNs have been developed and optimized, since obtaining human 
relevant cells appears pivotal for the development of in vitro models that recapitulate mechanisms 
responsible for the establishment of pathologies [21]. Obtained results could be crucial in guiding the 
process of finding an effective treatment for ALS, SMA and other MNDs. Fibroblasts can be easily 
obtained from skin biopsies and grown in culture, thus making the premises for a simple disease 
model [22]. Furthermore, MNDs with a genetic background may benefit from in vitro models 
obtained from iPSC-derived differentiated cells, like iPSC-MNs, exhibiting the affected  
genotype peculiar to the disease. So far, the great potential of iPSCs led to the generation of 
patient-specific cells for several neurodegenerative disorders, including Alzheimer’s Disease [23], 




considerations suggest that iPSCs could be the key to unravel pathogenetic processes behind human 
diseases which are challenging to study in the animal models for their specific features (Figure 1). 
Obtained results may pave the way to the development of effective treatments targeting specific 
disease mechanisms. Here, we review the recent advances in the field of iPSCs as regards their use in 
modeling and studying MNDs, with a focus on ALS and SMA pathogenesis. 
Figure 1. iPSC-based platforms for motor neuron disease modeling. Patients-derived 
somatic cells can be reprogrammed into iPSCs. Obtained cells can be differentiated 
towards the subtype of interest and studied in their development. Further analyses 
include the investigation of the transcriptional profile and the elucidation of molecular 
pathogenetic pathways. Human iPSCs are also a valuable tool for the identification of 
molecular targets and the screening of potential therapeutic compounds. 
 
2. Modeling and Studying Amyotrophic Lateral Sclerosis Using IPSCs 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with adult onset. 
Symptoms reflect the dysfunction and death of motor neurons (MNs) and are characterized by 
muscular weakness and atrophy progressively leading to paralysis [27]. Upper and lower MNs 
appear to be particularly vulnerable to the disease process since they are the most relevant affected 
cells in the context of a relative sparing of other neuronal populations [28]. Also among MNs, 
specific subtypes of differently affected cells can be identified: oculomotor and Onuf’s nucleus MNs 
proved to be much more resistant to the disease process [29]. Reasons accounting for the selective 
vulnerability of MN populations and, in general, for mechanisms of neurodegeneration remain poorly 
understood. Several pathogenetic mechanisms have been taken into consideration, including 
impaired RNA metabolism, aberrant proteic misfolding, mitochondrial alterations, defective axonal 
transport, excitotoxicity and local inflammation [30,31]. The discovery of causative genes has given 
new inputs to the field. After the first report of ALS causative mutations in the gene encoding the 
Cu/Zn-dependent antioxidant enzyme superoxide dismutase-1 (SOD1) [32], researchers have started to 




of the oxidative damage). The identification of C9ORF72 repeat expansion as the major factor 
responsible for ALS onset in the familial forms has focused attention on the causative role  
of alterations in RNA metabolism [33–35], a line of research supported also by the involvement  
of mutations in TARDBP and FUS genes (encoding DNA/RNA binding proteins) in ALS 
development [36]. 
The establishment of human cell platforms has allowed for the first time to test in vitro some of 
these pathogenetic hypotheses and to model and investigate early disease mechanisms. Eggan’s group 
pioneered the field in 2008, when they investigated the potential of human MNs derived from 
embryonic stem cells (ESCs) to provide key data on ALS pathogenesis [37]. ESC-derived human 
MNs were cultured on primary cortical glia obtained from SOD1 mutated mice. After 10 days in 
culture, a significant decrease in MN number could be observed in a time-dependent manner, thus 
suggesting a strong implication of non-cell autonomous mechanisms in ALS onset. Moreover, they 
tested if the same toxic glial effect could be detected with human interneurons and they found that the  
glia-induced toxicity is rather specific for MNs: interneurons treated for 20 days with SOD1G93A  
glia-conditioned medium appeared fully preserved. Complementary, MNs co-cultured with 
SOD1G93A mouse embryonic fibroblasts remained unaffected, thus indicating that the toxic effect is 
specifically related to the presence of astrocytes. Oligonucleotide arrays were exploited to identify 
genes differentially expressed in mutant glia. After these analyses, Di Giorgio and colleagues 
focused their investigation on the role of prostaglandin D2, which resulted responsible for a 
significant decrease of MN survival in culture. This work proved the advantages to use human cells 
for in vitro disease studies and provided the basis for further investigations on ALS pathogenesis. 
The same research group proceeded beyond these results with a recent study aiming to elucidate 
pathways which are impaired by the expression of mutated SOD1 in human MNs [26]. Kiskinis and 
colleagues derived iPSCs from skin fibroblasts of ALS patients; these cells harbored the  
patient-specific genetic combination, thus providing a precious tool to model the development of 
human pathology. Human iPSCs were differentiated towards MNs and compared with two healthy 
human iPSC lines. Diseased MN number decreased in culture in a time-dependent manner, a process 
that did not affect the non-motor neuronal cells present in the plate. Both control and SOD1 iPSC 
lines presented a further reduced survival when co-cultured with SOD1 glia, but this effect was much 
more amplified in the latter case implying the presence of a strong cell-autonomous component in 
ALS pathology. SOD1 MNs presented also an unhealthy morphology with shorter processes and 
reduced soma, thus summarizing the changes observed in the human pathology. Importantly, 
ZFN-mediated gene correction of SOD1 mutation resulted in the rescue of both altered morphology 
and reduced lifespan. Data from RNA-seq of SOD1 MNs highlighted a strong down-regulation of 
genes related to mitochondria functions and protein translation. Further analyses showed impairment 
in mitochondria motility in addition to an enrichment of mitochondria number located in neuronal 
processes. A substrate of ER stress has been found in healthy human MNs, which could be related to 
the cell size; this result is in line with the well-known early degeneration of largest alpha MNs in ALS. 
A combination of oxidative and ER stress and the up-regulation of the unfolded protein response 
(UPR) have been shown and could be additive causative mechanisms of neuronal toxicity. Moreover, 




the report of the intrinsic hyperexcitability displayed by iPSCs-derived MNs from ALS patients [38]. 
Finally, comparison between human-iPSCs derived C9ORF72 and SOD1 lines led to the discovery of 
common pathways downstream of these mutations related to enhanced oxidative stress response and 
decreased mitochondria activity. 
C9ORF72 iPSC lines were obtained by Sareen et al. to investigate the pathological processes 
underlying the most common genetic form of ALS [39]. They investigated whether the toxicity 
linked to the repeat expansion in C9ORF72 was due to either gain of function or loss of function or 
both mechanisms. To address this question, iPSCs lines were developed from different C9ORF72 
hexanucleotide expansion carriers affected by ALS and/or frontotemporal lobar degeneration 
(FTLD). Southern blot analyses were performed on derived MNs assessing the expansion and also 
highlighting differences among patients, which in some cases could be reflected in more severe 
forms of the disease. FISH analyses detected the presence of RNA foci within C9ORF72-ALS MNs 
(and also in the neuronal progenitors and astrocytes), in line with previous data from patients’  
tissues [40]. Observed RNA foci co-localized with Pur-alpha and hnRNAP1 but not with FUS or 
TDP43, responsible for other genetic forms of ALS. However, hnRNAP1 is known to interact with 
TDP43 [41] and its involvement in the disease process could suggest an indirect connection between 
C9ORF72 and TDP43 ALS forms. This work provided data in the direction of a “gain of function” 
mechanism linked to C9ORF72 hexanucleotide expansion. It has been shown that the mutated allele 
is usually transcribed and its downregulation using antisense oligonucleotides did not affect cell 
viability, but resulted in the correction of cell transcriptional profile. The specific pathogenetic role 
of the involvement of different RNA binding proteins interacting with RNA foci needs further 
investigations and could represent a common causative mechanism shared by different forms of 
ALS. Indeed, the aberrant cytoplasmatic aggregation of TDP43 represents a rather common 
pathological hallmark both in familial and sporadic ALS. Processes leading from the cytoplasmic 
aggregation to the selective MN loss appear to be exquisitely human and not easily detectable in 
animal models, where overexpression of TDP43 is ubiquitously provoked. Indeed, the majority of 
cell platforms and animal models considered in ALS pathogenesis studies relied on the 
overexpression of TDP43 in nonhuman or nonneuronal cells. Reason underlying the selective 
vulnerability of MNs to the disease process could be misled as well as the investigation of key 
molecular events that cause the human disease [40]. The establishment of human iPSC-derived 
platforms has allowed significant advances in the field. Bilican et al. generated iPSCs from a patient 
affected by ALS carrying the TDP43 M337V mutation and used them as a tool to investigate TDP43 
pathology in human neuronal cells [42]. No differences in the differentiation and maturation  
towards a motor neuronal fate could be observed between TDP43-iPSCs and healthy controls. 
However, affected MNs presented reduced survival in culture and higher levels of soluble and 
detergent-resistant TDP43, probably due to an alteration in post-translational mechanisms. 
Interestingly, mutant MNs appeared to be vulnerable to PI3K inhibition, while they were not affected 
by inhibitors of other kinase pathways. This suggests also a specificity in the neuronal response to 
different neurotrophic factors involved in PI3K rather than MAPK pathways. The role of 
neurotrophines in the survival of TDP43 MNs is worthy of further investigation and this work 




Alami et al. proceeded beyond these data to elucidate the role of TDP43 in physiological 
conditions and its impairment in ALS related disease [43]. Using at first a Drosophila model, they 
discovered that TDP43 cytoplasmatic granules are motile and dynamically transported along axons. 
Further studies in murine cortical neurons showed that this transport is microtubule-dependent and 
resulted in impaired in TPD43 mutated neurons, where granules appeared more immotile and often 
reversed direction. Other forms of axonal transport, such as mitochondria movement, were 
unaffected, thus suggesting a selective function and, consequently, alteration of TDP43 granules. 
These granules were found to be directly involved in the transport of specific mRNAs, such as 
Neurofilament-L (NEFL) mRNA, along the axons. To avoid influences related to the overexpression 
of TDP43 in the animal models, these results needed to be validated in patients’ iPSC-derived MNs. 
NEFL transport was analyzed in iPSC-MNs derived from patients carrying the same mutations studied 
in Drosophila and murine neurons (M337V and A315T) plus G298S. An impairment of the 
anterograde transport of NEFL granules was demonstrated together with an increase of retrograde 
movement. It is also important to highlight that TDP43 domain affected by the mutation is a 
prion-like domain known to be involved in the assembly of RNA granules. This study provided 
important data on a physiological function of TDP43 cytoplasmatic granules and how their 
impairment could significantly contribute to ALS pathology. 
Neurofilament aggregation is a well-known pathological hallmark of ALS. Thanks to iPSC-based 
technology, Chen et al. could investigate the causative role of mutant SOD1 in impairing 
neurofilament (NF) turnover within MNs [44]. To bypass concerns related to heterogeneity among 
individuals, they generated ALS patients’ iPSCs and used transcription activator-like effector 
nucleases (TALEN) technology to correct the D90ASOD1 mutation, thus obtaining isogenic controls. 
A modified differentiation protocol was applied to originate synchronized mature cells avoiding the 
generation of later-born MNs or glial cells. 
Indeed, challenges that need to be overcome when producing iPSC-derived neurons involve both 
the generation of immature cells and significant differences in the time rate of differentiation among 
iPSC colonies. These issues could lead to the production of heterogonous populations in terms of 
neural differentiated phenotype. The optimization of differentiation protocols has allowed generating 
neural cell populations that are synchronized regarding their growth in culture, in order to properly 
observe and investigate all the phases of their development [42]. 
NF subunits in ALS-MNs appeared to be unbalanced and developed a tendency to aggregate 
leading to neurite degeneration, an effect that probably interests the early phases of the disease  
in vivo when patients present phenotypically asymptomatic or with very mild symptoms. This effect 
was due to the presence of mutated SOD1, as demonstrated by gain of function and loss of function 
experiments. Further analyses revealed that binding of SOD1 to 3  UTR of NF-L mRNA could cause 
the alteration of NF structure, making them prone to aggregate. These events were selectively present 
in ALS-MNs and not in control cells or non-MNs. Moreover, human ALS MNs presented in vitro 
lower/normal levels of SOD1 (and increased amount of NF) compared to control MNs, strongly 
contrasting data from animal models where mutant SOD1 levels are much higher. 
Overall, these results highlight the importance of validating data obtained from animal models in 




physiology and pathology. The identification of the mechanisms underlying the development of ALS 
is crucial for the discovery of new therapeutic compounds. Indeed, the elucidation of the role of 
misregulated neurofilament turnover [44], granular impaired trafficking [43] rather than the 
mitochondrial dysfunction [26], together with other recent discoveries [45], may be a key moment in 
the identification of specific molecular targets for the development of effective therapies. Most 
likely, an effective therapeutic approach should be as comprehensive as possible to counteract the 
multiple aspects of ALS multifactorial pathogenesis. Certainly, the use of human cells for disease 
modeling in vitro has provided crucial data for this purpose (Table 1). The optimization of 
iPSC-based platforms can also represent an effective tool for in vitro screening of potential 
therapeutic compounds previously identified [46]. Finally, it is worth mentioning that Kondo et al. 
reported very recently how local transplants of human iPSC-derived glial-rich neural progenitors 
(hiPSC-GRNPs) were able to reduce MN degeneration and increase lifespan in a murine model of 
mutant SOD1 ALS [47]. ALS astrocytes are known to contribute to neuroinflammation and neuronal 












HiPSC-GRNPs represent a renewable source of autologous cells able to give rise to healthy 
astrocytes, which can provide trophic support to endogenous diseased MNs. Kondo and colleagues 
observed an improvement of ALS pathology even when hiPSC-GRNPs were transplanted after the 
disease onset (the most probable clinical setting) thus providing evidence that glia cells could play a 
major role in ALS pathogenesis and, eventually, therapy. 
3. Modeling and Studying Spinal Muscular Atrophy Using IPSCs 
Ebert and Svendsen were the first authors to demonstrate that human iPSCs can be employed to 
recapitulate the specific pathology that underlies SMA [48]. Until then, the only models available for 
research purposes on the disease were provided by worms, flies and mice, which presented 
considerable limitations, including technical constraints like the necessity of performing complicated 
knockout strategies. Similarly, human fibroblasts did not prove to be suitable for the study of the 
disease mechanisms and the screening of new drug compounds, since the SMN protein presents 




iPSCs were generated from fibroblasts of a 3 years old boy affected by type I SMA. Wild-type (WT) 
iPSCs derived from fibroblasts of his unaffected mother served as controls. Through RT-PCR 
analysis, that was performed in both WT and SMA iPSCs and fibroblasts in order to assess SMN 
mRNA, WT-iPSCs turned out to have comparable levels of SMN to WT fibroblasts, while SMA 
iPSCs showed significantly reduced levels of SMN full-length transcripts, as a result of the loss of 
SMN1 gene. RT-PCR analysis also detected a few truncated transcripts lacking exon 7, along with 
the full-length SMN transcripts, witnessing the maintenance of functional SMN2 gene and its 
alternative splicing. Since lower alpha MNs are the main target of the pathological processes of 
SMA, iPSCs from SMA and WT fibroblasts were directed towards a motor neuronal and glial fate, in 
order to disclose in which phase of maturation the pathogenetic events occur. If in the early stages of 
the differentiation protocol a robust production of MNs was described and no significant difference 
was documented between the SMA- and WT-derived MNs, interestingly, around week 10 of the 
protocol, the SMA-derived MNs appeared to be decreased both from a quantitative and a qualitative 
point of view, as they were fewer and smaller compared to the WT-derived MNs. It was then 
speculated that the SMA phenotype hampers MN ontogenesis at later developmental time periods, 
either by inhibiting the generation of new cells or increasing the degeneration of those already 
matured. This was the first study to report that human iPSCs can be adopted as a reliable model of a 
genetically inherited disease, such as SMA, and serve as a powerful tool for a better understanding of 
its etiopathogenesis. 
Sareen and Svendsen’s group carried on the experiment for a more precise definition of the 
mechanisms that are responsible for the post-developmental damage that leads to cell death, as 
observed in vitro [49]. Sareen and colleagues generated two lines of iPSCs from two patients affected 
by SMA type I and one line of control iPSCs, and then differentiated them into MNs. The first results 
were consistent with the previous work: after a normal production of MNs at 4 weeks into the 
differentiation protocol, the cell population underwent a selective reduction in number and size 
compared to the control iPSC-derived MN cultures. The group ascribed this degeneration to the 
activation of apoptosis pathways, as suggested by the significantly high percentage of apoptotic cells 
after 7–10 weeks of differentiation. In particular, the assay of increased levels of apoptotic markers at 
8 weeks of differentiation, namely cleaved caspase-3 and caspase-8, supported the assumption that 
apoptosis plays a crucial role in cell death in SMA iPSCs-derived MN cultures. The intracellular 
apoptotic signaling cascade is known to be initiated by caspase-8, triggered by the binding of  
Fas-ligands to their receptors (a TNF family transmembrane protein) [51]. This was confirmed by 
increased levels of membrane-bound Fas ligand in SMA MNs after 6 weeks of differentiation. The 
next step was to evaluate whether the inhibition of the Fas-receptor apoptotic pathway could rescue 
the degeneration of MNs in the SMA lines: the administration of a monoclonal antibody targeting the  
Fas-receptor (Anti Fas-Ab), starting from the second week of differentiation and for the whole 
duration of the differentiation process, proved to significantly increase the number of MNs in SMA 
lines at 8 weeks of differentiation, compared to the untreated cultures [49]. Taken together, these data 
suggest that an iPSCs-based model of SMA not only may provide new insights on the molecular and 




invaluable testing ground for the screening and development of new drug compounds, that may 
eventually be beneficial for patients. 
Another contribution to the knowledge on the pathogenic mechanisms of SMA was given by 
Corti and colleagues [20]. Using a viral- and transgene-free method, they reprogrammed fibroblasts 
of two type I SMA patients into iPSCs by nucleofecting them with plasmids encoding pluripotency 
factors (OCT4, SOX2, NANOG, LIN28, c-Myc, and KLF4). A parallel experiment was conducted 
on a subpopulation of the obtained iPSCs that were treated, and therefore genetically corrected, with 
SMN2 sequence-specific oligodeoxynucleotides. The correction of SMA iPSCs consisted in the 
exchange of a T to C at position +6 of exon 7, thus converting SMN2 into SMN1 through the  
inclusion of exon 7 in SMN2 transcripts. Subsequently, the model required the differentiation of 
SMA fibroblasts-derived iPSCs, both treated and untreated, into MNs, the cell-type majorly involved 
in SMA, in order to evaluate the effects of SMN1 deficiency on these cells. At week 8 of the 
multistage differentiation protocol, based on the administration of Retinoic Acid and Sonic 
Hedgehog, they observed specific disease effects of the SMN1 defect on untreated SMA 
iPSCs-derived MNs compared to the cultures treated with oligodeoxynucleotides. The statistically 
significant alterations included an overall reduction in cell soma size, axonal elongation and in the 
ability to form neuromuscular junctions, resulting in a decreased survival of MNs derived from 
untreated iPSCs. This experiment well demonstrates that a SMA model reproducing at least some 
aspects of the disease can be generated, and that MN dysfunction in SMA is the result of multiple 
neuropathological events likely occurring at a late differentiative state. Genetic correction of SMN2 
via oligodeoxynucleotides proved to rescue the cellular damage to the defective SMN1 gene and to 
significantly increase the number of detectable gems, nuclear aggregates of SMN protein which 
correlate with the rate of translation of the full-length protein. 
Given the recent hypothesis on the role of RNA and splicing abnormalities as a primary 
determinant of selective MN death in SMA [52,53], the experiment was then directed to the analysis 
of transcriptional changes in untreated SMA iPSC-derived MNs compared to heterozygous  
iPSC- and treated SMA iPSC-MNs. Gene expression and exon array analysis of RNA revealed a 
different splicing profile in a subset of genes encoding transcripts that are considered to play a crucial 
role in SMA pathogenesis, being involved in RNA metabolism, MN differentiation, axonal guidance 
and signal transduction. Remarkably, the molecular correction with oligodeoxynuleotides proved to 
shift most of the genes that are differentially expressed or spliced in SMA iPSC-derived MNs 
towards the heterozygous pattern, further supporting the data on the efficacy of this strategy in 
correcting the alterations secondary to SMN1 deficiency. 
Following the hypothesis that a cell population other than MNs may be implied in the activation 
of the apoptotic cascade, the attention was then focused on glial cells. Indeed, astrocytes had already 
proved to contribute to MN dysfunction in SOD1 mutated models of ALS [54,55] and to play a key 
role as mediators of neurodegeneration in a variety of nosological conditions, including Parkinson’s 
disease [56]. In order to examine morphologic and functional alterations in glial sub-populations, 
Ebert’s group differentiated human SMA-derived iPSCs and WT iPSCs into astrocytes [50], the 
most abundant cell type in the central nervous system, that are supposed to be responsible for the 




phenotype of SMA astrocytes, as shown by the intense cytoplasmic staining of Glial Fibrillary 
Protein (GFAP) and Nestin, two components of intermediate filament proteins that are upregulated 
in reactive glial cells. The activation state was accompanied by significant changes in astrocyte 
morphology, as they displayed enlarged bodies and thick, short processes. The observation that such 
alterations occur in the early stages of the differentiation protocol of SMA-derived iPSCs into 
astrocytes was crucial to infer that the MN loss is preceded by the activation of glial cells, suggesting 
a causal relationship between the two events. The alterations in the phenotype of astrocytes turned 
out to be the epiphenomenon of their functional impairments, as ratiometric live-cell calcium 
imaging reported increased basal calcium levels with a minimal response to ATP in SMA astrocytes 
compared to WT iPSCs-derived astrocytes. The authors concluded that the defective calcium 
homeostasis may lead to the activation of apoptotic pathways triggered by the upregulation of pERK1/2 
in SMA iPSCs-derived astrocytes, and the resulting increased expression of proinflammatory cytokines 
like TNF-alpha, IL-1 and IL-6. The ERK programmed cell death cascade was speculated to be initiated 
also by the deficiency of trophic factors, as witnessed by a decrease in the secretion of Growth 
Derived Neurotrophic Factor (GDNF), and the whole apoptotic process was attributed to a 
Fas-mediated mechanism. 
Overall, the possibility to isolate cell types that are specifically damaged in the disease process, 
like MNs and glia cells in SMA, makes iPSCs an unprecedented tool to disclose pathogenetic 
mechanisms that have been inaccessible so far (Table 1). Moreover, the establishment of reliable 
disease models is a fundamental milestone in the process of testing novel therapeutic strategies and 
finally finding a definitive treatment for SMA [58]. 
4. Discussion 
The pathogenesis of several MNDs is still obscure under multiple aspects, thus hampering the 
development of potential therapies [2]. Experimental studies conducted on animal models are 
crucial, but unfortunately results so far are insufficient [2]. Concerning ALS research, it has been 
found the overexpression of SOD1 which characterizes mutant SOD1 mice may influence observed 
molecular phenotypes [59]. With regard to SMA, mice physiologically lack the homologous SMN2 
gene, which plays a crucial role in determining clinical phenotypes [60]. As a consequence, data 
derived from pathogenetic studies need to be validated in human cellular models. Human ESCs have 
been largely employed for this purpose [37,61], but their use may be limited by ethical issues. 
Moreover, ESCs are not always available in substantial amount for large scale in vitro studies. On the 
other hand, the development of iPSC-based technology has allowed to generate human pluripotent 
cells in abundance to perform any in vitro study bypassing ethical constraints [22]. Furthermore, a 
great advantage of iPSCs is that they carry the genetic combination of an individual, thus permitting 
the study of patient-specific mutations. Issues concerning the heterogeneity of iPSC lines, which 
could provide misleading results, may be overcome by a careful experimental setting. This should be 
based on rigorous statistical analysis and standardized protocols. Moreover, the use of cutting-edge 
molecular methods allows correcting the mutation in patient-derived iPSCs, thus obtaining isogenic 
controls [44]. Another critical issue is represented by reprogramming techniques: reliable results 




genotype [20]. It is crucial to pay attention to the cellular subtypes obtained in culture with varying 
differentiation protocols in order to avoid misleading results: well established cellular markers need 
to be used to assess both the neuronal phenotype and the maturation state. In addition, several studies 
have highlighted the possibility that reprogrammed cells might maintain an epigenetic memory of 
the cell of origin, which could interfere with the expression of membrane markers [62]. Recently, 
advances in reprogramming methods have led to the possibility of directly differentiating mature 
cells (i.e., fibroblasts or astrocytes) into relevant cell types (i.e., induced neurons) [63]. These rather 
novel methods are quite efficient in reducing time in culture and speed up the differentiation 
protocol, but need further assessment. It also needs to be pointed out that pathogenesis studies benefit 
from long-term observation, from the cell pluripotent state to the mature phenotype, in order to 
speculate on the time-dependent disease alteration. 
5. Conclusions 
The development and optimization of iPSC-based platforms has allowed elucidating disease-specific 
mechanisms, which are exquisitely human (Figure 1). Further advances may finally open up the path 
to a full understanding of key pathogenetic events, leading to the development of effective treatments 
for ALS, SMA and other MNDs. 
Acknowledgments 
Cariplo grant to SC 2012-0513. 
The support of Associazione Amici del Centro Dino Ferrari is gratefully acknowledged. 
Author Contributions 
We confirm that all authors have participated in the writing of the manuscript (Irene Faravelli and 
Emanuele Frattini conceived the idea, revised all the literature and contributed to all parts;  
Giulia Stuppia revised the literature regarding ALS, and Agnese Ramirez revised the literature 
regarding SMA; Monica Nizzardo and Stefania Corti supervised and critically revised the 
manuscript, contributed to the revision of online websites and editing).  
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. McDermott, C.J.; Shaw, P.J. Diagnosis and management of motor neurone disease. BMJ 2008, 
336, 658–662. 
2. Gordon, P.H. Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, 
management and therapeutic trials. Aging Dis. 2013, 4, 295–310. 
3. Patten, S.A.; Armstrong, G.A.; Lissouba, A.; Kabashi, E.; Parker, J.A.; Drapeau, P. Fishing for 




4. Rafiq, M.K.; Proctor, A.R.; McDermott, C.J.; Shaw, P.J. Respiratory management of motor 
neurone disease: A review of current practice and new developments. Pract. Neurol. 2012, 12, 
166–176. 
5. Kiernan, M.C.; Vucic, S.; Cheah, B.C.; Turner, M.R.; Eisen, A.; Hardiman, O.; Burrell, J.R.; 
Zoing, M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377, 942–955. 
6. Finsterer, J.; Burgunder, J.M. Recent progress in the genetics of motor neuron disease.  
Eur. J. Med. Genet. 2014, 57, 103–112. 
7. Logroscino, G.; Traynor, B.J.; Hardiman, O.; Chio, A.; Mitchell, D.; Swingler, R.J.;  
Millul, A.; Benn, E.; Beghi, E. Incidence of amyotrophic lateral sclerosis in europe.  
J. Neurol. Neurosurg. Psychiatry 2010, 81, 385–390. 
8. Beghi, E.; Chio, A.; Couratier, P.; Esteban, J.; Hardiman, O.; Logroscino, G.; Millul, A.;  
Mitchell, D.; Preux, P.M.; Pupillo, E.; et al. The epidemiology and treatment of als: Focus on the 
heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 
2011, 12, 1–10. 
9. Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment 
and time. Nat. Rev. Neurol. 2013, 9, 617–628. 
10. Majounie, E.; Renton, A.E.; Mok, K.; Dopper, E.G.; Waite, A.; Rollinson, S.; Chio, A.;  
Restagno, G.; Nicolaou, N.; Simon-Sanchez, J.; et al. Frequency of the C9ORF72 
hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and 
frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012, 11, 323–330. 
11. Lorson, C.L.; Rindt, H.; Shababi, M. Spinal muscular atrophy: Mechanisms and therapeutic 
strategies. Hum. Mol. Genet. 2010, 19, doi:10.1093/hmg/ddq147. 
12. Prior, T.W.; Snyder, P.J.; Rink, B.D.; Pearl, D.K.; Pyatt, R.E.; Mihal, D.C.; Conlan, T.;  
Schmalz, B.; Montgomery, L.; Ziegler, K.; et al. Newborn and carrier screening for spinal 
muscular atrophy. Am. J. Med. Genet. A 2010, 152A, 1608–1616. 
13. Russman, B.S. Spinal muscular atrophy: Clinical classification and disease heterogeneity.  
J. Child Neurol. 2007, 22, 946–951. 
14. Lefebvre, S.; Burlet, P.; Liu, Q.; Bertrandy, S.; Clermont, O.; Munnich, A.; Dreyfuss, G.;  
Melki, J. Correlation between severity and smn protein level in spinal muscular atrophy.  
Nat. Genet. 1997, 16, 265–269. 
15. Monani, U.R.; Lorson, C.L.; Parsons, D.W.; Prior, T.W.; Androphy, E.J.; Burghes, A.H.; 
McPherson, J.D. A single nucleotide difference that alters splicing patterns distinguishes the 
SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8, 1177–1183. 
16. Vitte, J.; Fassier, C.; Tiziano, F.D.; Dalard, C.; Soave, S.; Roblot, N.; Brahe, C.; Saugier-Veber, P.; 
Bonnefont, J.P.; Melki, J.; et al. Refined characterization of the expression and stability of the 
smn gene products. Am. J. Pathol. 2007, 171, 1269–1280. 
17. Wang, C.H.; Finkel, R.S.; Bertini, E.S.; Schroth, M.; Simonds, A.; Wong, B.; Aloysius, A.; 
Morrison, L.; Main, M.; Crawford, T.O.; et al. Consensus statement for standard of care in 
spinal muscular atrophy. J. Child Neurol. 2007, 22, 1027–1049. 
18. Wee, C.D.; Kong, L.; Sumner, C.J. The genetics of spinal muscular atrophies. Curr. Opin. Neurol. 




19. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell 2006, 126, 663–676. 
20. Corti, S.; Nizzardo, M.; Simone, C.; Falcone, M.; Nardini, M.; Ronchi, D.; Donadoni, C.;  
Salani, S.; Riboldi, G.; Magri, F.; et al. Genetic correction of human induced pluripotent  
stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 2012, 4, 
doi:10.1126/scitranslmed.3004108. 
21. Chipman, P.H.; Toma, J.S.; Rafuse, V.F. Generation of motor neurons from pluripotent stem 
cells. Prog. Brain Res. 2012, 201, 313–331. 
22. Sandoe, J.; Eggan, K. Opportunities and challenges of pluripotent stem cell neurodegenerative 
disease models. Nat. Neurosci. 2013, 16, 780–789. 
23. Kondo, T.; Asai, M.; Tsukita, K.; Kutoku, Y.; Ohsawa, Y.; Sunada, Y.; Imamura, K.;  
Egawa, N.; Yahata, N.; Okita, K.; et al. Modeling alzheimer’s disease with ipscs reveals  
stress phenotypes associated with intracellular abeta and differential drug responsiveness.  
Cell Stem Cell 2013, 12, 487–496. 
24. Camnasio, S.; Delli Carri, A.; Lombardo, A.; Grad, I.; Mariotti, C.; Castucci, A.; Rozell, B.;  
Lo Riso, P.; Castiglioni, V.; Zuccato, C.; et al. The first reported generation of several induced 
pluripotent stem cell lines from homozygous and heterozygous huntington’s disease patients 
demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 2012, 46, 41–51. 
25. Chung, C.Y.; Khurana, V.; Auluck, P.K.; Tardiff, D.F.; Mazzulli, J.R.; Soldner, F.; Baru, V.;  
Lou, Y.; Freyzon, Y.; Cho, S.; et al. Identification and rescue of alpha-synuclein toxicity in 
parkinson patient-derived neurons. Science 2013, 342, 983–987. 
26. Kiskinis, E.; Sandoe, J.; Williams, L.A.; Boulting, G.L.; Moccia, R.; Wainger, B.J.; Han, S.;  
Peng, T.; Thams, S.; Mikkilineni, S.; et al. Pathways disrupted in human ALS motor neurons 
identified through genetic correction of mutant SOD1. Cell Stem Cell 2014, 14, 781–795. 
27. Miller, R.G.; Brooks, B.R.; Swain-Eng, R.J.; Basner, R.C.; Carter, G.T.; Casey, P.; Cohen, A.B.; 
Dubinsky, R.; Forshew, D.; Jackson, C.E.; et al. Quality improvement in neurology: 
Amyotrophic lateral sclerosis quality measures: Report of the quality measurement and 
reporting subcommittee of the american academy of neurology. Neurology 2013, 81, 
2136–2140. 
28. Tovar, Y.R.L.B.; Ramirez-Jarquin, U.N.; Lazo-Gomez, R.; Tapia, R. Trophic factors  
as modulators of motor neuron physiology and survival: Implications for ALS therapy.  
Front. Cell. Neurosci. 2014, 8, doi:10.3389/fncel.2014.00061. 
29. Brockington, A.; Ning, K.; Heath, P.R.; Wood, E.; Kirby, J.; Fusi, N.; Lawrence, N.;  
Wharton, S.B.; Ince, P.G.; Shaw, P.J.; et al. Unravelling the enigma of selective vulnerability in 
neurodegeneration: Motor neurons resistant to degeneration in als show distinct gene expression 
characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol. 2013, 125,  
95–109. 
30. Sreedharan, J.; Brown, R.H., Jr. Amyotrophic lateral sclerosis: Problems and prospects.  
Ann. Neurol. 2013, 74, 309–316. 
31. Vucic, S.; Rothstein, J.D.; Kiernan, M.C. Advances in treating amyotrophic lateral sclerosis: 




32. Rosen, D.R.; Sapp, P.; O’Regan, J.; McKenna-Yasek, D.; Schlumpf, K.S.; Haines, J.L.;  
Gusella, J.F.; Horvitz, H.R.; Brown, R.H., Jr. Genetic linkage analysis of familial amyotrophic 
lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am. J. Med. Genet. 
1994, 51, 61–69. 
33. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; 
Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC 
hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD 
and ALS. Neuron 2011, 72, 245–256. 
34. Su, X.W.; Broach, J.R.; Connor, J.R.; Gerhard, G.S.; Simmons, Z. Genetic heterogeneity of 
amyotrophic lateral sclerosis: Implications for clinical practice and research. Muscle Nerve 
2014, 49, 786–803. 
35. Ling, S.C.; Polymenidou, M.; Cleveland, D.W. Converging mechanisms in ALS and FTD: 
Disrupted RNA and protein homeostasis. Neuron 2013, 79, 416–438. 
36. Renton, A.E.; Chio, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics.  
Nat. Neurosci. 2014, 17, 17–23. 
37. Di Giorgio, F.P.; Boulting, G.L.; Bobrowicz, S.; Eggan, K.C. Human embryonic stem 
cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an 
ALS-causing mutation. Cell Stem Cell 2008, 3, 637–648. 
38. Wainger, B.J.; Kiskinis, E.; Mellin, C.; Wiskow, O.; Han, S.S.; Sandoe, J.; Perez, N.P.;  
Williams, L.A.; Lee, S.; Boulting, G.; et al. Intrinsic membrane hyperexcitability of 
amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014, 7, 1–11. 
39. Sareen, D.; O’Rourke, J.G.; Meera, P.; Muhammad, A.K.; Grant, S.; Simpkinson, M.; Bell, S.; 
Carmona, S.; Ornelas, L.; Sahabian, A.; et al. Targeting RNA foci in iPSC-derived motor  
neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013, 5, 
doi:10.1126/scitranslmed.3007529. 
40. Renton, A.E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J.R.;  
Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A hexanucleotide 
repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 
2011, 72, 257–268. 
41. Buratti, E.; Brindisi, A.; Giombi, M.; Tisminetzky, S.; Ayala, Y.M.; Baralle, F.E. TDP-43 binds 
heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail J. Biol. Chem. 2005, 
280, 37572–37584. 
42. Bilican, B.; Serio, A.; Barmada, S.J.; Nishimura, A.L.; Sullivan, G.J.; Carrasco, M.;  
Phatnani, H.P.; Puddifoot, C.A.; Story, D.; Fletcher, J.; et al. Mutant induced pluripotent stem 
cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.  
Proc. Natl. Acad. Sci. USA 2012, 109, 5803–5808. 
43. Alami, N.H.; Smith, R.B.; Carrasco, M.A.; Williams, L.A.; Winborn, C.S.; Han, S.S.;  
Kiskinis, E.; Winborn, B.; Freibaum, B.D.; Kanagaraj, A.; et al. Axonal transport of TDP-43 




44. Chen, H.; Qian, K.; Du, Z.; Cao, J.; Petersen, A.; Liu, H.; Blackbourn, L.W., IV; Huang, C.L.; 
Errigo, A.; Yin, Y.; et al. Modeling als with ipscs reveals that mutant SOD1 misregulates 
neurofilament balance in motor neurons. Cell Stem Cell 2014, 14, 796–809. 
45. Poppe, L.; Rue, L.; Robberecht, W.; van Den Bosch, L. Translating biological findings  
into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp. Neurol. 2014, 
doi:10.1016/j.expneurol.2014.07.001. 
46. Egawa, N.; Kitaoka, S.; Tsukita, K.; Naitoh, M.; Takahashi, K.; Yamamoto, T.; Adachi, F.; 
Kondo, T.; Okita, K.; Asaka, I.; et al. Drug screening for ALS using patient-specific induced 
pluripotent stem cells. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3004052. 
47. Kondo, T.; Funayama, M.; Tsukita, K.; Hotta, A.; Yasuda, A.; Nori, S.; Kaneko, S.;  
Nakamura, M.; Takahashi, R.; Okano, H.; et al. Focal transplantation of human iPSC-derived 
glial-rich neural progenitors improves lifespan of als mice. Stem Cell Rep. 2014, 3, 242–249. 
48. Ebert, A.D.; Yu, J.; Rose, F.F., Jr.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. 
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457,  
277–280. 
49. Sareen, D.; Ebert, A.D.; Heins, B.M.; McGivern, J.V.; Ornelas, L.; Svendsen, C.N. Inhibition of 
apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular 
atrophy. PLoS ONE 2012, 7, e39113. 
50. McGivern, J.V.; Patitucci, T.N.; Nord, J.A.; Barabas, M.E.; Stucky, C.L.; Ebert, A.D. Spinal 
muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor 
production. Glia 2013, 61, 1418–1428. 
51. Lafont, E.; Milhas, D.; Teissie, J.; Therville, N.; Andrieu-Abadie, N.; Levade, T.; Benoist, H.; 
Segui, B. Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase 
inhibitor zVAD-fmk. PLoS One 2010, 5, e13638. 
52. Zhang, Z.; Lotti, F.; Dittmar, K.; Younis, I.; Wan, L.; Kasim, M.; Dreyfuss, G. SMN deficiency 
causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in 
splicing. Cell 2008, 133, 585–600. 
53. Baumer, D.; Lee, S.; Nicholson, G.; Davies, J.L.; Parkinson, N.J.; Murray, L.M.;  
Gillingwater, T.H.; Ansorge, O.; Davies, K.E.; Talbot, K.; et al. Alternative splicing events are a 
late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet. 2009, 5, 
e1000773. 
54. Brites, D.; Vaz, A.R. Microglia centered pathogenesis in als: Insights in cell interconnectivity. 
Front. Cell. Neurosci. 2014, 8, 117, doi:10.3389/fncel.2014.00117. 
55. Benkler, C.; Ben-Zur, T.; Barhum, Y.; Offen, D. Altered astrocytic response to activation in 
SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis.  
Glia 2013, 61, 312–326. 
56. Hirsch, E.C.; Hunot, S.; Hartmann, A. Neuroinflammatory processes in parkinson’s disease.  
Park. Relat. Disord. 2005, 11 (Suppl. 1), 9–15. 




58. Garbes, L.; Heesen, L.; Holker, I.; Bauer, T.; Schreml, J.; Zimmermann, K.; Thoenes, M.;  
Walter, M.; Dimos, J.; Peitz, M.; et al. VPA response in sma is suppressed by the fatty acid 
translocase CD36. Hum. Mol. Genet. 2013, 22, 398–407. 
59. Van Den Bosch, L. Genetic rodent models of amyotrophic lateral sclerosis. J. Biomed. 
Biotechnol. 2011, 2011, doi:10.1155/2011/348765. 
60. Schmid, A.; DiDonato, C.J. Animal models of spinal muscular atrophy. J. Child Neurol. 2007, 
22, 1004–1012. 
61. Re, D.B.; Le Verche, V.; Yu, C.; Amoroso, M.W.; Politi, K.A.; Phani, S.; Ikiz, B.; Hoffmann, L.; 
Koolen, M.; Nagata, T.; et al. Necroptosis drives motor neuron death in models of both sporadic 
and familial ALS. Neuron 2014, 81, 1001–1008. 
62. Vaskova, E.A.; Stekleneva, A.E.; Medvedev, S.P.; Zakian, S.M. “Epigenetic memory” 
phenomenon in induced pluripotent stem cells. Acta Naturae 2013, 5, 15–21. 
63. Hermann, A.; Storch, A. Induced neural stem cells (iNSCs) in neurodegenerative diseases.  


















Bioengineering and Stem Cell Technology in the Treatment of 
Congenital Heart Disease 
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Abstract: Congenital heart disease places a significant burden on the individual, family and community 
despite significant advances in our understanding of aetiology and treatment. Early research in 
ischaemic heart disease has paved the way for stem cell technology and bioengineering, which 
promises to improve both structural and functional aspects of disease. Stem cell therapy has 
demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. 
This finding, together with promising case studies in the paediatric setting, demonstrates the 
potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell 
technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects  
of disease. 
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1. Clinical Consideration of Congenital Heart Disease 
Treatment of congenital heart disease (CHD) occupies a unique place in the human history of 
cardiovascular medicine. This dates back to the pioneering development of early heart-lung 
machines in the early 1950s. Subsequent development of this technology allowed correction of 
simple heart defects in childhood that would have otherwise led to early death, with further evolution 
permitting routine adult cardiac surgery for ischaemic and valvular heart disease, now accepted as  
“everyday surgery”. 
In modern CHD clinical research, both patients and practitioners look forward to similar paradigm 
shifts in treatments to address some of the inadequacies of current management that continue to 
impact individuals, families and workplaces. There are now more adults with congenital heart 
disease than children in advanced societies [1] and whilst many are effectively “cured” with 
childhood intervention (such as closure of infant ventricular septal defects) others have an ongoing 
need for close medical management including those with single ventricle physiology [2] or who 
require repeated surgeries, for example, those who will need replacement of right ventricle to 
pulmonary artery conduits. 
The burden of disease is significant and has physical, psychological and economic impacts [3].  
CHD occurs in ~7–8 in 1000 live births [4,5]. A subset of CHD is invariably lethal around birth 
unless treated, and these cases present significant challenges with respect to surgical reconstruction, 
critical care patient management, long term follow up and the ethics of focusing major health 
resources onto few individuals. CHD successfully treated in childhood carries a strong likelihood of 




The dramatic reduction in mortality after surgical correction of CHD in recent years has been 
accompanied by increasing recognition of poor neurological outcomes in survivors of CHD, which 
may involve genetic factors, abnormal brain perfusion and development in utero and/or susceptibilities 
to hypoxia resulting from CHD, or other environmental parameters such as anesthesia [7,8]. A key 
bottleneck in patient care is the transition from childhood to adulthood, where patients may be lost to 
follow up. 
Childhood treatment is very costly and paediatric cardiac surgery is the most common reason for 
admission to paediatric intensive care. Over the last three decades, surgery has become more 
complex and is generally performed earlier—often during the neonatal period—to gain better 
functional outcomes in the long term. A diagnosis of CHD is associated with important psychosocial 
dysfunction with many parents reporting symptoms equivalent to post-traumatic stress disorders, 
high levels of parental depression and ongoing anxiety with similar problems observed in adolescent 
and adult survivors [9]. 
Addressing causation of CHD has been a high priority over the last decades, particularly for the 
minority of cases that show familial inheritance. Classical linkage analysis has been the mainstay 
methodology underpinning these studies. Studies on the interaction between genetic and environmental 
factors have revealed clinically important perturbations of the highly conserved and tightly regulated 
developmental cardiogenic processes but only in a smaller number of patients with single gene 
disorders and associated syndromes [10]. In the new era of genetic research, genome wide 
association studies have identified areas of common chromosomal variation associated with the most 
common but simple form of CHD, secundum ASD [11], but with relatively low odds ratios and 
limited clinical application. Massively parallel sequencing of the whole exome [12] and its more 
targeted approaches [13] have dramatically accelerated the disease gene discovery pipeline, yielding 
answers for additional families. Polygenic contribution, variable penetrance and variation in 
phenotype present ongoing challenges. 
On the horizon is a new era of stem cell-based therapies and bioengineering, and it is hoped that 
these approaches can help reduce the burden of CHD. In broad terms, stem cell and bioengineering 
approaches may make contributions to: (i) improving structural solutions in repair of malformed 
hearts; (ii) improving the function of repaired hearts and their circulation; and (iii) facilitating 
modelling of CHD to advance our understanding of its molecular underpinnings. These will be 
discussed further below. 
1.1. Structural Solutions 
In paediatric heart surgery, there is a need to address the current demands of the circulation as  
well as future growth. Many forms of advanced neonatal surgery involve utilisation of the existing  
ventriculo-arterial connection as the systemic outflow (usually through a large ventricular septal 
defect) and creation of an extra-anatomic right ventricle to pulmonary artery conduit. Repairs of 
pulmonary atresia with VSD, and truncus arteriosus are examples that utilise this approach. Usually 
either a human cadaveric allograft (homograft) is used for this purpose, or a bovine jugular venous 




Fallot, may require pulmonary valve replacement, currently also utilising allograft or xenograft 
tissue valves. 
Whilst effective in the short term, the long term functional outcomes of such approaches are poor, 
with all requiring replacement within 3 to 8 years depending on the size of the patient, patient 
growth, host response to the allograft or xenograft and other factors including the occasional 
development of endocarditis. Supplies of both types of conduit are limited and are associated with 
significant expense. Allosensitisation to donated human products can also be a problem if 
transplantation is later required. Percutaneous approaches are now available that are suitable for 
some patients, particularly in the adolescent group, but as xenoproducts they remain susceptible to 
immune mediated structural valve deterioration and infection. 
Many biologic approaches have been attempted to improve longevity of the implanted valve, 
including decellularising and re-seeding allograft tissue with host endothelial cells [14]; however this 
approach has not yet been shown to produce meaningfully increased graft survival or somatic  
growth [15]. Generation of a vascularised matrix that can then be seeded and shaped [16] is emerging 
as an approach that avoids the need for allograft material but will require complex 3D construction to 
simulate tube and valve formation. Patients undergoing the Fontan operation as a final step in 
construction of a cavo-pulmonary connection have been managed with tissue engineered vascular 
grafts to convey the inferior vena caval blood to the pulmonary arteries [17]. This is valuable proof of 
principle work yielding understandings of optimal matrix construction, albeit that no significant 
growth is presently required of this connection using current surgical approaches [18]. 
Electrospinning and microfabrication techniques to engineer scaffolds that support the growth of 
valvular interstitial cells and mesenchymal stem cells [19] offer a way to customise the size and shape 
of the replacement tissue, perhaps guided by 3D imaging of the planned recipient. Repopulation with 
engineered patient-specific cells utilising adult stem cell or induced pluripotent stem cell 
technologies would seem logical for the future [20,21]. 
1.2. Stem Cells to Improve Cardiac Function 
There is extensive and ongoing work to support the use of stem cells in recovery from myocardial 
infarction in adult populations, particularly using bone marrow derived cells, albeit that the rationale 
for such studies is under intense scrutiny [22]. Regeneration of scar tissue into functional 
myocardium and improved ventricular performance are the aims of such interventions with recent 
promise [23–25]. In paediatric cardiology the aim would be the optimisation of ventricular 
performance for children subjected to volume or pressure loads, usually after correction of the 
structural abnormalities that promote ventricular dysfunction. There is particular interest in the 
subpopulation of patients with a functional single ventricle, especially those who have undergone 
complex single ventricle surgery such as the Norwood operation for hypoplastic left heart  
(HLH) [26]. 
Typically HLH patients would be infants after the first two stages of surgery involving long 
periods of cardiopulmonary bypass and shorter periods of planned and “protected” myocardial 
ischaemia. An increased volume load related to the shunt providing pulmonary blood flow after the 




anatomic disadvantage being a morphologic right ventricle working against systemic vascular 
resistance. It is not uncommon for the function of such ventricles to deteriorate, particularly after 
second stage surgery, promoting atrioventricular valve regurgitation which positively reinforces the 
ventricular dysfunction. Relative coronary insufficiency [27] or a primary myocardial process may 
contribute. Structural abnormalities have been identified in single right ventricular tissue [28]. 
Ventricular performance is a major determinant of suitability for the last stage of the single ventricle 
pathway, Fontan completion (total cavo-pulmonary connection) as well as performance and survival 
with the Fontan circulation. 
In parallel with studies in animal models [29,30], various approaches to ventricular support using 
stem cell technology are being trialled in CHD patients with differing donor cell origins and modes 
of administration, as outlined by Tarui et al. [31]. A number of stem cell populations have  
been described in the mammalian heart using cell surface markers and various functional  
assays including colony formation, and growth and differentiation potential in vitro and in vivo [22] 
Cardiosphere-derived cells are among the first populations to be trialled in humans for ischaemic 
heart disease in adults [32,33]. They are heterogeneous cell preparations derived from the 3D cellular 
clusters (cardiospheres) that can be readily established from heart biopsies, and which are thought to 
provide a harbour (niche) for cells with stem or progenitor cell properties during in vitro culture. 
Cells derived from atrial tissue and administered via the intracoronary route at cardiac 
catheterisation, have been trialled in patients with HLH in Phase I and Phase II clinical trials, with 
other groups utilising umbilical cord [34] and bone marrow derived cell fractions [31]. Phase 1 trials 
have indicated the safety of this approach with some improvement in right ventricular systolic 
function evident, and Phase 2 studies are underway. In the recently reported Phase 1 study of 
autologous cardiosphere-derived cells delivered via the intracoronary route [35], no safety concerns 
were raised and an improvement in right ventricular function was observed at 18 months compared 
to controls. The effect size is encouraging and clinically relevant (a 10% increase in right ventricular 
ejection fraction). The use of autologous cells represents a clear advantage in this environment. 
Similar approaches may be of benefit in paediatric heart failure presenting as dilated cardiomyopathy. 
Uncertainty persists about the mechanism by which the stem cells might induce functional 
improvement. In ischaemic disease and cardiomyopathy, paracrine activation of local regenerative 
pathways may significantly contribute to the improvements in performance, while tissue 
replacement due to stem cell deployment does not seem to be a dominant feature in animal  
studies [36]. 
Cord blood stem cells have been shown to engraft and augment right ventricular function in an 
ovine model in the presence of increased workload [30]. A similar model of right ventricular 
overloading in rats demonstrated improved diastolic dysfunction and suppression of ventricular 
fibrosis following skeletal myoblast transplantation (Hoashi et al. 2009). Case reports demonstrate 
improvement in ventricular function following intracoronary delivery of bone marrow derived cells 
in children with terminal cardiomyopathy [37,38] as well as ventricular failure following surgery for 
HLH [39]. In HLH, adaptation of the right ventricle to increased work load may require cellular 
proliferation beyond the capability of the intrinisic regenerative systems. The capacity for autologous 




by the persistence of genetic characteristics that caused or contributed to abnormal development during 
primary cardiogenesis. However, the development of refined cell therapy approaches may support the 
growth and development required. 
2. Induced Pluripotent Stem Cells to Study Causation in Congenital Heart Disease 
Induced pluripotent stem cells (iPSC) can be created from virtually any somatic cell, most 
commonly from dermal fibroblasts [40]. These pluripotent cell types are created by the 
reprogramming of adult cells to a pluripotent state, giving them the ability to differentiate into all cell 
types of the human body, including cardiomyocytes (see Figure 1) as well as smooth muscle, 
endothelial and epicardial cells, the highly specialised cell types of the heart. This makes iPSC an 
invaluable resource for the study of CHD. The technology offers the unique opportunity to create 
human models of disease and development in a patient-specific context that incorporates the 
individual clinical features of the disease. Additionally, iPSC provide material to study the earliest 
time points in development, previously difficult due to restrictions on the availability of primary 
human tissue for study. 
 
(A) (B) (C) (D) 
Figure 1. (A) Patient-derived fibroblasts generated from a skin biopsy; (B) Undifferentiated 
iPSC colonies derived from patient-derived fibroblasts; (C) Cardiomyocytes derived 
from iPSC stained for the sarcomeric protein, cardiac troponin T; (D) Smooth muscle cells 
derived from iPSC stained for the cell scaffolding protein, alpha smooth muscle actin. 
iPSC are playing an increasing role in personalised medicine, specifically in disease profiling of 
both rare and common diseases, and in the design of personalised therapies. Due to the recent success 
of directed differentiation protocols [41–43], iPSC allow the provision of lineage-specific stem and 
progenitor cells, as well as differentiated specialised cell types, for disease research, cellular  
therapies and tissue engineering. However, before iPSC are used as a source of biologic material for 
clinical application, concerns regarding the oncogenic effect of retained transgenes [44] and  
trans-differentiation need to be addressed [45]. Until then, iPSC are being increasingly used as a test 
bed to study development and disease mechanism. In the cardiac area, iPSC approaches have been 
successful in assessing the functional disorder associated with LEOPARD Syndrome [46,47] and 
various arrhythmias and cardiomyopathies [48,49]. 
iPSC are playing an increasing role in personalised medicine, specifically in disease profiling of 
both rare and common diseases, and in the design of personalised therapies. Due to the recent success 




progenitor cells, as well as differentiated specialised cell types, for disease research, cellular 
therapies and tissue engineering. However, before iPSC are used as a source of biologic material for  
clinical application, concerns regarding the oncogenic effect of retained transgenes [44] and  
trans-differentiation need to be addressed [45]. Until then, iPSC are being increasingly used as a test 
bed to study development and disease mechanism. In the cardiac area, iPSC approaches have been 
successful in assessing the functional disorder associated with LEOPARD Syndrome [46,47] and 
various arrhythmias and cardiomyopathies [48,49]. 
The approach is applicable to CHD particularly for cell-autonomous genetic disorders affecting, 
for example, the development or function of cardiomyocytes that can be modelled in 2D cell cultures 
or 3D tissue constructs [50,51]. The approach has its obvious limitations with respect to modelling 
the complex tissue interactions necessary for organ structure, and the non-cell autonomous 
environmental or epigenetic influences on disease. However, rapid progress is being made on directed 
differentiation of highly complex organoids and tissue layers from pluripotent stem cells [52,53], 
opening up vast new potential for therapies and modelling disease in this system. 
Using a patient-specific in vitro model of HLH is of particular interest to clinicians and scientists 
in the field attempting to reconcile the most common theory about the genesis of HLH—reduced 
transventricular flow and altered loading during development—with the heterogeneity in 
morphology as well as performance and decline observed in clinical cases [54,55]. An iPSC 
approach will complement the forward genetic approach being taken in mice [56]. While it has been 
suggested that HLH is essentially a severe form of valve malformation [56,57], some cases of HLH 
have a bulky LV and small but formed mitral and aortic valves, whilst others have barely a 
recognisable LV cavity. In combination these studies lead to speculation that a primary myocardial 
disorder is present in HLH, which likely predetermines the size and function of the ventricle and 
perhaps contributes to difficulties in later childhood in some with this condition. HLH is thought to 
have a high genetic component with complex inheritance, and is often associated with chromosomal 
abnormalities [58], which could impact on either valvular structures or ventricular cardiomyocyte 
growth and function, or both. Of the limited number of gene pathways implicated in HLH [58], the 
transcription factors NKX2-5 and NOTCH1 are known to be involved in both valvular and chamber 
development [59,60]. Both genes are also involved in aortic coarctation and bicuspid aortic valve, 
which exist within the spectrum of left-sided abnormalities that includes HLH at its most severe  
end [61–63]. 
Jiang and colleagues made iPSC from a single HLH patient and used them to derive 
cardiomyocytes by directed differentiation. They found a number of important primary cardiac 
defects including altered expression of key cardiac transcription factors, fewer beating clusters and 
reduced myofibrillar organisation, persistence of a fetal gene expression pattern as well as altered 
calcium transients and calcium handling [54]. Kobayashi et al. analysed single clones from three 
HLH patients, using a clone from a patient with bicuspid aortic valve and total anomalous pulmonary 
venous connection as a control [55]. They showed reduced expression of a number of cardiac 
transcription factors at late time points after induced cardiomyocyte differentiation, and associated 
changes in total chromatin marks—di-methylation on histone H3 lysine 4, tri-methylation on histone 




of HLH remains to be seen. Such molecular phenotypes in patient specific iPSC-derived 
cardiomyocytes raises the possibility that disease modelling using the iPSC platform can provide both 
molecular diagnosis, as has been utilised in other cardiovascular diseases [64] and cell therapy into  
the future. 
Bioengineering Heart Muscle Using iPS Cells 
Investigations into the creation of functional heart tissue in vitro by tissue engineering techniques 
using donor cardiomyocytes is still in its very early stages [65–68]. While there are no clinical 
applications of the method to date, cardiac tissue engineering has seen progress over the last twenty 
years in all four of the elements central to this method: generation of donor cardiomyocytes, 
development of scaffold materials and control of cell survival, engraftment and growth with 
bioactive molecules (see recent reviews [51,69,70]). The latest developments include ex vivo and  
in vivo approaches that promote the growth of vascular and structural elements of cardiac  
tissue [71,72]. Growing cells as sheets has made possible the insertion of iPSC-derived 
cardiomyocytes into the porcine heart for short term benefits [73]. Human embryonic stem 
cell-derived cardiomyocytes have been successfully engrafted in a non-human primate model of 
myocardial infarction [74]. This approach included development and application of mass culture 
techniques able to support production and delivery of a billion cells, selection of delivery techniques 
to optimise survival, such as a supportive hydrogel scaffold and application of a cocktail of 
preconditioning regimes. While this demonstrates potential for successful remuscularization of the 
human heart, issues with the incomplete maturation of cardiomyocytes, as well as arrhythmogenesis, 
need to be addressed. Contractile and vascularised human cardiac tissues have also been created 
from iPS cells [75,76] to provide long term survival and contractility, and 3D microtissues derived 
from iPSC also show promise for transplantation [77]. 
The ability to make whole functional hearts or bioengineered patches and conduits is challenging 
and has not been achieved for clinical use thus far. A form of bioengineered hearts have been 
configured using human iPSC-derived multipotential cardiovascular progenitors (MCP), which are 
likely similar to the earliest cardiac progenitors in heart development, by implanting them into a 
decellularized donor mouse heart [78]. The decellularized heart provides an excellent 3D structure 
for bioengineering whole organs or surgical implants as it utilises the natural extracellular matrix to 
promote cardiomyocyte proliferation, differentiation and function. The use of such native cardiac 
scaffold provides appropriate cues for engraftment, promotes rapid vascularisation and also avoids 
the biocompatibility problems of some artificial scaffold materials. MCP may offer an advantageous 
cell type for cardiac tissue bioengineering applications as they can potentially self-organise into 
structures containing cardiomyocytes, smooth muscle cells and endothelial cells, guided by 
extracellular matrix cues. However, before a whole heart can be bioengineered, a number of 
challenges remain, including safeguards surrounding the use of iPSC as discussed, as well as 
modulation of the immune response and, in CHD applications, finding ways that allow growth of the 






Emerging technology in stem cells and bio-engineering may address major issues in congenital 
heart disease that limit lifespan and reduce quality of life for a significant number of children and 
adults. iPSC technology offers an opportunity to provide both molecular diagnosis and, in the future, 
tissue based therapy for some of the more complex reconstructive tasks in congenital heart disease. 
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Scalable Electrophysiological Investigation of iPS  
Cell-Derived Cardiomyocytes Obtained by a Lentiviral 
Purification Strategy 
Stephanie Friedrichs, Daniela Malan, Yvonne Voss and Philipp Sasse 
Abstract: Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and 
differentiated into functional cardiomyocytes for characterization of the disease and for drug 
screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, 
we here report a novel non-clonal purification strategy by using lentiviral gene transfer of a 
puromycin resistance gene under the control of a cardiac-specific promoter. We have applied this 
method to our previous reported wild-type and long QT syndrome 3 (LQTS 3)-specific mouse iPS 
cells and obtained a pure cardiomyocyte population. These cells were investigated by action 
potential analysis with manual and automatic planar patch clamp technologies, as well as by recording 
extracellular field potentials using a microelectrode array system. Action potentials and field 
potentials showed the characteristic prolongation at low heart rates in LQTS 3-specific, but not in 
wild-type iPS cell-derived cardiomyocytes. Hence, LQTS 3-specific cardiomyocytes can be 
purified from iPS cells with a lentiviral strategy, maintain the hallmarks of the LQTS 3 disease and 
can be used for automated electrophysiological characterization and drug screening. 
Reprinted from J. Clin. Med. Cite as: Friedrichs, S.; Malan, D.; Voss, Y.; Sasse, P. Scalable 
Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral 
Purification Strategy. J. Clin. Med. 2015, 4, 102–123. 
1. Introduction 
Long QT syndrome (LQTS) is an inherited cardiac disease caused by mutations of cardiac ion 
channels or accessory subunits, which leads to the loss of function of repolarizing currents or the 
gain of function of depolarizing currents. Clinically, this disease is characterized by abnormal 
prolonged QT intervals in the ECG, and the patients affected can develop Torsades de Pointes 
ventricular tachycardia, which causes syncope and sudden cardiac death [1]. One of the most 
common LQTS gain of function mutations in humans is the deletion of three amino acids ( KPQ) 
in the -subunit of the cardiac sodium channel (SCN5A) [2], which is classified as LQTS Type 3 
(LQTS 3). This mutation results in faster recovery from inactivation of the sodium current and 
enhanced late sodium currents, which both lead to prolonged action potentials (APs) and early 
afterdepolarizations (EADs). Because the impact of this mutation is strongest at a low heart rate, 
lethal cardiac events mostly occur at rest or during sleep [1]. 
In the past, LQTSs were studied on heterologous expression systems that lack the typical cell 
biological and physiological features of cardiomyocytes and that do not generate APs [3,4]. 
Recently, we have shown that LQTS 3-specific cardiomyocytes can be generated from mouse iPS 
cells carrying the human KPQ mutation and recapitulated the disease-specific biophysical effects 




groups have successfully generated iPS cells from LQTS 1, 2 and 3 patients, and the 
cardiomyocytes differentiated from these cells recapitulated the typical characteristics of the 
respective disease [6–11]. Therefore, human iPS cell-derived cardiomyocytes are a great advance 
for the understanding of LQTS, especially because “real” cardiomyocytes provide a model that is 
close to the patient’s heart cells. 
The unlimited proliferation of personalized iPS cells and the differentiation into cardiomyocytes 
would allow disease- or even patient-specific drug testing. In order to find new drugs to treat 
LQTS, pharmaceutical compound libraries have to be screened with scalable automatic assays.  
Potential automatic electrophysiological screening methods are planar patch clamp systems [12] or 
microelectrode array technologies [13]. One big challenge for all automated assays is the generation 
of a pure cardiac population, because during iPS cell differentiation, also non-cardiomyocytes  
are generated. 
To date, several purification methods have been used to enrich cardiac cells. Fluorescence-activated 
cell sorting of cardiomyocytes with cardiac-specific GFP expression or after labeling with 
mitochondrial dyes can be used, but these methods result only in low amounts of pure cardiac cells 
and are difficult to scale up [14,15]. Better yields are achieved with scalable antibiotic selection  
of cardiomyocytes, which express a resistance gene under a cardiac-specific promoter [16,17].  
For antibiotic selection, cells must be genetically modified, and here, we report a highly efficient 
and straightforward lentiviral gene transfer for the selection of cardiomyocytes by an antibiotic 
resistance gene without a time-consuming screening of individual clones. We have applied this 
method to obtain pure populations of cardiomyocytes from LQTS 3-specific iPS cells with the 
human KPQ mutation and wild-type controls. Furthermore, we proved that purified 
cardiomyocytes showed the typical features of LQTS 3 in manual patch clamp, automatic planar 
patch clamp and scalable microelectrode array recording technologies. 
2. Experimental Section 
2.1. Generation of the Lentiviral PaG-RexNeo Plasmid and Lentivirus Production 
The lentiviral PaG-RexNeo plasmid is based on a pRRLSIN lentiviral backbone from 
pRRLSIN.cPPT.PGK-GFP.WPRE (kindly provided by Didier Trono through Addgene #12252). 
Multiple cloning steps according to standard procedures were used to create an insert containing a 
short version of the cardiac-specific alpha myosin heavy chain ( -MHC) promoter, a puromycin 
resistance gene, the green fluorescence protein (GFP) and a fragment with the Rex-1 promoter 
driving a neomycin resistance gene. The short -MHC promoter was excised from the -MHC-pBK 
plasmid (kindly provided by Jeffrey Robbins) and contained 1745 bp from the 3  part of the full  
-MHC promoter. Parallel expression of puromycin and GFP was achieved by the introduction of 
the 2A self-cleaving peptide sequence (APVKQTLNFDLLKLAGDVESNPGP) [18] that was 
generated by annealing and in-frame ligation of appropriate oligonucleotides (MWG-Biotech, 
Ebersberg, Germany). The Rex-1-neomycin sequence was cut from the -MHC-puro Rex-neo 
plasmid (kindly provided by Mark Mercola through Addgene #21230). Successful cloning was 




Germany). All enzymes for cloning were from Life Technologies (Darmstadt, Germany) and 
Thermo Scientific Fermentas. For the preparation of lentivirus, 40 g of the PaG-RexNeo plasmid, 
8.5 g of the pMD2.G plasmid (for the VSV-G envelope, Addgene #12259), 16 g of the 
pMDLg/pRRE plasmid (for Gag/Pol expression, Addgene #12251) and 7 g of the pRSV-Rev 
plasmid (for Rev expression, Addgene #12253, all kindly provided by Didier Trono through 
Addgene), were cotransfected into 7 × 106 HEK293FT cells (ATCC) in a T75 culture flask,  
as previously described [19]. After 24 h, the medium was changed with fresh HEK cell medium 
that consisted of Dulbecco’s Modified Eagle Medium (DMEM), 15% fetal calf serum (FCS),  
0.1 mmol/L MEM nonessential amino acids, 0.1 mmol/L 2-mercaptoethanol, 100 U/mL penicillin 
and 100 mg/mL streptomycin (all from Invitrogen/Bernardi). Virus-containing supernatants were 
collected at Days 3 and 4 after transfection, passed through a 0.45- m filter (Sigma-Aldrich, 
Taufkirchen, Germany) and concentrated by ultracentrifugation at 19.400 rpm for 2 h at 17 °C 
using an Optima L-90K ultracentrifuge with an SW 32 Ti rotor (Beckman Coulter, Krefeld, 
Germany). The pellet was resuspended in 50 L HBSS without Ca2+ and Mg2+ (Life Technologies, 
Darmstadt, Germany) and stored frozen at 80 °C. 
2.2. Cell Culture and Lentiviral Gene Transfer of iPS Cells 
The iPS cells were cultured as reported before [5] on irradiated mouse embryonic feeder (MEF) 
layers (PMEF-NL; Millipore, Schwalbach, Germany) in iPS cell medium containing DMEM, 15% 
FCS, 0.1 mmol/L nonessential amino acids, 0.1 mmol/L 2-mercaptoethanol, 100 U/mL penicillin,  
100 mg/mL streptomycin (all from Invitrogen/Life Technologies), 1000 U/mL leukemia inhibitory 
factor (Chemicon/Millipore), 3 mol/L CHIR99021 and 1 mol/L PD184352 (Axon Medchem, 
Groningen, The Netherlands). Every 2 to 3 days, iPS cells were passaged and seeded at a density of 
0.1 to 0.2 × 106 cells in a T75 culture flask. 
For gene transfer of PaG-RexNeo, 0.2 × 106 iPS cells were plated on a T25 culture flask on 
irradiated MEFs, and 24 h later, the PaG-RexNeo lentivirus from the production described in 
section 2.1 was added in 5 mL of iPS cell medium in the presence of 6 g/mL protamine sulfate  
(Sigma-Aldrich) to enhance infection. The next day, fresh iPS cell medium was applied, and the 
selection of iPS cells with lentivirus integration was initiated 24 h to 48 h later by the addition of  
300 g/mL neomycin (G418, Invitrogen/Life Technologies). The genetically-engineered wild-type 
and Scn5a /+ iPS cells were further cultivated and passaged in iPS cell medium in the presence of  
300 g/mL neomycin to avoid lentivirus silencing. 
2.3. Differentiation of iPS Cells and Purification of Cardiomyocytes 
Cardiomyocyte differentiation was induced using embryoid body (EB) formation with the 
hanging drop method in combination with a suspension protocol, as previously described [16]. 
Briefly, EBs were generated by aggregation of 400 cells in 20 L differentiation medium for 2 days 
and subsequently cultured in suspension in 10-cm bacteriological dishes on a horizontal shaker in 
differentiation medium containing Iscove’s Modified Dulbecco’s Medium, 20% FCS, 0.1 mmol/L 




streptomycin (all from Invitrogen/Life Technologies). EBs started to beat at day 10 to 12 of 
differentiation and 10 g/mL puromycin (Sigma-Aldrich) was added at that time point to initiate 
the selection of cardiomyocytes. One day later, EBs were pooled, washed with PBS and dissociated 
with 1 mg/mL collagenase B (Roche Diagnostics, Mannheim, Germany) in 1.6 mL in a 50-mL 
falcon tube for 60 min at 37 °C under shaking condition. The enzymatic reaction was stopped with 
the addition of 30 mL of differentiation medium. In order to avoid a centrifugation step that was 
found to be lethal for the freshly-dissociated cardiomyocytes, a subsequent passive sedimentation 
step was performed for 60 min in the incubator. The supernatant was removed except ~10 mL, in 
which the cardiomyocytes were resuspended and collected. For further selection and cultivation, 
cells were seeded on 0.01% fibronectin-coated (Sigma-Aldrich) 10-cm cell culture dishes in 
differentiation medium supplemented with 2.5 to 5 g/mL puromycin. To obtain a more mature 
stage for electrophysiological analysis, single purified cardiomyocytes were kept in culture for an 
additional 6 to 10 days, because we have shown that longer differentiation leads to more cells with 
functional Na+ currents [5]. 
2.4. Immunocytochemistry 
For immunostainings, cells were fixed with 4% paraformaldehyde for 30 min, permeabilized  
with 0.2% Triton X-100 for 10 min (both from Sigma-Aldrich) and blocked with 5% donkey or 
goat serum for 30 min (Jackson ImmunoResearch, Suffolk, England). The primary antibodies were 
diluted in 0.5% donkey or goat serum, and cells were incubated for 2 h. Colonies of iPS cells were 
stained against Oct3/4 (rabbit, 1:100; Santa Cruz Biotechnology, Heidelberg, Germany) and 
SSEA1 (mouse, 1:80; Developmental Studies Hybridoma Bank, Iowa, USA). Single cardiomyocytes 
were stained against -actinin (mouse, 1:400; Sigma-Aldrich) and the cardiac Na+ channel (Nav1.5, 
rabbit, 1:400; Alomone Labs, Jerusalem, Israel). The appropriate fluorescence-conjugated 
secondary antibodies, donkey anti-mouse Cy2-labeled, donkey anti-rabbit Cy3-labeled (both 1:400; 
Jackson ImmunoResearch) and goat anti-mouse Alexa647-labeled (1:500; Invitrogen/Life 
Technologies), were diluted in 1 g/mL of Hoechst 33342 (Sigma-Aldrich) and applied for 1 h. 
Samples were embedded in polyvinyl alcohol mounting medium (FLUKA; Sigma-Aldrich) and 
analyzed using an AxioObserver Z1 microscope equipped with an ApoTome optical sectioning 
device and the AxioVision software (Zeiss, Jena, Germany). 
To analyze the purity of iPS cell-derived cardiomyocytes, purified cells at Days 13 to 15  
of differentiation from 4 to 5 independent biological replicates were stained against -actinin.  
The ratio of -actinin-positive cells to the total cell number analyzed by nucleus labeling was 
quantified from large overview pictures that were acquired with the MosaiX function of the 
AxioVision software (Zeiss). 
2.5. Conventional Manual Patch Clamp Analysis 
Purified wild-type and Scn5a /+ cardiomyocytes were dissociated and replated for 48 to 72 h at 
low densities on fibronectin-coated (0.01%) coverslips. Patch clamp experiments were performed 




cell configuration and the current clamp mode, as reported earlier [5], with continuous superfusion 
with extracellular solution at 37 °C containing (in mmol/L) 140 NaCl, 5.4 KCl, 1.8 CaCl2,  
1.2 MgCl2, 10 Hepes and 10 glucose, pH 7.4 (NaOH), and an internal solution containing  
(in mmol/L) 50 KCl, 80 K-aspartate, 1 MgCl2, 3 MgATP, 10 EGTA and 10 HEPES, pH 7.2 (KOH) 
(all from Sigma-Aldrich). APs were elicited by 2.5 ms-long current injections, and the strength of 
the pulse was increased stepwise until a stable action potential with a peak over the 0 mV line was 
reached. The stimulation frequency and amplitude was controlled by an external stimulator (Model 
2100, A–M Systems) attached to the EPC10 amplifier. 
2.6. Automated Planar Patch Clamp Analysis 
For automated planar patch clamp measurements, single dissociated cardiomyocytes are 
required in suspension without damage of the cell membrane or transmembrane ion channels. 
Therefore, purified wild-type and Scn5a /+ cardiomyocytes in a 10-cm cell culture dish were 
washed with 5 mL PBS containing EDTA (2 mM) and stored for 10 min at 4 °C in order to 
facilitate the detachment of cells by subsequent incubation with 2 mL 0.05% Trypsin in 4 mM 
EDTA (Gibco/Life Technologies) for 3 to 8 min. Cells were collected in 10 mL of differentiation 
medium, gently centrifuged for 3 min at 500 rpm, resuspended in 200 to 500 L external solution 
and incubated at room temperature for at least 2 h to recover from dissociation. Automated 
electrophysiological recording was performed with a planar patch clamp robot (Patchliner, Nanion 
Technologies, Munich, Germany) equipped with an EPC-10 quadro patch clamp amplifier (HEKA 
Elektronik) for parallel recording of 4 cardiomyocytes in the whole cell configuration. Single-use 
borosilicate glass chips with medium resistance (1.8 to 3 M , NPC-16, Nanion Technologies) were 
used for all recordings. The PatchControlHT software (Nanion Technologies) in combination with the 
PatchMaster software (HEKA Elektronik) was used for cell capture, seal formation, whole-cell 
access and subsequent recording of voltage ramps, automated determination of AP stimulus 
thresholds and AP measurements at different stimulation frequencies. The internal solution used 
contained (in mmol/L) 50 KCl, 60 K-fluoride, 10 NaCl, 20 EGTA and 10 HEPES, pH 7.2 (KOH), 
and the external solution 140 NaCl, 4 KCl, 2 CaCl2, 5 Glucose and 10 HEPES, pH 7.4 (NaOH) (all 
from Sigma-Aldrich). A seal enhancer solution containing (in mmol/L) 80 NaCl, 3 KCl, 10 MgCl2, 
35 CaCl2 and 10 HEPES (Na+ salt), pH 7.4 (HCl) (all from Sigma-Aldrich), was automatically 
applied to the extracellular channel after cell capture in order to achieve better G -seals and 
replaced with external solution when the whole cell configuration was established. 
In order to identify mature cardiomyocytes, depolarizing voltage ramps ( 100 mV to +60 mV in 
250 ms) were applied, and the responding current was analyzed to identify the fast spike of Na+ 
currents. APs were recorded in current clamp mode and to avoid spontaneous activity, and to 
record APs from a stable resting potential, the membrane potential was adjusted to 70 mV by 
current injection using the low frequency voltage clamp circuit of the amplifier. Before each AP 
recording, the low frequency voltage clamp was switched off, and the actual current was 
continuously injected to maintain the resting membrane potential. To determine the current 
injection threshold for AP generation for each cell individually, an automated macro was 




intensities and automatically monitored the voltage responses. Leak subtraction was used to 
subtract the passive capacitive responses to the stimulus. Once the stimulus generates voltage 
responses with an amplitude of >30 mV above the resting membrane potential, this value was used, 
and 80 pA was added for safety. Subsequently, APs were automatically evoked and recorded for  
30 to 60 s at 0.5 Hz, 1 Hz and 2 Hz by a protocol in the Patchmaster software (HEKA Elektronik). 
Data from both conventional and planar patch clamp were acquired with the Patchmaster  
software and analyzed offline using the Fitmaster (HEKA Elektronik) and the Labchart software  
(AD Instruments, Oxford, England). The action potential duration at 90% of repolarization 
(APD90) was analyzed with the peak analysis module of Labchart software (AD Instruments). To 
quantify the frequency-dependent AP duration, cardiomyocytes were stimulated at different pacing 
periods (0.5 to 6 s for manual patch clamp and 0.5 to 2 s for automatic patch clamp), and at each 
period, the average APD90 was determined. For each individual cell, the APD90 values were 
plotted against the period between stimulation (1/frequency), and a linear regression analysis was 
used to determine the slope of this relationship. 
2.7. Microelectrode Array Analysis 
For the microelectrode array (MEA) measurements, purified cardiomyocytes from wild-type and 
Scn5a /+ iPS cells were detached with 0.05% Trypsin in 0.5 mM EDTA (Gibco/Life Technologies) 
for 5 min at 37 °C, centrifuged for 5 min at 1000 rpm and resuspended in differentiation medium. 
Then, 20,000 to 40,000 cells were plated in each well of a 6-well MEA (60-6wellMEA200/30iR-Ti-tcr, 
Multi Channel Systems, Reutlingen, Germany) coated with 0.01% fibronectin (Sigma-Aldrich). 
After 24 to 72 h, the medium was replaced with external solution (see Section 2.5), and field 
potentials were recorded at a sampling rate of 10 kHz with the MC-Rack software at room 
temperature (22 °C) and at 37 °C by switching on the TC02 2-channel temperature controller  
(both from Multi Channel Systems). Triggered field potentials were averaged over 50 s, and the 
mean of all 9 electrodes in one well was calculated (OriginPro8G, OriginLab) to obtain one 
averaged field potential for further analysis. The field potential duration was manually measured 
from the minimum of the sharp negative spike to the following maximum (Figure 6c, right). 
2.8. Statistics 
Data are expressed as the mean ± S.E.M. Statistical tests were performed using appropriate 
unpaired or paired Student’s t-test with Welch’s correction for data with unequal variance using 
Prism (GraphPad software). A p-value of <0.05 was considered significant and is indicated by an 
asterisk (*) in the figures. Because of high variations in temperature-induced frequency between 
Scn5a /+ and wild-type cardiomyocytes using MEA recordings (Scn5a /+: high 1.4–1.8 Hz, low 
0.7–1.0 Hz; wild-type: high 1.6–4.7 Hz, low 1.0–3.5 Hz), in these experiments, only paired 





3.1. Lentiviral Strategy for Purification of iPS Cell-Derived Cardiomyocytes 
In order to obtain a pure cardiomyocyte population from iPS cell differentiation, we have 
modified a previously-reported antibiotic resistance strategy [16] and used high efficiency lentiviral 
gene transfer [17]. Therefore, we have generated a lentiviral plasmid ( PaG-RexNeo) for the 
expression of a puromycin resistance gene and the green fluorescent protein (GFP) reporter gene 
under the control of a short (1.7 kb) version of the cardiac-specific alpha myosin heavy chain  
( -MHC) promoter (Figure 1a). In addition, the plasmid contained a fragment with a neomycin 
resistance gene expressed under the control of the pluripotency promoter Rex-1 [20]. After 
infection of cells with this lentiviral plasmid, undifferentiated stem cells with stable integration of 
the lentivirus can be selected by cultivation in the presence of neomycin [17]. Upon differentiation, 
cardiomyocytes can be purified by puromycin application and used for electrophysiological 
investigations (Figure 1b). To test this strategy for the investigation of a clinically relevant cardiac 
disease, we have purified LQTS 3-specific cardiomyocytes from previously-reported Scn5a /+ iPS 
cells [5] with the human KPQ mutation in the cardiac sodium channel. 
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Figure 1. Lentiviral strategy for the purification of iPS cell-derived cardiomyocytes.  
(a) The lentiviral construct contains a puromycin resistance gene (PurR) and a GFP 
reporter gene separated by a 2A self-cleaving peptide sequence (2A) under the control 
of the cardiac -MHC promoter, as well as a neomycin resistance gene (NeoR) under 
the control of the Rex1 promoter; (b) strategy of lentivirus gene transfer into iPS cells 
and purification of cardiomyocytes for electrophysiological analysis; (c,d) after 
lentiviral gene transfer and selection, wild-type and Scn5a /+ iPS cell lines maintained 
the characteristic embryonic stem cell-like morphology (c) and expressed the 
embryonic stem cell-specific markers, Oct3/4 (d, green) and SSEA1 (d, red). Nuclei are 




Therefore, a monolayer of undifferentiated Scn5a /+ and wild-type iPS cells were infected with 
the PaG-RexNeo lentivirus and further kept under neomycin selection for the isolation of cells 
with a stable integration. The surviving iPS cells were collected and pooled for each genotype. 
Although this non-clonal strategy results in a mixture of individual cell clones with uncontrolled 
variations in the number and location of lentiviral integrations, it does not require the very 
laborious picking and characterization of several individual clones. Importantly, after PaG-
RexNeo gene transfer and selection, we found that both wild-type and LQT 3-specific iPS cells 
maintained their characteristic embryonic stem cell morphology (Figure 1c) and expressed the stem 
cell-specific markers Oct3/4 and SSEA1 (Figure 1d). 
3.2. Purification of PaG-RexNeo iPS Cell-Derived Cardiomyocytes 
In vitro differentiation of PaG-RexNeo wild-type and Scn5a /+ iPS cells was performed using 
the hanging drop method for embryoid body (EB) generation [21] followed by a mass culture 
protocol (Figure 2a) [16]. EBs showed spontaneously beating areas at Days 10 to 12 of differentiation 
with weak GFP signals. At this stage, cardiomyocyte selection was started by puromycin 
application for one day, and single cells were re-plated on fibronectin-coated culture dishes. Longer 
selection at the EB stage was inefficient, because dissociation of older and more compact EBs with 
enhanced extracellular matrix failed, resulting in a low number of single cardiomyocytes. Single 
dissociated cardiomyocytes were spontaneously beating and weakly GFP-positive (Figure 2b). 
 
Figure 2. Purification of iPS cell-derived cardiomyocytes. (a) The cardiac 
differentiation protocol used in this study; (b) single dissociated cardiomyocytes were 
GFP-positive and beating, but some non-contracting and GFP-negative cells remained 
(arrows) after the puromycin selection for 24 h; (c) after further purification of single 
cells, mostly -actinin-positive cardiomyocytes survived (red); (d) cell counting at 
Days 13 to 15 of differentiation showed the very high purity of wild-type and Scn5a /+ 




Because cells without GFP expression or contractions were still present (Figure 2b, arrows), 
cultures were maintained under a low dose of puromycin selection, which led to further 
purification. Subsequently, the purity of cardiomyocytes was assessed by staining against cardiac 
-actinin and cell nuclei (Figure 2c), and quantitative cell counting showed an almost pure population 
of cardiomyocytes (Figure 2d) from wild-type (92.8% ± 6.2%, n = 5) and Scn5a /+ iPS cells 
(87.7% ± 9.7%, n = 4). 
3.3. Phenotyping of Purified LQTS 3-Specific Cardiomyocytes from Scn5a /+ iPS Cells 
Purified cardiomyocytes from wild-type and Scn5a /+ iPS cells showed no obvious difference 
in cardiac sodium channel distribution or sarcomeric structure (Figure 3a). To exclude that the 
lentivirus integration, the non-clonal strategy or the purification affect the LQTS 3-specific 
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Figure 3. Patch clamp analysis of purified iPS-derived cardiomyocytes. (a) 
Cardiomyocytes from wild-type and Scn5a /+ iPS cells showed a similar cardiac 
sodium channel distribution (green) and sarcomeric -actinin pattern (red); (b) 
representative examples of action potentials (APs) from purified wild-type and 
Scn5a /+ cardiomyocytes at high and low pacing frequencies; (c) relationship between 
action potential duration at 90% of repolarization (APD90) and pacing period from a 
representative wild-type and Scn5a /+ cardiomyocyte with the analysis of the slope by 
linear fit (dashed lines); (d) statistical analysis of the slope of APD90 to the pacing 
period relationship from individual wild-type (WT) and Scn5a /+ cardiomyocytes ( /+); 
(e) typical long QT syndrome 3 (LQTS 3)-specific early afterdepolarizations (EADs) 
observed in a Scn5a /+ cardiomyocyte. Scale bar: 20 m. Error bars: S.E.M. Dotted 




APs were evoked at various frequencies by current injection, and the frequency-dependent 
action potential duration at 90% repolarization (APD90) was analyzed. In Scn5a /+ cardiomyocytes, 
but not in wild-type cells, we found a prolongation of APD90 at lower heart rates (Figure 3b, Table 1), 
which did not reach statistical significance because of the high variability of APD90 between 
individual cells. The high variability was not due to the non-clonal purification approach, because it 
was similarly observed in non-purified cardiomyocytes from the original iPS cell clones [5].  
To compensate for this variability, we performed a longitudinal analysis for each individual cell 
and determined the slope of the relationship between APD90 and basic cycle length (APD 
restitution) using a linear fit (examples shown in Figure 3c), as reported before [5,22]. This analysis 
showed almost no influence of cycle length on APD90 in purified wild-type cardiomyocytes 
yielding flat slopes of APD restitution ( 1.85 ± 0.73 ms/s, n = 10, Figure 3d). In contrast, purified 
Scn5a /+ cardiomyocytes had a significant different positive slope (7.94 ± 4.05 ms/s, n = 18, 
Figure 3d) highlighting the prolongation of APD90 with a longer cycle length. This is the 
characteristic feature of LQTS 3 in patients [22] and is fully in line with previous reports on  
non-purified cardiomyocytes from Scn5a /+ iPS cells [5], as well as on cardiomyocytes from the 
KPQ LQTS 3 mouse model [23]. Importantly, these slope values are almost identical to those 
obtained from the non-purified original iPS cell clones (wild-type: 2.92 ± 1.27 ms/s; Scn5a /+: 
9.08 ± 3.60 ms/s; see Table 2 in Malan et al. [5]). Moreover, we detected EADs in some purified 
Scn5a /+ cardiomyocytes (10.5%, n = 19, Figure 3e), but never in wild-type cells (0%, n = 10). 
Resting membrane potential, action potential amplitude and maximum upstroke velocity were not 
different between wild-type and Scn5a /+ cardiomyocytes (Table 1). 
Table 1. Action potential parameters determined by manual and automated planar 
patch clamp analysis. RMP, resting membrane potential; APA, action potential 
amplitude; Vmax, maximum upstroke velocity; APD90, APD at 90% of repolarization; 
Slope, slope of the linear relationship between APD90 and the pacing period. Values 
are the means ± S.E.M. 
Method Manual Patch Clamp Automated Planar Patch Clamp 
Genotype Wild-Type Scn5a /+ p-Value Wild-Type Scn5a /+ p-Value 
RMP at 1 Hz 77.4 ± 4.9 74.7 ± 3.5 
0.6589 
69.4 ± 6.4 78.2 ± 3.0 
0.2040 
(mV) n = 10 n = 17 n = 7 n = 9 
APA 1 Hz 106.2 ± 5.7 103.3 ± 5.7 
0.7207 
81.1 ± 13.2 85.8 ± 10.1 
0.7746 
(mV) n = 10 n = 17 n = 7 n = 9 
V max at 1 Hz 93.7 ± 11.1 71.6 ± 9.6 
0.1484 
56.6 ± 15.5 52.6 ± 10.2 
0.8248 
(V/s) n = 10 n = 17 n = 7 n = 9 
APD90 at 2 Hz 36.2 ± 3.5 39.5 ± 5.1 
0.6004 
78.0 ± 28.7 64.9 ± 17.1 
0.7019 
(ms) n = 10 n = 14 n = 7 n = 7 
APD90 at 1 Hz 35.5 ± 3.3 45.8 ± 6.8 
0.1913 
70.1 ± 26.6 76.7 ± 20.4 
0.8454 
(ms) n = 10 n = 15 n = 7 n = 9 
APD90 at 0.2 Hz (manual) 
or 0.5 Hz (automated) (ms) 
39.7 ± 2.2 46.8 ± 6.7 
0.1761 
69.6 ± 24.3 91.5 ± 25.0 
0.5440 
n = 5 n = 5 n = 7 n = 8 
Slope 1.85 ± 0.73 7.94 ± 4.05 
0.0287 
5.39 ± 4.82 4.13 ± 1.20 
0.0494 




Importantly, we did not find differences in action potential parameters between early and late 
passages of the non-clonal iPS cell clones (Table 2). 
Table 2. Action potential parameters at early (P12–P18) and late (P19–P35) passages 
determined by manual patch clamp recordings (the abbreviations are as in Table 1). 
Genotype Wild-Type Scn5a /+ 
Passage Early Passage Late Passage p-Value Early Passage Late Passage p-Value 
RMP at 1 Hz 71.8 ± 2.3 68.3 ± 9.7 
0.7061 
71.5 ± 7.3 67.3 ± 5.6 
0.6593 
(mV) n = 4 n = 3 n = 4 n = 7 
APA 1 Hz 105.5 ± 6.9 99.7 ± 16.5 
0.7312 
97.3 ± 9.0 91.3 ± 8.1 
0.6513 
(mV) n = 4 n = 3 n = 4 n = 7 
V max at 1 Hz 98.8 ± 6.8 88.3 ± 31.7 
0.7215 
81.8 ± 15.6 59.6 ± 17.6 
0.4230 
(V/s) n = 4 n = 3 n = 4 n = 7 
APD90 at 1 Hz 33.1 ± 3.6 27.7 ± 0.7 
0.2657 
49.1 ± 15.7 52.8 ± 11.3 
0.8499 
(ms) n = 4 n = 3 n = 4 n = 7 
Slope 1.10 ± 0.32 1.10 ± 0.57 
1.00 
14.75 ± 13.12 8.94 ± 6.68 
0.7106 
(ms/s) n = 4 n = 3 n = 4 n = 8 
3.4. Automated Electrophysiological Investigation and AP Measurements of Purified 
Cardiomyocytes with a Planar Patch Clamp System 
In order to implement the use of purified wild-type and Scn5a /+ cardiomyocytes for automated 
screenings, we performed electrophysiological analysis with a planar patch clamp robot 
(Patchliner, Nanion Technologies). For this technique, freshly dissociated single cells in suspension 
are required. Therefore, a new and gentle dissociation procedure was used to minimize cell stress 
and to avoid partial digestion of ion channels, which are required for intact AP generation. 
Dissociation was facilitated by removal of Ca2+ and cooling of cells at 4 °C, which allowed 
subsequent dissociation with the very short application of Trypsin. After dissociation, cells were 
gently centrifuged and carefully resuspended in external solution. In order to let cardiomyocytes 
recover from the dissociation process, cells remained at least 2 h at room temperature before planar 
patch clamp experiments were performed. To verify the dissociation efficiency, single cells were 
counted, and the cell concentration was adjusted to 0.1 to 1 × 106 cells/mL to ensure a good catch 
rate by the planar patch clamp robot. For planar patch clamp measurements, 20 L containing 2000 
to 20,000 purified cardiomyocytes, was automatically pipetted into each recoding unit of the planar 
patch clamp chip. Once a cell was caught, a negative pressure was automatically applied and a seal 
enhancer was injected to form a good G -seal for stable recording without leaks. 
To estimate the quality of recording and the differentiation stage of cardiomyocytes, 
depolarizing voltage ramps were applied in the voltage clamp mode. This allowed determination of 
the intact seal without major leak conductance, as well as the detection of typical inward and 
outward currents of voltage-dependent ion channels (Figure 4a). Voltage ramps were also used to 
classify cardiomyocytes in immature cells with a slow inward Ca2+ current peak (Figure 4a, left, 
arrow) and in more mature cells with an additional fast Na+ current component (Figure 4a, right, 




cardiomyocytes with a clear Na+ current peak were subsequently used to record APs. APs were 
evoked by current injection in the current clamp mode (Figure 4c). To identify the minimal current 
required, a special protocol was executed by the PatchControlHT software (Nanion Technologies). 
Briefly, stepwise (100 pA steps) increasing 2 ms-long current stimuli were applied, and the voltage 
responses were analyzed (Figure 4b). As soon as the resulting amplitude was >30 mV above the 
resting membrane potential, the applied current was defined as the threshold-current and 80 pA was 
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Figure 4. Automated planar patch clamp analysis of purified wild-type iPS-derived 
cardiomyocytes. (a) Examples of voltage ramps of an immature cardiomyocyte with 
Ca2+ current (left, arrow) and of a more mature cell with an additional fast Na+ current 
(right, arrow); (b) Representative membrane potential changes in response to stepwise 
increasing current pulses during the protocol for finding the AP threshold; (c) Example 
of automated AP recording at fixed pacing rate (left) with magnification (right);  
(d) representative APs before (black) and after blocking of K+ channels with automated 
application of 4-AP (red); (e) Statistical analysis of APD90 measured under control 
conditions and after 4-AP application. Error bars: S.E.M. Dotted lines indicate 0 mV or 
0 pA. 
To determine if AP recordings with a planar patch clamp system are useful to investigate LQTSs  
that mainly affects cardiac repolarization, we inhibited the repolarizing K+ channels by automated 
application of 4-aminopyridine and measured the effect on APD90. As expected, we found AP 
prolongation in purified wild-type cardiomyocytes from 120.1 ± 30.5 ms to 188.9 ± 24.0 ms (n = 4,  




3.5. Automated Phenotypic Characterization of LQTS 3-Specific Purified Cardiomyocytes from 
Scn5a /+ iPS Cells with a Planar Patch Clamp Robot 
To proof the feasibility to characterize LQTSs with automated electrophysiological analysis, we 
recorded APs from purified cardiomyocytes using the planar patch clamp system. Frequency 
dependence was determined with APs elicited at 2, 1 and 0.5 Hz pacing frequencies using the 
automatically determined current threshold (see the above Section 3.4). Similar to the results from 
manual patch clamp recordings (Figure 3), we found prolonged APs at low heart rates in Scn5a /+ 
cardiomyocytes, but not in wild-type cells (Figure 5a,b). Furthermore, the longitudinal analysis of 
APD restitution in individual cells (examples shown in Figure 5c) showed a positive slope in 
Scn5a /+ cardiomyocytes (4.13 ± 1.20 ms/s, n = 9) and a significant different negative slope in 
wild-type cells ( 5.39 ± 4.82 ms/s, n = 7, Figure 5d, Table 1). Finally, we observed EADs in 30% 
of purified Scn5a /+ cardiomyocytes (Figure 4e, n = 10), but none in wild-type cells (n = 7). 
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Figure 5. Automated characterization of LQTS 3-specific cardiomyocytes by planar 
patch clamp. (a,b) Representative traces of APs from wild-type (a) and Scn5a /+ (b) 
cardiomyocytes at high and low pacing frequencies; (c) relationship between APD90 
and the pacing period from a representative wild-type and a Scn5a /+ cardiomyocyte 
with analysis of the slope by linear fit (dashed lines); (d) statistical analysis of the slope 
of APD90 to the pacing period relationship from individual wild-type (WT) and 
Scn5a /+ cardiomyocytes ( /+); (e) typical LQTS 3-specific EADs observed in a 




3.6. Analysis of Field Potentials from Purified iPS Cell-Derived Cardiomyocytes with  
Microelectrode Arrays 
The duration of APs can not only be determined by patch clamp analysis, but can also be 
estimated indirectly from extracellular field potential recordings with microelectrode arrays, 
because of the good correlation of field potential duration to APD [24]. To prove the functionality 
of this technology for the characterization of LQTS 3, we plated purified cardiomyocytes obtained 
from wild-type and Scn5a /+ iPS cells on six-well microelectrode arrays on which they formed a 
monolayer of synchronously beating cells (Figure 6a). This allowed recordings of field potentials 
from nine electrodes in six individual wells (example recording in Figure 6b). To determine 
frequency-dependent field potential duration, measurements were performed at 22 °C and at 37 °C, 







































































Figure 6. Field potential analysis with microelectrode arrays. (a) Image of the 
recording electrodes of a six-well microelectrode array with a monolayer of purified 
cardiomyocytes; (b) overview of field potential recordings from three wells with purified 
wild-type (bottom) and three wells with Scn5a /+ cardiomyocytes (top); (c) examples 
of averaged field potentials with slow beating at 22 °C (black) and faster beating at  
37 °C (grey) from purified wild-type and Scn5a /+ cardiomyocytes. The analysis of  
the field potential duration is shown in the Scn5a /+ recording; (d) statistical analysis 
of the field potential durations at low and high spontaneous beating frequencies  





Field potential duration was analyzed after trigger-based averaging over 50 s and calculation of 
the mean field potential from all nine electrodes (for details, see Section 2.7), resulting in one 
averaged field potential for each well (examples in Figure 6c). Scn5a /+ cardiomyocytes showed  
a significantly (p = 0.011) longer field potential duration at low frequencies (132.4 ± 25.2 ms,  
n = 3) compared to high frequencies (88.0 ± 22.6 ms, n = 3, Figure 6d). Importantly, such a 
frequency-dependent effect was not observed in wild-type cardiomyocytes (low frequency: 45.5 ± 
9.5 ms, n = 3; high frequency: 42.1 ± 10.5 ms, n = 3; p = 0.78). Thus, also field potential analysis 
with a microelectrode array showed the disease-specific frequency dependence of prolonged AP 
durations in purified Scn5a /+ cardiomyocytes. 
4. Discussion 
In this study, we present a novel, simple and fast lentiviral strategy for the purification of 
cardiomyocytes from iPS cells and show the feasibility of using these cells for automated 
electrophysiological investigations. The adverse effects of the random lentivirus integration, the  
non-clonal cell selection and the antibiotic purification on the pluripotency of iPS cells or the 
electrophysiological characteristics of cardiomyocytes were not detected. Importantly, purified 
cardiomyocytes had fast depolarizing Na+ currents, AP generation and intact repolarization by K+ 
currents and, therefore, were well suited to investigate LQTS in which these parameters are 
affected. We have proven this by showing the intact electrophysiological phenotype of purified 
LQTS 3-specific cardiomyocytes from previously published Scn5a /+ iPS cells [5]. Furthermore, 
we have characterized purified cells with the automated planar patch clamp recordings and scalable 
microelectrode array analysis, which highlights the usefulness of these technologies for drug 
screening. Following, we discuss the achievements so far and the hurdles to overcome for large-scale 
purification and electrophysiological screening of cardiomyocytes. 
4.1. Lentiviral Non-Clonal Gene Transfer Strategy 
We have chosen cardiac-specific expression of an antibiotic resistance gene in order to kill all  
non-cardiomyocytes by antibiotic application. In contrast to low throughput single-cell sorting  
of labeled cardiomyocytes [14,15], this strategy enables the large-scale purification of cells. 
Because transfection of plasmid with common chemical, electroporation or lipofection methods 
suffers from poor efficiency in undifferentiated iPS cells, viral gene transfer methods are suitable 
alternatives [25,26]. We have used a lentivirus strategy that allows not only high efficient gene 
transfer, but also stable integration into the genome [25]. In addition to the cardiac-specific 
antibiotic resistance, we have employed a neomycin resistance gene under the control of the  
stem cell-specific promoter, Rex-1 [20], which was shown before to be useful for the selection  
of embryonic stem cell clones [17]. Thus, neomycin treatment allowed the selection of 
undifferentiated cells with stable lentivirus integration and without silencing or adverse positional 
effects of the surrounding host chromatin. One further advantage of using Rex-1-neomycin is that 
the continuous selection pressure at undifferentiated stages prevents iPS cell differentiation or 




Usually, after classical or viral gene transfer into pluripotent stem cells, several single-cell 
clones are picked, propagated and characterized individually [16], a very time-consuming 
procedure and, therefore, an expensive task. In contrast to previous work, we decided to pool all 
iPS cells that survived the neomycin selection and generated one non-clonal iPS cell line for each 
genotype. This strategy harbors the risk that a single iPS cell clone with enhanced proliferation by 
lentivirus-induced mutations or chromosomal aberrations could overgrow the mixed population. 
However, the intact stem-cell morphology, the expression of stem cell markers, the normal 
proliferation of the mixed clones and the high similarity of all electrophysiological parameters in 
cardiomyocytes from early and late passages of the non-clonal iPS cell lines suggest no adverse 
effects of this strategy. Importantly, the phenotypical fingerprint of LQTS 3 (APD prolongation at 
slow rates) was only observed in Scn5a /+ cardiomyocytes, both at early and late passages. 
Furthermore, the slope values of cardiomyocytes from the non-clonal iPS cells were almost 
identical to those from the original iPS cell clones [5]. 
The novel possibility to work with non-clonal iPS cells is also supported by a previous report on 
the successful generation of iPS cell clones in bulk culture without clone picking, which did not 
reveal differences with clonal selected iPS cell lines regarding pluripotency, gene expression 
profiles or differentiation potential [27]. Because a non-clonal strategy avoids manual clone 
picking and could be applied in 96-well or scalable formats, it enables the parallel generation and 
genetic modification of iPS cell lines from different patients at once. This would allow the 
purification of cardiomyocytes from many different patients for parallel and comparative 
electrophysiological screening. 
The non-clonal lentiviral cardiomyocyte purification strategy might also have limitations and 
variations in efficacy because of uncontrolled variations in copy numbers and integration sites 
between iPS cells. High concentrations of neomycin could be used for selecting clones with the 
highest copy numbers, and this should be investigated in the future. Because lentiviruses have the 
tendency to integrate into euchromatin [28], infection at the stem cell level could lead to clones that 
are neomycin resistant at undifferentiated stages, but encounter lentiviral silencing upon 
differentiation and, therefore, fail to express puromycin for cardiomyocyte purification. Furthermore, 
the random integration of lentiviruses could cause insertional mutagenesis; however, this seems not 
to be frequent, because they tend to integrate away from promoters [29]. 
Recently, metabolic selection by the cultivation of stem-cell-derived cells in glucose-depleted 
medium containing only lactate as the energy source was described to be an efficient non-genetic 
method for the purification of cardiomyocytes [30]. Although the authors report a purity of 99% 
cardiomyocytes, this method seems to be highly dependent on the cell line used. In fact, although 
we have extensively tried to reproduce these purity values, we only obtained 45%–80% 
cardiomyocytes from mouse embryonic stem and human iPS cell lines using identical metabolic 
selection procedures [31]. 
4.2. Choice of a Cardiac-Specific Promoter 
For cardiac-specific expression of the puromycin resistance gene, we have used the -MHC 




and human iPS and embryonic stem cells [16,17,32,33]. Because of the size limitation for gene 
transfer using lentivirus (~9–10 kb between LTRs [27]), we had to use a short version (~1.7 kb) of 
the 3  end of the classical 6.5 kb-long -MHC promoter. Although this fragment contained 
important gene expression regulatory elements (TATA box, MEF-1 MEF-2 and Nkx2.5 binding 
sites) [34], it is likely that unidentified enhancing elements were not present explaining the weak 
GFP expression. Nevertheless, purification of cardiomyocytes was unharmed, indicating sufficient 
expression of the puromycin resistance gene. This indicates a lower threshold for puromycin 
resistance than for GFP fluorescence, because the use of a 2A self-cleaving peptide should result in 
equimolar expression of both proteins [18]. 
In the future, the use of other promoters should be considered. Although the -MHC promoter is 
labeling mature cardiomyocytes in mice, -MHC is the predominant isoform in the human 
ventricle, and -MHC is a marker rather for atrial or failing human cardiomyocytes [35]. Therefore, 
mature cardiomyocytes from human iPS cells should be selected with the -MHC promoter. 
Furthermore, the choice of other subtype-specific promoters could be very useful to obtain the 
cardiomyocyte population of interest. For instance, LQTS could be best investigated in ventricular 
cardiomyocytes that have long AP durations and could be selected using the MLC2v promoter. 
Moreover, mutations inducing atrial fibrillation might be better investigated with atrial cell 
selection by the MLC2a promoter, and for studying inherited sick sinus syndromes, pacemaker 
cells could be purified with sinus node-specific HCN or Tbx promoters. 
4.3. Automatable and Scalable Electrophysiological Screening 
The use of screening procedures to analyze APs of iPS cell-derived cardiomyocytes is 
particularly important to identify drugs that induce LQTS or to screen compounds that could treat 
inherited LQTS. For the systematic screening of many compounds, the classical manual patch 
clamp is not suitable, and automated and scalable systems are mandatory. For instance, the planar 
patch clamp technique [12] or the microelectrode array system [24,36] allow the acquisition of 
more data points per day (planar patch clamp: 200–1000; microelectrode array: 500) than the 
conventional patch clamp (50 data points/day) [36]. 
The planar patch clamp system that we have used in this study allows the automated recording 
of up to eight cells in parallel, as well as the automated application of several compounds. Because 
cells must be measured in suspension, very gentle dissociation methods have to be further 
optimized to avoid digestion of transmembrane ion channels. 
We found that most action potential parameters were similar between manual and planar patch 
clamp recordings; however, APD90 tends to be longer (statistically not significant) in the latter 
(Table 1). We speculate that when using the automated planar patch clamp method, the dissociation 
procedure or the suction process onto the small holes of the borosilicate glass chips could kill 
smaller atrial or pacemaker cells with shorter APD or might favor larger ventricular cells with 
longer APD. However, although absolute APD values seems to vary with the method, the 
phenotypical fingerprint of LQTS 3-specific cardiomyocytes (positive slopes in the longitudinal 




Similar to the conventional patch clamp, also during automated planar patch clamp analysis, the 
intracellular milieu is dialyzed against the internal solution, which leads to the wash out of 
important intracellular components and, therefore, reduces the stability of long-term recordings. 
This limits the duration of electrophysiological recording of one cell and, therefore, also the 
number of different compounds and dosages. Thus, this technology seems to be not suited for real 
high throughput analysis of several thousands of compounds. 
Although, here, we only performed six recordings on a microelectrode array in parallel, scalable 
and automatable systems were developed (QT screen Multi Channel Systems) for parallel field 
potential recording and compound testing on 96 channels. In contrast to conventional 
microelectrode measurements (500 data points/day), such systems allow the recoding of 6000 data 
points/day [36]. One remaining challenge is the almost impossible electrical stimulation  
of cardiomyocytes on microelectrode arrays for standardized recordings and to determine  
frequency-dependent effects. This could be solved by using optogenetic technology, which was 
shown to be effective for the stimulation of purified cardiomyocytes on microelectrode arrays [37]. 
5. Conclusions 
The herein reported non-clonal lentiviral strategy for the purification of cardiomyocytes from 
iPS cells is simple, fast and cheap and could be applied to large numbers of different iPS cell lines 
at once. In contrast to the picking of classically-transfected iPS cell clones, this strategy would 
allow the parallel purification of cardiomyocytes from many different patients for comparative 
electrophysiological analysis. Because the disease-specific phenotype of purified iPS cell-derived 
cardiomyocytes was retained and could be analyzed with automated planar patch clamp and 
scalable microelectrode array technologies, these assay systems will be useful for patient-specific 
drug screening in the future. 
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Clinical Potentials of Cardiomyocytes Derived from  
Patient-Specific Induced Pluripotent Stem Cells 
Kwong-Man Ng, Cheuk-Yiu Law and Hung-Fat Tse 
Abstract: The lack of appropriate human cardiomyocyte-based experimental platform has largely 
hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic 
cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and 
subsequently differentiated into functional cardiomyocytes. This powerful reprogramming 
technology provides a novel in vitro human cell-based platform for the study of human hereditary 
cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac 
disorders for therapeutic studies have been increasingly highlighted. In this review, the standard 
procedures for generating patient-specific iPSCs and the latest commonly used cardiac 
differentiation protocols will be outlined. Furthermore, the progress and limitations of current 
applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease 
modeling, drug-testing and toxicology studies will be discussed in detail. 
Reprinted from J. Clin. Med. Cite as: Ng, K.-M.; Law, C.-Y.; Tse, H.-F. Clinical Potentials of 
Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells. J. Clin. Med. 2014, 
3, 1105–1123. 
1. Introduction 
Cardiomyocytes, or heart muscle cells, are fragile but important constituents of the myocardium.  
It is generally believed that humans are born with a fixed amount of cardiomyocytes; therefore, the 
death of these muscle cells may cause permanent damage to the heart. Recently, Bergmann and 
colleagues have evidenced a revolutionary notion of the in vivo regeneration and renewal of 
cardiomyocytes in humans [1]; nevertheless, the rate of cardiomyocyte turnover in their experiment 
appeared to be extremely slow. In fact, following myocardial injury, the heart usually repairs itself by 
cellular hypertrophy [2]. In case of a substantial loss of cardiomyocytes such as severe myocardial 
infarction, the damaged tissue is replaced with fibroblasts, rather than functional cardiomyocytes.  
To this end, the heart function is permanently impaired. Attempts of using adult stem cells or 
embryonic stem cells in replacing the damaged myocardium have been made, and several successful 
cases have been reported. Yet, such a replacement approach is impeded by various factors, for 
instance, the limiting sources of stem cells as well as the non-self rejection issues. In 2007, 
Yamanaka and colleagues demonstrated the first time that adult human fibroblasts could be 
reprogrammed into the pluripotent stem cells when supplemented with well-defined culturing 
factors [3]. Based on this revolutionary reprogramming approach, any fully differentiated cells 
obtained from patients should be theoretically able to be reprogrammed into induced pluripotent 
stem cells (iPSCs), and further differentiated into specialized cells of desired interest such as 
cardiac derivatives. The iPSCs obtained would be patient-specific; they not only provide a new 




modeling of inherited cardiac diseases and screening of potential cardiovascular drugs. In this 
review, the clinical potentials of patient-specific iPSCs in therapeutic treatments of cardiac 
disorders will be addressed in detail. 
2. Patient-Specific iPSCs and Their Cardiac Derivatives 
In 2006, Yamanaka and colleagues demonstrated for the first time that the exogenous expression 
of four transcription factors—Oct4, Klf-4, Sox-2 and c-Myc [4]—Initiated the reprogramming of 
terminally differentiated murine somatic cells (skin fibroblasts) into iPSCs, which were characterized 
with adequate pluripotency. Similar to embryonic stem cells, these iPSCs were able to self-renew, 
proliferate and differentiate into various cell types including neurons and cardiomyocytes [5,6].  
The same research group at a later time showed that human somatic cells could also be 
reprogrammed into iPSCs [3,7]. These technological breakthroughs have made substantial impacts 
in cell replacement therapy, disease modeling and therapeutic discovery sectors. Although the cells 
from a patient with myocardial infarction can be reprogrammed and differentiated into functional 
cardiomyocytes, the replacement of the defective cells of a particular patient is still theoretical. 
Nevertheless, iPSCs generated from patients with inherited cardiac diseases, following in vitro 
cardiac differentiation, are still valuable tools for disease modeling and development of personalized 
medicine (Figure 1), as the iPSCs-derived cardiomyocytes possess the defective genes of the patients. 
Figure 1. The clinical applications of the cardiomyocytes derived from patient-specific iPSCs. 
 
3. Standard Procedures in Generating Patient-Specific iPSCs and Their Cardiac Derivatives 
In general, the generation of human iPSCs-derived cardiomyocytes involves three major steps:  
(i) collection of somatic tissues/cells; (ii) reprogramming; and (iii) cardiac differentiation. 
3.1. Collection of Somatic Tissues/Cells 
The protocol of Yamanaka and colleagues suggested the use of skin fibroblasts as the starting 
material of iPSCs generation. However, the invasive procedures of collecting skin biopsy actually 




generation. In this regard, less invasive alternatives are obviously more preferable in clinical 
practices. It is now evidenced that apart from skin fibroblasts, many other cell types, such as hair 
follicle cells, peripheral blood cells as well as uro-epithelial cells, could also be reprogrammed into 
iPSCs [8–13]. Among these cells, the collection of uro-epithelial cells from urine accounts for the 
simplest and most convenient way. This non-invasive method eliminates pain or wound caused by 
skin biopsy collection; thus, is more likely to be accepted by patients. In fact, our laboratory is now 
routinely collecting urine samples from patients for iPSCs generation [14,15]. 
3.2. Reprogramming 
The first generation of reprogramming method involved the use of retrovirus vectors in infecting  
four transcription factors (Oct4, Klf4, Sox2 and c-Myc) into cultured fibroblasts. This method is 
quite robust; for this reason, many laboratories, including ours, are routinely using this method  
for iPSCs generation. However, the reprogramming efficiency of this method is not high  
(about 0.0002%). Moreover, the use of retrovirus vectors is a big concern in clinical applications. 
Therefore, several alternative methods have been proposed. For example, Nanog and Lin28 are 
suggested as additional reprogramming factors in some protocols since the addition of these  
two factors increased the efficiency to about 0.05% for fetal fibroblasts [16]. As retrovirus only 
infects actively dividing cells, the use of lentivirus-based vectors may be a better option for the cell 
types that are non-actively dividing or less proliferative (e.g., cardiac fibroblasts). It is generally 
accepted that lentivirus-based vectors can transduce both dividing and non-dividing cells. On top of 
that, lentivirus-based vectors can accommodate much larger inserts. The four essential 
reprogramming factors Oct4, Klf4, Sox2 and c-Myc could be linked up within one single expression 
cassette [17] and simultaneously inserted into a single vector. This strategy eliminates the need for 
producing multiple transducing vectors; thus it avoids the possible stoichiometric and temporal 
interference among individual viruses [18]. 
Despite that retrovirus- and lentivirus-based vectors are widely used in iPSCs generation, the 
incorporation of viral sequences into the host genome is still an important concern in clinical 
applications, especially in the cell replacement therapy utilizing patient-specific iPSCs. For addressing 
this issue, the application of a Cre-loxP system in the lentivirus backbone has been suggested, so that 
the viral sequences could be eventually cleaved from the host genome upon the execution of 
Cre-recombinase [19,20]. Nevertheless, the use of non-integrative viruses appears to be a more 
acceptable method. For example, non-integrative viruses, such as adenovirus and Sendai virus, have 
been successfully used in some reprogramming protocols of human fibroblasts [21,22]. In addition, 
epigenetic reprogramming methods, such as transfection of mRNA, miRNA, minicircle vectors and 
episomal plasmids are regarded as the possible alternatives for footprint-free iPSCs reprogramming. 
3.3. Cardiac Differentiation 
In spontaneous differentiation, cardiomyocyte is one of the most easily identifiable cell types.  
Even in the absence of specific growth factors, spontaneous beating clusters could be observed when 




actual number of cardiomyocytes within a spontaneous beating embryoid body may comprise as low 
as merely 1% of the total cell population. It is obvious that spontaneous differentiation is not 
sufficient for the generation of iPSCs-derived cardiomyocytes in an adequate quantity for most 
experimental assays or applications. Early methods of directing cardiac differentiation involved the 
co-culture of iPSCs with END-2 endodermal cells. This END-2 co-culturing method has been used 
widely for cardiac differentiation of human embryonic stem cells and is relatively robust [23,24]. 
However, the difficulty in separating the cardiomyocytes from the feeder layers denotes a main 
drawback of this method. To date, many feeder-free cardiac differentiation protocols have been 
developed, so that problems associated with feeder layers can be eliminated. Most of these 
feeder-free methods involve the incubation with growth factors, such as the BMP4, Activin A, VEGF 
and DKK that regulate the pathways directing heart formation during fetal developments [6,25]. 
Recently, Palecek and colleagues reported a successful application of Wnt pathway inhibitors in 
directing cardiac differentiation of human iPSCs [26,27]. By modulating the Wnt/ -catenin signaling 
under fully defined conditions, monolayers of virtually pure cardiomyocytes (up to 98%) were 
obtained in merely 14 days. 
4. Application of Patient-Specific iPSCs in Cell Replacement Therapy/Regenerative Medicine 
Increasing evidences showed that the adult human heart possesses a certain degree of regenerating 
power. Following severe cardiac injury, cardiac hypertrophy and scarring are indeed the major 
repairing mechanisms to maintain minimum cardiac functions and prevent further damages. 
However, without the replacement of new cardiomyocytes, the ordinary repairing mechanisms 
usually result in the continual increase of cardiac workload that further worsens the injured 
condition and even leads to chronic heart failure of the patient. To this end, various studies have been 
converged on the use of pluripotent stem cells in cardiac recovery. 
A previous study reported that the transplantation of human embryonic stem cells-derived 
cardiomyocytes into the infarcted myocardium of an immunodeficient rodent partially remuscularized 
myocardial infarcts and improved cardiac function [28,29]. At a later stage, Gaballa and colleagues 
demonstrated that cell sheets composed of rat or human cardiac progenitor cells, when transplanted 
into the infarcted heart, could proliferate and differentiate into functional cardiomyocytes, and rescue 
myocardial function [30]. 
Besides human embryonic stem cells, human iPSCs also possess the ability to differentiate into 
cardiac lineages. Since iPSCs can be derived from any individual, the use of human iPSCs in 
regenerative medicine can avoid the ethical issues arising from the use of embryonic materials. 
Furthermore, iPSCs can be produced from the same individual who is receiving the cell 
replacement therapy, so that immunological incompatibility should become less significant. 
Recently, Watt and colleagues attempted to investigate the potential benefits of human  
iPSCs-derived progenitors. In their study, human iPSCs-derived cardiac progenitor cells were 
injected into the pre-infarct hearts of rats. The injected cells were able to differentiate into 
cardiomyocytes and smooth muscle fibers, and were retained in the rat hearts for at least 10 weeks 




human-iPSCs-derived cardiac progenitor cells showed some improvement in the left ventricular 
ejection fraction [31]. 
It should be noted that although many studies have pointed out the beneficial effects of human 
embryonic stem cells and iPSCs against ischemic cardiac injuries, most of the studies only 
involved a relatively short follow-up period (see Table 1); thus, the long term efficacy of 
iPSCs-derived cardiac progenitors remains questionable. 








Timing of  
the Delivery 
Follow up  
Duration 
Reference 
iPSC Mouse 50,000 IM 
Immediately after 
MI induction 
2 weeks [30] 
iPSC-derived 
cardiac progenitors 
Rat 2 × 106 IM 
10 min after  
MI induction 
10 weeks [31] 
Cardiosphere Rat - Cell sheet 
Immediately after 
MI induction 
3 weeks [32] 
5. Applications of iPSCs-Derived Cardiomyocytes in Modeling Genetic Cardiomyopathies 
Cardiomyopathies are heterogeneous groups of diseases of cardiomyocytes. Pathologically, the 
diseases could be caused by non-genetic factors such as viral infection though genetic contributions 
are frequently observed [33]. To date, over 50 genes have been reported to be associated with various 
forms of cardiomyopathies; yet, the studies of the pathogenic mechanisms underlying specific 
genetic defects remain elusive due to the lack of appropriate experimental models. 
Theoretically, the affected tissues obtained from patients with cardiomyopathies are the best 
options for pathophysiological studies; however, for cardiac diseases, the limitation in obtaining and 
maintaining cardiac biopsy samples highly hindered this strategy. 
To compensate this limitation, transgenic animals are commonly used for modeling human 
genetic defects. Nonetheless, due to the substantial physiological differences between the hearts of 
human and those of mice [34–36], the use of transgenic mouse lines in modeling human genetic 
cardiomyopathies is of little practical value. For example, in terms of ion-channel physiology, 
transgenic mouse models, in most cases, only partly recapitulate the disease phenotypes [36,37].  
The phenotypic differences between species accentuate the importance of a novel human 
cardiomyocyte-based model in the studies of heritable cardiac defects, and the cardiomyocytes 
derived from patient-specific iPSCs should be one of the most desirable options. 
In general, if the mutation of the gene of interest does not interfere in cardiac differentiation, 
cardiomyocytes can be continually generated from patient-specific iPSCs. This continuous supply of 
cardiomyocytes indeed resembles the cardiac biopsy samples that could hardly be obtained from 
patients with specific inherited cardiac defects; thus these patient-specific iPSCs-derived cardiomyocytes 
provide a convenient and valuable platform for research purposes. In fact, various recent reports 
have demonstrated that the cardiomyocytes derived from patient-specific iPSCs were able to 




clearly evidenced the feasibility of utilizing the patient-specific iPSCs-derived cardiomyocytes in 
modeling heritable cardiomyopathies. 
In 2010, Laugwitz and colleagues established the first patient-specific iPSCs based model for type 1 
Long QT syndrome [41]. In their study, the skin fibroblasts from patients carrying an autosomal 
dominant missense mutation (R190Q) in the KCNQ1 gene were effectively reprogrammed into iPSCs. 
The resultant iPSCs were further differentiated into atrial- and ventricular-like cardiomyocytes and 
subjected to patch-clamp analysis. When comparing to the control, the iPSCs-derived cardiomyocytes 
with the KCNQ1 mutation showed a markedly prolonged duration of action potential, altered 
activation and deactivation properties of IKs, and an abnormal response to catecholamine 
stimulation. Immunostaining analysis demonstrated the failure of mutated Kv7.1 potassium channel 
protein in its trafficking to the plasma membrane; this finding may provide an explanation to the 
cellular pathogenic mechanism of the KCNQ1R190Q mutation. Undoubtedly, the use of iPSCs-derived 
cardiomyocytes in modeling inherited cardiac disorders is feasible. 
In addition to Long QT syndromes, cardiomyocytes derived from patient-specific iPSCs have also 
been used in the modeling of some other genetic cardiac disorders (Table 2); examples are outlined  
as follows: 
Table 2. Examples of using iPSCs-derived cardiomyocytes for modeling genetic cardiomyopathies. 
Disorder Gene Involved Details of the Mutation Ref. 
Long QT syndrome, Type 1 KCNQ1 missense mutation (R190Q) leads to the production of a mutant protein [41] 
Long QT syndrome, Type 2 KCNH2 missense mutation (A614V) leads to the production of a mutant protein [38] 
Long QT syndrome, Type 2 KCNH2 missense mutation (G1618A) leads to the production of a mutant protein [40] 
Long QT syndrome, Type 2 KCNH2 missense mutation (R176W) leads to the production of mutant protein [42] 
Long QT syndrome, Type 3 SCN5A 
Multiple mutations (G5287A; V1763M) leads  
the production of a mutant protein 
[43] 
Long QT syndrome, Type 8 CACNA1C Missense mutation (G406R) leads to the production of a mutant protein [44] 
Catecholaminergic polymorphic 
ventricular tachycardia, Type 1 
RYR2 
Missense mutation (F2483I) leads to the production of  
a mutant protein with an altered FKBP12.6 binding domain 
[45] 
Catecholaminergic polymorphic 
ventricular tachycardia, Type 1 
RYR2 Missense mutation (S406L) leads to the production of a mutant protein [46] 
Catecholaminergic polymorphic 
ventricular tachycardia, Type 2 
CASQ2 Missense mutation (D307H) leads to the production of a mutant protein [47] 
Catecholaminergic polymorphic 
ventricular tachycardia, Type 2 
CASQ2 Missense mutation (D307H) leads to the production of a mutant protein [47] 
Dilated cardiomyopathy TNNT2 missense mutation (R173W) leads to the production of a mutant protein [48] 
Dilated cardiomyopathy DES missense mutation (A285V) leads to the production of a mutant protein [49] 
Hypertrophic cardiomyopathy MYH7 Missense mutation (R663H) leads to the production of a mutant protein [50] 
Friedreich ataxia-associated  
hypertrophic cardiomyopathy 
FXN 
GAA repeat expansion in the first intron leads to  
the partial silencing of gene expression 
[51] 
5.1. Modeling Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
Although inherited arrhythmogenic disorders are frequently associated with the mutations in the 




catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by the mutations in genes 
encoding the proteins mediating intracellular calcium transient. In response to emotional or physical 
stress, CPVT patients may manifest ventricular premature beats and bidirectional or polymorphic 
ventricular tachycardia, which leads to episodic syncope, seizures and sudden death [52,53]. So far, 
two types of CPVT have been described based on their difference in the mode of inheritance.  
The autosomal dominant form that accounts for up to 50% of the cases has been linked to the 
mutations in the RYR2 gene that encodes the cardiac ryanodine receptor [54], while a rare 
autosomal recessive form results from the mutations in the CASQ2 gene that encodes the cardiac 
calsequestrin [55]. Functionally, ryanodine receptor and calsequestrin work together to mediate the 
release of calcium ions from the sarcoplasmic reticulum (SR) in the cardiac muscles during 
excitation-contraction coupling. As such, it is not surprising that mutations in the RYR2 and CASQ2 
genes that result in functional derangements in intracellular calcium handling may result in 
arrhythmia. Since 2004, the pathophysiological roles of various RYR2 and CASQ2 mutations in 
driving the development of CPVT have been investigated in several transgenic animal or cell 
models [56–59]. Although most of the models were able to recapitulate the major CPVT 
phenotypes, such as SR calcium leak and catecholamine-induced delayed after-polarizations 
(DADs), the clinical significance of these models were limited by the substantial difference in the 
cardiac electrophysiology between rodents and human. Addressing this issue, the pathogenic effects 
of various CPVT associated mutations have been studied in patient-specific iPSCs models. These 
include the RYR2F24831I, RYR2S406L, CASQ2D307H mutations [45–47]. Similar to the rodent models, all 
these iPSCs-based models were able to recapitulate the CPVT phenotypes, and the results confirmed 
that the diastolic SR calcium leak contributes to generation of DADs [45–47]. Except for disease 
modeling, the iPSCs-based CPVT models also provided a human cardiomyocytes-based platform for 
drug testing and toxicology studies. For example, in a recent report, Laugwitz and colleagues 
demonstrated that dantrolene ameliorates the CPVT phenotypes caused by RYR2S406L mutation using the 
cardiomyocytes differentiated from the CPVT patient-specific iPSCs [46]. So far, only limited 
therapeutics, such as beta-blockers, are being used for treating CPVT. It is anticipated that the 
success in generating the CPVT-specific iPSCs may help facilitate the development of novel 
therapeutic approaches in treating CPVT. 
5.2. Modeling Dilated Cardiomyopathy Associated with TNNT2 Mutation 
Dilated cardiomyopathy (DCM) is the most common subtype of cardiomyopathy, and is 
characterized by the abnormal enlargement of ventricles, thinning of ventricular walls and the  
marked systolic dysfunction [33]. It has been estimated that about 50% of the cases are of genetic 
causes [60–63]. The pathological mechanisms associated with TNNT2 gene mutations have been 
evaluated in a transgenic mouse model, in which the null mutation of this gene denoted an impaired 
contractile function of the heart [64,65]. Yet, how the specific TNNT2 mutation contributes to the 
development of DCM phenotype in human remains ambiguous. 
In 2012, Wu and colleagues generated iPSCs from DCM patients carrying a disease associated- 
mutation in the gene encoding cardiac troponin-T (TNNT2) [48]. Sequencing analysis showed that 




arginine (R) to a tryptophan (W). Clinically, patients with this mutation develop the typical DCM 
symptoms including left ventricle dilation and reduced ejection fraction. Skin biopsy samples were 
collected from affected and normal individuals of three generations of a single family for iPSCs 
generation. The resultant iPSCs were then differentiated into cardiomyocytes for functional 
analyses. When comparing to the control, the cardiomyocytes derived from the mutation 
containing-iPSCs showed abnormal sarcomeric alpha-actinin distribution. Functionally, the mutant 
cardiomyocytes exhibited impairments in contractility and reduction in calcium handling ability 
upon -adrenergic stimulation. These observations indicated that the increased susceptibility to 
inotropic stress may be a signature characteristic of the TNNT2R173W mutation in DCM development. 
5.3. Modeling Cardiomyopathy Associated with DES Mutation 
The DES gene encodes the intermediate filament protein desmin, but the exact function of desmin  
is not well defined. Nevertheless, mutations in the DES gene are commonly observed in DCM  
patients [66]. Phenotypically, mutations leading to the loss of DES gene function usually give  
rise to a significant accumulation of desmin-positive aggregates in the cardiomyocytes of  
affected individuals. 
Lately, by utilizing the whole-exome sequencing approach, our laboratory has identified a  
novel DES mutation in a patient with left ventricular dilation and impaired left ventricular ejection 
function [49]. In this DES mutation, we recognized a change of the alanine (A) residue to valine (V) 
at the 285th amino acid position. In the transgenic mouse model with complete desmin deficiency, 
phenotypes such as hypertrophic and dilated cardiomyopathy [67] were observed. Surprisingly, the 
patient with DESA285V mutation produced a mutant desmin possessing molecular weight and 
immunoreactivity comparable to the wild type desmin protein. To investigate the pathological 
significance of this novel DES mutation, we have generated skin fibroblasts-derived iPSCs from this 
DESA285V patient. These DESA285V iPSCs were subsequently differentiated into cardiomyocytes for 
structural and functional studies. When compared to the normal cardiomyocytes, the ones carrying 
the DES mutation exhibited abnormal protein aggregations in sarcomere and Z-disc streaming.  
In addition, contraction arrest was observed in the mutant cardiomyocytes upon isoproterenol 
stimulation. These observations not only provided an explanation to the pathogenic mechanism 
underlying the DESA285V mutation, but also validated the causal ion relationship between the DES 
mutation and the DCM phenotype observed in that patient [49]. 
5.4. Modeling Hypertrophic Cardiomyopathy Associated with MYH7 Mutation 
Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by the 
abnormal left ventricular thickening and diastolic dysfunction in the absence of an identifiable 
hemodynamic cause [68]. About 13 HCM-associated genes have been identified to date and most of 
them encode sarcomeric proteins [69]. Transgenic mouse and rabbit models have been established 
for studying the pathological mechanisms of HCM [70–72]; however, the mechanistic roles of 
altered contractile function in the development of HCM remain inconclusive. Very recently, Lan and 




MYH7 gene. In their case, the 663rd residue of the -myosin heavy chain is changed from an arginine 
to a histidine as a result of a missense mutation. The patient-specific iPSCs were differentiated into 
cardiomyocytes for functional analyses. The mutant-containing cardiomyocytes recapitulated the 
key features of HCM, including increased cell size and arrhythmia. The intracellular calcium 
transient profile indicated that the diseased cardiomyocytes showed a significant increase in the 
resting intracellular calcium level when comparing to the normal cardiac muscle fibers. Interestingly, 
pharmaceutical inhibition of calcium entry helped to prevent the development of HCM phenotypes 
in the mutant cardiomyocytes suggesting the MYH7 mutation altered the calcium homeostasis 
dysfunction [50]. 
5.5. Modeling Friedreich Ataxia Associated Cardiomyopathy 
Apart from sarcomeric proteins, abnormality in the mitochondrial proteins may also contribute to 
HCM development. For example, deficiency in the mitochondrial protein frataxin may lead to 
Friederich ataxia (FRDA), in which patients usually develop with HCM phenotype to varying  
degrees [73]. In FRDA, abnormal expansions of the GAA repeat within the first intron of the FXN 
gene may result in the silencing of the gene, which in turn reduces or completely abolishes the 
production of the frataxin protein. 
Frataxin has been implicated in the mechanism of iron-sulfur cluster biosynthesis; however, the 
contribution of frataxin-deficiency to cardiomyopathy development has yet to be elucidated. 
To test whether iron homeostasis deregulation accelerates the reduction in energy synthesis 
dynamics that contributes to impaired cardiac calcium homeostasis and contractile force, we have 
recently generated skin fibroblasts-derived iPSCs from a FRDA patient [51]. The FXN gene 
expression in that patient was endogenously silenced. Phenotypically, the FRDA iPSCs-derived 
cardiomyocytes exhibited a disorganization of the mitochondrial network complemented with 
mitochondrial DNA depletion. Consistent with the mitochondrial disorganization, the energy 
synthesis dynamics, in terms of ATP production rate, in the diseased cardiomyocytes was impaired. 
Interestingly, when the diseased cardiomyocytes were subjected to iron overloading, a significant 
impairment in the calcium handling property was observed. These results indicated that 
patient-specific iPSCs are useful tools for studying FRDA-associated cardiac defects. 
6. Application of Patient-Specific iPSCs-Derived Cardiomyocytes in Efficacy Testing and  
Drug Screening 
Owing to the limited sources of human cardiomyocytes for in vitro analyses, the effects of a 
putative cardiac drug have to be conventionally tested in the well-established rabbit or canine 
Purkinje fiber model before proceeding to clinical trials. Nevertheless, as the non-human based 
cellular models often give false-positive or inconsistent results [74–76], many drugs that have passed 
the animal tests ended up with failure in the clinical trials. Recent reports demonstrated that human 
embryonic stem cells-derived cardiomyocytes exhibited excellent pharmacological response to 
various known antiarrhythmic agents; thus they may be a potential alternative to animal 




similar cardiac disorders could show quite different responses towards a particular drug. In this 
regard, the patient-specific iPSC-derived cardiomyocytes offer an exclusive platform for evaluating 
the efficacy of a particular drug or treatment strategy on a personal basis. 
Based on the latest breakthrough in the cardiac differentiation protocol, a yield of more than 80% 
in cardiomyocyte differentiation has been achieved [27]. When these patient-specific iPSCs-derived 
cardiomyocytes are applied to a high throughput assay platform, such as multielectrode arrays 
analysis, the effects of a testing drug on cellular electrophysiology can be evaluated in a short period of 
time. Emerging evidences from our group and other investigators have pointed out that altered calcium 
handling could be an important pathogenic mechanism underlying cardiomyopathies [48,49,79,80]; 
drugs that affect calcium homeostasis should be of great therapeutic potential. Mercola and 
colleagues have recently developed a high throughput automated kinetic image cytometry system for 
the measurement of calcium ion dynamics. This system enabled the authors to simultaneously 
measure individual calcium transients from 100 human iPSCs-derived cardiomyocytes [81]. Taking 
advantage of such system, high throughput screenings of calcium handling-enhancing properties of 
known or novel drugs can be performed on patient-specific iPSCs-derived cardiomyocytes. 
7. Application of Patient-Specific iPSCs-Derived Cardiomyocytes in Toxicology Test 
In addition to pharmacological studies, the cardiomyocytes derived from iPSCs are of great 
potential in the toxicology tests. So far, isolated canine cardiomyocytes are the most popular  
pre-clinical model for cardiac safety testing of a developing drug. However, as mentioned in the last 
section, the reliability of such model remains questionable. As a matter of fact, many drugs that have 
passed the animal tests turned out to show unanticipated cardiac toxicity when administered to  
patients [82], thus, a more predictive and reliable human cardiomyocyte-based model for toxicology test 
is of immediate demand. Increasing evidences suggested that the pharmacological sensitivities of human 
ESCs and iPSCs-derived cardiomyocytes are much more advanced than any animal models [77,78], and 
they should be good detectors for any undesired proarrhythmic side effects of a developing drug. 
Recently, Mendenius and colleagues proposed the possibility of using human ESCs and  
iPSCs-derived cardiomyocytes in the evaluation of drug-induced cardiac injury [83,84]. In their 
studies, the human ESCs- and iPSCs-derived cardiomyocytes were treated with doxorubicin, and the 
release of cardiac troponin T in culture medium was measured utilizing a Biocore-based system for 
the degree of cell injury. Compared to the conventional ELISA based assay, the surface plasmon 
resonance-based method not only provides superior sensitivity and specificity, but also allows 
simultaneous analysis of multiple samples. Consequently, the use of iPSCs-derived cardiomyocytes 
in toxicity predication appears to be feasible. 
8. Limitations of iPSCs 
The recent achievement in the patient-specific iPSC technology has created a new platform for 
regenerative medicine, disease modeling and personalized medication development. Yet, like many 
other technologies, the clinical applications of patient-specific iPSCs-derived cardiomyocytes are 




protocol allows efficient generation of cardiomyocytes in a high yield, the human iPSCs-derived 
cardiomyocytes are actually less mature in terms of calcium homeostasis when compared to the 
human ESCs-derived cardiomyocytes as demonstrated earlier by our laboratory [85]. In other words, 
the patient-specific iPSCs-derived cardiomyocytes may not be suitable for modeling cardiac defects 
resulted from mutations of genes that regulate calcium transients, such as the mutations in the gene 
encoding the phospholamban. 
Furthermore, it should be noted that a high yield of cardiac differentiation is not equivalent to 
high purity. In fact, iPSCs-derived cardiomyocytes are always grown in a mixed population of 
atrial, ventricular and nodal subtypes. These subtypes do possess different electrophysiology 
properties. So far, most transplantation studies were performed in rodent models [28,29].  
As rodents have a much faster heart rate compared to humans, the injection of human 
cardiomyocytes into rodent hearts may not create significant arrhythmia problems. However, the 
injection of mismatched subtypes of cardiomyocytes into a patient’s heart may lead to a medical 
emergency. Unfortunately, no efficient way is available to sort the subtypes of iPSCs-derived 
cardiomyocytes into pure populations. The direct application of patient-specific iPSCs 
cardiomyocytes in regenerative medicine, therefore, remains a theoretic foundation. Besides the 
issue of mixed subtypes, the immature phenotype of iPSCs-derived cardiomyocytes also limits its 
application in drug screening experiments. To this end, it is important to verify and validate the 
results obtained in the initial screening steps. 
9. Conclusions 
The cardiomyocytes derived from patients-specific iPSCs are of great potential in many clinical 
applications. This authentic human cardiomyocyte-based system is expected to compensate for the 
limitations of the current experimental animal models. This review provides detailed descriptions 
in the strategies and workflow of using the patient-specific iPSCs-derived cardiomyocytes in 
regenerative medicine, disease modeling and pharmacological applications. The examples 
illustrated in this review clearly evidenced the practical values of this novel technology. However, 
various limitations, such as the immaturities of iPSCs-derived cardiomyocytes, still need to be 
addressed, and future studies resolving these issues would be beneficial to the use of patient-specific 
iPSCs in clinical applications. 
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iPS Cells for Modelling and Treatment of Retinal Diseases 
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David A. Mackey 
Abstract: For many decades, we have relied on immortalised retinal cell lines, histology of 
enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials 
to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent 
availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has 
added a powerful alternative tool for discovering new disease-causing mutations, studying 
genotype-phenotype relationships, performing therapeutics-toxicity screening and developing 
personalised cell therapy. This review article provides a clinical perspective on the current and 
potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited 
retinal diseases and age-related macular degeneration. 
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1511–1541. 
1. Introduction 
The ability to convert a differentiated somatic cell from a patient into a pluripotent stem cell has 
provided new tools for studying organ development and genotype-phenotype relationships.  
Three-dimensional tissue structures and cells derived from these induced pluripotent stem cells 
(iPSCs) are now being used to screen and test the therapeutic and toxic effects of potential 
pharmacologic agents and gene therapies. More importantly, iPSCs could also be used to provide an 
easily accessible source of tissue for autologous cellular therapy. To date, the greatest potential 
benefit of iPSC technology is in the treatment of retinal diseases. 
The retina is a complex neurovascular tissue within the eye. It contains a network of neurons 
nourished by the retinal and choroidal circulations. Specialised neuronal cells, called rod and cone 
photoreceptors, capture light that enters into the eye. Through phototransduction within the 
photoreceptors and downstream neural processing by the bipolar, amacrine, horizontal and ganglion 
cells within the retina, light signals are transmitted to the primary and secondary visual cortex of the 
brain to enable visual sensation. The functions of these specialised neuronal cells are supported by 
the Muller glial cells and the retinal pigment epithelium (RPE). The ease of visualising retinal 
neurons and assessing the structure-function correlation in detail using readily available imaging 
devices will facilitate the in vivo clinical translation of iPSC technology in the diagnosis and 
treatment of retinal diseases (Figure 1). 
Among hundreds of human retinal diseases, the most significant are age-related macular 
degeneration (AMD) and the inherited retinal diseases (IRDs). Both AMD and IRDs are neither 
preventable nor curable, and they remain the most significant causes of irreversible blindness.  




related to single gene mutations to complex gene-metabolic-environment interaction, resulting in 
extracellular remodelling, abnormal angiogenesis, chronic inflammation, defective lipid metabolism 
and oxidative injury, as proposed in AMD [1]. The discovery of the pathological basis of these 
diseases was made possible through clinical observation using detailed retinal imaging techniques, 
human genetic studies, histology of post-mortem, enucleated or aborted foetal eyes, immortalised 
cell line culture systems and animal models of retinal diseases. However, in routine clinical practice, 
retinal diagnosis is rarely based on retinal histology because of the significant morbidity associated 
with retinal biopsy and the ease in making a diagnosis, because the retina is easily visualised.  
The availability of iPSC technology provides an opportunity to obtain retinal tissue without retinal 
biopsy. There are now several examples in which iPSC-derived retinal cells are used to confirm the 
clinical and genetic diagnosis of IRDs [2,3], understand the molecular mechanisms of developmental 
anomalies of the eye [4] and explore the cellular mechanisms of specific genetic mutations [5–8]. In 
addition to improving diagnostic capability, the use of iPSCs in clinical practice could also lead to 
new treatments for retinal diseases (Figure 2). 
Figure 1. An example of high-resolution retinal images from a patient with 
hydroxychloroquine toxicity. (A) Wide-field colour photography; (B) Zoomed-in colour 
image highlighted by the yellow box in (A) of the macular region showing no obvious 
abnormality; (C) Near-infrared reflectance image of the macula showing no obvious 
abnormality; (D) Adaptive optics retinal image highlighted by the yellow box in  
(C) showing the loss of wave-guiding cone outer segments in the perifoveal region;  
(E) Microperimetry showing reduced sensitivity to light in the macular region;  
(F) Zoomed-in image of the perifoveal region showing reduced sensitivity (<25 dB is 
abnormal); (G) Corresponding optical coherence tomography through the fovea showing 
no obvious loss of the ellipsoid zone of the photoreceptors (yellow arrow). 
 
Central to most blinding retinal diseases is the loss of cone photoreceptors. Strategies to preserve 
or replace cone cells are under intense investigation. Cones can be preserved by: (1) anti-oxidant 
therapy; (2) pharmacological therapy that provides neuroprotection; (3) gene correction therapy; and  




cone cells can be replaced by: (1) transplantation of patient-specific or allogeneic photoreceptor 
precursors (along with supporting cells); (2) recruitment of endogenous cells to differentiate into 
new photoreceptor or to become light-responsive cells (optogenetics); or (3) implantation of 
epi-retinal, sub-retinal, suprachoroidal or optic nerve visual prostheses [9–11]. Some of these 
treatment modalities have been investigated in cell culture systems and animal models, and many of 
these have also been tested in phase I/II clinical trials [12–15]. A major limitation of clinical 
therapeutics trial in IRDs is the vast heterogeneity of the underlying genetic mutation. Many of the 
approaches to preserve cones may only be suitable for one genetic variant, but not another, despite a 
similar clinical phenotype. Given the rarity of many IRDs, randomised clinical trials are not feasible. 
As an alternative, iPSC-derived retinal tissue from many patients with IRDs can now be tested in vitro, 
simultaneously, in a pre-clinical study, for the potential dose-therapeutic effect response and toxicity of 
various pharmacologic agents or gene therapies. As genomic editing techniques are emerging and 
iPSCs are being used as a cell source for replacing lost retinal cells, we now also have the capability of 
eliminating specific mutations prior to retinal differentiation, thus providing the option of autologous 
transplantation even to patients with IRDs [16]. 
Figure 2. A somatic cell from the patient is used to derive induced pluripotent stem cells 
(iPSCs). The iPSC colonies are characterised to ensure pluripotency markers are present, 
they form teratoma or embryoid body and they have stable chromosomes. It may take up 
to three months to derive and validate iPSC lines. The validated iPSC colonies are 
differentiated to form optic vesicle structures, which contain retinal pigment epithelium 
and neural retinal cells. Mature retinal cells can be used for confirming the pathogenicity 
of newly-discovered genetic variants, modelling of developmental or degenerative retinal 
disease, testing of pharmacologic agents or gene therapy and autologous cellular therapy. 
 
There are several excellent reviews on the use of human iPSCs in the study of retinogenesis, 
modelling retinal disease, screening of therapeutics and cell replacement therapy in both AMD and  
IRDs [17–22]. The purpose of this review is to provide an update, from a clinical perspective, on the 




expand on clinically relevant issues related to laboratory techniques to derive clinical grade  
iPSC-retina and illustrate examples in which iPSC technology has translated into patient care. 
2. Derivation of Patient-Specific Retinal Cells from iPSC for Clinical Use 
The availability of human retinal tissue and pure populations of specific types of retinal cells is 
critical to our ability to diagnose and treat retinal diseases. Allogeneic sources of retinal tissue and 
cells can be obtained from donor eyes or cell lines. However, these are not clinically useful for 
confirming genetic diagnosis of a patient or for autologous cellular therapy. Access to 
patient-specific retinal tissue requires an intraocular procedure, called a vitrectomy, followed by 
detachment of the retina, retinectomy, laser retinopexy and a vitreous substitute to provide a 
temporary tamponade. Although this type of procedure is rarely performed for obtaining retinal 
tissue for the diagnosis of vitreoretinal lymphoma, there are significant blinding complications, such 
as retinal detachment, and the harvested retinal tissue will not be of adequate quantity or quality for 
disease modelling, retinal regenerative therapy or screening new therapeutics. Therefore, there is a 
clinical need for obtaining patient-specific retinal cells without the need to perform retinal biopsy. 
2.1. Creating iPSC from Patients 
2.1.1. Using Pluripotent Stem Cells 
An alternative method to obtain patient-specific retinal cells is to use patient-derived adult stem 
cells for differentiation into retinal lineages. Retinal neural and pigment epithelial progenitor  
cells [23,24] have been found in the adult retina, but access to these cells is also limited, as they will 
require vitrectomy surgery, making them equally unsuitable for clinical use in testing therapeutics 
and administering personalised cell therapy. Multipotent neural stem cells capable of generating 
retinal lineages have also been found in the ciliary margin zone and corneoscleral limbus [25–28]. 
The former source is located adjacent to the lens within the eye, and it is even more difficult to access 
than the retina. In contrast, limbal tissue is routinely harvested by corneal surgeons for autologous 
limbal transplantation. Despite the ease of limbal cell harvesting and the long-term safety of the 
limbal graft donor site [29,30], its use for retinal regeneration and disease modelling has not yet been 
explored due to limited data on the ability for in vitro expansion and the potential for differentiation 
into all retinal cell types. 
Unlike adult stem cells that are multipotent or unipotent, i.e., committed to specific cell  
types, pluripotent stem cells (PSCs) have a capacity for unlimited self-renewal (hence, large 
quantities of cells) and differentiation into any somatic cell type, including all classes of retinal cells. 
One source of PSC is the embryonic stem cells (ESCs), harvested from the inner cell mass of the 
blastocyst, from which each of the three germ layers—the endoderm, ectoderm and mesoderm—can 
be derived. However, ESCs are derived from discarded surplus embryos, and this is not 
patient-specific. Human ESC-derived RPE is currently being used in several clinical trials, but 
recipients are being immunosuppressed, because of the potential risk of graft rejection [12]. 
More recently, PSCs can also be generated by dedifferentiating a terminally differentiated  




reprogramming. There are three established methods to induce pluripotency: (1) transfer of the 
nucleus of a differentiated cell into an enucleated oocyte (nucleus removed), so that pluripotency 
genes within the somatic cell genome are activated by the regulators within the oocyte cytoplasm 
(nuclear transfer) [31]; (2) fusion of a somatic cell with an ESC to create a hybrid or heterokaryon in 
which pluripotency regulators override cell differentiation regulators (cell fusion) [32]; and  
(3) induced overexpression of specific pluripotency transcriptional factors through transfection of an 
adult somatic cell with integrating virus, non-integrating virus, plasmids, mRNA or even exposure to 
protein or small molecules (induced pluripotent stem cell (iPSC) reprogramming) [33]. 
2.1.2. Induced Pluripotent Stem Cells 
Since the original description of the iPSC protocol by Yamanaka [34], there has been significant 
development in the reprogramming approach, and many types of somatic cells have been 
successfully induced into a pluripotent state. Conceptually, this is a two-step process of (1) nuclear 
reprogramming of a chosen somatic cell into several clones of iPSC and (2) validation of the 
pluripotency of the various clones of iPSC to select the most suitable clone for the specific purpose 
that iPSCs will be used, for diagnostics or therapeutics. The time lag from biopsy to obtain patient’s 
somatic cells to full validation of the best iPSC clone may take 2–3 months. Several factors will 
influence the choice of somatic cell for deriving iPSC. 
For therapeutic purposes, such as autologous cell replacement therapy, the ideal iPSC clone 
should be derived from an easily accessible somatic cell type in facilities that comply with good 
manufacturing practice guidelines related to cell therapy. Both adult stem cells and differentiated 
cells have been used to derive good quality iPSC lines. Although adult stem cells may already 
express some of the pluripotency-related genes, their expression is significantly lower than that seen 
in ESC or iPSC. Therefore, the same protocol for deriving iPSC is generally required for adult stem 
cells as for differentiated cells. Cells that proliferate well also reprogram well. However, there is 
significant variability in genetic and epigenetic patterns and the degree of reprogramming, even 
between iPSC clones from the same cell source. Hu et al. showed that iPSCs derived from RPE retain 
a “memory” of cellular origin with respect to the propensity for differentiation back to RPE [35]. 
However, it will not be feasible to use patients’ RPE as a source for deriving iPSC, due to surgical 
complications associated with tissue harvest. Furthermore, even without “memory” in source cells, 
RPE and neuroretinal cells have been generated readily from iPSC derived from cells of diverse 
background, such as cord blood cell, lymphocyte, keratinocyte, adipocyte and fibroblast [2,4,36–38]. 
Another easily accessible source of somatic cells is the ocular surface. The potential to generate iPSC 
from cells on the ocular surface (corneal epithelium and limbal niche) warrants further investigation, 
as they can potentially be reprogrammed to pluripotency without the introduction of transcriptional 
factors, as shown in rodent limbal-derived neurospheres [39,40]. In contrast to autologous 
transplantation of iPSC-derived retinal cells, special consideration needs to be given to the ease of 
transport and storage of somatic cells for deriving iPSC for the purpose of genetic diagnosis, disease 
modelling and high throughput drug screening. In this situation, blood-derived cells (activated T 
lymphocytes and endothelial progenitor cells) may be preferable, as they are easily collected, 




The reprogramming protocol should preferably avoid the use of viruses, such as retroviruses, that 
were used to create the first human iPSC [34,44]. Non-integrating viral vectors, DNA plasmids, 
modified RNA, protein and small molecules have all been reported to induce a pluripotent state in a 
somatic cell [45–50]. There is no one perfect methodology for creating iPSC for all types of clinical 
use. The main trade-off for the potential mutagenesis by integrating virus is the lower efficiency and 
higher cost associated with non-integrating methods. There have also been variations on the 
transcriptional factors used for reprogramming since the original description by Yamanaka (OCT4, 
SOX2, KLF4 and c-MYC) and Thomson (OCT4, SOX2, NANOG and LIN28) (Figure 3) [34,44]. Some 
protocols also use additional small molecules, such as 5-aza-deoxycytidine, valproic acid or ascorbic 
acid, to modify the epigenetic environment and enhance the efficiency and accuracy of nuclear 
reprogramming. Ultimately, these protocol modifications will also have an impact on the cost and quality 
of the human iPSC line and the suitability for clinical application, such as autologous transplantation. 
Regardless of the cell source and reprogramming protocol, successful generation of retinal tissue from 
iPSCs will depend on the skills of the operator in identifying the “right” iPSC clones for retinal 
differentiation. 
Figure 3. Retrovirus vector for induced pluripotent stem cell (iPSC) reprogramming.  
(A) Map of polycistronic retroviral vector. Human fibroblasts two days after infection 
with polycistronic GFP Oct4/Sox2/Klf4/cMyc; (B) iPSC after four weeks post infection 
negative for GFP indicating that the transgene is silenced in iPSC clone. 
(A) 
(B) 
2.1.3. Validation of Human iPSC Lines 
The key defining features of iPSC are the self-renewal capacity and the ability to produce all  




patient will be fully reprogrammed or truly pluripotent, and the efficiency of various protocols in 
generating iPSC clones can vary from 1:100 to 1:10,000. Screening to distinguish partially and fully 
reprogrammed colonies may add further delay and cost to the generation of patient-specific iPSC lines, 
and the thoroughness of this process depends on the clinical reasons for deriving the iPSC. It has been 
suggested that between five and 10 clones may need to be isolated for characterisation and future 
differentiation, because not all clones will have the same propensity for retinal lineage derivation, despite 
their potential [6,7,51,52]. 
Four techniques are used for characterising and subsequently selecting iPSC clones: cellular, 
molecular, functional and genetic (Table 1). The extent of characterisation required will again 
depend on the purpose of generating iPSC. Less rigorous criteria may be sufficient for genetic 
diagnosis and disease modelling compared to drug screening and cellular therapy. However, a 
minimum set of criteria for establishing putative iPSC has been recommended by the European 
Consortium of stem cell research (the ESTOOLS project). 
The unpredictable variability between clones may be related to the somatic origin of iPSC, the 
reprogramming technique or the intrinsic clonal variability within the individual. Furthermore, equal 
performance of iPSC clones against the same “pluripotency” tests does not translate to equal 
propensity for retinal lineage derivation. Further investigation is required to establish a selection 
screen and criteria for reducing clonal variation and identifying iPSC clones that have optimal retinal 
differentiation propensity. It can be envisaged that different criteria for establishing pluripotency 
may emerge for diagnostic and therapeutic use of iPSC. 
2.2. Creating Retinal Tissue from iPSC 
2.2.1. Derivation of Retina Lineages 
The fundamental principles for differentiating iPSC into retinal progeny have been laid down by 
previous work on mouse and human ESCs. However, the different propensity between iPSC and 
ESC for retinal differentiation brings into question the validity of the various protocols proposed. 
Most of these protocols rely on the initial spontaneous induction of retinal differentiation, but there is 
variability between cell lines. The lack of reproducibility by other laboratories also raises concern 
regarding their utility in the clinical setting. Nevertheless, there are two broad approaches: one by default 
differentiation of iPSC into neuroectodermal lineages (upon withdrawal of FGF2) and the other through 
directed differentiation by the addition of extrinsic molecules, such as growth and transcription factors. 
A common approach in deriving retinal cells is to allow human iPSCs to overgrow as adherent 
layers. With the use of specific extracellular matrix in addition to certain inducing factors and 
proteins, iPSCs may be preferentially differentiated into RPE or photoreceptor phenotypes. For 
example, Tucker et al. described the formation of two-dimensional eyecup-like structures in a 
synthetic xeno-free culture substrate when skin keratinocyte-derived iPSCs were used [2]. After 
formation of small pigmented foci at around 45 days, these clumps expanded over 150 days.  
In some of these clumps, neural cells fill the centre, whilst in other colonies, pigmented cells  




Similar two-dimensional eye-cup structures have also been reported by Jin et al. [53] and  
Reichman et al. [54]. 
 
An alternative approach is to culture iPSCs as suspended aggregates to enable the formation of  
three-dimensional cellular structures. Recapitulation of ocular organogenesis through the formation 
of an optic cup structure using a serum-free suspension culture system was first demonstrated using 
murine ESC by Eiraku et al. and then human ESC by Nakano et al. [55,56]. More recently,  
Meyer et al. described human iPSC-derived cell aggregates with vesicle-like and non-vesicular 
configurations after 20 days of culture using successive media changes from embryoid body medium 
(four days) to neural induction medium (seven days) and, finally, to retinal differentiation  
medium [6,51]. The vesicle-like structures expressed CHX10, a marker of retinal progenitor cells, 
whereas the non-vesicular spheres expressed ISLET-1, a homeodomain protein involved in early 
forebrain development. Upon further differentiation, photoreceptor-like cells and RPE were derived 
from the vesicle-like structures. Similar optic vesicle-like structures have also been generated from 
lymphocyte-iPSC [4,36]. Zhong et al. recently reported three-dimensional laminated retinal cups 
generated from human iPSC with distinct populations of neural retinal cells interacting through 
synaptic junctions and photoreceptor cells capable of forming outer segment discs and responding to 
light [57]. However, it is important to note that efficiency in generating PAX6+ neuroectodermal 
cells amongst different iPSC clones can vary from 5% to 56% of the total cell population using the 
same protocol, highlighting the need for further investigation into the methods and screening criteria 
to identify the most suitable iPSC clone for retinal differentiation [51]. 
Irrespective of the protocol used for inducing retinal differentiation, the timing of the derivation  
of specific retinal cell types generally reflects the timeline of embryological development.  
This temporal recapitulation of embryogenesis by iPSC differentiation supports the notion that 




permissive microenvironment. During the first month of embryonic development, the forebrain 
portion of the primitive anterior neuroepithelium gives rise to cells expressing markers specific for 
the eye field. Optic vesicles then develop from the eye fields at the end of the first month with cells 
expressing PAX6 and MITF. Retinal progenitors destined to become RPE preferentially express 
MITF, whereas those becoming neuronal cells downregulate MITF in response to increased CHX10 
expression. Then, there is a 1–2 month(s) lag in the expression of CRX and opsin genes in neural 
retinal cells after the formation of RPE. Hence, the time to generate RPE from iPSC is typically 
around 4–6 weeks, whereas differentiation of photoreceptor precursors occurs at 2–3 months after 
retinal induction. Formation of outer segments and the development of light response was reported 
by Zhong et al. at six months after retinal induction [57]. Recently, Reichman et al. described a 
floating culture system for generating neuroretinal-RPE containing retinal progenitor cells within 
two weeks, which bypassed embryoid body formation and obviated the need for exogenous 
molecules, coating or Matrigel [54]. 
The ability to recapitulate retinogenesis using iPSC has tremendous potential for studying 
diseases that interfere with retinal development and non-cell autonomous mechanisms, in addition to 
those that cause post-natal cell autonomous retinal degeneration. On a practical level, there are still 
significant barriers to routine clinical use of this technology, since the generation of patient-specific 
retinal cells may take 4–6 months from the time of biopsy, and there is significant overhead infrastructure 
cost to maintain an iPSC laboratory. Future advancement in three-dimensional culture and differentiation 
techniques may one day enable iPSCs to differentiate into other structures of the eye, such as the choroid 
and sclera, thus expanding the use of iPSC in understanding complex retinal diseases, such as AMD  
and myopia. 
2.2.2. iPSC to Photoreceptor Cells 
Hirami et al. described deriving photoreceptor cells using human iPSC from dermal fibroblast,  
serum-free embryoid body culture system, defined factors (Wnt and Nodal inhibitors) and 
subsequent plating of aggregates onto poly-D-lysine, laminin and fibronectin to generate retinal 
progenitors expressing RX, PAX6 and MITF [58]. From Day 90, the application of retinoic acid and 
taurine to the culture system induced the expression of the photoreceptor marker, recoverin, in a 
quarter of the colonies by Day 120 (four months). Half of these recoverin-positive cells were also 
immune-positive for rhodopsin. Notably, only two of three iPSC lines could be differentiated into the 
retinal lineage, and functional assays of putative photoreceptor cells were not performed.  
Osakada et al. from the same group, at the RikenCenter for Developmental Biology, also reported a 
modified protocol using small molecules (casein kinase I inhibitor CKI-7, Rho-associated kinase 
inhibitor Y-27632 and ALK4 inhibitor SB-431542) to block Wnt and Nodal pathways to induce retinal 
progenitors [59]. This method has been used in generating photoreceptor cells from patients with RP1, 
RP9, PRPH-2 and RHO mutations [7,53]. 
Meyer et al. [51] described a different culture system using embryonic stem cell medium without 
FGF2, then chemically-defined neural induction medium with N2 supplement followed by another 
chemically-defined retinal differentiation medium supplemented with B27. Rosettes were picked 




of the neurospheres expressed rod- and cone-specific transcription factor Crx, within which 65% of 
the cells were expressing Crx. However, only 8% of the cells within Crx+ spheres expressed 
recoverin and/or opsin. This protocol was modified by Zhong et al. to generate photoreceptor cells 
(within laminated retinal cup structure) that express synaptic junction proteins, phototransduction 
molecules, to form outer segments and to respond to light stimulus [57]. The optic vesicle-like 
system was used to study the effect of CHX10 mutation [4]. 
Several other groups have also described the derivation of photoreceptor cells from human iPSC  
(Table 2). There are many morphological, cellular, molecular, functional and genetic assays for the 
characterisation of iPSC-derived photoreceptors and their precursors, but there is no consensus on 
the minimum criteria (Table 1). Lamba et al. used their protocol for ESC [60] to derive photoreceptor 
cells from human iPSCs [52]. Although, they did not test the function of these cells, they 
demonstrated integration into mouse retina following sub-retinal transplantation. Mellough et al. 
combined the techniques described by Lamba et al. and Osakada et al. for deriving retinal cells  
from ESC and added activin A, Shh and T3 to enhance photoreceptor differentiation from human 
iPSCs [60–62]. Their three-step differentiation protocol involved inducing a neural lineage,  
then retinal progenitors and, finally, photoreceptor cells expressing blue, red and green opsin.  
For iPSC-derived photoreceptor cells to be used in human transplantation, animal-derived products 
should be avoided where possible. Tucker et al. and Sridhar et al. recently reported the generation of 
photoreceptor cells from iPSCs using a xeno-free system, where a synthetic culture surface 






2.2.3. iPSC to Retinal Pigmented Epithelial Cells 
Although the embryoid body culture system can generate RPE from iPSC, adherent culture has 
been favoured if RPE is the only cell that is required. Hirami et al. and Meyer et al. showed RPE 
differentiation occurs earlier than neural retinal progeny derivation [51,58]. Carr et al. and  
Buchholz et al. demonstrated that RPE differentiation from human iPSC can be achieved within four 
weeks, and these cells demonstrated morphological and molecular signatures of RPE, as well as  
in vitro and in vivo functional characteristics [65,66]. Morphologically, RPE derived from iPSCs is 
indistinguishable from RPE in post-mortem eye or human ESC-derived RPE (Figure 4). 
Characterisation of iPSC-RPE involves morphological, cellular, molecular, functional and 
genetic assays (Table 1). Key morphological features include pigmentation, monolayer of hexagonal 
cells and electron microscopic features of apical microvilli, tight junctions, basal infoldings and 
cytoplasmic melanosomes. The molecular signature of RPE cells reflects their eye field origin 
(PAX6 and MITF) and function: RPE65 and CRALBP (retinoid cycle), MERTK (phagocytosis), 
bestrophin (modulating calcium flux in endoplasmic reticulum) and ZO-1 (tight junctions). In vitro 
functional assessment includes transepithelial resistance measurement, vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF) and pigment epithelium-derived factor 
(PEDF) secretion, extracellular matrix production (laminin and type IV collagen) and phagocytosis 
assay using photoreceptor outer segments. In vivo functional assessment requires subretinal 
transplantation in an animal model of RPE or retinal dystrophy, such as the Royal College of 
Surgeons (RCS) rat, to assess the rescue of visual function [65,67–69]. Gene expression comparing 
human iPSC-RPE to adult and foetal RPE and other controls through microarray and hierarchical 





Figure 4. Morphology of the retinal pigment epithelium monolayer. (A) Hexagonal 
pigmented monolayer of retinal pigment epithelium derived from induced pluripotent 
stem cells; (B) Comparison of the morphology of retinal pigment epithelial stem cells 
derived from human embryonic stem cells (HESC), post-mortem (PM) eyes and induced 





For autologous transplantation of iPSC-RPE, immunogenicity, cell survival and tumourigenicity 
studies are also required. These have been addressed for iPSC-RPE specifically by Kamao et al. and  
Kanemura et al. [70,71] as part of a pre-clinical study in preparation for human iPSC-RPE 
autologous transplantation. The generation of patient-specific iPSC-RPE has also been performed in 
gyrate atrophy and Best disease (BD) [5,6]. The following section will illustrate clinical examples of 
the use of iPSC-derived retinal cells in genetic diagnosis, discovery of genotype/phenotype 
relationship, screening of pharmaco- and gene therapies and as a source of autologous cell therapy. 
3. Clinical Use of Patient-Specific iPSC-Derived Retinal Cells 
The ability to generate patient-specific retinal tissue and cells offers the opportunity to study the 
relationship between genetic variants and disease phenotypes. This technology is particularly useful 
in modelling IRDs, as there are around 200 genes with over 4200 known and many other unknown 
mutations causing disease phenotype in IRDs [72]. One in 2000–3000 individual are affected by 
IRDs, and these, collectively, are the most common cause of blindness in children and young adults.  
Given that emerging therapies for IRDs are likely to be mutation specific, it is important to identify 
pathogenic mutation(s) in every affected individual [73–75]. 
Many IRDs have a poor genotype-phenotype correlation; defects in a single gene may lead to a 




caused by mutations in a large number of different genes. Adding to the challenge of identifying 
causative mutations is the relatively common occurrence of X-linked and de novo autosomal 
dominant variants. Although Sanger sequencing of selected genes followed by targeted 
next-generation sequencing (NGS) can identify known pathogenic mutation in many individuals, 
exome or whole genome NGS combined with genetic linkage studies are required for the 
identification of novel mutations. Traditionally, these rare mutations (<1%) have been validated 
through functional modelling, mouse and zebrafish studies and replication of genotyping in large 
patient and relevant control cohorts. More recently, iPSC technology has also been used to confirm 
the pathogenicity of genetic variants and to unravel the molecular mechanism of disease phenotype 
through the in vitro study of cellular function and the histogenesis of iPSC-derived retinal tissue. 
3.1. IPSC for Genetic Diagnosis and Modelling 
3.1.1. Confirming Pathogenicity of Mutation 
Patient-specific iPSC has been used to confirm the pathogenicity of new rare genetic variants.  
For example, using NGS, single-strand conformation polymorphism screening and Sanger 
sequencing of a large validation cohort, Tucker et al. [3] identified a new mutation (Alu element 
insertion) in the male germ cell-associated kinase (MAK) gene causing rod-cone dystrophy. This was 
confirmed by examining and comparing the transcripts of MAK between iPSC and iPSC-derived 
photoreceptors from the patient and his unaffected sibling. The proband had no family history of 
retinal dystrophy, and the affected individual was heterozygous for pathogenic variants in ABCA4 
and USH2A. Using iPSC, they discovered a previously unrecognized exon 12 of the MAK gene  
that is expressed in cells differentiated into retinal precursors, but not in undifferentiated cells.  
This observation confirmed that the homozygous Alu element insertion in exon 9 is pathogenic by 
affecting the developmental switch from MAK bearing only exon 9 to a retina-specific transcript 
bearing both exons 9 and 12. The insertion of a 353-bp Alu repeat between codons 428 and 429 in 
exon 9 results in the insertion of 31 incorrect amino acids followed by a premature termination.  
In another study, Tucker et al. [2] reported the discovery of a new pathogenic variant of USH2A in 
another patient with rod-cone dystrophy who was presumed heterozygous for a pathogenic variant in 
ABCA4 and USH2A. The second possibly disease-causing variant was found in intron 40 of USH2A, 
and this was confirmed by real-time PCR of patient-specific iPSC-derived photoreceptor precursor 
cells. A pseudoexon (IVS40) was formed by the intronic splice site mutation in the intervening 
sequence 40 of USH2A, and this caused a translation frameshift and a premature stop codon. 
Lustremant et al. [76] examined the transcriptomics of human iPSC-derived neural stem cells and 
RPE from two patients with Leber congenital amaurosis (LCA). Although the pathogenic mutation 
was not known, they showed changes in the expression of 21 genes when compared to wild-type 
controls. Amongst these, three downregulated genes—TRIM61, ZNF558 and GSSTT1—were related 
to the LCA disease process through protein degradation, altered transcription regulation and 
oxidation. With better understanding of the interactions between molecular pathways, detection of 





3.1.2. Modelling Developmental Diseases of the Retina 
The impact of known mutations on retinogenesis and cellular function has also been explored.  
The transcription factor CHX10 (Caenorhabditis elegans Ceh-10 homeo-domain-containing  
homolog 10), also known as VSX2 (visual system homeobox 2), has a critical role in the development 
of the retina. The very rare mutation in VSX2 leads to severe malformation of the eye. Although 
animal models of this disease (the VSX2 /  and (R200Q) VSX2 mice) have contributed greatly to our 
understanding of the importance of VSX2 in repressing MITF, production of the bipolar cell and 
maturation of the photoreceptors, it was not possible to confirm that the same mechanism occurs in 
humans. Phillips et al. [4] used iPSCs from a patient with a (R200Q) VSX2 mutation to generate an 
embryoid body and then vesicles that recapitulated retinogenesis [6,36]. They confirmed previous 
observations in animal models and went a step further, using lentiviral VSX2 overexpression to 
examine the reversibility of the developmental defect in vitro. Although suppression of MITF and 
enhanced photoreceptor maturation was achieved, bipolar cell markers were not restored by 
wild-type lenti-VSX2. Transcriptome analysis at Day 20 and 30 cells demonstrated overall 
upregulation of genes. Most of these were related to the WNT and TGFb signalling pathways that 
promote RPE differentiation. In contrast, the FGF pathway, which promotes neuroretinal 
differentiation, was downregulated. 
The process of deriving retinal cells from iPSCs provides an opportunity for studying retinal 
development and developmental anomalies due to specific mutations that cause ocular and retinal 
dysgenesis (e.g., MITF, PAX6, VSX2, CRB1, etc.). However, terminally differentiated retinal cells 
from iPSCs can also be tested for altered cell function to understand degenerative diseases of the 
retina (see below). IRDs that have an earlier onset may be expected to demonstrate abnormality 
earlier in the differentiation protocol, whilst late onset IRDs (e.g., BD, pattern dystrophy, Sorsby 
fundus dystrophy and Doyne honeycomb retinal dystrophy) may not manifest altered cellular 
physiology unless the cells are aged and stressed in vitro to recapitulate senescence. 
3.1.3. Modelling Degenerative Diseases of the Retina 
Both RPE and photoreceptor disease models have been created using patient-specific iPSCs.  






Figure 5. Clinical images of early age-related macular degeneration and its variants.  
(A) Colour photograph of the macula of a 72-year-old male showing soft drusen;  
(B) Optical coherence tomography (OCT) shows a sub-retinal pigment epithelial (RPE) 
deposit, which did not significantly alter fundus autofluorescence (C); (D) Colour 
photograph of the macula of a 78-year-old female showing reticular pseudo-drusen;  
(E) OCT shows deposits above the RPE, resulting in subtle hypo autofluorescent lesions 
(F); (G) Colour photograph of the macula of a 57-year-old female showing basal laminar 
drusen; (H) OCT shows a compact sub-RPE deposit forming a saw-tooth pattern, and 
these lesions were mildly hyper autofluorescent (I); (J) Colour photograph of the macula 
of an 83-year-old female showing dominant drusen or Doyne honeycomb retinal 
dystrophy; (K) OCT shows outer retinal layer loss; (L) The fovea was hypo 
autofluorescent due to RPE loss, and the linear radial drusen are seen as hyper 
autofluorescent streaks. 
 
Chang et al. reported reduced ZO-1 and RPE65 staining in iPSC-RPE generated from five atrophic 
AMD patients compared to two controls [38]. There was also increased accumulation of reactive 
oxygen species following exposure to H2O2 compared to controls. Furthermore, expressions of 
antioxidant genes (HO-1, SOD2 and GPX1) were lower, whilst PDGF, VEGF and IGFBP-2 
expressions were higher compared to controls. There were no details regarding the age of the two 
control subjects, and the AMD risk allele profiles for all seven subjects were not reported. Further 
studies are needed to replicate these findings by controlling other potential confounders. It is 
particular important that control subjects are age matched when iPSC is used to model late-onset 
degeneration as AMD. This is because AMD cannot be diagnosed until drusen is visualised, usually 
after the age of 50 years. Although the presence of risk alleles and family history increases the risk of 
developing AMD, these biomarkers are not 100% predictive. Therefore, somatic cells from young 
healthy individual cannot be used as controls, because it is not possible at this stage to predict if this 




Heterozygous, compound heterozygous and homozygous mutation of the BEST1 gene 
(bestrophin protein) can cause ocular disease characterised by abnormal RPE function, accumulation 
of debris between RPE and photoreceptors and a variable amount of retinal degeneration and ocular 
dysgenesis (Figure 6). There are over 100 mutations in BEST1, and the pathogenicity and molecular 
mechanism of RPE dysfunction arising from these mutations is not well understood. The traditional 
approach to study the effects of BEST1 mutation is based on transfection of mutant BEST1 gene into 
the human foetal RPE or Madin Darby canine kidney (MDCK II) epithelium cell lines. Sing et al. 
described the use of RPE derived from patient-specific iPSCs to study the impact of two mutations in 
the BEST1 gene, (A146K and N296H) on RPE function. They demonstrated increased intracellular 
accumulation of autofluorescent materials compared to controls after long-term (3.5 months) feeding 
of the BD hiPSC-RPE with bovine photoreceptor outer segments (POS, 50/cell) and decreased net 
fluid transport. Conflicting data at 4 and 24 hours were shown regarding delayed degradation of POS 
when overfed with FITC-POS (50 vs. 20 POS per cell). As expected, there was no significant 
difference in the RPE differentiation potential of BD hiPSC compared to controls. BD hiPSC-RPE 
also had a similar transepithelial resistance, level of BEST1 mRNA and localisation pattern of the 
mutant bestrophin compared to controls. The dysfunction in mutant bestrophin was found to be 
associated with altered endoplasmic reticulum (ER)-mediated calcium homeostasis. Furthermore, 
there was increased expression of genes involved in regulating oxidative stress (GPX1, SOD2) and 
iron homeostasis (TRF, TRFR) after long-term (3.5 months) POS feeding [5]. In this study, the 
genetic background between the cell lines was not controlled by genomic editing of the BEST1 
mutation into the control iPSC or out of the BD hiPSC (see below). Nevertheless, this is a good 
example where early onset disease with a well-characterised clinical disease phenotype can be 
recapitulated in vitro. It is not known if similar cellular abnormalities can also be detected in 
iPSC-RPE from patients with the much commoner late-onset vitelliform macular dystrophy due to 
other types of BEST1 mutations. Phagocytosis assay may be a better readout for iPSC-RPE generated 
from patients with a known genetic defect that impairs phagocytosis, such as MERTK or REP-1 
mutation (choroideremia). 
In a very different RPE dystrophy, gyrate atrophy, homozygous mutation in the 
ornithine- -aminotransferase gene (OAT) leads to RPE damage and loss, leading to severe peripheral 
and central vision loss. RPE has been successfully generated from iPSCs derived from the fibroblasts 
of a patient with OAT mutation (A226V). Enzyme activity of OAT within the iPSC-RPE can be 
measured [6]. Correction of the OAT mutation by bacterial artificial chromosome-mediated 
homologous recombination restored the enzymatic activity [77]. There are other RPE dystrophies 
resulting from mutations affecting visual cycle enzymes or regulators (e.g., the acyltransferase, 
LRAT, the isomerohydrolase, RPE65, the dehydrogenase, RDH12, and RPGR and RLBP1). 
Deriving iPSC-RPE from patients with various genetic mutations in these enzymes or regulators may 





Figure 6. Clinical images of various types of inherited retinal diseases. (A) Colour 
photograph of the macula of a 10-year-old boy showing multifocal vitelliform lesions 
resulting from homozygous deletion of exon 2–6 of the BEST1 gene; (B) Optical 
coherence tomography (OCT) shows intraretinal cystic change with sub-retinal fluid and 
vitelliform deposits; (C) Increased fundus autofluorescence was noted in the area of 
vitelliform deposits; (D) Colour photograph of the macula of a 57-year-old male showing 
yellow deposits due to pattern dystrophy of the retinal pigment epithelium (RPE);  
(E) OCT shows deposits above and below the RPE; (F) Multifocal hyper autofluorescent 
lesions are seen; (G) Colour photograph of the macula of a 56-year-old female showing 
extensive macular atrophy with cone-rod dystrophy due to two missense mutations in the 
ABCA4 gene (c.2915 C > A and c.3041 T > G); (H) OCT shows severe retinal and 
choroidal atrophy with pigment migration into the fovea; (I) Extensive RPE loss 
resulting in wide-spread hypo autofluorescent lesions; (J) Colour photograph of the 
macula of a 32-year-old male showing retinal flecks with mild cone dysfunction due  
to two pathogenic mutations in the ABCA4 gene (c.4139 C > T and c.6079 C > T);  
(K) OCT shows outer retinal layer loss to retinal atrophy; (L) Retinal flecks were  
hyper autofluorescent. 
 
Many genes are involved in photoreceptor cell degeneration. Clinically, there are two broad 
classes of disease phenotypes based on electrophysiology: macular dystrophy, which is limited to the 
macular region, and retinal dystrophy, where the entire population of photoreceptors (central and 
peripheral) is affected. Generalised retinal dystrophy can affect cones or rods predominantly. 
Different mutations in one gene, such as ABCA4, can have varied disease phenotypes, including 
macular dystrophy, cone dystrophy, cone-rod dystrophy or rod-cone dystrophy (Figure 6). The 
overlap between various disease phenotypes and causative mutation reinforces the importance to 




Amongst the genes causing rod-cone dystrophy, the molecular effect of mutations in RHO, RP1, 
RP9, PRPH-2 and USH2A have been studied using iPSCs. Jin et al. [7] used iPSCs from patients 
with RHO, RP1, RP9 and PRPH-2 to generate rod photoreceptor precursors. They demonstrated 
reduced rod cell number at Day 120 in iPSC-rod precursors derived from patients with RP9 mutation  
(early-onset retinal degeneration). This effect was seen in RHO, RP1 and RHO mutation at Day 150, 
whereas no rods were detectable for the iPSC line carrying the RP9 mutation. They also showed that 
the RP9 mutant iPSC-rod precursors had increased oxidative stress. In contrast, the RHO mutant  
iPSC-rod precursors had mislocalisation of the rhodopsin protein and increased expression of ER 
stress markers, which might be explained by the accumulation of unfolded rhodopsin [7,53].  
Tucker et al. also examined the impact of USH2A mutation on photoreceptor precursor cells. They 
described increased expression of GRP78 and GRP94 in iPSC-derived photoreceptor precursor cells, 
indicative of ER stress related to protein misfolding. It is important to note that controls used in these 
reports were not genetically matched, i.e., the mutation was not removed by genomic editing. 
A major limitation of these genotype-phenotype studies is the choice of controls. For metabolic 
syndromes or disease with early manifestation (ocular dysgenesis or early degeneration), healthy 
related or unrelated controls will be adequate, because of the robust and rapid cellular manifestation 
of the phenotype. However, controls used for studying diseases with delayed onset will need to be 
genetically matched to avoid the cofounding effect of the (1) genetic background, (2) retinal cell 
differentiation process and (3) genetic alteration introduced during the process of iPSC reprograming. 
Yoshida et al. confirmed the effect of RHO mutation (E18K) on rod precursor cell ER stress 
responses, apoptosis markers and autophagy activation by repairing and introducing the mutation in 
the affected and control (provided by Yamanka laboratory) cell lines, respectively, using a 
helper-dependent adenoviral vector gene transfer [8]. Similar genetic control was also reported for 
gyrate atrophy-iPSC-RPE, where restoration of the OAT gene in the iPSC using bacterial artificial 
chromosome-mediated homologous recombination resulted in normalisation of OAT enzyme 
activity in iPSC-RPE [6,77]. 
Once the clinically-relevant cellular phenotype and readouts can be defined for the specific 
genetic variant and mutation, high throughput analysis will need to be developed to enable a large 
number of therapeutics to be screened across the potential thousands of genetic variant cell lines 
from patients with IRDs. Although this is not yet possible, there are several examples where this has 
been reported on a smaller scale (see below). Further investigations are needed to determine if 
late-onset retinal or macular degeneration, such as reticular pseudodrusen (Figure 5), basal laminar 
drusen (Figure 5), pattern dystrophy of the RPE, vitelliform macular dystrophy and mutations arising 
from EFEMP-1 (Doyne honeycomb retinal dystrophy, Figure 5), TIMP-3 (Sorsby fundus dystrophy) 
or CTRP5 (late-onset retinal degeneration), can also be modelled through derivation of retinal cells 
from iPSCs. The readout or functional assay for each of these diseases may differ significantly 
because of variable environmental contribution to the disease phenotype and diverse molecular 
pathogenic mechanisms. For example: Sorsby fundus dystrophy may be caused by deposition of 
abnormal extracellular protein (TIMP-3); Doyne honeycomb retinal dystrophy may be related to 
activation of unfolded protein response due to misfolded fibulin-3 (EFEMP-1); and late-onset retina 




extracellular deposition [78–81]. There are also many IRDs that affect retinal cells downstream from 
the photoreceptors, such as congenital stationery night blindness and X-linked retinoschisis [82]. 
Patient-specific iPSC-derived laminated retinal structures may be ideal for the study of 
pathophysiology of these inner retinal IRDs, since many of the genes involved in these diseases (e.g., 
NYX, CACNA1F, GRM6, TRPM1, CABP4, CACNA2D4 and RS1) are involved in the extracellular 
matrix of neural retina and the synaptic interaction between photoreceptor and bipolar cells [83]. 
3.2. IPSC for Therapeutics Development and Treatment 
3.2.1. IPSC for Drug Screening 
Current therapeutic modalities in IRDs are aiming to preserve residual cells or replace missing 
cells. Because gene therapies and many pharmacotherapies will need to be tailored for individual 
genetic variants or mutations, iPSCs provide an ideal platform for pre-clinical therapeutic and 
toxicology testing. There are several examples in both AMD and IRDs, where pharmaco- and gene 
therapies are tested using iPSC. 
Chang et al. tested the protective effect of curcumin on iPSC-RPE derived from AMD  
patients [38]. They showed that curcumin had a beneficial effect on H2O2-induced cell death and 
reactive oxygen specifies generation in both control and AMD iPSC-RPE. Exposure of curcumin 
also increased the expression of HO1, SOD2 and GPX1 and decreased the expression of PDGF, 
VEGF and IGFBP-2 in AMD iPSC-RPE. Whether this also occurred in control iPSC-RPE was  
not reported. 
OAT deficiency in the RPE leads to a buildup of ornithine and a reduction in high-energy creatine 
phosphate. In some patients, the OAT enzymatic activity can be reversed by a high dose pyridoxine 
(vitamin B6) supplement, because of the effect of OAT mutation on the binding affinity to 
pyridoxine. Clinically, vitamin B6 responsiveness is tested in patient fibroblasts. Although based on 
the fibroblast assay, A226V OAT mutation is not responsive to vitamin B6, Meyer et al. has 
demonstrated that iPSC-RPE from this patient is, in fact, responsive to vitamin B6 based on an  
in vitro dose titration experiment. Therefore, this patient has directly benefited from iPSC disease 
modelling and pharmacotherapy screening. 
Jin et al. [7] demonstrated the benefit of -tocopherol (vitamin E) on improving the survival of  
iPSC-rod precursor cells in the RP9 mutation. They also confirmed no toxic effect from 1.6 M of 
ascorbic acid (vitamin C) and -carotene (vitamin A) on iPSC-rod precursors affected by RP1, RP9, 
PRPH-2 and RHO mutations. In addition to vitamins, modulators of signal pathways have also been 
screened using iPSC. Yoshida et al. showed that inhibition of mTOR (using rapamycin or PP242), 
activation of AMP kinase (using AICAR), inhibition of apoptosis signal-regulating kinase (using  
NQDI-1) and inhibition of protein synthesis (using salubrinal to inhibit eukaryotic translation 
initiation factor 2 subunit  phosphatase) can reverse the increased ER stress and apoptosis and 





3.2.2. IPSC for Testing Gene Therapy 
In addition to screening prospective pharmacological agents, iPSC has also been used to test the 
efficacy of gene therapy approaches in LCA and choroideremia, which aim to deliver the CEP290 
and REP-1 genes, respectively, to retinal cells. CEP290 is a centrosomal protein involved in 
ciliogenesis and ciliary trafficking. Mutation in CEP290 leads to abnormality of the inner and outer 
segments of cone cells, resulting in early-onset severe visual loss. Previous ocular gene therapy used  
adeno-associated viral (AAV) vectors for delivery of the RPE65 gene. However, the large size of 
CEP290 precludes the use of AAV, and therefore, lentivirus is necessary for gene delivery.  
Burnight et al. [64] described the method to package full-length human CEP290 into a lentiviral 
vector and demonstrated restoration of a ciliogenesis defect in LCA patient-derived fibroblasts. 
Although they also demonstrated expression of wild-type CEP290 after lentiviral transduction of the  
iPSC-photoreceptor precursor cells, they did not examine the impact of this on cone development 
and the formation of inner or outer segments. In contrast, Vasireddy et al. [84] showed successful 
transfection of AAV2 carrying full-length human REP-1 cDNA into iPSCs rather than transfection 
into differentiated retinal cells, the presumed target cell primarily affected in choroideremia. They 
used a prenylation assay to confirm restoration of REP-1 function following AAV2. REP-1 infection 
of the iPSC. There was also improved trafficking of RAB27 in iPSCs, because of prenylation by  
viral-derived REP-1. The efficiency and toxicity of iPSC transduction was compared to patients’ 
fibroblasts, but not patient-derived iPSC-RPE. These two examples demonstrate the potential of 
iPSC in pre-clinical studies of patient-specific gene therapy. 
3.2.3. iPSC for Cellular Therapy 
Cell therapy for retinal disease aims to replace (1) photoreceptors and/or (2) supporting cells that 
provide trophic and metabolic support to prevent further degeneration of remaining photoreceptors.  
The main challenges in establishing clinically acceptable cell therapy for retinal disease are: patient 
selection, surgical technique, carrier system and choice of cell source. Each of these questions has its 
complexity in several dimensions. However, the use of iPSCs as a source for retinal cell 
transplantation is one of the most exciting, but also complex and challenging, issues facing scientists, 
clinicians, pharmaceutical companies and regulatory authorities. 
In comparison to human ESC, the use of iPSC-derived cells for cell therapy has the additional 
requirement of quality control associated with the surgical procedure in harvesting patient somatic 
cells, isolation of a single cell type from the tissue biopsy, reprogramming vectors and techniques, 
methods of genomic editing in the case of IRDs and techniques of hiPSC clone selection and storage. 
Some of these steps have been defined in standard operating procedures for the production of  
clinical-grade iPSCs from retrovirus reprogramming. However, this is yet to be established for the 
numerous published non-integrating reprogramming methods. 
Derivation of clinical-grade retinal cells from hESC has been conducted in GMP facilities, and it 
is currently being used in phase I/II clinical trials as hESC-RPE suspension for Stargardt disease, 
geographic atrophy due to AMD and myopic atrophic macular degeneration (Clinical Trial: 




AMD (NCT01691261). There is only one human trial using iPSC-RPE, at the RIKEN Center for 
Developmental Biology (CDB), Japan. In the CDB trial, a monolayer of iPSC-RPE without substrate 
is used to treat neovascular AMD after a course of ranibizumab injections. One patient, in her 70s 
with wet AMD, has already received her own iPSC-RPE as a 1.3 × 3.0-mm cell patch at Kobe City 
Medical Center General Hospital in September [85]. This group has published data to support the  
in vitro and in vivo function of the iPSC-RPE in performing the visual cycle [68]. They also 
demonstrated suppression of the tumour-forming potential of iPSC by iPSC-RPE following 
subcutaneous transplantation in NOD/Shi-scid/IL-2R null (NOG) mice. They postulated that pigment  
epithelium-derived factor secreted from iPSC-RPE or RPE of host tissue can cause apoptotic cell 
death of iPSC [86]. Following from this, the tumourigenicity of iPSC-RPE was also tested in nude, 
severe combined immune deficiency (SCID), non-obese diabetic (NOD)-SCID and NOG mice in the 
subretinal and subcutaneous location. They observed no tumour formation at 6–12 months following 
transplant [71]. Immune reaction to autologous iPSCs has not been studied, but Kamao et al. [70] 
demonstrated a lack of immune response after one year when nonhuman primate iPSC-RPE was 
transplanted as an autograft into the subretinal space. This study also confirmed no evidence of 
tumour formation following monkey iPSC-RPE autograft [70]. The RIKEN CDB has already 
enrolled patients with neovascular AMD for iPSC-RPE transplantation after the disease is stabilised 
with anti-VEGF therapy. Although the functionality of the graft seems to be well characterised, 
significant work still needs to be done in developing the optimal surgical instrumentation, technique 
and approach in resurfacing the RPE in the submacular space and patient selection for optimal visual 
and anatomical outcome. It is not known if iPSC-RPE survive, as multiple small patches of epithelial 
monolayer are superior to cell suspension and not inferior to a single large sheet of 
epithelial-substrate complex that can cover the entire macular region. The importance of restoring 
damaged Bruch’s membrane during iPSC-RPE replacement therapy in AMD cannot be 
underestimated, as this is considered as an important aspect of the pathophysiology of AMD [87]. 
In vitro genomic editing or mutation repair of harvested somatic cells, iPSCs or iPSC-derived 
retinal cells will provide patients with IRDs the opportunity to receive autologous cell therapy. For 
some IRDs that develop late-onset degeneration, genetic mutation correction in the patient-specific 
iPSCs may not be necessary [2]. This is relevant in the situation where the strategy is to transplant (1) 
iPSC-derived retinal supporting cells that are not affected by the mutation (e.g., RPE cells for 
ABCA4 retinopathy); or (2) iPSC-derived retinal cells affected by the mutation, but it has delayed 
non-cell autonomous effects due to reduced trophic factor release (e.g., rod precursor cells for  
the cone preservation function through the release of rod-derived cone viability factor) [88].  
For replacement of cone photoreceptor cells in cone dystrophy or RPE in RPE dystrophy, in vitro 
genomic editing may be required to allow iPSCs to differentiate into mature photoreceptors or the 
RPE phenotype and to ensure long-term survival of the autograft. Examples of in vitro gene therapy 
testing have been described in the previous section. Future strategies may include site-specific 
transcription activator-like effector nucleases (TALEN) or clustered regularly interspaced short 
palindromic repeats (CRISPR) based genome editing techniques, where the mutation is edited 




Following induction and subsequent homology-directed repair (HDR), the corrected gene will 
remain under the normal endogenous expression control elements. 
4. Conclusions 
Since the description of iPSCs in 2006, there has been an exponential increase in the translation  
of this technology towards understanding disease mechanisms and the discovery of therapeutics.  
The full potential is yet to be realised because of the complexity and variations in reprograming 
technology and retinal differentiation protocols. The relationship between the clinical disease 
phenotype and the molecular and cellular features of specific genetic variants in iPSC-derived retinal 
cells is still poorly understood. These issues will need to be resolved for iPSC-derived retinal tissue 
to become clinically relevant and useful in modelling retinal dysgenesis and degeneration. 
Standardisation and development of high throughput technology to interrogate specific retinal 
progeny derived from iPSCs will facilitate screening of genetic mutation and testing of 
pharmacologic and gene therapy in rare IRDs. Early data from several publications show that this 
may have a direct benefit to the patient [2,3,64,84]. iPSCs as a source of autologous cells are an 
attractive option, but there is a significant barrier to overcome for this to become scalable to treat large 
numbers of patients. However, progress in cell culture automation and refinements of reprogramming 
methods will undoubtedly facilitate the translation of iPSC-derived tissue into clinically applicable 
personalized cell therapy. Despite the mountain of challenge, the escalating costs of biologic therapy 
for treating neovascular and atrophic AMD and the suffering from irreversible childhood blindness due 
to IRDs, further ophthalmic translational research in iPSCs is worthy of the costly investment. 
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Patient-Specific iPSC-Derived RPE for Modeling of  
Retinal Diseases 
Huy V. Nguyen, Yao Li and Stephen H. Tsang 
Abstract: Inherited retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, 
are the leading cause of blindness in the developed world. Currently, treatments for these  
conditions are limited. Recently, considerable attention has been given to the possibility of using 
patient-specific induced pluripotent stem cells (iPSCs) as a treatment for these conditions. iPSCs 
reprogrammed from adult somatic cells offer the possibility of generating patient-specific cell lines 
in vitro. In this review, we will discuss the current literature pertaining to iPSC modeling of retinal 
disease, gene therapy of iPSC-derived retinal pigmented epithelium (RPE) cells, and retinal 
transplantation. We will focus on the use of iPSCs created from patients with inherited eye diseases 
for testing the efficacy of gene or drug-based therapies, elucidating previously unknown mechanisms 
and pathways of disease, and as a source of autologous cells for cell replacement. 
Reprinted from J. Clin. Med. Cite as: Nguyen, H.V.; Li, Y.; Tsang, S.H. Patient-Specific 
iPSC-Derived RPE for Modeling of Retinal Diseases. J. Clin. Med. 2015, 4, 567–578. 
1. Introduction 
Human vision is vital for nearly every major activity of daily living, and degeneration of one of 
the responsible cell types, the retinal pigmented epithelium (RPE), leads to severe visual impairment 
and blindness. RPE cells exist as a monolayer located at the back of the eye between the retina and 
Bruch’s membrane and is essential for photoreceptor function and survival. Retinal diseases such as 
age-related macular degeneration (AMD) and retinitis pigmentosa (RP) result in clinical 
pathophysiology characterized by progressive loss of RPE. The adult retina does not intrinsically 
regenerate, so RPE degeneration may ultimately lead to blindness. Anti-vascular endothelial growth 
factor (VEGF) therapy has been shown to slow the rate of vision loss, but it has no more than a 10% 
rate of effectiveness in all AMD cases [1]. There are no other treatments currently established for 
RPE degenerative diseases, so the disease burden of these conditions are expected to continue to rise. 
AMD and RP are both leading causes of blindness in the developed world, affecting up to one third 
of people over the age of 75. Among the elderly, blindness is feared more than any other illness 
outside of cancer. Currently, nine million Americans have been diagnosed with AMD, and its 
incidence is expected to double within a decade, affecting 20% of Americans between the ages of  
65 and 75 years [2]. 
Cell transplantation into the human retina has the potential to restore vision and provide treatment 
in diseases like AMD and RP with significant RPE loss. Since these diseases spare the inner retina 
and optic nerve, retinal transplantation has focused on replacement of the photoreceptors and RPE. 
Retinal stem cells have been shown to be efficient at integrating into the degenerative host retina [3]. 




Food and Drug Administration advanced the treatment of macular degenerations by approving 
clinical trials using embryonic stem (ES) cell-derived RPE transplants [5]. 
Induced pluripotent stem (iPS) cells reprogrammed from adult somatic cells offer the possibility 
of generating patient-specific cell lines in vitro. As a platform to study patient-specific targeted 
disease cells, iPS cells (iPSC) have exciting potential in regenerative medicine and human disease 
modeling. As one example, after human embryonic stem cells were shown to be able to produce 3-D 
optic vesicle-like structures displaying a precise apical-basal orientation [6], human iPS cells were 
used to also create optic vesicle-like structures which self-assembled into rudimentary, multilayered 
retinal tissue [7]. Similarly, human iPSCs have been used to model primary open-angle glaucoma 
(POAG). The optineurin E50K mutation is a mutation currently affirmed as causative for POAG, and 
human iPSCs have been created with the E50K mutation to study the molecular and cellular 
characterization of POAG onset [8]. hiPSC modeling has also suggested that normal-tension glaucoma 
via TBK1 gene duplication is due increased levels of LC3-II, a key marker of autophagy [9]. 
Specifically, iPS-based therapies holds great promise for treating retinal degenerative diseases, 
given the advantage of ocular immune privilege and the ease of ocular non-invasive imaging. 
Moreover, iPS cell technology facilitates investigations of pathophysiological mechanisms of 
genetic mutations and testing of gene therapy vectors on RPE-based disease models. Indeed, 
iPS-derived RPE (iPS-RPE) can be reproducibly isolated and closely monitored both morphologically 
and functionally before experiments, effectively minimizing variability in the timing of differentiation. 
In addition, RPE, unlike many other human cell types, has a well-described culture standard, which 
ensures proper controls [4,10]. 
The in vitro phenotypes of disease-specific iPS-derived cells can be used to bridge the gap 
between the clinical phenotype and molecular or cellular mechanisms, creating new strategies for 
drug screening, and developing novel therapeutic agents [11]. Human iPS cell-based disease models 
can prove that a disease is caused by a genetic mutation, hypothesize potential treatment options before 
using more expensive animal models [12], and assist in the development of novel treatments for clinical 
trials [13–15]. 
2. iPSC Disease Modeling 
2.1. Use of iPS-Derived RPE Cells for Cell Therapy 
The eye is an ideal site for stem cell therapies. First, it is considered an immune privileged organ 
since the inflammatory responses of the eye differ significantly from those in other tissues. Second, 
the eye allows for easy accessibility for monitoring and imaging. Third, in the case of serious 
complications, the eye as a unit can be removed, due to its relative isolation from other body systems. 
Stem cells in turn are an appealing option for retinal cell replacement due to their pluripotency and 
potentially unlimited capacity for self-renewal. Currently, there are two leading options for stem 
cells in retinal transplantation: (i) embryonic stem cells (ESCs), which can be isolated from 
developing embryos four to five days after fertilization; and (ii) induced pluripotent stem cells 




However, due to the ethical and technical concerns with using ESCs, iPSCs have largely been 
favored for retinal transplantation. 
iPSCs in particular offer a compelling alternative approach for stem cell therapy. When derived 
from the transplant recipient, autologous iPS-derived cells reduce the risk of post-transplant rejection 
and obviate the need for immunosuppression after transplantation. The well-described iPSC culture 
standards also aid in the development of functional testing and optimization studies. Likewise, RPE 
transplantation into the retina poses fewer challenges than other kinds of cell transplantation since 
routine culture of RPE cells has been well described [17,18]. RPE monolayers exist in an easily 
identifiable hexagonal structure and can be isolated and transferred to a variety of substrates without 
the need for synaptic integration. Subsequently, studies on RPE replacement therapies using 
pluripotent stem cells have progressed rapidly. A multicenter trial focusing on the treatment of dry 
macular degeneration and Stargardt macular dystrophy showed that purified human ESC-derived 
RPE can be subretinally injected into patients with good results [5]. This is also possible since the 
retina normally enjoys relative immune privilege, due to the blood-retinal barrier. This barrier 
consists of non-fenestrated retinal vasculature ensheathed by pericyte and astrocyte processes on the 
inner aspect and by tight junctions between RPE on the outer aspect. In a healthy state, this 
blood-retinal barrier provides protection to transplanted cells beneath the retina from the systemic 
immune system. However, in a diseased RPE state, the monolayer is disrupted due to faulty tight 
junctions and the retina may also become much more pro-inflammatory [19,20]. Therefore, cells 
transplanted into a diseased retina are likely to be at a higher risk for rejection, so autologous iPSC 
transplantation represents the best stem cell approach for curing degenerative retinal diseases. In fact, 
hiPSC-derived RPE has recently been approved in Japan for use in patient safety trials for treatment 
of AMD [21]. 
Currently, human iPS-derived RPE (iPS-RPE) experiments are largely confined to animal 
models. In 2009, Carr et al. performed subretinal injections of dissociated human iPS-RPE into 
Royal College of Surgeons (RCS) rats and observed restoration of RPE phagocytotic function, as 
measured by intracellular RHO staining, and long-term preservation of visual function, as measured 
by optokinetic head-tracking [22]. Another model is the RPE-specific protein 65 kDA (RPE65) 
mutant mouse model, which is used to study Leber congenital amaurosis (LCA) and RP since the RPE 
65 defect leads to a faulty isomerase which can no longer convert the chromophore necessary for 
rhodopsin to detect light [23]. In 2012, Li et al. injected dissociated human iPS-RPE into the 
subretinal space of the RPE65 mutant mouse model and showed integration of the transplant with 
host RPE, as well as a modest improvement of visual function as measured by electroretinogram 
(ERG) [10]. The Mfrprd6/Mfrprd6 (rd6) mouse, which has a deletion in the Membrane Frizzled-Related 
Protein (Mfrp) gene, is another widely used model. The resulting MFRP protein, an RPE-specific 
membrane receptor of unknown function, is abnormal and the mice exhibit progressive retinal 
degeneration, making the model a preclinical and progressive model of RP [24]. In a recent study, 
subretinal injections of AAV-packaged wild-type Mfrp into rd6 mice showed improvement in visual 
function and RPE cell layer thickness [25]. 
The most advantageous aspect of iPSC based therapy is the potential of autologous transplantation, 




autologous cells should not provoke an immune response in the recipient from whom the cells were 
derived, there have been conflicting reports that raise some concern of the immunogenicity of iPSCs. 
In a recent study, teratomas originating from subcutaneous injection of murine derived iPSCs were 
found to have abnormal gene expression in some cells, which elicited a T-cell dependent immune 
response in syngeneic mice [26]. However, when Guha et al. transplanted various types of murine 
iPS-derived cells to a site under the kidney capsule of B6 mice, they found no evidence of immune 
response to the iPSCs, no increased T cell proliferation in vitro, no rejection of syngeneic 
iPSC-derived cells after transplantation, and no antigen-specific secondary immune response [27]. 
Findings by Liu et al. in 2013 suggests that iPSC immunogenicity increases with in vivo 
differentiation, as the authors observed immune responses after transplantation of differentiated 
iPS-derived cardiomyocytes but no response when transplanting undifferentiated iPSCs [28].  
In contrast, Morizane et al. performed a direct comparison between autologous and allogeneic 
transplantation of iPS-derived neural cells in brains of non-human primates and found that the 
autologous transplantation of iPS-derived neurons caused only a minimal immune response in the 
brain, while the allografts elicited an acquired immune response [29]. Moreover, a higher number of 
dopaminergic neurons survived in autografted iPS-derived cells, which further support their use. 
Taken together, these findings reveals that different cell types derived from iPSCs might have 
distinctive immunogenicities in their syngeneic hosts. For the development of human iPS-based cell 
therapy, there remains still a challenge to evaluate the immunogenicity of human iPS-derived cells in 
an autologous human immune system. 
2.2. Progress of RPE Disease Modeling Using iPSCs 
Human iPS cells are useful for modeling RPE disorders since they can be isolated, expanded,  
re-seeded, and closely monitored both morphologically and functionally prior to testing [30]. 
Phenotypes of patient-specific iPS cells may differ from those from a mouse model with the same 
mutation [25], underscoring the necessity for multiple models of human genetic diseases. Since 
differences in phenotypic expression can be observed among species with the same genetic mutation, 
it is important to study patient-specific cell lines as a complement to mouse models. 
The first retinal disease modeled with patient-specific iPS cells is Best vitelliform macular 
dystrophy (BVMD) [13]. Caused by a defect in the RPE gene BEST1, which results in the subretinal 
accumulation of photoreceptor waste products, BVMD is characterized by central vision loss due to 
photoreceptor death. Singh et al. created iPS-RPE from affected patients and compared them with 
those created from unaffected siblings. From their model, they concluded that the pathophysiology 
of the disease included delayed rhodopsin degradation after photoreceptor outer segment feeding,  
as evidenced by disrupted fluid flux and increased accumulation of autofluorescent material [13]. 
This hiPSC model of BVMD possessed functional deficiencies consistent with the clinical features 
of the disease and was used to characterize clinically relevant disease phenotypes for BVMD. 
iPS-derived RPE cells have also recently been used to model and study the pathophysiology of 
AMD. While genome-wide association studies (GWAS) have identified risk alleles for the disease, 
such as the ARMS2 and HTRA1 genes, how these alleles lead to pathology is still unclear. There is 




possess terminal changes and cannot be used to determine how abnormal gene expression can lead to 
RPE pathology, and mice do not have maculae. To bypass these obstacles, Yang et al. created  
a model for AMD by obtaining patient-specific iPS-derived RPE and pharmacologically accelerating 
the aging process with treatment of bisretinoid N-retinylidine-N-ethanolamine (A2E) and blue  
light [12]. From a proteome screen of multiple A2E-aged patient-specific iPS-RPE lines, impaired 
superoxide dismutase 2 (SOD2) function was identified as a high risk factor for developing  
AMD. Using their iPS model, the researchers concluded that the ARMS2/HTRA1 risk alleles 
decreased SOD2 defense, making RPE more susceptible to oxidative damage and thus contributing 
to AMD pathogenesis. 
3. Personalized Medicine: Patient-Specific iPSC-Based Therapy 
3.1. Development of Gene Therapy on Patient-Specific iPSCs 
Gene-corrected patient specific iPSCs offer a unique approach to autologous therapies, which 
have the potential to treat a wide range of acquired and inherited diseases. However, gene targeting in 
human pluripotent stem cells has been exceedingly difficult [31]. One approach is using recombinant  
adeno-associated virus (AAV) as a gene transfer vector to carry the missing gene into affected cells. 
Vasireddy et al. published the first study which successfully transduced iPSCs developed from a 
patient with choroideremia with AAV subtype 2 (AAV2) [32]. Choroideremia is an inherited 
disorder due to loss of the CHM gene and the resulting Rab Escort Protein 1 (REP-1), which leading 
to degeneration of the choroid and retina and blindness by the 2nd decade of life. Research moving 
towards clinical trials has been stymied due to a lack of an animal model with similar functional and 
morphological features as the human retina, since the knockout of the murine Chm is lethal. The 
authors developed a preclinical model of choroideremia using iPSCs and successfully transduced 
wildtype human Chm cDNA into these cells using AAV2 mediated therapy. They observed a 
functional restoration of REP-1 enzymatic activity and protein trafficking, showing that their gene 
therapy was successful and that iPSCs can be used as a preclinical model for choroideremia [32]. 
The development of genome editing tools such as zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas system have facilitated gene targeting in human iPSCs [33]. These tools use 
double strand break induction and subsequent homology-directed repair to edit the mutations in the 
patients’ genomic DNA, so that the corrected gene will remain under the normal endogenous 
promoters and enhancers. Thus, compared to conventional viral-mediated gene replacement, gene 
editing using ZFNs, TALENs, or the CRISPR system can avoid genetic expression in inappropriate 
cell types as well as incorrect levels of expression [34]. 
The CRISPR-Cas system has several advantages over ZFNs and TALENs for enhancing gene 
targeting efficiency. Most CRISPR-Cas subtypes target DNA directly, suggesting the possibility of 
engineered, RNA-directed gene editing systems. This usage of easily generated RNA guides avoid 
the need for repeated protein design, which sets CRISPR-Cas apart from ZFNs and TALENs, which 
use protein-based DNA targeting motifs. Using the CRISPR-Cas9 system, Mali et al. targeted the 




iPSCs [35]. Recently, Hou et al. developed a CRISPR-Cas system from N. meningitides to generate 
accurately targeted clones in human iPSCs with increased efficiency as compared to TALENs [36]. 
There several concerns with CRISPR-Cas technology in human genome editing, primarily off-target 
DNA cleavage [37]. However, recent experiments showed that “nickases”, or enzymes that cleave 
only a single strand of DNA in DNA repair, can increase the specificity and safety of the 
CRISPR-Cas9 system [38]. 
3.2. Gene Therapy on Patient-Specific iPSC-Derived RPE Cells 
With the aim of correcting genetic defects, gene therapy has been attempted not only on  
patient-specific iPS cells, but also RPE cells derived from these cell lines. A proof of concept study 
was performed by Cereso et al. which used a hybrid vector comprised of AAV2 and AAV5 
(AAV2/5) to mediate gene therapy to the RPE derived from iPS created from a choroideremia  
patient [39]. The authors successfully developed a human iPS-derived retinal cell model of 
choroideremia, performed gene therapy on the iPS-RPE, and showed that AAV2/5-mediated therapy 
could potentially restore RPE phenotype. Working with MFRP, Li et al. also showed that 
patient-specific iPS-RPE could be a recipient for gene therapy [25]. The researchers applied the 
AAV8 vector expressing human MFRP to iPS-RPE from patients with MFRP mutations and 
confirmed that gene therapy led to restoration of RPE phenotype, specifically with regards to actin 
organization. These studies suggest that gene therapy using AAV vectors can be applied to RPE 
created from patient-specific iPS for retinal diseases without previous models, and that these diseases 
may be potential targets for additional gene therapy trials. 
3.3. Transplantation of iPSC-Derived RPE Cells 
Considerable attention has been paid to the potential of human iPSCs as a source for regenerative 
medicine, disease modeling, and drug testing. In particular, the limitations in existing treatments for 
AMD have led to attention being given to alternative approaches in which damaged RPE is replaced 
by healthy RPE. In a recent landmark trial in Japan, patient specific iPSC-derived RPE cells were 
transplanted for the first time into a human patient with AMD. Clearance for a human trial was given 
after Takahashi et al. showed that transplantation of iPSC-derived RPE did not provoke an immune 
reaction nor lead to tumor growth in monkeys or mice [40]. Autologous iPSCs were created from the 
patient’s skin cells and then differentiated into RPE so that they would grow in a monolayer without 
the use of synthetic scaffolds or matrices. To achieve this, iPSC-RPE were seeded onto type I 
collagen gel on a Transwell insert. After the RPE reached confluence, collagenase was applied to 
dissolve the collagen gel and leave a sheet of RPE. A 1.3 millimeter by 3.0 millimeter cut of this 
sheet was then grafted into the patient’s retina following excision of her existing damaged RPE. 
This marks the first clinical trial on humans using iPSCs. The safety and feasibility of using iPSCs 
from patients to treat their blindness is still being established, but this trial holds great potential for 





4. Future Directions 
Patient-specific iPSCs have been shown to not only complement animal models of human 
disease, but also function as an excellent model in their own right. Patient-specific cell lines created 
from somatic cells from patients with inherited eye diseases can: (i) provide a window for testing the 
efficacy of gene or drug-based therapies; (ii) elucidate previously unknown mechanisms and 
pathways of disease; (iii) demonstrate the pathogenicity of unusual mutations in individual patients; 
and (iv) enable researchers to optimize parameters for successful cell replacement therapy in vitro. 
Skin-derived iPSCs can be used to investigate the function or dysfunction of a mutant gene product 
in tissues such as retina that are inaccessible to molecular analysis in living patients [41].  
Finally, gene therapy tools such as ZFNs, TALENs, and the CRISPR-Cas system are rapidly 
improving the prospects of restoring the function of diseased RPE from patients with inherited retinal 
diseases. These patient-specific iPS-RPE, after undergoing gene therapy, can be optimized to  
become transplantable retinal cells, with the goal of restoring sight to patients with no other 
therapeutic options. 
However, despite these advances, improvements still must be made in reprogramming, 
differentiation, and cell characterization protocols before employing this technology in clinical 
transplantation trials. In moving from animal models to human trials, potential safety issues must be 
carefully addressed. The use of potent oncogenic transgenes such as c-myc and Klf4 in the 
reprogramming process as outlined by Yamanaka is one area of concern [16]. If these transgenes are 
not silenced or are reactivated after reprogramming, genomic instability may result and not only 
confound results of disease modeling studies but also cause tumor formation after transplantation.  
To this end, iPS reprogramming protocols are still being optimized. An alternative reprogramming 
protocol by Yu et al. obviates the use of oncogenic transgenes by using a combination of Oct4, Sox2, 
Nanog, and Lin28 [42]. The methodology for generating iPSCs has markedly improved and now 
integration-free iPSCs, without transgene insertion in the host genome, can be obtained using 
plasmid vectors, RNA viruses, or mature microRNAs [43–47]. Integration-free iPSCs appear ideal 
since exogenous genes integrated in the host genome may affect the genetic properties of the iPSCs 
generated and thus modify the resulting cellular phenotypes of differentiated progeny. Additional 
studies are also required to ensure that the risk of rejection is significantly reduced in patient-specific 
iPSCs, given that immune rejection when certain tissues derived from iPSCs were transplanted into 
syngeneic murine hosts have been reported [26]. 
ESCs are still the gold standard for in vitro pluripotency. A significant concern of using iPSCs in 
development of therapies is still whether they are truly equivalent to ESCs. For example, key 
differences between iPSCs and ESCs in transcribed genes, epigenetic landscape, differentiation 
potential, mutational load, and premature senescence has been described [48]. If iPSCs cannot 
closely replicate ESCs, the results from studies using iPSCs must be interpreted with this in mind. 
Significant differences between iPSCs and ESCs may hinder the translation of study results from an 
in vitro iPSC-based disease model to human disease. 
A further step likely to accelerate the integration of iPS technology in regenerative medicine is the 




production [49]. In this way, availability of iPS-based technology will increase, making them more 
widespread in investigative and translational studies in the future. Patient-specific iPS-derived cells 
offer the hope of slowing progression or improving visual function for patients with currently 
untreatable retinal diseases. In addition to curing blindness, stem cell transplantation in the eye can 
also be seen as a model system for investigating cell-based treatments for other degenerative 
disorders of the CNS. 
5. Conclusions 
Stem cells have revolutionized the field of human cell culture because they provide an immortal 
population of pluripotent cells which can theoretically differentiate into any cell type in the body. 
This technology, when applied to retinal cells, has the promise to make significant contributions to 
our understanding of the most pressing blinding diseases of our time. Stem cells also allow for the 
development of therapies for exceedingly rare retinal conditions which currently have little to no 
funding for research. In particular, patient-specific iPSCs represent an excellent tool for modeling 
retinal disease since they can be generated from adult somatic cells, thus avoiding the ethical 
considerations involved with using embryonic stem cells. iPSCs will continue to be a sustainable 
method to model disease as gene therapies, drug therapies, and transplantable retinal cells continue to 
be developed for inherited retinal disorders. 
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Potential Role of Induced Pluripotent Stem Cells (IPSCs) for 
Cell-Based Therapy of the Ocular Surface 
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Abstract: The integrity and normal function of the corneal epithelium are crucial for maintaining the 
cornea’s transparency and vision. The existence of a cell population with progenitor characteristics 
in the limbus maintains a dynamic of constant epithelial repair and renewal. Currently, cell-based 
therapies for bio replacement—cultured limbal epithelial transplantation (CLET) and cultured oral 
mucosal epithelial transplantation (COMET)—present very encouraging clinical results for treating 
limbal stem cell deficiency (LSCD) and restoring vision. Another emerging therapeutic approach 
consists of obtaining and implementing human progenitor cells of different origins in association 
with tissue engineering methods. The development of cell-based therapies using stem cells, such as 
human adult mesenchymal or induced pluripotent stem cells (IPSCs), represent a significant 
breakthrough in the treatment of certain eye diseases, offering a more rational, less invasive, and 
better physiological treatment option in regenerative medicine for the ocular surface. This review 
will focus on the main concepts of cell-based therapies for the ocular surface and the future use of 
IPSCs to treat LSCD. 
Reprinted from J. Clin. Med. Cite as: Casaroli-Marano, R.P.; Nieto-Nicolau, N.;  
Martínez-Conesa, E.M.; Edel, M.; Álvarez-Palomo, A.B. Potential Role of Induced Pluripotent 
Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface. J. Clin. Med. 2015, 4, 318–342. 
1. Introduction 
The ocular surface is mainly composed of the cornea and the conjunctiva with their epithelia.  
The cornea is the primary refractive element at the anterior surface of the eye that is responsible for 
approximately two-thirds of its total optical power. Basically, the cornea is composed of five 
well-defined layers (Figure 1). It consists of an outermost stratified, squamous and non-keratinized 
epithelial layer (corneal epithelium) limited posteriorly by Bowman’s layer. The underlying stroma, 
which accounts for about 90% of the middle thickness of the cornea, comprises aligned arrays of 
collagen fibrils interspersed with cellular components (keratocytes) and it is this highly organized 
arrangement of lamellae that is responsible for the cornea’s transparency. The stroma is separated 
from the endothelial layer (corneal endothelium) by Descemet’s membrane, which acts as a 
basement membrane for these endothelial cells. The corneal endothelium is a single cuboidal layer of 
metabolically active cells that are in direct contact with the aqueous humor in the anterior chamber. 
These cells help to maintain corneal transparency by actively pumping water out of the stroma [1]. 
The corneal epithelium has a key role in keeping the cornea transparent and free of blood vessels and, 
to this end, presents permanent repair phenomena essential for the conservation of the cornea’s 
physiology [1–3]. The homeostasis of the corneal epithelium is crucial to maintaining the structural 




1.1. Limbal Stem Cells 
It has been observed that progenitor cells responsible for the continual renewal of the corneal 
epithelium are located in the basal layers of the sclerocorneal limbus. The human limbus—the 
circumferential anatomic area (approximately 1.5 mm wide) that separates the clear cornea from the 
opaque sclera, which is covered by conjunctiva—serves as the “reservoir” for the stem cells and also 
provides a barrier to the overgrowth of conjunctival epithelial cells and its blood vessels onto the 
cornea [1–3] (Figure 1). Due to their particularities, the limbal stem cells (LSCs) have a crucial role 
in maintaining the integrity and in the renewal events of corneal epithelium. Their main features are 
highlighted: it is their behavior as oligopotent progenitor cells, with high nuclear-cytoplasmic ratio a 
slow cell cycle, and a high proliferative potential that adds its great capacity for self-renewal by 
asymmetric division [3–5]. In the limbus, it is possible to identify several cell subpopulations of 
different progenies (typical progenitors and amplifying cells at different stages of differentiation), 
melanocytes, antigen-presenting and mesenchymal cells, vascular elements and nerve endings that 
form a specialized and unique environment called niche. This particular microenvironment is 
considered responsible for the proliferative and self-renewal cellular characteristics of the limbal 
region [2,3,6]. The LSC niche is an anatomically defined area that is thought to provide a variety of 
factors, such as physical protection, survival factors and cytokines and is deemed essential to the 
maintenance of the “stemness” of the stem cell population while preventing entry into  
differentiation [2,6]. Within the niche, LSCs maintenance and function are controlled in a particular 
environment by several elements, including extracellular matrix components, cell adhesion 
molecules, and growth and survival factors secreted by stromal fibroblasts, mesenchymal stem cells and 
blood capillaries [6]. To date, four limbal anatomic structures have been proposed as the corneal stem 







Figure 1. The corneal limbus is the circumferential anatomic area, approximately 1.5 mm 
wide, which separates the clear cornea from the opaque sclera (a); The limbal region 
represents the “reservoir” for LSCs in the ocular surface. In a cross-section of the human 
cornea stained with hematoxylin-eosin, (b) to (d), details of its main layers can be 
observed. The cornea is composed of a stratified non-keratinized squamous epithelial 
layer (epithelium), the stroma and an endothelial cuboidal layer (endothelium) (b);  
The corneal epithelium (48 to 55 μm thick) consists of the outermost layer, which 
presents five to seven stratified cell layers (c), limited posteriorly by Bowman’s layer  
(10 to 12 μm thick; c, asterisk). The stroma (480 to 510 μm thick; b), composed of 
compacted collagen lamellae and keratocytes (c and d), offers transparency and 
scaffolding to maintain the shape of the cornea in its middle portion. The stroma is 
separated from the endothelium (about 5 μm thick; d, large arrows) by Descemet’s 
membrane (8 to 10 μm thick; d, narrow arrows), which acts as a basement membrane for 
the corneal endothelial cells (d). Bar = 150 μm for b; Bar = 25 μm for c and d. 
1.2. Renewal of Corneal Epithelium 
It has been shown that cell subpopulations with progenitor features, located in the deeper basal 
layers of the corneal epithelium, have the capacity to differentiate into post-mitotic cell populations 
located in the outermost epithelial layers. This continuous centripetal movement (the XYZ 
hypothesis)—from the peripheral deeper epithelial layers to the more central outermost 
layers—ensures constant renewal of the corneal epithelium and maintains its integrity [1–6,9]. The X 
component represents the anterior migration from cells of the basal epithelium of the limbal region, 




represents the desquamation from the surface of corneal epithelium. However, this XYZ theory has 
recently been challenged by evidence in the mouse and other mammals suggesting that uninjured 
cells in the central cornea can generate holoclones with characteristics of stem cells, presenting 
regenerative epithelial capabilities, which may also be responsible for the maintenance of the corneal  
epithelium [10]. Also, in support of these controversial findings, the presence of central islands of 
normal corneal epithelial cells has been described in patients with apparently complete clinical 
absence of LSCs [11]. These interesting observations may have the following interpretation: the 
central basal epithelial cells of the surviving corneal epithelium present the capability to regenerate, 
or some LSCs remain and contribute to the maintenance of the central epithelium.  
1.3. Limbal Stem Cell Multipotency 
An in vitro study of the clonogenic capacity of epithelial cells located in the ocular limbal region 
revealed a progenitor cell system stratified into levels (cellular stages or “compartments”) [2,6,12]. 
Undifferentiated small cells presenting progenitor cell features with high self-renewal capacity are 
found in the first compartment but they lose these characteristics as they migrate through the 
following compartments. Lastly, the final level contains a cell population with terminal differentiation 
features associated with little or no self-renewal capability. The latter cells, once their epithelial 
differentiation events are completed, lose their ability to self-renew and are incorporated as corneal 
epithelial cells on the surface of the central cornea. In this regard, some studies [12,13] concluded 
that epithelial cells of the limbal region can form holoclones with higher clonogenic potential, in 
contrast to epithelial cells from the central cornea. In addition, epithelial cells isolated from basal 
layers in the limbal region exhibit a high proliferative potential in vitro during expansion or in 
response to corneal injury [14], and show an undifferentiated phenotype lacking the expression of 
differentiated corneal cell markers such as cytokeratins 3 and 12 [15]. They have also been shown to 
retain labeled precursors of DNA for an extended time, in contrast to more differentiated cells that 
quickly lose them due a higher division rate [16]. This lack of differentiation and slow cell cycling 
are characteristics of the quiescent state of stem cells.  
2. Limbal Stem Cell Deficiency (LSCD) 
The disappearance, reduction or functional impairment of LSCs may produce a clinical state  
(limbal stem cell deficiency, LSCD) that can give rise to significant changes in the ocular surface. 
These changes include the occurrence of persistent corneal defects, epithelial keratinization, 
conjunctivalization phenomena with the development of newly formed vessels in the corneal tissue, 
and scarring. All this compromises the corneal physiology, reducing transparency and decreasing 
vision [1–5]. The presence of a complete loss of the corneal-limbal epithelium leads to a reactive 
reepithelialization by conjunctival cells, which have a high proliferative capacity. This event is 
followed by neovascularization, chronic inflammation with scarring of corneal stroma, causing a 
pronounced decrease in vision and severe discomfort (Figure 2). Furthermore, the chronic 
inflammatory condition not only leads to the death of more LSCs but also leaves the surviving 




features over time [17–24]. In patients with severe lacrimal dysfunction syndrome (dry eye) 
suffering from LSCD, the conjunctival epithelium that replaced the corneal epithelium 
(conjunctivalization) becomes partially or totally keratinized [18,21,22,24]. Several processes and 
diseases (Table 1) may lead to unilateral or bilateral LSCD, and depending on its extent, the disorder 
can be classified as either partial or total. Chemical burns (alkalis and acids) are, however, the most 
frequent cause of limbal ischemia and epithelial destruction causing the loss and/or impairment of 
LSCs function, and are the main indication for cell-based therapy approaches [18–24]. 
 
Figure 2. Clinical findings related to Limbal Stem Cell Deficiency (LSCD). Limbal 
deficiency secondary to ocular cicatricial pemphigoid with the presence of peripheral 
newly formed vessels leading to a loss of corneal transparency (a); Limbal deficiency, 
secondary to a chemical burn (bleach) of the ocular surface leads to a corneal 
conjuntivalization and neovascularization with loss of transparency (b). LSCD can be 
treated with cell therapy techniques such as cultured limbal epithelial transplantation 





Table 1. Main etiologies and pathological conditions for primary and secondary Limbal 
Stem Cell Deficiency (LSCD). 




Autosomal dominant keratitis  
Gelatinous drop-like corneal dystrophy  
Iris coloboma 
Xeroderma pigmentosa  
Epidermolysis bullosa  
Dyskeratosis congenita  
Ectodermic dysplasia 
Multiple endocrine neoplasia  
Polyglandular autoimmune syndromes 
Neoplasic 
Intraepithelial neoplasia 




Salzmann nodular corneal dystrophy  
Infections 
Severe infeccious keratitis 
Chlamydia conjunctivitis  
Mechanical  
Alkali, acid, thermal burns 
Bullous keratopathy  
Tumor excision  
Cryotherapy, radioterapy 
Systemic and local chemotherapy (MMC, 5FU) 
UV radition 
Phototherapeutic keratectomy  
Anoxic  Contact lenses misuse or prolonged use 
Trophic  Neurotrophic keratopathy 
Inflammation 
Superior limbic keratoconjunctivitis 
Collagen diseases related ulcers 
Mooren ulcer 
Atopic keratoconjunctivitis 
Ocular pemphigoid  
Ocular rosacea 
Stevens-Johnson syndrome 
Graft-versus-host disease  
Vitamin A deficiency  




2.1. Cell-Based Treatments for LSCD 
The concept of ocular surface reconstruction was introduced with the application of autologous 
conjunctiva for unilateral ocular chemical alkali burns [25]. Since then, several surgical approaches 
have been developed with the aim of restoring the corneal epithelium on the diseased ocular surface. 
In recent decades, limbal transplantation techniques using auto or allografts have been introduced as  
bio-replacement approaches for limbal tissues to improve and reconstruct the altered ocular  
surface [5]. Building on previous experience treating patients with large surface areas of burned skin, 
the epithelial cells of the ocular surface have been obtained by cell culture techniques for ex vivo 
expansion. Subsequently, the ocular surface was successfully reconstructed by using LSCs in 
patients with severe unilateral ocular surface pathology [17]. Since then, various translational 
approaches have been developed and optimized, with satisfactory long-term clinical results [18–23]. 
Treatment approaches for LSCD can be divided into three main categories [4,5,23,24]: (a) 
transplants and bio-replacement of tissue; (b) cell-based therapy by ex vivo cell culture expansion; 
and (c) symptomatic and alternative treatment: keratoprosthesis implantation, provisional 
debridement of conjunctival corneal tissue, therapeutic contact lenses and drug (steroids, 
anti-angiogenic drugs, tear substitutes, autologous serum) therapy [5].  
Ex vivo expansion of LSCs is the most innovative approach for ocular surface bio-replacement 
(CLET: cultured limbal epithelial transplantation). From a minimally invasive biopsy (1–2 mm2) of 
the healthy limbal region (the same or the contralateral eye), an explant culture technique can be 
applied on a suitable substrate (such as the amniotic membrane) or by separating the epithelial layer 
from the fragment obtained by enzymatic treatment [19,21,22,26–29]. In the latter approach, the 
cells obtained are in vitro co-cultured on feeder-layers (3T3 murine fibroblasts growth arrested by 
irradiation or mitomycin-C). Once cell growth is achieved, the cell suspensions are transferred to 
suitable substrates, such as fibrin, collagen or biocompatible polymers. The bio-replacement  
is carried out after removal of most of the diseased tissue from the ocular surface [17–21].  
This methodology has many advantages over the tissue transplantation techniques used to date: 
essentially, it requires a substantially smaller limbal biopsy, which reduces the risk of limbal 
deficiency in healthy donor tissue. Its other advantages include a final high cell population that is 
more efficiently selected, homogeneous and, theoretically, more enriched with progenitor 
characteristic cells [26–29]. However, enzymatic techniques involve a more complex approach, with 
additional manipulation of the tissue and the need for xenoproducts at different stages of cell culture 
production. For its part, the explant technique has certain advantages—among them its technical 
simplicity, the lack of xenoproducts and its cost-effectiveness, despite the heterogeneity of the cell 
population cultured (sclera fibroblasts, antigen presenting cells, melanocytes, conjunctival 
epithelium cells and others) [21,22,26–29]. It is always desirable to use autologous cells for ex vivo 
expansion to avoid the risk of immune response. However, in the presence of severe bilateral ocular 
pathology, the use of heterologous epithelial cells (from cadaveric or related living donor corneas) is 
acceptable [18–21]. Autologous oral mucosal epithelia expanded ex vivo have also been successfully 





The mechanism by which cultured LSCs may restore the ocular surface is still poorly understood. 
Cells may replace the progenitor population, and/or “reactivate” nonfunctioning host progenitor cells 
by providing stimuli for growth, or change niche behavior. It has been speculated that there may be 
“dormant” stem cells despite clinical features of LSCD [11]. 
Currently, ex vivo expansion methods applied in cell-based therapy for clinical application are 
based mostly on the use of xenogeneic or allogeneic products such as murine cells for feeder layer 
approaches, fetal calf or bovine serum in culture media, supplements of non-human origin for cell 
growth and maintenance and the human amniotic membrane as a cell carrier. These products 
potentially carry a risk for transmitting diseases; they may induce tumorigenesis or precipitate an 
immunological response in the host [18,20–23,28,29]. They also show idiosyncratic biological 
variability that may adversely affect the quality of cultured grafts and also the final results after 
transplantation. Thus, there is currently a special need to investigate options for replacing potentially 
hazardous xenobiotic materials with others of human origin or xeno-free chemically defined media. 
2.2. Alternative Cell Sources for LSCD Treatment 
Corneal transplantation (penetrating keratoplasty) is considered the conventional therapy to 
restore the corneal tissue. However, this technique is not a viable strategy for patients suffering 
LSCD because it does not replace the LSCs population [32]. Cell-based therapy is the most rational 
approach for ocular surface bio-replacement, and the ideal cells for corneal reconstruction are 
autologous corneal LSCs using CLET approach. Minimally invasive biopsy of the limbal tissue from 
the same patient’s healthy eye (unilateral disease) is the preferred method, although this source of 
progenitor cells is not always available. If both eyes present serious surface damage, the source of 
healthy LSCs will be lost; COMET is among the current therapeutic alternatives. In fact, therapy for 
LSCD is also rapidly evolving to include alternative cell types (of autologous or heterologous origin) 
and clinical approaches as treatment modalities. As a consequence, other strategies, such as the use of 
mesenchymal stem cells from adult tissue (bone marrow mesenchymal stromal cells or adipose 
derived stromal cells, among others) for cell regenerative therapy in corneal injuries, are gaining 
prominence at present. Other sources of cells or stem cells have been tested with regenerative aims in 
the ocular surface, and may be useful in situations where both eyes are affected although many of 





Table 2. Cell sources for ex vivo expansion cell-based therapy to treat Limbal Stem Cell 
Deficiency (LSCD). 
Cell Sources Application References 
Cultured Limbal Epithelial Cells (CLET) Clinical application [17–21] 
Cultured Oral Mucosal Epithelial Cells (COMET) Clinical application [30,31,33–37] 
Cultured Conjunctival Epithelial Cells Clinical application [38–41] 
Cultured Embryonic Stem Cells Mice model [42–45] 
Cultured Adult Epidermal Stem Cells  Goat model [46–48] 
Cultured Bone-Marrow Derived Mesenchymal Stem Cells Rat and rabbit models [49–53] 
Cultured Adipose Derived Mesenchymal Stem Cells In vitro model [54,55] 
Cultured Orbital Fat Mesenchymal Progenitor Cells Mice model; in vitro model [56–58] 
Cultured Immature Dental Pulp Stem Cells Rabbit model [59,60] 
Cultured Hair Follicle-Derived Stem Cells Mice model [61,62] 
Cultured Umbilical Cord Stem Cells Rabbit model [63,64] 
Nevertheless, the application of CLET using human amniotic membrane (hAM) or fibrin gel as a 
scaffold has been clinically validated and today is the most frequently used cell-based therapy 
applied at clinical level in ophthalmology [18–21]. Since its introduction [17], it has been used with 
long-term clinical follow-up periods. Despite many differences between studies regarding 
inclusion/exclusion criteria, the culture methods applied, transplantation techniques, and clinical 
outcome measures, the overall success rate of this procedure is around 70% [18,21,23]. On the other 
hand, oral mucosa has also been shown to be an attractive autologous epithelial cell source for cases 
of severe bilateral LSCD. COMET has already been used in clinical settings, offering promising 
long-term results with improved vision in over half of treated patients [30–35]. However, peripheral 
corneal neovascularization is commonly found with this approach since oral mucosal cells have 
greater angiogenic potential than limbal epithelial cells [65,66]. It has been suggested that these 
new-formed vessels may regress following local anti-angiogenic therapy [33–35]. Further studies are 
needed in this regard to assess the long-term efficacy of COMET technique. In the past five years, 
several clinical trials have been conducted to test, compare or consolidate the application of other 







3. IPSCs and Corneal Epithelial Differentiation 
As discussed above, adult stem cells make it possible to repair and regenerate damaged epithelial 
tissue. In general, these cells reside in the basal layer of the epithelium, are able to self-renew 
continuously, and produce transient amplifying cells (TACs) that differentiate terminally after a brief 
period of proliferation [68–72]. However, there are limitations to LSCs transplantation therapies.  
On one hand, for unilateral LSCD, taking biopsies from the healthy eye carries along the risk of 
damaging the donor eye. On the other hand, for bilateral LSCD, allogenic transplantation presents 
the risk of immune rejection by the patient. In this sense, induced pluripotent stem cells (IPSCs) can 
be obtained from minimally invasive sources from the patient himself and be differentiated into 
LSCs, avoiding immune rejection problems and cell availability. The discovery of IPSCs has been 
one of the most significant advances in regenerative medicine in the last decade. Overexpression of a 
specific set of transcription factors (e.g., Oct4, Sox2, c-Myc, and Klf4; or Oct4, Sox2, Lin28 and 
Nanog) in adult differentiated cells can reprogram cell fate and IPSCs [68–70]. These can be 




the investigation of cell states, the mechanisms of differentiation, pluripotency and other related 
cellular identities and behaviors. Contrary to embryonic stem cells, IPSCs can be created from easy 
access differentiated cells, such as fibroblast or keratinocytes, and allow the creation of autologous 
sources of different cell types for regenerative therapies or disease modeling. 
More recently, direct reprogramming of cells into different states (either pluripotent or somatic) 
offers one of the most promising approaches in the field of regenerative medicine, with enormous 
potential for examining clinical and therapeutic applications in more depth [71]. The “direct 
reprogramming” is characterized by a process wherein mature, fully differentiated somatic cells, can 
be induced to other cell types without necessarily going through a pluripotent state [71]. To this end, 
cells can be reprogrammed by transient overexpression of transcriptional factors for a relatively short 
time interval. The cells in this state are called IPS-partial cells; they respond to different signal 
environments (e.g., growth factors, cytokines, inductors agents, etc.) and have the ability to direct 
cell fate decisions in reprogramming [71]. For corneal repair direct reprogramming would be of great 
advantage by not only eliminating the pluripotent stages (potentially carcinogenic) but also avoiding 
the lengthy production and characterization of IPSC lines. As very few cells are needed for ocular 
surface cell therapy, the limited expansion capacity of IPSCs is not a limiting factor as well as the 
production time, which would be much shorter with an easier methodology. However, there are still 
very limited references to the LSCs production by transdifferentiation from easily accessible adult 
somatic cells. Rat adult stem cells from the bulge of hair follicle were transdifferentiated into corneal 
epithelial-like cells by culturing with corneal limbus soluble factors and forced overexpression of the 
transcripton factor Pax6 [73]. More recently, Sainchanma and colleagues [74] described a method to 
obtain corneal epithelial-like cells from human skin-derived precursor cells—which present some 
multipotency markers—by culturing them with three specific growth factors: epidermal growth 
factor (EGF), keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF) [74]. These are 
encouraging results to open the way for new sources of LSCs autologous supply. However further 
work is necessary to refine the protocol to obtain final cells that are closer to LSCs in their marker 
profiling and their functionality in restoring corneal epithelium should be tested. 
3.1. Application of IPSCs for Ocular Pathology 
Regarding the application of IPSCs in the field of cell therapy for ocular pathology, IPSCs have 
shown great promise in treating certain degenerative retinal diseases, particularly those that affect the 
functionality of the retinal pigment epithelium (RPE) due to its dysfunction or loss. In this  
context—dry age-related macular degeneration (geographic atrophy)—cell-based therapy may be a 
rational and effective therapeutic alternative for certain forms of retinitis pigmentosa and gyrate 
atrophy [75]. 
The use of stem cell therapy for eye diseases presents many advantages, for a variety of reasons:  
(a) the intraocular environment benefits from a state of immune privilege; (b) the target tissue to be 
treated has certain individual anatomical and functional characteristics (defined subretinal space and 
specialized single stratified epithelium); (c) the intraocular space is small and limited, as is required 
by the treatment given the low number of cells involved; and (d) the intraocular space is easily 




monitoring with satisfactory clinical follow up—for example, by injection of cells under the 
subretinal space or into the vitreous body—which permits the visualization of the therapeutic  
effect and possible complications. For this reason, several recent research studies are being carried 
out [75–77]. 
The regeneration of the ocular surface and restoration of corneal transparency following injury is 
one of the fields where IPSCs may also be applicable. The first attempt to obtain LSC-like cells from 
pluripotent cells were carried out by Notara and colleagues [78]. Using mouse ESCs treated with 
conditioned media from limbal fibroblasts they obtained cells with cobblestone morphology that 
expressed cytokeratin (CK) 12 and Np63 , opening the door for the study of pluripotent 
cells-derived cells in the regeneration of corneal epithelium. Yu and co-researchers [79] also 
obtained about 13% of conversion of mouse IPSCs to corneal epithelium-like cells by co-culture of 
IPSCs with corneal limbal stroma in the presence of additional growth factors related to corneal 
development: basic fibroblast growth factor (bFGF), EGF and nerve growth factor (NGF).  Moving 
toward human cells, Hayashi and colleagues [80] aimed to establish IPSCs derived from human 
LSCs and to examine the ability of both limbal-derived and human dermal fibroblast-derived IPSCs 
to differentiate into corneal epithelial cells. Corneal epithelial cells were then successfully induced 
by the stromal cell-derived inducing activity (SDIA) differentiation method, after prolonged 
differentiation culture (12 weeks or later) in both, limbal (with higher corneal epithelial differentiation 
efficiency) and fibroblastic IPSCs. This study was the first to demonstrate a strategy for corneal 
epithelial cell differentiation from human IPSCs, and further suggested that an epigenomic status 
related to DNA methylation in specific epithelium-related genes—CK3, CK12 and Pax6—was 
associated with the propensity of IPSCs to differentiate into corneal epithelial cells and could be used 
as a criteria to choose IPSCs source for LSCs differentiation However, this protocol is lengthy and 
the efficiency is low, as the population obtained after the differentiation protocol is mixed with other 
cell types, such as RPE or lens epithelium. Ljubimov’s group [81] recently successfully generated 
IPSCs from human primary LSCs to re-differentiate these IPSCs back into the limbal corneal 
epithelium, maintaining them on natural substrate that mimicked the native LSC niche, including 
denuded hAM and de-epithelialized corneas. This choice of parent cells represented an improvement 
for limbal cell differentiation by partial retention of parental epigenetic signatures in IPSCs.  
The authors observed that when the gene methylation patterns were compared in IPSCs to parental 
LSCs, limbal-derived IPSCs presented fewer unique methylation changes than fibroblast-derived 
IPSCs, suggesting the retention of epigenetic memory (genes promoting methylation) during 
reprogramming. Interestingly, limbal-derived IPSCs cultured for two weeks on hAM induced 
markedly higher expression of LSC markers (ABCG2, Np63, CK14, CK15, CK17, N-cadherin, 
and TrkA) than fibroblast-derived IPSCs. On hAM, the methylation profiles of select limbal-derived 
IPSC genes became closer to the parental cells, but fibroblast-derived IPSCs remained closer to 
parental fibroblasts. On denuded air-lifted corneas, limbal-derived IPSCs even upregulated 
differentiated corneal CK3 and CK12. Taking all the data together, the authors emphasize the 
importance of the natural niche and the limbal tissue of origin in generating IPSCs as LSCs for 
clinical aims [81]. Compared to the previous work of Hayashi and colleagues [80], this method 




defined growth supplements, allowing for a more standardized protocol and bringing it closer to a 
clinical application. Also, differentiating the IPSCs on hAM provides an advantage for the success of 
future transplantation [21]. Both research [80,81] lead to the conclusion that the initial cell type from 
which IPSCs are derived is important for the quality of the final LSC-like cells obtained. However, 
for clinical applications easily accessible donor cell types should be identified to create IPSCs-LSCs. 
Other than fibroblasts, adult progenitor cells like bone-marrow or hair follicle -derived mesenchymal 
stem cells should be also tested.  
In an elegant approach applying a directed two-stage differentiation protocol without the use of 
feeder cells or serum in the culture medium, researchers generated relatively pure populations of 
corneal epithelial-like progenitor cells capable of terminal differentiation toward mature corneal 
epithelial-like cells [82]. Early developmental mechanisms could be reproduced in vitro by blocking 
the transforming growth factor  (TGF- ) and Wnt-signaling pathways with small molecule 
inhibitors and activating bFGF signaling. IPSCs were cultured onto collagen IV substrate in specific 
corneal epithelial cell growth media which differentiated them into LSCs. Cells expressed typical 
LSC markers such as cytokeratins (CK3, CK12 and CK15) as well as Pax6, ABCG2 and Np63 after 
five weeks of differentiation [82]. Interestingly, the differentiation protocol described by the authors, 
using growth factors and small molecules inhibitors, can be performed totally in xeno-free, 
feeder-free and serum-free conditions, allowing for a reproducible and clinical grade production of 
the IPSCs-LSCs ready to be used in the clinical setting. To bring one more step closer into the clinic, 
Wu’s team [83] described a IPSCs-LSCs transplantation system that introduces a 3D scaffolding in 
which IPSCs are seeded, differentiated and grafted into an acellular porcine matrix scaffold.  
This bioengineering system is aimed to overcome the gradual loss of viability over time of LSC 
grafted cells and the limitations of amniotic membrane. The method improved the outcome in rabbit 
experimental models [83].  
In conclusion, even if several adult stem cells types have been used for regeneration of corneal 
epithelium, LSCs themselves have shown superior results and are the cells of choice for LSCD 
treatment. Since IPSCs grow indefinitely, IPSC-derived LSCs are an unlimited source of autologous 
LSCs for patients with bilateral LSCD—and therefore no LSCs left—and to avoid the risks of 
surgical intervention in unilateral LSCD. Moreover, the idea of creating IPSCs banks to provide 
HLA matched (immune-compatible) tissues is being strongly considered by the scientific 
community [84]. This would provide a ready-to-go source of material for LSCs derivation avoiding 
the high cost of personalized IPSCs development.  
3.2. Molecular Mechanisms of Corneal Epithelial Reprogramming 
Molecular mechanisms of epithelial reprogramming have been analyzed, and Np63 has emerged 
as a central protein in IPSC reprogramming routes. Np63 has been found to enhance IPSCs 
generating efficiency, as the loss of function of this protein decreased the mesenchymal-epithelial 
transition (MET) and pluripotency genes [85]. Accordingly, in cell oncogenic transformation  
(a process that may share similarities with IPSCs reprogramming at signaling level) it was found that 
Oct4 upregulation could enhance the expression of Np63 while repressing p53 [86]. APR-246/ 




that target mutant forms of Np63) was found to reverse corneal epithelial lineage commitment and 
to reinstate a normal p63-related signaling pathway [87]. In this study [87], the authors designed a 
unique cellular model that recapitulated major embryonic defects related to ectrodactyly ectodermal 
dysplasia cleft (lip/palate) syndrome (EEC syndrome), which is caused by single point mutations in 
the p63 gene. Fibroblasts from healthy donors and from EEC patients carrying two different point 
mutations in the DNA binding domain of p63 were reprogrammed into IPSC lines. Phenotypic 
defects in EEC syndrome include skin defects and LSCD, with loss of corneal transparency. In this 
interesting in vitro model, EEC-derived IPSCs failed to terminal differentiate into CK14 cells 
(epidermis and LSCs) or CK3/CK12 cells (corneal epithelial cells) [87]. This research team also 
described previously the possible roles of specific miRs in corneal development using IPSC corneal 
differentiation methods [88]. Similarly, IPSC epithelial somatic differentiation seems to recapitulate 
the molecular steps during embryonic development, in which Np63 is a master regulator of 
epithelial differentiation. Moreover, during IPSCs generation it is widely accepted that MET is 
needed [89]. Blocking MET during cell reprogramming (using TGF-  or Snail1) prevents IPSCs 
induction. In this change of cell state, the inverse of MET occurs during embryonic development, in 
which epithelial-mesenchymal transition (EMT) pointing out the parallelism between embryonic 
development and cell reprogramming [89]. Another interesting signaling pathway that may be 
involved in the IPSC differentiation into epithelial cells is the Pax6/ -catenin pathway [90]. During 
the embryonic development of the chicken eye, eye specification seems to be established by the 
inhibition of the canonical Wnt pathway and TGF- , which induces the upregulation of Pax6 in the 
lens ectoderm [87]. In support of this theory, the trans-differentiation of multipotent hair follicle stem 
cells into corneal epithelial-like cells is mediated by the upregulation of Pax6 and the inhibition of 
the canonical Wnt-signaling pathway [73]. Thus, further investigation is needed to clarify whether 
this mechanism really affects the differentiation of IPSCs into corneal epithelial cells. 
3.3. Restoration of Corneal Stromal Transparency  
The restoration of corneal transparency after stromal or endothelial damage is another field of 
interest in which IPSCs generation and differentiation may have an impact. The production of 
corneal keratocytes from pluripotent cells also has significant implications for cell-based therapy and 
tissue engineering for treatment of corneal diseases. At present, however, there are very few studies 
of the use of IPSCs as an effective and conclusive approach for cell therapy applications for recovery 
corneal stroma, and the results are very preliminary. 
Funderburgh’s group [91] developed a methodology for inducing the differentiation of human 
embryonic stem cells (hESCs) into cells with a gene-expression phenotype similar to that of adult 
human corneal keratocytes. The transparency of the cornea depends on the unique molecular 
composition and organization of the extracellular matrix of the stroma (collagen fibrils), which is a 
product of keratocytes—specialized neural crest (NC)-derived mesenchymal cells. In Funderburgh’s 
study, neural differentiation of the hESC cell line was induced by co-culture with mouse PA6 
fibroblasts as a feeder-layer. After a few days in co-culture, hESCs acquired the ability to express  
cell-surface nerve growth factor receptor (NGFR, p75NTR) of low affinity. These cells were then 




keratocyte phenotype was induced in serum-free medium containing ascorbate and was independent 
of the substratum for cultivation. Interestingly, hESC co-cultures upregulated the expression of some 
specific NC genes, and when NGFR-expressing cells were expanded as a monolayer, mRNAs 
typifying adult stromal stem cells were detected. Further, when these cells were cultured as 
substratum-free pellets, several corneal keratocyte markers were upregulated, among them 
keratocan, a corneal stroma-specific proteoglycan. The analysis of culture medium obtained from the 
pellets also contained high concentrations of keratocan modified with keratan sulfate, considered a 
unique molecular component of corneal stroma. This study showed the possibility to differentiate 
keratocytes in vitro. The authors also hypothesized that IPSCs derived from adult somatic cells could 
be used in place of hESCs for both, to provide autologous material for bioengineered corneal matrix 
or for direct stromal cell-based therapy [91]. 
Human corneal keratocytes could also be reprogrammed into IPSCs exhibiting pluripotent 
properties. To prevent feeder cell contamination and to improve the clinical utility of reprogrammed 
IPSCs, Chien and colleagues [92] developed a feeder-free (without MEF, mouse embryonic 
fibroblasts cells) and serum-free method to stably expand human IPSCs in vitro. This approach 
allows cells to remain stable through 30 passages, maintaining ESC-like pluripotent properties. 
Furthermore, to improve IPSCs delivery and engraftment, a biocompatible injectable nanogel 
(thermo-gelling carboxymethyl-hexanoyl chitosan; CHC) was developed. The authors also 
evaluated whether the viability and pluripotent properties of human corneal keratocyte-derived 
IPSCs can be retained in a CHC hydrogel system, and explored the therapeutic potential of these 
cells on corneal impairment using CHC hydrogel as delivery vehicle in a rat model of corneal 
damage induced by either chemical burns or surgical ablation. They concluded that the IPSC/CHC 
system enhanced corneal regeneration by downregulating oxidative stress and recruiting endogenous 
epithelial cells to restore corneal epithelial thickness, and also reconstructing the corneal 
microenvironment niche [92]. 
Very recently, Fukuta and co-researchers [93] developed an efficient induction protocol using 
chemically defined culture medium containing inhibitors for TGF-  signaling and inhibitors for  
Wnt-signaling pathway (GSK3 ). This approach allow differentiate human neural crest cells 
(hNCC) from human pluripotent cells, with the same efficiency (70%–80%), independent of the 
parental cell type (ESCs or IPSCs), or method of generation (viral-integrated or plasmid-episomal). 
Furthermore, cells have been kept under feeder-free and xeno-free culture systems. Interestingly, 
generated hNCCs could be differentiated into corneal endothelial cells, among other complex cell 
types, such as peripheral neurons, glial cells and melanocytes. Endothelial cells of the cornea have 
been differentiated culturing hNCCs in corneal endothelial cell conditioned medium supplemented 
with selective ROCK inhibitor (Y-27632). After two weeks of induction, cells changed their 
morphology into that of polygonal corneal endothelial-like cells and started to express ZO-1, type IV 
and type VIII collagens, which are recognized corneal endothelial cell markers [93]. These results 
also open new and promising perspectives for possible clinic applications in corneal pathologies 





3.4. Future Trends for IPSC Technology 
The ideal source of cells for ocular clinical application needs to meet certain criteria: (a) easy 
accessibility and minimal risks for patients; (b) availability in sufficient quantities for bio-replacement; 
and (c) a high likelihood of successful reprogramming [72]. However, present evidence confirms 
that the methods involving IPSCs production should be considered with caution before immediate 
clinical application. An example is exome sequencing of several human IPSC lines, identified over a 
hundred point mutations in the generated cells but not in the parental cells. Many missense mutations 
associated with the function of different proteins and other point mutations in genes related to 
cancers have been observed [94]. In this sense, a better understanding of the molecular mechanisms 
for differentiation into various cell types associated with more directed protocols for the 
reprogramming, without the need to induce complete states of non-differentiation, could contribute 
to mitigate possible aberrations in the genome of produced cell populations. 
4. Conclusions 
In recent years there have been significant developments in the use of cell-based cultures 
combined with biomaterials or biocompatible substrates for corneal epithelial tissue engineering 
bio-replacement. Current approaches for improving these therapeutic strategies include standardization 
of culture conditions and development of xenobiotic free culture systems, evaluation of novel 
bio-functional scaffolds to enhance stem cell expansion and transplantation efficacy, and exploration 
of alternative autologous progenitor cell sources. To date, the search for innovative strategies and 
approaches in the field of ocular surface reconstruction has produced some encouraging results. 
Several new strategies have emerged for future therapies for LSCD, although the best cell source and 
the ideal technique still need to be established. One of the key elements is the role of the cellular 
microenvironment or niche. The limbal stem cell niche contains stem cells that promote proliferation 
and migration and have immunosuppressive mechanisms to protect them from immunological 
reactions. The current findings suggest that the CLET and COMET approaches using autologous 
epithelial progenitor cells are the most widely accepted clinical techniques for treating LSCD. 
One emerging alternative cell source for treating the ocular surface is the use of adult stem cells, 
which provide high proliferative potential, differentiated capability and lower immunogenicity; they 
are non-tumorigenic and can be obtained by minimally invasive methodologies. They represent a 
more physiological, more rational, and less invasive treatment. Meanwhile, stem cells from adult 
tissue, as in the case of mesenchymal stem cells, although they have showed an intrinsic potential for 
a possible epithelial differentiation, this has not yet been achieved. Also, the prospects for therapies 
derived from autologous mesenchymal and IPSCs that may yield a multitude of engineered tissue 
types are exciting. Although IPSCs are yet to be used for ocular surface reconstruction, a recent study 
has shown successful corneal epithelial cell generation. The search for alternative sources of stem 
cells in the treatment of ocular surface diseases represents a challenge. IPSCs represent a very 
promising option for obtaining corneal epithelial cells to apply in cell-based therapy for the ocular 




well as of proliferation and differentiation pathway events should help to expand and develop the use 
of IPSCs in ocular surface regenerative medicine. 
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The Potential for iPS-Derived Stem Cells as a Therapeutic 
Strategy for Spinal Cord Injury: Opportunities and 
Challenges 
Mohamad Khazaei, Ahad M. Siddiqui and Michael G. Fehlings 
Abstract: Spinal cord injury (SCI) is a devastating trauma causing long-lasting disability. Although 
advances have occurred in the last decade in the medical, surgical and rehabilitative treatments of 
SCI, the therapeutic approaches are still not ideal. The use of cell transplantation as a therapeutic 
strategy for the treatment of SCI is promising, particularly since it can target cell replacement, 
neuroprotection and regeneration. Cell therapies for treating SCI are limited due to several 
translational roadblocks, including ethical and practical concerns regarding cell sources. The use of 
iPSCs has been particularly attractive, since they avoid the ethical and moral concerns that surround 
other stem cells. Furthermore, various cell types with potential for application in the treatment of SCI 
can be created from autologous sources using iPSCs. For applications in SCI, the iPSCs can be 
differentiated into neural precursor cells, neurons, oligodendrocytes, astrocytes, neural crest cells and 
mesenchymal stromal cells that can act by replacing lost cells or providing environmental support. 
Some methods, such as direct reprogramming, are being investigated to reduce tumorigenicity and 
improve reprogramming efficiencies, which have been some of the issues surrounding the use of 
iPSCs clinically to date. Recently, iPSCs have entered clinical trials for use in age-related macular 
degeneration, further supporting their promise for translation in other conditions, including SCI. 
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1. Current Outlook on the Pathophysiology and Treatment of Spinal Cord Injury 
1.1. Epidemiology of Spinal Cord Injury 
Dislocation or fracture of the spine in the neck or back as a result of vehicle accidents, falls,  
sports accidents, work accidents or other causes commonly results in spinal cord injury (SCI).  
The seriousness of the damage varies depending on the severity of the injury and the level of injury. 
Over half of SCIs occur at the cervical level of the spinal cord [1]. The global prevalence of SCI 
varies between 250 and 906 per million of the population depending on global region [1–3]. There 
have been many advances in the medical, surgical and rehabilitative treatment of SCI in the last few 





1.2. Pathophysiology of SCI 
The mechanical crushing, stretching or rupture of the spinal cord at the time of injury leads to 
axonal damage, quick necrotic death and loss of neurons and glia, which are collectively referred to 
as the primary injury [4–6]. Axon damage and disruption of the cell membrane that occurs during the 
primary injury results in a cascade of molecular and signaling pathways that initiate a series of 
secondary injuries to the spinal cord. Formation of free radicals and oxidative stress as a consequence 
of secondary injuries result in more neuronal and glial death, mainly due to apoptosis [7]. 
Disintegration of myelin and demyelination are another consequence of secondary injury in the 
spinal cord. The mechanical insult to the spinal cord also results in the disruption of the blood spinal 
cord barrier (BSCB). This increases the permeability of the BSCB, allowing the infiltration of 
immune cells from the blood and increasing inflammation, which augment secondary injury [8]. The 
activation of astrocytes results in reactive gliosis and subsequent formation of the glial scar which 
acts as a physical and chemical barrier that inhibits axon regeneration. Progressive loss of neurons 
and glial cells results in the formation of a cystic cavity in the spinal cord [5,9,10].  
1.3. Approaches and Progresses towards the Treatment of SCI 
The current treatment options for SCI are mainly focused on stabilizing the spine, preventing the 
progress of secondary injuries and controlling inflammation. Fractured vertebrae and bone fragments 
that compress the spinal cord may need to be surgically removed by spinal decompression  
surgery [11]. Corticosteroid drugs (like methylprednisolone) may be used within 8 h of the injury, 
although their application is controversial. Methylprednisolone appears to work by modulating 
inflammation near the site of injury and reducing damage to nerve cells [12]. After the initial 
treatment and stabilization of patients with an SCI, much of the current treatment approaches are 
geared toward rehabilitation. However, there are many promising advancements in research towards 
protecting surviving neural cells from further damage, stimulating axonal regeneration and replacing 
damaged nerve or glial cells. Several medications that can increase neuronal survival and reduce 
inflammation are in clinical trials, including corticosteroids, minocycline, erythropoietin and 
gangliosides [12]. Riluzole is a drug with neuroprotective effects that has been investigated by our 
laboratory as a part of an international, multicenter effort sponsored by AOSpine and the North 
American Clinical Trial Network [13]. Therapeutic interventions to promote axonal regeneration 
have also entered clinical trials. In a phase I/IIa clinical trial, in which our laboratory was also 
involved, the RhoA inhibitor C3 transferase (Cethrin) was tested on patients with SCI. The observed 
motor recovery in this open-label trial suggests that inactivation of RhoA may increase neurological 
recovery after complete SCI [14,15].  
1.4. Cell Therapy: Promise and Progress 
Stem cell transplantation is a promising therapeutic strategy for the treatment of SCI that works 
through several different mechanisms [16,17]. Preclinical studies have shown encouraging 
beneficial effects of cell therapies in animal models of SCI. Cell therapies have been shown to have 




primary and secondary phases of SCI. One of these mechanisms is the replacement of cells that are 
lost or damaged during the injury, through differentiation or transdifferentiation into mature neurons 
and through myelination of oligodendrocytes. Some transplanted cells render their therapeutic effect 
by providing neurotrophic factors that are crucial in order to enhance neuronal regeneration and 
survival. Some other cell types are beneficial to SCI through downregulation of inhibitory 
molecules, immunomodulation, modulation of the environment and extracellular matrix or by 
providing scaffold support for the regeneration of axons [16–18]. 
Several differentiated, multipotent or pluripotent cell types have been investigated so far for the 
treatment of SCI. Some of these cells have entered clinical trials. One such study is a phase I/II trial 
using human neural progenitor cells (NPCs) sponsored by Stem Cells Inc. (Newark, CA, United 
States of America). Our centre (Toronto Western Hospital) is involved in this trial, in collaboration 
with other centers at the University of Calgary and the University of Zurich. The first patient in this 
trial was treated in Toronto in February, 2014. Despite these advances, stem cell therapy for SCI is 
limited by the availability of the ideal cell source, the control and safety of the transplantation and the 
ethical and logistical challenges surrounding the use of stem cells.  
Here, we briefly describe some of the most important cell types that have been investigated so far 
for the treatment of SCI. For a more thorough review on the application of these cells, refer to the 
recent review from our laboratory on this topic [17]. 
1.4.1. Neural Progenitor Cells 
Neural progenitor cells (NPCs) have attracted great interest as a potential source for replacing 
damaged or lost neurons and glia in SCI [16]. Our laboratory and others have shown that 
transplantation of rodent and human NPCs into the spinal cord improves neural repair and 
regeneration, as well as functional recovery following traumatic SCI in rodents. This occurs via cell 
replacement and plasticity, remyelination and nutrient secretion, increasing axonal regeneration and 
immunomodulatory effects [19–24]. Although adult NPCs, derived from the CNS, are attractive for 
use after SCI due to their neural commitment and lack of tumorigenicity [20,22,24], the derivation of 
adult or embryonic NPCs for autologous transplantation is not feasible. This is due to the fact that 
these cells are collected from the brains of aborted fetuses or post-mortem patients, which possibly 
excludes their application in the clinical treatment of SCI. Furthermore, concerns regarding donor 
cell rejection have been problematic in SCI, in which activated inflammatory responses can present 
an intrinsically hostile environment to any allogeneic grafts. 
1.4.2. Mesenchymal Stromal Cells 
Mesenchymal stromal cells (MSCs) are multipotent cells that originate from the mesodermal  
germ layer. Several labs have studied the effect of MSCs for the treatment of SCI. These  
studies demonstrate that MSCs exert their beneficial effect mostly by providing immunomodulation, 
trophic support, environmental modification and by providing physical scaffolding for elongating  
axons [25–28], resulting in improvement of locomotor function [29–33]. Due to poor engraftment and 




replacement therapy for SCI, and their therapeutic effect is limited to providing trophic support. An 
additional limitation is the potential of MSCs to differentiate into unwanted mesenchymal lineages. 
1.4.3. Schwann Cells 
Schwann cells (SCs) are one of the first cell types to have been used for the treatment of SCI.  
In the past two decades, many studies have demonstrated positive results and potential for SC 
transplantation as a therapy for SCI. They may do this by sustaining regeneration and through 
remyelination of damaged CNS axons, as well as by secreting several neurotrophic factors (such as 
NGF, BDNF and CNTF) [34] that aid the survival and intrinsic regeneration ability of damaged 
neurons. SCs have also been investigated in a clinical trial for the treatment of SCI [35]. In this trial, 
SCs were transplanted into the spinal cord one year after injury. This study demonstrated no adverse 
effects from SC transplantation, and one patient showed improvements in motor and sensory 
functions combined with extensive rehabilitation [35]. 
1.4.4. Olfactory Ensheathing Glia 
Olfactory ensheathing glia (OEG) are a type of myelinating cell derived from the olfactory mucosa. 
Like SCs, OEGs have also been transplanted as myelinating cells for the treatment of SCI in numerous 
studies in animal models of SCI. OEGs have been shown to facilitate remyelination and tissue 
scaffolding and can stimulate the regeneration of lesioned axons [36,37]. OEGs have also entered into 
clinical trials for the treatment of SCI. In one trial, no complications were reported one year after 
transplantation of OEG, but no functional recovery on the ASIA (American Spinal Injury Association) 
scale was found [38,39]. 
1.4.5. Embryonic Stem Cell-Derived Cells 
The isolation and propagation of the various cells types discussed above is difficult, and it is often 
a tedious and lengthy process to produce sufficient cells for treatment of SCI. The optimal time point 
for the application of cell therapy for SCI patients is 2–4 weeks after the injury [22,40], and it is 
important to have a sufficient amount of cells at this time window ready for transplantation. 
Embryonic stem cells (ESCs) are pluripotent cells derived from the inner cell mass of blastocysts 
with the ability to replicate indefinitely and the potential to differentiate into the cell types discussed 
above and, thus, may be useful as an accessible source for providing these cells for SCI treatment. 
Several studies have shown the beneficial effects of cells derived from ESCs in functional recovery 
in animal models of SCI [41–46]. Although providing a sufficient quantity of multipotent cells and 
differentiated ESCs is more feasible and requires less time, there are ethical issues concerning the 
destruction of human embryos or fertilized oocytes to obtain such stem cells. This has been a major 
impediment to developing clinically useful stem cell sources and to using them in clinical 





2. Induced Pluripotent Stem Cells 
The discovery of induced pluripotent stem cells (iPSCs) by Takahashi and Yamanaka in  
2006 [47] opened novel opportunities in providing pluripotent stem cells for the treatment of patients 
with SCI and other injuries/diseases. They showed that stem cells with properties similar to ESCs 
could be generated from mouse fibroblasts by simultaneously introducing four factors: Oct4, Sox2, 
Klf2 and c-Myc [47]. In 2007, they reported that a similar approach was applicable for human 
fibroblasts to generate human iPSCs [48]. At the same time, James Thomson’s group also reported 
the generation of human iPSCs using a different combination of factors including: Oct4, Sox2, 
Nanog and Lin28 [49]. Since iPSCs can be derived directly from adult tissues, they can be made  
in a patient-specific manner that circumvents ethical and moral concerns while allowing for 
autologous transplantation.  
2.1. Methods of Generating iPSCs 
It is very important to have a safe and reliable method for the generation of iPSCs for clinical 
purposes. To reprogram the somatic cells into a pluripotent state, reprogramming factors should be 
introduced to the cells. Different combinations of reprogramming factors can be used with different 
efficiency and outcomes [50,51], which may be critical for clinical applications. Reprogramming 
methods that do not use the oncogene, c-Myc, are desirable to reduce the risk of tumor formation, but 
methods that exclude c-Myc are associated with significantly lower reprogramming efficiency [52]. 
Recently, the Yamanaka group has shown that the transcription factor, Glis1, can be used as a 
substitute for c-Myc for the induction of pluripotency [53]. 
The suitability of iPSCs for use in the clinic is also dependent on the method by which the 
reprogramming factors are delivered to the cell. Traditionally, lentiviruses have been used to deliver 
the reprogramming factors, but random integration of the lentivirus DNA into the host genome raises 
concerns about the risk of tumorigenicity and the safety of this method. Other viruses, like  
adenovirus [54] and Sendai virus (SeV) [55], have also been used as less risky options. Adenovirus is 
considered to be safer than lentivirus, because it does not incorporate any of its own genes into the 
targeted host and, thus, avoids the potential for insertional mutagenesis [54]. SeV has higher 
efficiency in infecting a wide spectrum of host cell species and tissues compared to adenoviruses. 
Furthermore, SeV vectors replicate in the form of negative-sense single-stranded RNA in the 
cytoplasm of infected cells, which do not go through a DNA phase nor integrate into the host  
genome [55]. 
Various studies have recently described the induction of pluripotency without the use of viruses, but 
instead by using recombinant proteins [56], mRNAs [57], microRNAs [58], episomal vectors [59] and 
even removable transposons [60]. The piggyBac transposons have been shown to be able to deliver the 
reprogramming factors without leaving any footprint mutations in the host cell genome. The piggyBac 
system involves the re-excision of exogenous genes, which eliminates issues, such as insertional 
mutagenesis [61]. 
Another exciting approach that has been investigated recently is the use of small molecules and 




(HDAC) inhibitor, valproic acid, has been shown to be able to mimic the signaling that is caused by 
the transcription factor, c-Myc, and can be used instead of c-Myc for reprogramming [62]. A similar 
type of compensatory mechanism has been proposed to mimic the effects of Sox2 by inhibition of 
histone methyl transferase (HMT) with BIX-01294 in combination with the activation of calcium 
channels in the plasma membrane [63]. More recently, Deng et al. (2013) showed that iPSCs could 
be created without any genetic modification. They used a cocktail of seven small-molecule 
compounds, including DZNep (3-deazaneplanocin A), to induce mouse somatic cells into stem cells, 
which they called CiPS (chemically induced pluripotent stem) cells, with an efficiency of 0.2%, 
comparable to those using standard iPSC production techniques [64]. 
2.2. Cell Sources for Generating iPSCs 
Along with choosing the right reprogramming factors and delivery method for the generation of 
iPSCs, it is also important to use a source of cells that will generate the desirable cell types for 
transplantation into the spinal cord. Several different types of cells have been used to produce iPSCs, 
including fibroblasts, neural progenitor cells, keratinocytes, melanocytes, CD34+ cells, hepatocytes, 
cord blood cells and adipose stem cells (Figure 1).  
iPSCs can even be derived from terminally-differentiated post-mitotic neurons. The cell types that  
are reprogrammed to become iPSCs can influence the differentiation capacity of the resultant iPSCs,  
due to epigenetic memory and genetic variations of their original cell line (Figure 2) [65–69].  
The ideal iPSC source for the treatment of SCI should reprogram efficiently, be able to be isolated in 
large quantities in a reasonable period of time and, more importantly, should be able to differentiate 
into the desired multipotent/differentiated cell types that are required for the treatment of SCI. The 
efficiency of cell reprogramming varies among different cell types. For example, human 
keratinocytes from skin biopsies can be reprogrammed to pluripotency at a much higher frequency 
and more quickly than fibroblasts [70]. On the other hand, the iPSCs derived from keratinocytes have 
an increased tendency to differentiate into NPCs than do iPSCs from CD34+ blood cells [66]. More 
research is needed to determine the best starting somatic cell for iPSC generation that allows for 
reproducible differentiation into NPCs and other multipotent cell types for transplantation into SCI. 
2.2.1. Skin Fibroblasts 
Skin fibroblasts are one of the most used cell types for reprogramming. Adult human fibroblasts 
can be easily isolated and maintained in culture [71,72], which makes them ideal for autologous 
transplantation in SCI patients. However, it takes a long time to reprogram these cells into iPSCs. 
Three to four weeks are required for expanding fibroblasts taken from human skin biopsy [73].  
It takes another three to four weeks for iPSC colonies to appear [73]. Even after two months of 
culturing, the reprogramming efficiency of adult human fibroblasts from the skin is only 0.01% when 
the four Yamanaka factors are used and can be even lower if three or less of the factors are used [62]. 
Yamanaka postulated that since fibroblasts are terminally-differentiated cells, they require greater 




that it is possible to enhance the efficiency of iPSC generation by up to 100-fold, by using different 
combinations of reprogramming factors [51]. 
 
Figure 1. Several different types of cells have been used to produce iPSCs, including 
fibroblasts, neural progenitor cells, keratinocytes, melanocytes, CD34+ cells, cord blood 
cells and adipose stem cells. The next step, after generating iPSCs, towards the treatment 
of spinal cord injury (SCI) is to differentiate the iPSCs to the appropriate multipotent or 
differentiated cell type that can be used for the treatment of SCI. To date, several 
different cell types have been successfully derived from iPSCs and have been 
transplanted into SCI animal models, including neuronal progenitor cells, neurons, 
oligodendrocytes, astrocytes, neural crest cells and mesenchymal stromal cells. 
2.2.2. Keratinocytes 
There has been some interest in using keratinocytes for reprogramming, because they can be 
easily obtained from the human foreskin with minimal invasiveness [75]. This presents the 
opportunity to use keratinocyte-derived iPSCs for autologous transplantation in patients with SCI. 
Keratinocytes take longer to expand than fibroblasts, but can be reprogrammed more quickly  
(10 days) and have a higher reprogramming efficiency [76]. The higher reprogramming efficiency 
may be due to the higher levels of endogenous Klf4 and C-Myc [76], meaning that these cells require 
less energy to reach pluripotency. Although it is thought that cells isolated from younger sources are 
better suited for reprogramming, Linta et al. were able to achieve a reprogramming efficiency  




















This demonstrates the importance of considering the appropriate age and reprogramming conditions, 
as well as the cell type when determining the ideal method for developing iPSCs.  
 
Figure 2. The epigenetic and genetic variations among different cell sources used for 
reprogramming can affect the properties of the iPSC and its differentiation to the target  
cell type. The characteristics of the different cell sources are at the core of defining how 
easily hiPSCs (human induced pluripotent stem cells) can be produced and their 
characteristics. Variations in aneuploidy, subchromosomal copy number variations 
(CNV), single-nucleotide variations (SNV), methylation, X chromosome inactivation 
(XCI) and source memory in the different cell sources can affect the differentiation 
potential, tumorigenicity and phenotypic status of hiPSCs. Aneuploidy is an abnormality 
in chromosome number. It is estimated that 13% of hiPSC cultures have karyotype 
abnormalities, commonly trisomy 12 [68]. CNVs are alterations in the DNA that lead to an 
abnormal number of a segment of the chromosome. They can occur around pluripotency 
genes, such as NANOG on chromosome 12 [67]. There can be as many as a dozen SNVs 
in a hiPSC line that may be inherited from their somatic cell source [69]. XCI is a process 
where one of the X chromosomes in the cell isolated from a female source is inactivated, 
so that it does not receive a double dose of the gene product. Reprogramming of certain 
cells may be more prone to XCI variations than others. Different lines of hiPSCs may 
have different methylation states, as shown by the fact that blood-derived iPSCs have  
an enhanced ability to become blood cells. This type of source memory is important to 






Like fibroblasts, melanocytes can also be isolated from skin biopsies. Melanocytes contain high  
levels of endogenous Sox2, so they can be reprogrammed using just the other three factors [79].  
In addition, melanocytes take only 10 days to reprogram and have been shown to have a 
reprogramming efficiency of 0.19% [79]. All of this suggests that melanocytes may be a better 
option for use as sources for iPSCs than fibroblasts for autologous transplantation.  
2.2.4. CD34+ Cells 
CD34+ cells isolated from human umbilical cord blood and peripheral blood have been used to 
generate iPSCs [80]. The collection of CD34+ cells from the peripheral blood of SCI patients is not 
thought to be ideal, since it has to be collected from patients undergoing granulocyte colony 
stimulating factor (G-CSF) mobilization [80]. G-CSF use is associated with increased risk of 
complications and side effects [81], which might not be well tolerated by SCI patients. CD34+ cells 
have a low reprogramming efficiency of 0.01%–0.02% with the Yamanaka factors [80]. The 
reprogramming efficiency is even lower for CD34+ cells isolated from umbilical cord blood [82]. 
2.2.5. Cord Blood Cells 
Umbilical cord blood may be a better source of iPSCs, since the method of isolation is less invasive, 
and they can be cryopreserved for more than five years and still be used to generate iPSCs [83]. 
Another benefit of cord blood is that many cord blood banks exist worldwide. CD133+ cells from 
umbilical cord blood can be reprogrammed to iPSCs using just Oct4 and Sox2 with a reprogramming 
efficiency of 0.45% [83]. Endothelial cells can also be isolated from cord blood and reprogrammed 
to iPSCs [84]. Cell isolated from the umbilical cord have primitive characteristics that make them ideal 
for reprogramming, since they may be epigenetically closer to iPSCs than other differentiated  
cells [85]. However, iPSCs derived from the umbilical cord cannot be considered as sources of 
autologous transplantation for SCI patients, unless the patient had already deposited his/her 
umbilical cord in cord blood banks after birth.  
2.2.6. Adipose Stem Cells 
Adipose stem cells are multipotent cells that are collected by lipoaspiration [86]. As many as  
100 million cells can be isolated from a 300-mL sample and can be expanded for reprogramming in 
approximately 48 h [87]. Using the Yamanaka factors, adipose stem cells can be reprogrammed in  
10 to 15 days at a reprogramming efficiency of 0.2% [87]. Adipose stem cells express high levels of  
Klf4, and their multipotent nature would theoretically make them require fewer epigenetic changes to  
reach pluripotency [88]. 
2.2.7. Neural Progenitor Cells 
Multipotent cells, such as neural progenitor cells (NPCs), require fewer factors to be 




Oct4 [89]. However, the reprogramming efficiency is very low, at 0.004%. NPCs are not an ideal 
source for generating iPSCs for use in the treatment of SCI, because they are not readily available 
and there are ethical issues associated with their use. 
3. Using iPSC-Derived Cells for Treatment of SCI 
The next step towards the treatment of SCI after generating iPSCs is to differentiate the iPSCs into 
the appropriate multipotent or differentiated cell type that can be used for the treatment of SCI  
(Figure 1). Due to the high risk of teratoma formation, the differentiation process should be 
“definitively” completed, and the cell population should be devoid of pluripotent cells. The direct 
injection of iPSCs into the injured spinal cord can be problematic. In an un-published study,  
Hodgetts et al. transplanted undifferentiated hiPSCs into the spinal cord in a thoracic level 7 (T7) 
contusion model of SCI in nude rats at seven days post injury [90]. They did not observe any 
significant improvement in motor function by five weeks after SCI with this method, despite subtle 
differences in some neuronal marker expressions at the lesion site [90]. 
To date, several different cell types have been successfully derived from iPSCs and have been 
transplanted into animal models of SCI. These studies have provided a proof of principle that iPSCs 
can be successfully differentiated in vitro to yield desirable progeny. They can be safely transplanted 
into models of SCI and survive, integrate and differentiate into desired phenotypes, as well as 
promoting functional recovery with an outcome comparable to the counterpart ESC therapy.  
iPSC-derived cells can be useful in the treatment of SCI through cell replacement and restoration of 
lost myelin and through trophic support, which results in the induction of neuroprotection and a 
reduction in cell loss. They may also be a source of increased regeneration and neuroplasticity. 
Cytokines and chemokines, which are secreted by iPSC-derived cells, can also have 
immunomodulatory effects. iPSC-derived cells can help remodel the physical structure of the tissue 
following injury to make it a less inhibitory and more permissive substrate for neural regeneration. 
The influence of iPSC-derived cells on astrogliosis at the early stages of injury can halt the expansion 
of the cystic cavity. The different potential cellular and molecular mechanisms through which  
iPSC-derived cells can exert their therapeutic effects in SCI are illustrated in Figure 3.  
3.1. iPSC-Derived NPCs 
One of the most promising cell types that has been studied so far for the treatment of SCI are 
NPCs. However, as discussed in the previous section, the availability of adult NPCs for SCI patients 
is limited, if even available at all. NPCs can also be derived from ESCs. However, the logistical and 
ethical issues surrounding the use of ESCs are quite significant. iPSCs present an alternative and 





Figure 3. iPSC-derived cells exert their therapeutic effects for the treatment of SCI  
through different mechanisms. Some transplanted cells, like iPSC-derived neural 
progenitor cells (NPCs), can replace lost or damaged cells through differentiation or 
transdifferentiation into mature neurons and oligodendrocytes . iPSC-derived neurons 
and oligodendrocytes can also potentially replace lost or damaged cells. iPSC-derived 
cells, such as mesenchymal stromal cells (MSCs), NPCs astrocytes and oligodendrocytes, 
provide neurotrophic factors (like GDNF, NGF, BDNF and CNTF), which are crucial to 
enhancing neuronal regeneration and survival . iPSC-derived MSCs can also be 
beneficial to SCI by downregulating inhibitory molecules and immunomodulation . 
iPSC-derived astrocytes and oligodendrocytes can potentially modulate the environment 
and provide a scaffold support for the regeneration of axons .  
Several protocols have been developed to differentiate iPSCs into neural precursors and specific 
neuronal and glial lineages. In our lab, definitive neural progenitor cells were recently generated  
from piggy-Bac transposon iPSCs, and by inducing the NOTCH signaling pathway, we enhanced NPC 
generation with reduced expression of pluripotency and nonectodermal markers [61]. We have 
shown that this method is safe and effective [61]. Other studies using iPSC-NPCs in rodent and 
primate models of SCI have indicated that transplanted cells differentiate into neurons and glia  
in vivo, enhance remyelination and axon regeneration, supporte the survival of endogenous neurons 
and promote locomotor recovery and sensory responses [91–93]. These pre-clinical studies led to the 
launch of a collaborative team by Okano and Yamanaka laboratories, who are currently planning a 
clinical trial for hiPSC-derived NPC transplantation for SCI patients in the sub-acute phase. This 
study will use clinical-grade integration-free human iPSC lines that will be generated by Kyoto 
University’s Center for iPS Cell Research and Application (CiRA). 
The Okano group has done several pioneering studies examining the transplantation of  
iPSC-derived NPCs for the treatment of SCI [92,94,95]. They tested different iPSC lines derived 




differentiated into NPCs, and the tumorigenicity of each NPC line was pre-evaluated by 
transplantation into the brains of immunocompromised mice. They proposed that each iPSC line has 
to be pre-evaluated to assess teratoma formation after cell transplantation in animal models due to the 
differences among iPSC lines in differentiation capacity and teratoma formation. In this study, 
around 9.5 × 105 cells were transplanted into the spinal cord in a T10 contusion mouse model of SCI 
at nine days after injury, the time window when most of the inflammatory responses are reduced.  
The survival rate of transplanted cells was around 20%, and they differentiated into 30% neurons, 
50% astrocytes and 15% oligodendrocytes. In the transplantation group, motor function was restored 
for a long period of time without tumors developing. This study showed that the functional recovery 
after transplantation of iPSC-derived neurospheres is attributable to three possible mechanisms:  
(1) remyelination by mouse iPSC-derived oligodendrocytes; (2) axonal regrowth; and (3) trophic 
support. Those transplanted cells that differentiated into immature astrocytes may play a role in the 
guidance of regenerating axons [95]. The Okano group next proceeded to test the efficiency of iPSCs 
derived from human fibroblasts [94]. hiPSC-derived NPCs were transplanted into the spinal cord of 
NOD-SCID (non-obese diabetic-server combine immunodeficiency) mice with a T10 contusion 
injury. Transplanted cells survived, migrated and differentiated toward all neural cell fates (50% 
neurons, astrocytes and oligodendrocytes) and contributed to restoring motor function. These 
neurons could integrate into the host tissue and functioned as interneurons. They formed synapses 
with the host neurons and contributed to the reconstruction of neural circuits. This preclinical study 
serves to validate hiPSCs as a source of neural cells and represents an important step towards clinical 
practice [94]. In their next step towards the clinical application of hiPSC-NPCs in the treatment of 
SCI, they used a primate model of SCI [92]. This primate study demonstrated that hiPSC-NPCs can 
promote long-term functional recovery without tumorigenicity [92]. Similarly, Fujimoto et al. 
(2012) have shown that the transplantation of hiPSC-derived NPCs into a T9 contusion model of SCI 
in NOD-SCID mice could result in functional recovery [91]. NPCs were derived from iPSCs in a 
monolayer procedure, and around 10 × 105 cells were transplanted into the lesion epicenter at seven 
days post-SCI. Grafted cells showed a survival rate of 20% and differentiated into 75% neurons, 20% 
astrocytes and 1% oligodendrocytes. Differentiated neurons were able to form synapses with 
endogenous neurons [91].  
In a highly clinically-relevant study of chronic cervical SCI, Nutt et al. (2013) used a human  
iPSC line derived from human fetal lung fibroblasts for the generation of NPCs. This study 
transplanted 2 × 105 cells into a C4 contusion rat model of SCI at the chronic time point of four weeks 
after injury. By four weeks after transplant, hiPSC-NPCs were mainly differentiated to astrocytes 
(30%) and neurons (15%), but no oligodendrocyte marker was detected. However by eight weeks 
after transplantation, transplanted cells with an oligodendrocyte marker (17%) were detected, 
though none could convincingly form myelin. Despite thorough integration and differentiation into 
both neurons and glia, assessment of behavioral recovery indicated that transplantation of 
hiPSC-NPCs did not confer any significant improvement in functional recovery. This study 
suggests that the best time for cell transplantation for the treatment of SCI is likely to be in the 
acute phases [93]. In concordance, Romanyuk et al., 2014, transplanted hiPSC-NPCs into the spinal 




triple drug immunosuppression. Cell transplantation resulted in increased axonal regrowth, reduced 
lesion cavity size and improved hindlimb functional recovery, which may be due to trophic support 
from the cell transplant to the spared axons [96].  
In a recent study by the Tuszynski group, human iPSCs derived from the dermal fibroblasts of an  
89-year-old man were differentiated into NPCs [97]. These hiPSC-NPCs were used for 
transplantation into the spinal cord two weeks after C5 hemisection SCI in immunodeficient rats. 
Grafted hiPSC-NPCs showed a high survival rate three months post-transplantation and were 
distributed through most of the lesion. The majority of grafted hiPSC-NPCs (71%) were 
differentiated into neurons, and around 18% of grafted cells differentiated into astrocytes, but no 
oligodendrocytes were detected amongst transplanted cells. The differentiated neurons could 
extend their axons directly out of the lesion site and into the host spinal cord. Interestingly, these 
axons extended over very long distances in the host spinal cord, continuing to extend into the brain 
and even reaching the olfactory bulb. However, graft-derived human axons were not detectably 
myelinated by rat host oligodendrocytes. The synaptic structures were also formed between 
graft-derived human axons and host dendrites. Furthermore, host axons were shown to be capable 
of growing into grafted hiPSC-derived NPCs [97]. 
3.2. iPSC-Derived Oligodendrocyte Progenitor Cells 
Results from our laboratory and others show that functional recovery after NPC transplantation 
may be chiefly attributed to remyelination of host axons by myelinating oligodendrocyte progenitors 
differentiated from NPCs [22,23,98–101]. Therefore, a more direct approach of transplanting 
oligodendrocyte progenitor cells (OPCs) straight into the spinal cord may be warranted. Several 
protocols have been established to generate OPCs from iPSCs [102,103], including one protocol 
from our group, though none of these iPSC-derived OPCs have been used in models of SCI yet. 
However, there has been extensive research on the application of ESC-derived OPCs for the 
treatment of SCI, and the application of iPSC-derived OPCs is reinforced by this. The ESC-derived 
OPC experiments showed that their transplantation resulted in remyelination of spared axons [24,104], 
improved behavioral and electrophysiological outcomes [105], restoration of forelimb motor 
function, improved forelimb stride length, reduced cavitation and resulted in better white and gray 
matter sparing [24,104]. These exciting results led to FDA approval for the world’s first phase I 
clinical trial by Geron Corporation for the transplantation of hESC-derived OPCs into individuals 
with thoracic (T3–T11) SCI on January 23, 2009. hESC-OPCs were administered into the lesion site 
within 14 days of injury with a low dose of two million cells. The follow-up studies on the  
five patients have shown no serious side effects after cell transplantation. In four of the five patients, 
MRI scans showed that the injury site shrank and that the cells may have had some positive effects in 
reducing the deterioration of spinal cord tissue. However in November, 2011, Geron announced that 
it had ended its SCI stem cell research program for financial reasons [106,107]. In 2013, Asterias 
Biotherapeutics, Inc. purchased Geron’s hESC-OPCs and recently obtained FDA approval for a dose 





3.3. iPSC Derived Motor Neurons 
Stem cell-derived motor neurons (MNs) are increasingly utilized as cellular replacement 
strategies for the treatment of SCI. Motor neurons (MNs) and motor neuron progenitors (MNPs) 
have been successfully generated from iPSCs [109]. There are several protocols established for the 
generation of MNs from iPSCs. In one protocol, the exogenous expression of MN-specific factors,  
neurogenin 2 (NGN2), islet-1 (ISL-1) and LIM/homeobox protein 3 (LHX3), in hiPSCs derived 
from human fibroblasts resulted in the generation of motor neurons. There are also some other 
successful protocols for the generation of MNPs and MNs from iPSCs involving the sequential use 
of reprogramming factors, such as bFGF, activin, retinoic acid (RA) and Sonic hedgehog (SHH), in 
addition to growth factors, such as GDNF, BDNF and CNTF [110,111]. Although the efficiency of 
iPSC-derived MNs has not been tested yet for the treatment of SCI, previous data from ESC-derived 
MNs suggest that the application of iPSC-derived MNs may be promising. Transplantation of  
ESC-derived MNPs into the spinal cord of an adult rat after SCI resulted in enhanced sprouting of 
endogenous axons [44,45], and MNPs were shown to be able to mature into MNs and resulted in the 
improvement of functional recovery when transplanted in vivo [112].  
3.4. iPSC-Derived Neural Crest Cells 
Neural crest cells originate from cells at the border between the neuroectoderm and the surface 
ectoderm. They are a transient population of cells that give rise to neurons and the glial cells of the 
peripheral nervous system. They can be differentiated in vitro into Schwann cells (SC) by  
neuregulin-1 [113], which are capable of myelinating sensory axons in vitro [114], and can 
potentially be used for transplantation into SCI. Neural crest stem cells (NCSCs) are capable  
of integrating into spinal cord tissue and differentiating into neurons and myelinating 
oligodendrocytes [115,116]. However, human neural crest cells are difficult to obtain, because of 
their transient nature and the limited availability of human fetal cells [114]. There are several 
protocols established to derive NCSCs from iPSCs [117,118]. These iPSC-derived NCSCs can also 
be differentiated into Schwann cells [117,118]. hiPSC-derived NCSCs have been used in vivo for 
neural tissue engineering in athymic rat models of peripheral nerve injury. They were shown to 
differentiate into Schwann cells and participate in the myelination of regenerating axons [119]. The 
first description of iPSC-NCSC survival and integration into the spinal cord was demonstrated in a 
lamb spina bifida model [120], findings that support the potential application of iPSC-derived 
NCSCs for the treatment of SCI. 
3.5. iPSC Derived Astrocytes 
Although reactive astrocytes proliferate, form a glial scar, and secrete inhibitory agents, such as 
chondroitin sulfate proteoglycan, there are reports showing that the transplantation of purified 
astrocytes promotes axonal regeneration and functional recovery in a rat model of SCI [121].  
The compaction of the lesion center and seclusion of inflammatory cells by migrating reactive 
astrocytes seem to underlie this beneficial effect [122,123]. Astrocytes can be derived from  




after T9–10 level SCI in rats. The transplanted cells survived in the spinal cords eight weeks after 
transplantation, but they did not result in significant locomotor recovery. However, astrocyte 
transplantation increased the sensitivity to mechanical stimulus and thermal hyperalgesia [125].  
3.6. iPSC-Derived MSCs 
MSCs are a promising cell source for the treatment of SCI. Although easy access to MSCs is 
recognized as a great advantage, extended in vitro culture reduces the differentiation potential of 
MSCs, limiting their therapeutic efficacy. Bone marrow-derived MSCs, have a limited capacity to 
proliferate, quickly lose differentiation potential and reduce protective factors during ex vivo 
expansion before possible therapeutic use [127]. MSCs derived from iPSCs have the potential to be 
expanded indefinitely without senescence [128]. To overcome the limitations of MSCs, iPSC-derived 
MSCs have been considered as a promising alternative for cell therapy. 
MSCs have been successfully generated from iPSCs [127,129], and interestingly, they have been 
shown to have greater regenerative potential compared to MSCs derived from bone marrow [127]. 
This may be attributable to superior survival and engraftment after transplantation, because of higher 
telomerase activity and less senescence as compared to bone marrow-derived MSCs [127]. Future 
studies should examine the efficiency of iPSC-derived MSCs on different clinically relevant SCI 
models and compare them to umbilical cord-derived or bone marrow-derived MSCs. 
4. Future Approaches and Prospects 
4.1. Using Directly Reprogrammed Cells for the Treatment of SCI 
The process of deriving iPSC lines and subsequently inducing differentiation is very time 
consuming and inefficient (0.01%–1% cell yield). In addition, the use of pluripotent-derived cells 
might lead to the development of tumors if not properly controlled. The transdifferentiation of one 
mature somatic cell into another mature somatic cell without undergoing an intermediate pluripotent 
state or progenitor cell type has become possible in recent years. It is now possible to directly convert 
fully differentiated mature cells into a variety of other cell types, while bypassing an intermediate 
pluripotent state. Bypassing the intermediate pluripotent state reduces the time required for 
generating a specific cell type and, more importantly, reduces the risk of teratoma formation. It is 
postulated that the future direction of cell therapy will shift from iPSCs to directly reprogrammed 
cells. Different cell types with potential application for the treatment of SCI have been generated 
recently using direct reprogramming methods [130].  
4.1.1. iNPC 
Several studies have recently demonstrated the direct induction of neural progenitor cells (NPCs) 
from human and mouse fibroblasts using a range of pluripotent and neural transcription factors.  
Kim et al. (2012) have shown that fibroblasts can be directly reprogrammed into NPCs (iNPCs) by using 
a combination of Yamanaka factors and growth factors in culture media [130]. These iNPCs could 




oligodendrocytes. Later on, the Wernig lab overcame this problem and were able to generate  
self-renewing tripotent NPCs that could be differentiated not only into neurons and astrocytes, but 
also into oligodendrocytes [131]. In their method, they used Sox2, FoxG1 and Brn2 reprogramming 
factors. Removing Brn2 from this combination gave rise to the formation of bipotent iNPCs that 
could only differentiate into astrocytes and neurons [131]. Several other combinations of factors  
that can directly reprogram mouse or human fibroblast into iNPCs have subsequently been 
discovered [132–134]. Interestingly, all of these combinations had SOX2 in common. However, 
recently, Mitchel et al. (2014) showed that tripotent iNPCs can be generated from human fibroblast 
using only one reprogramming factor, Oct4 [135].  
4.1.2. iOPC 
As discussed earlier, myelination by transplanted cells has a great impact on functional recovery 
after SCI. Myelination is mainly accomplished by oligodendrocyte progenitor cells (OPCs) [136]. 
However, sources of OPCs are largely restricted, and they have limited expansion capacity. Recently, 
Najm et al. (2013) have succeeded in the direct generation of OPCs (iOPCs) from mice fibroblasts by 
using eight reprogramming factors (Olig1, Olig2, Nkx2.2, Nkx6.2, Sox10, ST18, Myrf and Myt1), 
collectively referred to as 8TF (eight transcription factors). These iOPCs were capable of generating 
compact myelin in hypomyelinated shiverer mice [137]. More recently, the Wernig group was able 
to generate iOPCs from rodent fibroblasts just by using the three factors, Sox10, Olig2 and Zfp536. 
These iOPCs had the ability to differentiate into oligodendrocytes in vitro and to myelinate host 
axons after transplantation into the demyelinated shiverer mouse brain [138].  
4.1.3. iN 
Transplantation of neurons and motor neurons has also shown promise as a cellular therapy  
in animal models of SCI. Several studies have demonstrated that combinations of neural 
transcription factors and/or microRNAs can directly convert both mouse and human fibroblasts into 
neuronal cells, including dopaminergic and motor neurons [139–141]. The Wernig group has 
recently shown that the three factors, Ascl1, Brn2 and Myt1l, are sufficient to rapidly and efficiently 
convert mouse embryonic and human postnatal fibroblasts into functional neurons [140,141].  
In another attempt, microRNA (miR-124) and two transcription factors (Myt1l and Brn2) [142] or 
just Ascl1 [143] were shown to be sufficient to directly reprogram postnatal and adult human 
primary dermal fibroblasts into hiN (human-induced neurons). Functionally induced motor neurons 
(iMNs) can be generated from mouse or human fibroblasts by using seven to eight factors (Ascl1, 
Brn2, Myt1l, Lhx3, Hb9, Isl1, Ngn2 and NeuroD1) [144]. iMNs displayed the electrophysiological 
characteristics of MNs, and they formed functional synapses with muscle fibers in culture. They 
were also capable of extending axons into the periphery when transplanted into the developing chick 





4.2. World’s First iPSC Clinical Trial 
The start of the first ever clinical trial using human iPSCs at the RIKEN (Rikagaku Kenky jo) 
Center for Developmental Biology in Japan has raised a lot of hope for the treatment of human injury 
and disease, including SCI. This trial is using retinal pigment epithelium (RPE) cells derived from 
hiPSCs to treat age-related macular degeneration (AMD).  
The Takahashi group at the RIKEN Center for Developmental Biology in Japan began a clinical  
pilot study to determine the safety and feasibility of using autologous hiPSC-derived RPE cell sheets 
in the treatment of wet AMD. The first patient was implanted with a 1.3 by 3.0-mm hiPSC-derived 
RPE sheet on September 12, 2014, in a 2-h procedure [145]. No initial complications from the 
surgery have been reported, and the patient will be followed up monthly for the first 24 weeks, 
bi-monthly for the next 28 weeks and then yearly for the next three years. Stem cell scientists around 
the world will be following this trial with interest.  
5. Conclusions 
There have been considerable advances in cell therapies for the treatment of SCI, some of which 
have entered clinical trials. iPSCs provide a cell source that has characteristics of embryonic stem 
cells, but are associated with fewer ethical and moral issues. In addition, they can be sourced from 
autologous sources, which may decrease the risk of immune rejection. However, there are some 
concerns about the use of iPSCs clinically, since many of the induction methods can increase the risk 
of tumors and have reprogramming efficiencies that would be too low for clinical use. In some cases, the 
issue of tumorigenicity may be due to partial reprogramming of the iPSCs, which may result in 
differentiated iPSCs reverting back to a pluripotent state [146]. Another limitation of using iPSCs 
clinically is that the histocompatibility of the cells may increase the risk of immune rejection. MHC I 
molecules make iPSCs a target of direct or indirect allorecognition [147]. Therefore, there is a need 
to develop histocompatible iPSC lines or to rely on patient-specific iPSCs, which adds to the time 
required before the treatment of the patient can begin. Lastly, there is a need to optimize the growth 
and expansion of iPSCs for clinical use. There is a common reliance on mouse fibroblast feeder cells 
to support the growth of iPSCs and the use of animal products either in the culture media or matrices 
used to grow the cells. This increases the risk of graft rejection [148]. One solution to this has been the 
use of TeSR™ media (STEMCELL Technologies, BC, Canada), which is free of animal products 
and does not require feeder cells to support the growth of iPSCs [149]. We also need to be able to 
culture the cells for use in patients at appropriate numbers, which 2D culturing systems cannot 
support. Microcarrier systems can be used to culture the cells in bioreactors. However, the appropriate 
coating, size and materials used in the microcarrier systems need to be optimized to support the growth 
of iPSCs, since these factors have been shown to affect cell yields of hESCs [150]. There are many 
methods under investigation to address these issues, including non-viral induction and direct 
reprogramming. With continued investigation into these methods and the start of a clinical trial using 
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The State of Play with iPSCs and Spinal Cord Injury Models 
Stuart I. Hodgetts, Michael Edel and Alan R. Harvey 
Abstract: The application of induced pluripotent stem cell (iPSC) technologies in cell based 
strategies, for the repair of the central nervous system (with particular focus on the spinal cord), is 
moving towards the potential use of clinical grade donor cells. The ability of iPSCs to generate donor 
neuronal, glial and astrocytic phenotypes for transplantation is highlighted here, and we review 
recent research using iPSCs in attempts to treat spinal cord injury in various animal models.  
Also discussed are issues relating to the production of clinical grade iPSCs, recent advances  
in transdifferentiation protocols for iPSC-derived donor cell populations, concerns about 
tumourogenicity, and whether iPSC technologies offer any advantages over previous donor cell 
candidates or tissues already in use as therapeutic tools in experimental spinal cord injury studies. 
Reprinted from J. Clin. Med. Cite as: Stuart I. Hodgetts, Michael Edel and Alan R. Harvey.  
The State of Play with iPSCs and Spinal Cord Injury Models. J. Clin. Med. 2015, 4, 193–203. 
1. Introduction 
Spinal cord injury (SCI) is characterised by damage to sensory and motor function, the extent  
of any functional loss dependent on the location, extent (severity) and type of injury (contusion  
vs. transection, incomplete vs. complete). Sensorimotor loss that results from a primary mechanical 
injury is a result of many interacting pathological factors, including: axonal damage, loss of neurons, 
activation of astrocytes and microglia, degeneration of oligodendrocytes, and demyelination [1].  
The extent of this initial damage is significantly increased by ensuing secondary cascades of 
ischaemia, anoxia, generation of damaging free-radicals, lipid peroxidation, excitotoxicity, and 
immune-mediated and inflammatory events (e.g., cytokines), which can stimulate further cell death 
and tissue loss. A region of spreading degeneration rostral and caudal to the injury site, together with 
inhibitor molecule production, eventually leads to cavitation as well as a glial scar rich in, among other 
things, various types of chondroitin sulphate proteoglycans (CSPG) that are extremely inhibitory to 
axonal regrowth. Strategies to induce repair and promote functional (locomotor) recovery generally 
aim to reduce the extent of secondary damage and demyelination, promote the re-myelination of 
damaged (but still viable) axons, induce axonal repair and/or regeneration, and perhaps stimulate an 
endogenous stem cell response. For decades, extensive research has been conducted into clinically 
relevant cell transplantation strategies to either promote regeneration or to replace damaged/missing 
cell populations using: fibroblasts, peripheral nerve grafts and Schwann cell bridges, olfactory 
ensheathing glia (OEG), embryonic stem cells (ESCs), oligodendroglial progenitor cells (OPCs), 
adult neural precursor cells (NPCs) and neural stem cells (NSCs), autologous macrophages and 
mesenchymal precursor cells (MPCs) isolated from bone marrow stroma (BMSCs) (for reviews  
see [2–5]). More recently, the possibility of developing strategies that use induced Pluripotent Stem 





2. iPSCs as Neuronal and Glial Candidate Donor Populations 
To date, iPSCs have been directed to generate neural crest cells [6,7], peripheral sensory  
neurons [8], neural stem cells and their neuronal progenitors including specific neuronal subtypes 
such as dopaminergic neurons [9–17] glutamatergic neurons [18–21], GABAergic neurons [18,19,22], 
motor neurons [23–26,27–29] (see also Faravelli et al. 2014 for review of methodologies of 
induction into motor neurons [30]), retinal neurons [31–34], as well as astrocytes [35–38] and 
oligodendrocyte lineages [37,39–43]. iPSCs and their derivatives have been tested in various in vivo 
animal models of neurological/neurodegenerative disorders including Parkinson’s Disease [9–12,14,44], 
demyelination [37,39–43], retinal regeneration [32,33], stroke [45–48] and peripheral nerve  
regeneration [7] as well as others (see [49,50]). These studies provide proof-of-principle that iPSCs 
can be successfully differentiated in vitro to yield a desired progeny that, if necessary, can be 
effectively subjected to ex vivo gene therapy [51,52] and then transplanted with similar outcomes to 
other pluripotent ESC therapies [53–56]. 
3. iPSCs in Spinal Cord Injury 
Despite a rapid increase in iPSC-based studies in recent years, currently there is only a small  
number of published preclinical studies describing the in vivo use of iPSCs in mouse [57–59],  
rat [36,50,57–62] or simian [37,60–62] models of SCI, or sub-dural parenchymal injections into  
non-injured rats [63]. 
Of these studies, rodent moderate contusion injuries were almost all made at the thoracic level  
(T9–T10) using the Infinite Horizon Impactor device (delivering 60–70 kDyne forces for mice and  
200 kDyne force for rat). An exception was a study that used C4 contusions using the Ohio State 
Injury Device [61], and Lu et al. [60] recently used C5 lateral hemisections in rats. Simian contusions 
have to date been more severe (17 g 50 mm drop at C5 using the NYU impactor [37] or a 50 g 10 mm 
drop at T9 [62]). All published studies using contusive SCI (apart from [62]) have reported neuronal, 
glial and astrocytic marker expression within or near the lesion after transplantation, with two groups 
reporting differentiation of donor cells into at least one or all these various cell types [37,50,58–63].  
These studies used iPSC donor cells that were pre-differentiated into either neurospheres  
(NS) [58,59], neural precursor cells (NPCs) [61,63], neural stem cells (NSCs) [60–62] astrocytes [36] 
or undifferentiated iPSCs [50]. Sareen et al. [63] found that NPCs derived from iPSCs showed 
variability in differentiation phenotype and survival characteristics following transplantation, but 
migrated and integrated within the uninjured cord. Superparamagnetic iron oxide labelled 
iPSC-derived NSCs were tracked non-invasively using magnetic resonance imaging (MRI) from the 
cell injection sites in monkeys that extended progressively to the lesion regions [62]. Transplanted 
iPSC-derived NPCs after early chronic cervical SCI were shown to form neurons, astrocytes and 
oligodendrocytes at 8 weeks post transplantation, however importantly failed to promote functional 
recovery in forelimb behavioural tasks. 
Whilst murine SCI studies using iPSC-derived donor cells showed functional improvements, 
others have reported no significant differences in morphological or functional outcomes in another 




transplantation, surviving human iPSC-derived NSCs from an 86 year old donor male exhibited 
extraordinarily long distance axonal growth with the host rat spinal cord, with human axons growing 
rostral and caudal to the lesion site and forming synaptic structures with host neurons and dendrites. 
Such extensive growth of immature human cells within the rodent central nervous system (CNS) is 
similar to that obtained many years ago using grafts of human fetal tissue and neuroblasts (e.g., [64]). 
In the iPSC study, host axons grew into the donor grafts and also formed synaptic structures, again 
similar to previous work that used donor fetal material of some kind (e.g., [65]). Taken together the 
new iPSC work confirms that even in the injured adult CNS it is possible, in some cases, to overcome 
the inhibitory environment of the lesion and elicit substantial regenerative growth and circuit 
construction. The grafting technique used by Lu et al. 2014 [60] involved a cocktail of growth factors 
(including brain-derived neurotrophic factor, neurotrophin-3, platelet-derived growth factor-AA, 
insulin-like growth factor-1, epidermal growth factor, basic fibroblast growth factor, acidic 
fibroblast growth factor, glial cell line-derived neurotrophic factor, hepatocyte growth factor, and 
calpain inhibitor in a fibrin matrix) that previously was shown by the same group to promote robust 
engraftment of donor (non-iPSC derived) NSCs, extensive integration with host tissue, long-distance 
outgrowth of axons from grafts and extensive ingrowth of host axons into the graft after acute 
thoracic (T3) SCI [66]. 
Significant functional improvement was reported in the initial NSC study [66]; however more 
recently, Lu et al. (2014) in a C5 lateral hemisection study [60], reported no measurable 
improvement in forelimb function in host rats despite the use of the same growth cocktail, extensive 
axonal outgrowth and cellular integration. The authors suggest that the injury type itself, the rate of 
maturation of donor cells (so that insufficient numbers of mature neurons were present to support 
recovery), inadequate myelination, undesirable ectopic projections and/or insufficient expression of 
neurotransmitters could account for the discrepancy between the functional recovery observed  
between the two studies. Whilst the extent of hindlimb versus forelimb recovery may vary depending 
on the type and complexity of restored or adapted neural circuitry [60], it is also important to note 
that independent researchers that attempted to replicate this study (as part of the NIH “Facilities of 
Research Excellence-Spinal Cord Injury” project to support independent replication) revealed 
conflicting data relating to ingrowth of host axons into the grafts and behavioural outcomes [67]. 
Overall, these are very important and influential studies, but the extent to which reported differences 
also reflect, for example, variation in surgical procedures, the individual contributions of factors in 
the growth cocktail [68], or differences in the nature and response of the donor cell type after 
transplantation, needs to be established, and future work should yield valuable information in  
this regard. 
The approach of using restricted or individual populations of donor cells in the hope of achieving 
regrowth or repair leading to morphological improvements and functional restoration has some 
limitations. The ability of a wide variety of adult somatic (e.g., Schwann cells, olfactory ensheathing 
glia) and precursor/progenitor (e.g., NPCs, NSCs, OPCs, MPCs) cells to undergo directed 
differentiation and perform functionally and phenotypically as required in vitro has not always been 
reproduced when cells are transplanted into the inhibitory environment of the injured spinal cord  




wide variety of controlled settings other than the injured spinal cord, simply fail to “perform” in 
animal models in vivo because of the antagonistic, often inflammatory environment they find 
themselves in after transplantation [69]. Those donor cells that eventually survive the host immune 
response may be unable to successfully respond to the new and dynamic myriad of both inhibitory 
and growth promoting stimuli of the host’s injured spinal cord that is known to occur in a temporal 
and spatial fashion after trauma. Simply, the “correct language” that equipped the donor cells with 
the ability to perform all of those functions observed under controlled conditions in vitro, is no longer 
able to be understood or followed in vivo. Perhaps by using combined populations of adult stem 
cell-derived oligodendrocyte, astrocyte and neuronal precursor cells in the same relative proportions 
as those found within the uninjured (normal) spinal cord, we may achieve a phenotypic state that will 
allow enhanced plasticity and optimal repair/regrowth. 
It is crucial to ensure that appropriate cell controls are used in preclinical SCI studies to evaluate 
the extent of contribution of different cell phenotypes to the morphological and functional outcomes 
observed after treatment. This applies to any small populations of incompletely reprogrammed donor 
cells and/or incompletely pre-differentiated donor iPSCs. Whilst the studies mentioned may suggest 
that improved outcomes were observed in mouse but not necessarily in rat models of SCI, the 
disparity in overall results from these very limited number of studies suggest that iPSC-based therapy 
in SCI warrants more extensive and thorough testing. Ideally, research in this area should be 
conducted using clinically relevant injury regimes in at least mouse and rat models as outlined in the 
recommendations and guidelines developed by the International Campaign for Cures of Spinal Cord 
Injury Paralysis (ICCP) [70] (see also [71,72]). Experimental studies in larger species (e.g., cats and 
primates) with an ascending and descending tract configuration more similar to the human [73], and 
capable of more complex sensorimotor behaviors, should also be undertaken. In addition, it may be 
important to include more relevant control donor cell types, such as cells that have been freeze-thawed. 
4. Conclusions 
There is a clear need to develop a gold standard positive control for use of stem cells in animal 
models of SCI, to determine the validity and reliability for future clinical application. It is most likely 
that stem cell therapy alone will not work for SCI, but will require new efforts to combine stem cell 
therapy with other treatments perhaps, such as bio-scaffolds, immune response modifications, and 
the timing of the use of different treatments, although the consensus at present is “the earlier the 
better”. The threat of tumorigenicity remains to be fully addressed. In SCI studies that used 
iPSC-derived donor cells, “unsafe” murine iPSC-derived donor cells, but not “safe” donor cells, 
produced teratomas [59], although another study did not report such teratoma formation [36].  
Of those studies using human iPSC-derived donor cells, one study did not report on teratoma 
formation [57], whilst others reported no evidence of tumour formation [37,50,58,60–63]. For 
clinical applications, donor cells must be grown in animal cell-free and serum-free conditions and 
derivation of the first hESC line with these properties has been a major advance for clinical 
applications of stem cell therapy [74]. Despite their highly similar expression of genes related to 
pluripotency and development, there is evidence that iPSCs may occupy a distinct pluripotent “state” 




whole spectrum of region-specific neural progenitors and functional neuronal subtypes for SCI 
therapies (and other CNS disorders). Nevertheless, the approaching capacity to produce clinical 
grade iPSCs, together with advances in the efficiency of transdifferentiation protocols for iPSCs into 
the required phenotypes, marks a potential focus toward the use of iPSC-derived donor cell 
populations for cell based therapies. If hESC-derived OPCs can be used in SCI trials (Geron), this 
should surely herald the addition of the clinical grade iPSCs to the potential repertoire of donor cell 
candidates for SCI and other neurotrauma related therapies, as long as they are conducted in 
accordance with Good Clinical Practise (GCP) and the associated regulatory directives. 
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Potential and Challenges of Induced Pluripotent Stem Cells in 
Liver Diseases Treatment 
Yue Yu, Xuehao Wang and Scott L. Nyberg 
Abstract: Tens of millions of patients are affected by liver disease worldwide. Many of these 
patients can benefit from cell therapy involving living metabolically active cells, either by treatment 
of their liver disease, or by prevention of their disease phenotype. Cell therapies, including 
hepatocyte transplantation and bioartificial liver (BAL) devices, have been proposed as therapeutic 
alternatives to the shortage of transplantable livers. Both BAL and hepatocyte transplantation are 
cellular therapies that avoid use of a whole liver. Hepatocytes are also widely used in drug screening 
and liver disease modelling. However, the demand for human hepatocytes, heavily outweighs  
their availability by conventional means. Induced pluripotent stem cells (iPSCs) technology  
brings together the potential benefits of embryonic stem cells (ESCs) (i.e., self-renewal, pluripotency) 
and addresses the major ethical and scientific concerns of ESCs: embryo destruction and 
immune-incompatibility. It has been shown that hepatocyte-like cells (HLCs) can be generated from 
iPSCs. Furthermore, human iPSCs (hiPSCs) can provide an unlimited source of human hepatocytes 
and hold great promise for applications in regenerative medicine, drug screening and liver diseases 
modelling. Despite steady progress, there are still several major obstacles that need to be overcome 
before iPSCs will reach the bedside. This review will focus on the current state of efforts to derive 
hiPSCs for potential use in modelling and treatment of liver disease. 
Reprinted from J. Clin. Med. Cite as: Yu, Y.; Wang, X.; Nyberg, S.L. Potential and Challenges of 
Induced Pluripotent Stem Cells in Liver Diseases Treatment. J. Clin. Med. 2014, 6, 3727–3733. 
1. Introduction 
Tens of millions of patients are affected by liver disease worldwide. Liver transplantation, the 
ultimate cell therapy, is presently the only proven treatment for many medically refractory liver 
diseases including end-stage liver disease and many inherited liver diseases. However, there is a 
profound shortage of transplantable donor livers. Regenerative medicine, which focuses on 
innovative approaches to repairing and replacing cells, tissues and organs, is undergoing significant 
revolution do to the unprecedented world-wide demand for organs. Many of the liver disease patients 
can benefit from cell therapy involving metabolically active cells. Cell therapies, including 
hepatocyte transplantation and bioartificial liver (BAL) devices, have been proposed as therapeutic 
alternatives to the shortage of transplantable livers. BAL is an extracorporeal supportive therapy 
developed to bridge patients with liver failure to liver transplantation or to recovery of the native 
liver. Hepatocyte transplantation is best suited for patients with metabolic liver disease for which 
smaller number of cells (<10% of liver mass) may be curative. Both BAL and hepatocyte 
transplantation are cellular therapies that avoid use of a whole liver. Hepatocytes are also widely 
used in drug screening and liver disease modelling. However, conventional methods of obtaining 




quality hepatocytes can be isolated. Furthermore, hepatocytes are not easily maintained in culture 
over extended periods of time. Moreover, hepatocyte propagation is minimal in vitro, even in the 
presence of growth factors such as hepatocyte growth factor [1]. Hepatocytes are also difficult to 
cryopreserve and highly susceptible to freeze-thaw damage [2]. The demand for human hepatocytes, 
therefore, heavily outweighs their availability.  
The recent discovery that human induced pluripotent stem cells (hiPSCs) can be derived from 
human somatic cells through forced expression of defined transcription factors such as OCT4 (O), 
SOX2 (S), KLF4 (K), and c-MYC (M) (so called OSKM cocktail) or O, S, NANOG (N) and 
LIN28 (L) (so called OSNL), has renewed hopes for regenerative medicine and in vitro disease 
modelling, as these cells are easily accessible. iPSC technology brings together the potential benefits 
of embryonic stem cells (ESCs) (i.e., self-renewal, pluripotency) and addresses major ethical and 
scientific concerns of ESCs: (1) iPSCs bypass the ethical concerns of embryo destruction since they 
are produced from somatic cells in vitro without embryonic tissues or oocytes; (2) the 
immune-compatibility issues since they are generated from patient-specific cell types. The field of 
iPSCs has undergone tremendous growth, and differentiated cell types produced from a patient’s 
iPSCs have demonstrated many potential therapeutic applications, including their use in tissue 
replacement and gene therapy. It was shown that HLCs could be generated from iPSCs. Our previous 
study [3] and others’ reports [4] of the potential benefits of HLCs generated from hiPSCs have 
described their secretion of human albumin, alpha-1-antitrypsin (A1AT), and hepatocyte nuclear 
factor 4-alpha (HNF4 ), synthesis of urea, and expression of cytochrome P450 (CYP) enzymes  
in vitro. Therefore, in theory, hiPSCs could provide an unlimited source of human hepatocytes and 
hold great promise for applications in regenerative medicine, drug screening and liver diseases 
modelling. More recently, investigators have reported that HLCs differentiated from hiPSCs of 
patients with the inherited metabolic conditions may be used to model inherited liver diseases [5]. 
Transplantation of HLCs derived from hiPSCs may provide alternatives to liver transplantation for 
the treatment of acute liver failure (ALF), liver cirrhosis, viral hepatitis, and the correction of 
inherited metabolic liver disorders. This review will focus on the current state of efforts to derive 
hiPSCs for potential use in modelling and treatment of liver disease. 
2. Hepatic Differentiation of iPSCs in Vitro 
We will first address the hepatic differentiation of iPSCs. The term HLCs refers to cells produced  
in vitro that possess some of the properties of mature hepatocytes. Song et al. [6] first demonstrated 
that hiPSCs can be induced to HLCs directly by the administration of various growth factors in a time 
dependent manner. The sequence of differentiation follows the normal sequence of human liver 
development, and includes: Stage 1-endoderm induction, Stage 2-hepatic specification, Stage 
3-hepatoblast expansion and Stage 4-hepatic maturation. Subsequent reports have focused on 
optimizing this method by adding modifications and improvements to the differentiation protocols. 
In addition to growth factors, a variety of factors have been used to enhance the differentiation of 
hiPSCs towards the hepatic lineage. For example, small molecules (i.e., dimethyl sulfoxide (DMSO), 
dexamethasone) have been shown to extend the hepatic differentiation of iPSCs. The characteristics 




critically reviewed [7]. Zhang et al. induced efficient generation of highly differentiated HLCs from 
mouse iPSCs by a combination of cytokines and sodium butyrate [8]. To promote hepatic 
maturation, Takayama utilized transduction of the hepatocyte HNF4  gene, which is known  
as a master regulator of liver-specific gene expression. Over expression of HNF4  in  
hepatoblasts derived from iPSCs led to up-regulation of markers of epithelial and mature hepatic 
development, such as CYP enzymes. HNF4  also promoted hepatic maturation by activating the 
mesenchymal-to-epithelial transition. The Takayama method is also a valuable tool for the efficient 
generation of functional hepatocytes derived from human ESCs and iPSCs, and these HLCs have 
been used for predicting drug toxicity [9]. A limitation of these four-stage protocols is that they are 
time consuming, usually requiring more than 20 days. In contrast, Chen [10] reported rapid 
generation of HLCs from hiPSCs by an efficient three-step protocol. Using Chen’s system, the 
differentiation of hiPSCs into functional HLCs requires only 12 days. Chen’s method is different 
from the typical protocols as they apply HGF in the first stage (endoderm induction), rather than 
during the hepatocyte maturation stage. It is expected that future research will facilitate the 
differentiated of iPSCs to fully mature functional hepatocyte. 
3. Applications of iPSCs in Liver Diseases 
The applications of iPSCs in liver diseases will be outlined in the Table 1. 
3.1. Regenerative Medicine 
iPSCs-Derived HLCs from normal individuals can be used in the establishment of cell banks for 
applications in regenerative medicine. Results from various studies have demonstrated the 
therapeutic potential of iPSCs-derived HLCs in liver diseases. Examples of the therapeutic potential 
of iPSC-derived HLC’s in rodent models include vivo transplantation of HLCs to reverse lethal 
fulminant hepatic failure [10], both the functional and proliferative potential of HLCs for enhanced 
liver regeneration [11], reduced liver fibrosis [12], and stabilization of chronic liver disease [13]. 
Disease models have utilized immunodeficient mice and immunosuppression to demonstrate a 
therapeutic benefit of human HLC’s. For human application, generating hiPSC-derived HLCs  
from selected adults and construction of libraries of cell lines with known genotypes, providing 
patients with a close HLA/MHC match, may minimize the need for immunosuppression to achieve 






Table 1. Applications of iPSCs in liver diseases. 
Applications Diseases iPSCs from Donor References 
Regenerative 
Medicine 
fulminant hepatic failure mouse normal iPSCs [10] 
liver regeneration mouse normal iPSCs [11] 
liver fibrosis mouse normal iPSCs [12] 
chronic liver disease mouse normal iPSCs [13] 
BAL liver failure human normal iPSCs [14] 
Gene Therapy 
A1AT deficiency A1AT deficiency patient iPSCs [15] 
WD WD patient [16] 
Liver Diseases 
Model 
HBV, HCV human normal iPSCs [17] 
HCV human normal iPSCs [18,19] 
A1AT deficiency  
GSD, FH, Crigler-Najjar syndrome, 
hereditary tyrosinemia 









The incidence of ALF is approximately 2500 cases per year in the United States and is much 
higher worldwide [26]. The shortage of liver donor for transplantation leads to approximately 40% 
of listed patients per year not receiving a liver transplant with a significant number of these patients 
either dying or becoming too sick to transplant. BAL is an extracorporeal supportive therapy 
developed to bridge patients with liver failure to liver transplantation or to recovery of the native 
liver. The BAL system removes toxins by filtration or adsorption (artificial liver) while performing 
biotransformation and synthetic functions of biochemically active hepatocytes. A major question in 
the clinical application of liver support devices is how to supply them with adequate numbers of 
functional hepatocytes to improve patient survival. Fortunately, cells in the BAL are separated from the 
patient’s circulation by a semi-permeable membrane to prevent allogenic rejection, thus patient-specific 
hepatocytes are not needed. 
To date, the various cell types that have been used in BAL devices have included primary human 
hepatocytes, primary porcine hepatocytes, immortalized human cell lines, fetal liver cells, and stem 
cell-derived cells. Primary human hepatocytes are not available in sufficient amounts needed for 
clinical usage of BAL, exceeding 200 grams per treatment. Furthermore, primary hepatocytes are 
limited by the short duration that they retain functionality and viability in vitro. Porcine hepatocytes 
are limited by immunogenic reactions resulting from the xenogenicity of porcine hepatocyte 
products and the possibility of xenozoonotic retroviral infection of patients with porcine endogenous 
retrovirus (PERV). However, the BAL membrane mitigates these concerns (the risk has never been 
quantified since no cases exist). Also of concern, immortalized cell lines lack essential functions, 
particularly the loss of urea cycle activity and lack of CYP enzyme expression [27]. Transfection 
methods to enable overexpression of CYP enzymes in these cells have been adopted, but this 




recapitulate the metabolic capacity of a fully functional hepatocyte [28]. Alternatively, human ESCs 
and iPSCs differentiated HLCs show great promise as cell sources for BAL devices. Patient specific 
iPSCs-HLCs transplantation can provide effective treatment to liver diseases. Of concern in acute 
situations, such as ALF, time to make, mature, and expand the patient’s somatic cells into iPSCs  
and then HLCs may be prohibitive for treatment of ALF, either as a cell transplant or BAL therapy. 
The cell banks of normal individual-derived iPSCs with close HLA/MHC match to the ALF patient 
and then rapid differentiation into HLCs for use in BAL and temporary treatment of ALF deserves 
further investigation. 
The Fox group has reported an implantable BAL device containing HLCs derived from ESCs in a 
murine model of liver failure [29]. They differentiated mouse ESCs into HLCs by coculture with a 
combination of human liver nonparenchymal cell lines and cytokines. Functional hepatocytes were 
isolated using albumin promoter-based cell sorting. The coculture differentiation strategy induced a 
50% increase in the number of ESCs becoming albumin positive, and resulted in 68.7% of the entire 
cell population differentiating toward a hepatocyte phenotype. This may be due to the heterotopic 
interactions between hepatocytes and hepatic nonparenchymal cells in liver development. Treatment 
of 90% hepatectomized mice with a subcutaneously implanted BAL seeded with ESCs-derived 
HLCs improved liver function and prolonged survival. Iwamuro [14] tested a BAL system whose 
cell source was HLC’s derived from mouse iPSCs. These cells were injected into a hollow fiber 
module with a 0.2- m pore size. The murine HLC’s adhered to the hollow fiber surface and produced 
albumin and urea for 7 days. Although further investigation and improvement of the device and the 
differentiation process are required, the authors concluded that the combination of a 0.2- m pore 
membrane and iPSC-derived HLCs showed promise as an improved BAL system. This paper 
provides the basic concept and preliminary data for BAL as an individualized treatment system 
employing the patient’s own cells. Despite the paucity of reports addressing functionality of HLCs 
derived from hiPSCs in BAL systems, we believe hiPSCs-HLCs are a promising resource for  
BAL therapy. 
3.3. Gene Therapy in Hereditary Liver Disease 
The liver is affected by many types of diseases, including inherited metabolic disorders. A major 
indication for hepatocyte transplantation is inherited metabolic liver diseases in children. The liver is 
a vital organ that represents a promising target for cell therapy, because of its ability to functionally 
integrate transplanted hepatocytes. Hepatocyte transplantation has been performed as a treatment for 
inherited liver diseases, either for bridging to whole organ transplantation or for long-term correction 
of the underlying metabolic deficiency [30]. However, as mentioned earlier, the both shortage of 
donor organs from which to isolate high quality primary hepatocytes and the possibility of allogeneic 
rejection hamper the advance of hepatocyte transplantation. Patient-specific cell therapy is an ideal 
option to prevent cell rejection. However, isolation of autologous hepatocytes requires a lobectomy 
(resection of at least 20% of the liver), a procedure with risk in patients. Fortunately, development of 
iPSCs from patient somatic tissues and then differentiation into HLCs may provide patient specific 
hepatocyte source for treatment for inherited liver diseases. In the case of monogenic inherited 




mutation in their genomic DNA, a gene correction approach is required to generate disease-free 
autologous cells. Thus, a combination of ex vivo gene therapy and cell transplantation has been 
considered [31,32]. 
iPSC-based gene/cell therapies have been applied in several animal models of liver-based 
metabolic disorders, with encouraging results. Yusa performed targeted gene correction of A1AT 
deficiency in iPSCs [15]. Mutation in A1AT gene is most commonly associated with Pizz-associated 
liver disease leading to cirrhosis. These investigators used the combined method of zinc finger 
nucleases (ZFNs) and piggyBac (PB) technology in hiPSCs to achieve biallelic correction of the 
culprit point mutation (Glu342Lys) in the A1AT gene. Genetic correction of hiPSCs restored the 
structure and function of HLC’s in vitro and subsequently corrected A1AT in vivo. Transplantation 
of these iPSC-derived HLCs into immunodeficient mice was able to produce albumin and provide 
functional A1AT protein. This approach is significantly more efficient than other gene-targeting 
technology currently available, and does not require homologous recombination that leaves residual 
sequences in the targeted genome, and which leads to unintended consequences. These studies 
provide the first proof of principle that combining genetic correction in hiPSCs will generate 
clinically relevant cells for autologous cell-based therapies. 
Wilson’s disease (WD) is an autosomal recessive inborn error of copper metabolism. Mutations in 
the ATP7B gene (located in chromosome 13) are responsible for WD with a prevalence of 1 in 
30,000–100,000 [33]. Zhang et al. [16] described the generation of iPSCs from a Chinese patient 
with WD bearing the R778L “Chinese hotspot” mutation in the ATP7B gene. These iPSCs were 
pluripotent and could be readily differentiated into HLCs that displayed abnormal cytoplasmic 
localization of mutated ATP7B and defective copper transport. This phenomenon is susceptible to 
correction using a chaperone drug. Gene correction was performed in HLCs using a self-inactivating 
lentiviral vector that expresses codon optimized-ATP7B. The newly produced HLCs reversed the 
functional defect in vitro. Hence, their work describes an attractive model for studying the 
pathogenesis of WD that is valuable for screening compounds or gene therapy approaches aimed to 
correct the abnormality. This approach may be used for other diagnosis and correction of diseases 
susceptible to gene therapy. Genetically corrected, characterized lines of patient-specific iPSCs can 
be obtained in 4–5 months [34]. 
3.4. iPSCs in Liver Diseases Model 
Liver tissue from patients is difficult to obtain and only reveals the disease aftermath, so several 
genetic disorders have been modeled in rodents and large animals [7]. Although these models of 
human inherited metabolic disease are invaluable, they provide a limited representation of human 
pathophysiology [35]. Animal models, especially those in rodents, do not always faithfully mimic 
human diseases, and most are imperfect [7]. Therefore, new advances in experimental techniques are 
needed to develop new models of human liver disease, especially large animal models that may be of 
greater clinical relevance [36]. Transplantation of hiPSCs into immunodeficient pigs with formation 





3.4.1. iPSCs from Normal Individuals 
Disease modelling and drug screening are two immediate applications of the reprogramming 
technology and the resulting iPSCs differentiated cells. hiPSCs offer the ability to produce 
host-specific differentiated cells and thus have the potential to transform the study of infectious 
disease. HLCs derived from hiPSCs are particularly important for patients with liver diseases who 
cannot undergo surgical biopsy for the isolation of hepatocytes for transplantation. Disease 
modelling using iPSCs has been achieved for a variety of genetic diseases [38].  
Research on HBV or HCV has been hampered by difficulty in culturing human primary 
hepatocytes, which tend to dedifferentiate and lose hepatic function after a limited time in vitro. 
Thus, alternative models have been used. In vitro models using animal hepatocytes, human HCC cell 
lines, or in vivo transgenic mouse models have contributed to understanding the pathogenesis of 
HBV and HCV [17]. However, host tropism of HBV or HCV is limited to human and chimpanzee. 
HBV and HCV infection has never been fully understood because there are few conventional models 
for hepatotropic virus infection. hiPSCs-derived HLCs from normal individuals would be useful for 
modelling susceptibility to infectious diseases. These hybrid cells provide an opportunity to elucidate 
the genetic basis of the mechanisms underlying cell susceptibility or resistance to viruses. In particular, 
HLCs derived from iPSCs of normal subjects are an appropriate target for studying the interactions 
between the host and virus with hepatic tropism. 
HCV is a prototypic pathogen for which host genetic factors have been implicated in modulating 
disease natural history and treatment response but whose functions remain poorly understood 
because of the lack of robust experimental systems. Yoshida [18] group investigated the entry and 
genomic replication of HCV in iPSCs-derived HLCs by using HCV pseudotype virus (HCVpv) and 
HCV subgenomic replicons, respectively. They showed that iPSCs-derived HLCs, but not iPSCs, 
were susceptible to infection with HCVpv. The iPSCs-derived HLCs expressed HCV receptors. 
HCV RNA genome replication occurred in the iPSCs-derived HLCs. Anti-CD81 antibody, an 
inhibitor of HCV entry, and interferon, an inhibitor of HCV genomic replication, dose-dependently 
attenuated HCVpv entry and HCV subgenomic replication in iPSCs-derived HLCs, respectively. 
These findings suggest that iPSCs-derived HLCs are suitable in vitro models of hepatocytes for the 
study of HCV infection. Schwartz reported that hiPSC-derived HLCs support the entire life cycle of 
HCV [19], including inflammatory responses to infection, enabling studies of how host genetics 
impact viral pathogenesis. Such models will advance our understanding of host-pathogen 
interactions and help realize the potential of personalized medicine. 
3.4.2. iPSCs from Patients 
Monogenic metabolic disorders of the liver are an ideal platform to explore the complexity of 
gene–environment interactions and the role of genetic variation in the onset and progression of liver 
disease. The use of human hepatocyte cultures may circumvent the problems of animal models of 
human diseases in some sense. Many traditional cell-based models have been used to study 
pathogenesis and to screen for candidate drugs. However, none has used symptom-relevant human 




hepatocytes lose their liver specific functions within a few days. Disease-relevant cell types could 
accurately reflect disease pathogenesis in vitro. iPSCs generated from patients who have monogenic 
inherited liver diseases and HLCs derived from iPSCs can be used as instruments to study the 
pathogenesis, disease mechanism(s) and possible cures for inherited liver disorders. 
Current animal models of WD, including the toxic milk mouse, ATP7B2/2 mouse and Long-Evans 
Cinnamon rat, have provided very useful representation concerning its pathogenesis. However, 
physiological differences in phenotype between species limit the conclusions. As mentioned earlier, 
Zhang reported establishment of an in vitro disease model using iPSCs from WD patients [16]. 
Recently, several liver-specific disease iPSCs, such as familial hypercholesterolemia (FH), 
glycogen storage diseases (GSD), Crigler-Najjar syndrome, A1AT deficiency and FH have been 
launched [5,20]. These cells can be used as suitable specific models to study the pathogenesis, 
mechanism(s) and possible treatment for inherited liver disorders. 
Rashid et al. demonstrate the possibility of modeling groups of diseases whose phenotypes are a 
consequence of complex protein dysregulation within adult cells. They derived iPSCs from the skin 
fibroblasts of patients with A1AT deficiency, GSD type 1a, FH, Crigler-Najjar syndrome type 1  
and hereditary tyrosinemia. These iPSCs were then differentiated into HLCs, and characterized  
with special attention to the phenotypic properties specific to the corresponding diseases [5].  
Rashid et al.’s results demonstrated that hiPSCs-derived HLCs can be generated from multiple 
patients of varied genetic and disease backgrounds. Their system has proved to be an efficient 
methodology for screening of early-stage safety and therapeutic effect of liver-targeted compounds 
of potential relevance to the pharmaceutical industry.  
Ghodsizadeh [20] derived iPSCs from liver-specific patients with tyrosinemia, GSD, progressive 
familial hereditary cholestasis, and two siblings with Crigler-Najjar syndrome. The hepatic 
lineage-directed differentiation of the iPSCs showed that the HLCs expressed hepatocyte-specific 
markers. Functionality of these cells was confirmed by glycogen storage and lipid storage activity, 
secretion of albumin, alpha-fetoprotein, and urea, CYP metabolic activity, as well as LDL and 
indocyanine green uptake. The large array of iPSCs lines produced in these studies will permit more 
in-depth characterization of disease phenotypes. The patient-derived HLCs from iPSCs can also be 
used as suitable specific models to study the pathogenesis, mechanism(s) and possible treatment for 
inherited liver disorders. 
3.5. In Drug Discovery and Hepatoxicity Screening 
An added benefit of iPSCs is that they can be used for drug screening. Adverse drug reactions 
continue to pose a major problem to the clinician, the pharmaceutical industry and the regulatory 
authorities. Amongst the different types of adverse drug reactions, drug-induced liver injury (DILI) 
is the most prominent cause of patient morbidity and mortality. Thus, a multitude of new drugs need 
to be efficiently screened every year to assess their potential for toxicity. A major challenge for drug 
discovery is to develop appropriate preclinical models. Human primary hepatocytes have become a 
major liver model for hepatotoxicity tests. Unfortunately, as mentioned above, there is also a 
shortage of primary hepatocytes, and it is difficult to culture the hepatocytes in vivo without losing 




differences, variable viability following isolation and rapid dedifferentiation of the hepatocyte 
phenotype in culture, particularly in the loss of CYP enzyme expression, impede their use.  
The pluripotent nature and the indefinite proliferative potential of ESCs are two major detractions of 
using ESCs in safety research in the fields of pharmacology and toxicology. However, directed 
differentiation of human ESCs to mature hepatocyte phenotypes in vitro could provide a readily 
available source of hepatocytes for early stage safety testing. Today, approximately 70% of the top 
20 pharmaceutical companies utilize stem cells in their research and among these, 64% use human 
ESCs or their derivatives. Human ESCs and their derivatives do not encompass all the variances 
within a population or between ethnicities. Alternatively, ideal cells for drug screening could be 
obtained from iPSCs-derived HLCs. Since cells from patients with many different metabolism 
phenotypes must be tested to establish safety, hiPSCs-derived HLCs from this wide range of patients 
are expected to improve the drug discovery process [5,21] and may lead to personalized drug 
administration. Specifically, iPSC-hepatocytes generated from individuals with different CYP 
polymorphisms would be of great value for study of drug metabolism and toxicity prediction of new 
drugs [7]. Moreover, iPSCs offer the opportunity to generate liver cells at different stages of 
maturation, as well as the potential to give rise to all the composite cells of the adult liver, which may 
provide extra advantages and substantially expand the scope of traditional studies in drug 
metabolism and toxicology [22]. Choi et al. used patient-specific iPSCs, screened the clinical-ready 
drug library (the JHDL), and identified and validated several hits for novel treatment of A1AT 
deficiency. With emerging new tools and technologies for gene manipulation, such as transcription 
activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats (CRISPRs), the feasibility of iPSC-based large-scale drug screening and highly efficient gene 
correction are anticipated. Integration of patient-specific iPSC-based screening in early stages of 
drug development will help to more accurately predict drug effects in humans, thereby significantly 
shortening the timeline and reducing the costs associated with clinical trials and high failure  
rates [23]. In view of the potential of hiPSCs in providing an alternative model for safety 
pharmacology and toxicology applications, many pharmaceutical and biotechnology companies in 
recent years have invested or have developed joint collaborations with academia, to develop in vitro 
systems based on hiPSCs [24]. Moreover, the potential to make genetically corrected hiPSCs from a 
diverse number of diseases and genetic subtypes also allows for the development of reliable models 
for studying the development and progression of genetic diseases in vitro [23,25]. For example, 
disease-causing gene mutation and/or correction of hiPSCs offer ideal controls for comparative 
studies of pharmaceutical agents in vitro. 
4. Challenges of iPSCs Application 
4.1. Large Expansion System of iPSCs 
A major technical hurdle that must be overcome before iPSCs can be implemented clinically is 
scalability, referring to the reproducible production of cells and their differentiated progeny on a 
large scale. All of the iPSCs lines established thus far have been generated and expanded under static 




Additionally, monolayer culture provides limited numbers of iPSCs, only sufficient for research. 
Therefore, large scale systems for rapid expansion and maintenance of iPSC’s and their 
differentiated progeny are required for further research as well as future clinical applications. 
Shafa reported expansion and long-term maintenance of iPSCs in a stirred suspension bioreactor 
(SSB) [39]. Their study showed that murine iPSCs can be maintained and expanded in SSB  
without loss of pluripotency over a long-term period. Kehoe also reported scalable SSB culture of 
hiPSCs [40]. They demonstrated SSB cultured iPSCs as aggregates, and the iPSCs aggregates 
retained the ability to express pluripotency markers, as well as the potential for multi-lineage 
differentiation in vitro and in vivo. Chen described the use of microcarriers (MCs) in suspension 
culture bioreactors for iPSCs cultivation [41]. Such a 3-dimensional culture system represents an 
efficient process for the large-scale expansion and maintenance of iPSCs, which is an important first 
step in their clinical application. 
4.2. Immaturity of the HLCs Derived from iPSCs 
Prior to clinical application, HLCs derived from iPSCs must be compared to primary 
liver-derived cells and shown to have similar morphology and functional properties such as nutrient 
processing, detoxification, plasma protein synthesis, and engraftment after transplantation into a 
suitable animal model. While a wealth of studies highlight the promise of iPSC-derived HLCs for 
transplantation therapies, several obstacles remain. So far, neither ESCs nor iPSCs can differentiate 
to fully mature hepatocytes in vitro. Researchers have then termed such populations of cells derived 
from iPSCs or ESCs as hepatocyte-like cells or “HLCs”. HLCs indicates that only some of the 
properties of mature hepatocytes are present. In general, HLCs demonstrate lower rates of albumin 
production, incomplete urea cycle activity, lower CYP activity, immature mitochondria and lower 
oxygen consumption than primary hepatocytes [3]. HLCs also show persistent expression and high 
levels of AFP production, suggesting that HLCs exhibit an inability to turn off early stage gene(s) as 
the mechanism of persistent immature phenotype [42]. Moreover, despite recent advances, the 
efficiency of human ESCs and iPSCs directed-differentiation into HLCs is highly variable and cell 
line-dependent. Since the undifferentiated iPSCs have the potential to form teratoma, research must 
be actively pursued to gain more information in order to clearly delineate the differentiation 
pathways of iPSC into specific cell types to ensure similar function and physiology. 
To address the issue of maturation of HLCs from iPSCs, Ogawa [43] used a method of modified 
growth factor and a 32-day 3D differentiation to show that the combination of 3D cell aggregation 
and cAMP signaling enhanced the maturation of hiPSCs-derived hepatoblasts to a hepatocyte-like 
population. The resulting cells displayed expression profiles and metabolic enzyme levels 
comparable to those of primary human hepatocytes. Importantly, they also demonstrated that 
generation of the hepatoblast population capable of responding to cAMP is dependent on appropriate 
activin/nodal signaling in the definitive endoderm at early stages of differentiation. Together, these 
findings provide new insights into the pathways that regulate maturation of iPSCs-derived HLCs.  





Shan [44] used a screening approach involving two different classes of small molecules to 
identify factors that induce the proliferation of mature primary human hepatocytes or induce the 
maturation of HLCs from hiPSCs. The first class induced functional proliferation of primary human 
hepatocytes in vitro. The second class enhanced hepatocyte functions and promoted the 
differentiation of iPSCs-derived HLCs toward a more mature phenotype than what was previously 
obtainable. Gene expression profiles showed that HLCs treated with small molecules more closely 
resembled mature hepatocytes. Marked increases in the amount of albumin and CYP3A were seen 
with treated cells vs. untreated cells. Of particular interest, AFP was largely absent in treated cells. 
The identification of these small molecules may have an impact on several areas of research, 
including maturation of other iPSCs-derived cell types, expansion of other “terminally” 
differentiated cell types, and the translational potential of these cell types.  
Zhang et al. [8] directly compared the hepatic-differentiation capacity of mouse iPSCs with three 
different induction approaches: conditions via embryonic body formation plus cytokines, conditions 
by combination of DMSO, and sodium butyrate, and chemically defined N2B27 medium, serum free 
monolayer conditions. In the mid-term induction stage, the investigators added sodium butyrate, a 
short-chain fatty acid and a histone deacetylase inhibitor. Sodium butyrate has been reported to 
induce growth arrest, differentiation, and apoptosis of cancer cells in chemically defined, serum free 
medium. Among these three induction conditions, more homogenous populations can be promoted 
under serum free conditions. Although efficient hepatic differentiation was achieved by these 
modifications, the present protocols are far from perfect. Further optimization is needed for clinical 
application of iPSCs-derived HLCs. Efforts are underway to define an ideal hepatic induction 
strategy for future individualized hepatocyte transplantation. 
The induction of HLCs from iPSCs is a complicated process that will eventually be replaced by 
less complex technology. Huang et al. demonstrated the direct induction of functional HLCs (named 
as iHep cells) from mouse tail-tip fibroblasts. Direct induction was accomplished by single step 
transduction of Gata4, Hnf1a and Foxa3, and inactivation of p19Arf. iHep cells show typical 
epithelial morphology, express hepatic genes, and perform hepatocyte functions. Notably, iHep cells 
showed an expression profile and hepatic function very similar to mature hepatocytes. Donor iHep 
cells repopulate the livers of FAH-deficient mice and rescued almost half of recipients from death by 
restoring liver functions. More importantly, iHep cells did not form tumors in immunodeficient mice. 
Their study provides a novel strategy to generate functional HLCs for the purpose of liver  
regenerative medicine [45]. 
4.3. Strategies to Purify the HCLs Differentiated from iPSCs 
Under current situations, transplantation of differentiated iPSCs into patients is risky as the 
residual undifferentiated iPSCs may retain the possibility of tumor formation. Therefore, the safety 
of clinical cell transplantation using differentiated hiPSC derivatives is contingent on novel methods 
to remove the undifferentiated iPSCs [46]. To date, strategies for purifying a given cell population 
have used either a cell surface protein specific for the target cell population, such as a cell surface 
marker specific to hepatic progenitors, or lentivectors expressing a reporter gene under the control of 




experiments by Basma et al. [48] generated human HLCs through embryoid bodies. These cell 
aggregates were purified using fluorescence-activated cell sorting for the asialoglycoprotein 
receptor. Purified epithelial cell adhesion molecule EpCAM-positive cells from fetal and postnatal 
livers have also been used to generate mature hepatocytes [49]. The EpCAM marker is also 
expressed in the visceral endoderm and in several progenitor cell populations and cancers, and is 
associated with undifferentiated hESCs [50,51]. Therefore, to date, purification of progenitors and 
mature cells generated from either ESCs or iPSCs remains challenging with use of conventional 
methods. More studies need to be carried out to develop better purification methods before iPSC can 
be used clinically. 
Yang et al. [52] reported the use of lentivectors encoding green fluorescent protein (GFP)  
driven by the liver-specific apoliprotein A-II (APOA-II) promoter to purify human hepatic 
progenitors. The investigators first differentiated a human ESC line into hepatic progenitors using a 
chemically defined protocol. Subsequently, cells were transduced with GFP and sorted at day 16 of 
differentiation to obtain a cell population enriched in hepatic progenitor cells. After sorting, more 
than 99% of these APOA-II-GFP-positive cells expressed hepatoblast markers such as AFP and 
cytokeratin 19. When cultured for an additional 16 days, the sorted hepatoblasts underwent 
differentiation into more mature cells and exhibited hepatocyte properties such as albumin secretion. 
Moreover, they were devoid of viral DNA integration. Their strategy produces a novel tool that could 
be used not only for cell therapy but also for in vitro applications such as drug screening. The present 
strategy should also be suitable for the purification of a broad range of cell types derived from either 
iPSCs or adult stem cells. 
4.4. Low Efficiency of Engraftment 
Functionality of human cells differentiated in vitro is currently best tested by transplantation into 
immunodeficient rodent models. However, low efficiency of engraftment and proliferation of 
transplanted cells into the host parenchyma is a limitation that must be considered. Alternatively, a 
selective growth advantage of donor cells over endogenous cells may address this limitation.  
For example, in some models, the survival and/or proliferation of native hepatocytes is impaired by a 
genetic or inherited inability to regenerate, as in fumarylacetoacetate hydrolase (FAH)-deficient 
mice and urokinase (Alb-uPA) transgenic mice [53,54]. These two murine models have been crossed 
with immunodeficient mice with a different genetic background [1]. Even with a suitable animal 
model, human HLCs generated from pluripotent or multipotent stem cells currently repopulate 
transplanted livers less efficiently than primary human hepatocytes [55]. These results suggest that 
fully mature donor HLCs may achieve higher engraftment efficiency. 
4.5. EP Cell Lines from iPSCs 
Besides the high variability and efficiency of differentiation, the pluripotent nature of ESCs  
and iPSCs results in production of cells types from different germ layers in most differentiation 
protocols. Thus, it is difficult to produce pure monolineage cultures of a desired cell type from  




germ layer stem cell line, such as a definitive endoderm (DE) progenitor line. The spectrum of 
differentiation of definitive germ layer stem cells is relatively narrow. Thus, the efficiency of 
directional differentiation from definitive germ layer stem cells to a specific cell type can be 
increased. On the other hand, definitive germ layer stem cells have broader differentiation potential 
than tissue stem cells, which is economical. Furthermore, definitive germ layer stem cell lines are 
less tumorigenic than ESCs and iPSCs. Endoderm stem cells can differentiate to the liver, pancreas, 
intestines, stomach, lung and other organs cells, but not teratomas. Therefore, endoderm stem cells 
have potential in clinical application. 
As noted earlier, differentiation from iPSCs toward hepatic lineage cells mimics in vivo step-wise 
developmental processes. Therefore, hiPSCs-derived hepatic progenitor-like cells (HPCs) might 
exist at an appropriate time point during similar in vitro differentiation steps. Yanagida reported that 
after differentiating with defined cytokines, HPCs from hiPSCs can be highly purified using cell 
surface markers CD13 and CD133. Further investigation revealed that hiPSCs-derived HPCs exhibit 
a long-term proliferative potential and maintain bipotent differentiation toward hepatocytic cells and 
cholangiocytic cells [57]. Their human HPCs derived from iPSCs may be useful for the analysis of 
human hepatic cell development. In addition, mature hepatocytes lose proliferative ability after 
cryopreservation. In contrast, hiPSCs-derived HPCs have a highly proliferate ability even after 
cryopreservation. Thus, the in vitro expansion system of HPCs may contribute to regenerative 
therapies of liver diseases using functional human hepatic progenitor cells and hepatocytes. 
Recently, Cheng et al. [58] generated self-renewing DE progenitor lines from both human ESCs 
and iPSCs. These cells, termed endodermal progenitor (EP) cell lines, displayed a proliferative 
capacity similar to ESCs, yet lacked teratoma-forming ability. In addition, EP cell lines generated 
endodermal tissues representing liver, pancreas, and intestine, both in vitro and in vivo. EP cell lines 
provide a powerful reagent to study gut tissues from a common multipotent endodermal progenitor 
and to optimize monolineage differentiation. Moreover, creation of EP cells from ESCs/iPSCs  
may represent a strategy to optimize the production of pure, non-tumorigenic cells for tissue 
replacement therapies. 
4.6. Large Expansion System of HLCs and Engineering Liver with iPSCs 
Large scale production of HLCs is needed for their clinical application. As mentioned earlier, 
generation of HLCs from iPSCs is very time consuming under monolayer culture conditions. 
Vosough [59] reported their generation of functional HLCs from hiPSCs in a scalable suspension 
culture with rapamycin for “priming” and activin A for induction. After transplantation of these 
HLCs into the spleens of mice with acute liver injury, an increased rate of survival was observed. 
Improved survival correlated with cell engraftment in the liver and hepatic function (i.e., albumin 
secretion after implantation). This novel enrichment strategy provides a new platform for generating 
HLCs, and it may open new windows in the clinical and pharmaceutical application of these cells. 
It has been shown that the efficient function of multiple cell types, including hepatocytes and islet 
hormone-producing cells, is dependent on matrix-producing cells and endothelial cells that provide a 
3D support structure and sufficient vascularization [60–62]. Thus, the liver extracellular matrix 




environmental factors induce hepatocyte homing, differentiation, and proliferation, and studies 
indicate that stem cells may differentiate toward mature hepatocytes following transfer into an 
injured liver. Therefore, the decellularized liver matrix has significant potential as the scaffold for 
hepatocyte maturation. This process may be further promoted by the sequential delivery of factors 
involved in the initiation and maturation of stem cells to liver cells [48], allowing temporal  
and spatial control over differentiation. Hannan [65] described a 25-day protocol to direct the 
differentiation of human pluripotent stem cells into a near homogenous population of HLCs.  
They demonstrated that day 25 of this protocol represents the earliest time point at which cells can be 
used to model basic hepatic metabolic function. However, cells differentiated at day 35 
systematically displayed the highest level of albumin secretion and CYP activity, suggesting that 
the later date was optimal for functional analyses and toxicology screening. This delayed approach 
enables the generation of a larger quantities of hESCs/hiPSCs for differentiation into hepatocyte-like 
cells and their clinical applications. 
4.7. In Vivo Differentiation of iPSCs 
Because even a small number of undifferentiated cells can result in teratoma formation, a goal of 
iPSCs differentiation is to avoid production of undifferentiated cells. To date, no iPSCs-derived 
differentiation protocol has succeeded in yielding high purity HLCs that fulfill both functional 
engraftment and response to proliferative stimuli in the diseased liver. Alternative strategies are 
needed to obtain mature hepatocytes. To exclude compensation by hepatocytes not derived from 
iPSCs, Espejel et al. transferred wild-type mouse iPSCs into the embryos of FAH-deficient mice to 
generate chimeric mice. These mice demonstrated the ability of iPSCs to develop into hepatocytes  
in vivo. Furthermore, recipient FAH-deficient mice were protected from developing hepatic  
failure [11]. Zhao also produced mice using iPSCs and tetraploid complementation [66], which can 
provide the liver organ for engineering liver. The tumor formation potential of these cells has not 
been completely eliminated. 
Takebe and his team grew bioengineered liver tissue from hiPSCs by reprogramming human skin 
cells to an embryo-like state. The researchers first placed the iPSCs on growth plates in a custom 
medium. After nine days, the mature cells were characterized by biochemical markers as 
hepatocytes. Umbilical endothelial cells and mesenchymal cells were then added to the culture 
system to induce formation of blood vessels and stroma, respectively. Two days later, 3D tissues of  
5 mm width were observed, which the researchers described as a “liver bud” at an early stage of liver 
development [67]. The liver-buds were transplanted and examined histologically at multiple  
time points. Of the cells from the hiPSC-derived liver buds, 32.9% are albumin positive. These  
buds quickly attached to nearby blood vessels and grew rigorously after transplantation. The  
vascular networks of liver buds were similar in density and morphology to those of adult livers  
after transplantation. 
Chan reported that they directly transplanted iPSCs into CCl4-induced liver injured mice [68]. 
They found that mice with transplants of iPSCs performed better than mice with transplants of 
iPSCs-derived HLCs. Performance was assessed by levels of serum alanine aminotransferase, 




increased chemokine inducible protein 10 (IP-10), a potential regulatory factor for amelioration of 
liver injury in vivo.  
Other possibilities for large scale expansion and maturation of HLCs include a genetically 
engineered large animal model [36] to serve as an in vivo hepatocyte incubator [69]. Prior studies 
have established immunodeficient FAH /  mice for this purpose [55]. Exposure to damaged liver 
tissue stimulates liver cell regeneration and can enhance homing and differentiation of stem cells to a 
hepatocyte phenotype. The future success of ex vivo cell therapies depends on novel techniques to 
provide an abundant, high quality supply of functionally normal hepatocytes. 
5. Conclusions 
iPSCs present exciting possibilities for the study and treatment of liver diseases. Areas of study 
and treatment include in vitro modeling, in vivo modeling of diseases, drug development, tissue 
engineering, and development of BAL devices. iPSCs also provide novel opportunities for 
autologous cell therapies and cell transplantation without risk of immune rejection. However, there 
are still several obstacles that need to be overcome before iPSCs reach the bedside. These include: (i) 
improved efficiency of iPSCs generation without viral integration; (ii) avoidance of animal feeders 
to culture hiPSCs; (iii) novel differentiation protocols for more efficient and economical production 
of mature cell types whose functionality are comparable to their in vivo counterparts; (iv) rapid 
differentiation protocols for emergent usage; and (v) enrichment of desired (mature) cells and 
removal of undesired (undifferentiated) cell types that have the potential for tumor formation  
in vivo. A recent report [70] that undifferentiated iPSCs elicit T-cell-dependent immune responses 
in syngeneic mice will require further investigation. This report suggests that host immune 
responses may be important for the removal of undifferentiated cells due to their abnormal 
expression of antigens following genetic manipulation. 
A thorough preclinical assessment of iPSCs in suitable large-animal models is prudent to ensure 
that the proposed treatment with iPSC-derived cells is both safe and effective before testing in 
humans. It has reported recently that transplantation of undifferentiated iPSCs demonstrated 
T-cell-dependent immune response in recipient syngeneic mice due to the abnormal expression of 
antigens following genetic manipulation [70]. Therefore, critical aspects need to be further 
addressed, including the long-term safety, tolerability, and efficacy of the iPSC-based treatments.  
It is paramount to conduct well-designed clinical trials to fully establish the safety profile of such 
therapies and to define the target patient groups with efficacy assessed by standardized protocols. 
Despite their limitations, iPSC-derived hepatocytes remain a promising population for liver cell 
therapies. Moreover, engineered donor grafts derived from iPSCs, including re-cellularized 
biomatrix [71] and liver buds produced from iPSCs [67], may someday provide organs for liver 
transplantation. These results highlight the enormous therapeutic potential for treating organ failure. 
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Myogenic Precursors from iPS Cells for Skeletal Muscle Cell 
Replacement Therapy 
Isart Roca, Jordi Requena, Michael J. Edel and Ana Belén Alvarez-Palomo 
Abstract: The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has 
been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from 
induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate 
skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, 
as compared to adult myoblasts, present more embryonic-like features and more proliferative 
capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. 
Different approaches have been described to make myogenic progenitors either by gene overexpression 
or by directed differentiation through culture conditions, and several myopathies have already been 
modeled using iPSC-MP. However, even though results in animal models have shown improvement 
from previous work with isolated adult myoblasts, major challenges regarding host response have to 
be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges 
we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle 
disease and sporting injuries. 
Reprinted from J. Clin. Med. Cite as: Roca, I.; Requena, J.; Edel, M.J.; Alvarez-Palomo, A.B. 
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy. J. Clin. Med. 
2015, 4, 243–259. 
1. Introduction 
Skeletal muscle is a dynamic organ in which an efficient regeneration process ensures repair after 
damage. The process of muscle regeneration creates new myofibers after necrosis resulting from 
injury or a degenerative process. The myonuclei of multinucleated myofibers are post mitotic, 
arrested in the G0 phase of the cell cycle and unable to proliferate. A resident population of adult 
myogenic stem cells called “satellite cells” is the main player in the regeneration process. These cells 
reside in a quiescent state, located between the basal membrane and the plasmalemma of each 
myofiber. Upon signaling from the damaged myofibers, satellite cells become activated, undergo an 
asymmetric division to self-renew, and produce activated myoblasts that are able to proliferate, 
migrate to the site of injury, and fuse with the existing myofibers or to form new myotubes [1]. 
Besides satellite cells, other populations with stem cell properties have been described as capable of 
undergoing myogenesis and contribute to myofiber repair, such as mesangioblasts, bone 
marrow-derived stem cells, pericytes, or interstitial muscle-derived stem cells, though it appears that 
in vivo they contribute to a much smaller extent than satellite cells [2].  
Repeated cycles of myofiber necrosis and regeneration in muscle dystrophies (MD), such as 
Duchenne muscular dystrophy (DMD) and some limb girdle dystrophies, result in exhaustion of 
satellite cell regenerative capacity in humans [3]. Similarly, neuromuscular diseases in which 




atrophy (SMA) and familiar amyotrophic lateral sclerosis (ALS), present deficiencies in the satellite 
cells compartment [4,5]. Moreover, the myofibers in both MDs and neuromuscular diseases present 
different abnormalities in their structure and functionality [6–8]. Other situations in which muscle 
regeneration is compromised are severe injury [9] and inflammatory myopathies [3]. Restoration of 
the satellite cell compartment with healthy cells would restore the regenerative capacity of the 
muscle and progressively substitute the defective myofibers. Therefore, in all of these conditions, 
myogenic cell replacement therapy provides a promising perspective for the treatment of 
degenerative myopathies. 
2. Using Myoblasts as a Cell Therapy 
Transplantation of donor myoblast or satellite cells isolated from healthy individuals has been 
tried extensively in the past with somewhat positive but insufficient results and scarce references to 
functional improvement [10]. In 1995, allogenic normal myoblasts were transferred into the biceps 
brachii arm muscles of DMD patients in order to restore the lack of dystrophin protein [11]. 
Although some fusion of donor nuclei into host myofibers was observed, there was no significant 
improvement in muscle function. Genetic correction has also been explored to allow for autologous 
transplantation of expanded myoblasts, but results again showed engraftment but a low contribution 
to host fibers [12]. Massive death of most of the transplanted cells within a few days after 
intramuscular delivery has been reported by several laboratories [13]. The reasons why the 
myoblasts die initially are not clear but probably relate to immune aspects, anoikis, and a hostile 
environment in the host damaged muscle. Moreover, using myoblasts as a donor source poses a 
limitation in the amount of original tissue for cell isolation from normal human muscle biopsies.  
It also limits the possibilities of in vitro expansion because myoblasts are limited to a few passages 
due to senescence and the decreased self-renewal capacity of the cells due to the expansion  
process [14]. Therefore, it is difficult to obtain a clinically relevant number of transplantable myoblasts 
from a donor source. The use of other adult stem cells, with high proliferative capacity, as an 
alternative source of myogenic cells has been investigated with disappointing or inconclusive results 
such as bone marrow-derived stem cells [15], pericytes [16], and mesangioblasts [17]. Further 
research is needed to establish the efficacy of cell therapy using these types of donor cells. 
Clinical trials using myogenic cell therapy to treat muscular dystrophies started in the 1990s, 
showed some engraftment of the donor cells but no clear signals of disease recovery or symptom 
alleviation (see Table 1). 
However, extensive preclinical and clinical work over the past few decades has helped to identify 
some relevant issues to address in order to improve cell therapy in muscular dystrophies. The main 
limitations of this therapy are transplanted cell engraftment and contribution to host myofibers, 
which seems to be highly dependent on survival—immunosuppression is thus required but other 
factors might be contributing as well—and migration out of the site of injection. The transplantation 
regime can also affect engraftment success [18].  
Taking all this into account, the ideal donor cell for skeletal muscle regeneration should be easily 
accessible and able to expand extensively without losing myogenic and engraftment capacity, have a 




spread within the muscle. Moreover, it should contribute to the satellite cell compartment, enabling 
indefinite muscle regenerative capacity. Finally, the ideal myogenic donor cell should have low 
immunogenicity, and be able to be delivered systemically, since intramuscular injection does not 
seem a feasible approach given the large volume of muscle tissue to be treated. 
However, extensive preclinical and clinical work over the past few decades has helped to identify 
some relevant issues to address in order to improve cell therapy in muscular dystrophies. The main 
limitations of this therapy are transplanted cell engraftment and contribution to host myofibers, 
which seems to be highly dependent on survival—immunosuppression is thus required but other 
factors might be contributing as well—and migration out of the site of injection. The transplantation 
regime can also affect engraftment success [18].  
Taking all this into account, the ideal donor cell for skeletal muscle regeneration should be easily 
accessible and able to expand extensively without losing myogenic and engraftment capacity, have a 
great survival and fusion rate with host myofibers (high myogenic capacity), and be highly motile to 
spread within the muscle. Moreover, it should contribute to the satellite cell compartment, enabling 
indefinite muscle regenerative capacity. Finally, the ideal myogenic donor cell should have low 
immunogenicity, and be able to be delivered systemically, since intramuscular injection does not 






3. Induced Pluripotent Stem Cells (iPSCs)-Derived Myogenic Progenitors (iPSC-MP) 
Embryonic stem cells (ESC) are pluripotent stem cells derived from the inner cell mass of a 
blastocyst that are able to self-renew and to be differentiated in all tissues in the body. Induced PSCs 
share most of the features of ESCs but are derived from adult somatic cells, e.g., dermal fibroblasts, 
by the transient expression of a defined set of reprogramming factors [28]. The fact that iPSCs do not 
involve the destruction of embryos, with the consequent ethical issues, and allow for autologous 
production of the pluripotent cells has opened up an enormous range of possibilities for the 
regenerative cell therapy field. Since iPSCs have limitless replicative capacity in vitro and can 
differentiate into myoblast-like cells, they represent an attractive source of myogenic donors for 
muscle regeneration. Induced PSC-MP also represents a highly valuable tool for in vitro drug testing 
and disease modeling for muscular genetic conditions that were so far limited because of the 
difficulties of obtaining large quantities of tissue. 
Initially, human ESCs (hESCs) proved to be difficult to differentiate into myogenic progenitors, 
probably due to the fact that paraxial mesoderm and subsequently the myogenic program are not  
well recapitulated during embryoid body (EB)—three-dimensional aggregates of pluripotent stem 
cells—formation [29]. The first protocols using different sequential culture conditions, including  
a mesenchymal differentiation step, were successful at producing myogenic progenitors capable of 
engrafting in vivo but these protocols were lengthy and inefficient [30]. It has been reported that the 
need for a mesodermal transition previous to a myogenic commitment is determined by the 
epigenetic landscape in human ESCs [31]. Higher efficiency and shorter protocols were designed by 
overexpression of myogenic transcription factors. Pax3 and Pax7 are paired box transcription factors 
that contribute to early striated muscle development and are expressed in the dermatomyotome of 
paraxial mesoderm. Darabi and colleagues showed that inducible expression of Pax3 using viral 
vectors at early EB formation overcame mesoderm patterning restrictions and yielded up to 50% 




transcription factor that appears after Pax3 and Pax7 in muscle development and in activated satellite 
cells—alone could not induce myogenic commitment directly on hESCs, but concomitant 
overexpression of the chromatin remodeling complex component BAF60C overcame the mesodermal 
transition limitation [32]. In opposition to these results, Rao et al. describe hESC-derived myogenic 
progenitors by inducible lentiviral overexpression of MyoD1 directly on hESC cells, without a 
previous EB formation [33]. 
Other more efficient and genetic modification-free protocols have been described to obtain  
myogenic progenitors from hESCs, such as isolation of the PDGFR + population from EB  
derived-paraxial mesoderm [34] or isolation of the SM/C-2.6+—satellite cell-like—population from 
differentiating mouse ESC-derived EB cultured in high serum [35].  
Since the appearance of iPSCs, extensive work has been done to obtain myogenic progenitors 
with a vision to their clinical application and disease modeling (Table 2). The first iPSC-MP came 
from mouse cells using a protocol similar to the one described above for ESC [35], based on 
spontaneous differentiation and sorting of SM/C2.6 positive cells [36]. Similarly, the group of 
Awaya reported a method of deriving mesenchymal cells with myogenic capacity from EB by a 
protocol based on selective enrichment though step-wise culture conditions [37]. The resulting cells 
showed long-term engraftment in immunocompromised mice pre-injured with cardiotoxin, and 
evidence of replenishing the satellite cell compartment. However, these protocols are long and not 
very efficient. Using an inducible lentiviral expression system, Darabi et al. produced satellite 
cell-like progenitors by overexpression of Pax7—a transcription factor required for somite 
myogenesis in the embryo and a marker for satellite cells in the adult—in EB from mice (miPSCs) 
and humans (hiPSCs) [38,39]. The resulting cells were able to engraft in a mouse model of muscular 
dystrophy and to produce regeneration and restore some muscle strength, and even showed evidence 
of donor-derived satellite cells—by expression of Pax7 and M-cadherin by the capacity of 
regeneration after a subsequent injury. They reported much better proliferative capacity of the 
myogenic progenitors in vitro and much better engraftment as compared to myoblasts. Lentiviral 
inducible overexpression of Pax3 in iPSCs from dystrophin-lacking mice, which were gene corrected 
with a truncated version of dystrophin ( -utrophin), produced in a similar fashion myogenic 
progenitors that engrafted, differentiated, and repopulated the satellite cell compartment and 
exhibited neuromuscular synapses [40]. Goudenege and colleagues described a two-step protocol 
consisting of first culturing in a myogenic medium and then infecting with an adenovirus expressing 
MyoD1 that rendered myogenic progenitors able to engraft in the muscular dystrophy model mdx 
mice [41]. Also, using a self-contained, drug-inducible expression vector, based on the PiggyBac 
transposon for overexpression of MyoD1 and an efficient and quick conversion of undifferentiated 
iPSCs into myogenic progenitors with the ability to engraft in immunocompromised mice has been 
described [42]. A limitation on the use of MyoD1 for generating myogenic progenitors is the 
induction of cell cycle arrest when expressed too long at high levels; therefore, as an excellent 
proliferative capacity is needed to expand in vitro and survive in vivo, careful dosage and timing are 
necessary when using this transcription factor.  
Though gene overexpression approaches are fast, efficient, and appropriate to generate myogenic 




them unsuitable for a future application in the clinic for regenerative cell therapy. Different ways to 
obtain transplantable myogenic progenitors that do not involve any genetic modification and are still 
efficient and fast have recently been described. Recently, several reports describe other protocols 
without gene overexpression that include high concentrations of bFGF and EGF on free floating 
spheres [32] and, faster and more efficient, the use of GSK3 inhibitors and bFGF [43,44] in one of 
the cases, producing myogenic progenitors that engrafted in immunocompromised mice that 
contributed to the satellite cell pool [43].  
Table 2. Protocols for myogenic progenitor derivation from iPSC and in vivo testing. 
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* NA = not assessed; ** Duchenne’s Muscular Dystrophy; & Becker’s Muscular Dystrophy; Ref.: Reference. 
Another way of avoiding introducing exogenous DNA is the transfection of in vitro-synthesized 
mRNA to overexpress the required transcription factors for myogenic conversion. It was recently 
shown as a proof of principle that transfection of MyoD1 mRNA in hiPSCs produced myogenic cells 
with the ability to fully differentiate [45] in vitro. 
Other cells with myogenic potential that are not myoblasts have been derived from iPSCs: the 
group of Tedesco has developed mesangioblast (pericyte progenitors)-like cells that have been tested 
in animal models [46]. 
4. Disease Modeling 
The different approaches published so far to make myogenic progenitors from hiPSCs are good 
models of myogenesis in vitro, as the produced cells recapitulate the expression of markers observed  
in vivo. They are able to fuse to produce premature myofibers in the animal in vitro and in most cases 
they have been tested in animal models for engrafting and fusion with host fiber. Several reports 
describe the establishment of myogenic cell lines produced from iPSCs from patients with different 
types of muscular dystrophy. Human iPSC-MPs have been established using MyoD1 overexpression 
by a PiggyBac vector on hiPSCs: Miyoshi Myopathy, a distal myopathy caused by mutations in 
DYSFERLIN, patients’ fibroblasts [42], and carnitine palmitoyltransferase II deficiency, is an 
inherited disorder that leads to rhabdomyolysis [47]. Duchenne muscular dystrophy, the most 




expression of MyoD1 [41] and by inducible lentiviral Pax3 overexpression [40]. The group of 
Hosoyama have also described the derivation of myogenic derivatives using their sphere-base 
culture system from hiPSCs from Becker’s muscular dystrophy, spinal muscular atrophy, and 
amyotrophic lateral atrophy [42]. The created cell lines make great tools for drug screening and 
further research into the molecular mechanisms of the different myopathies, and can be obtained in 
large quantities with minimal patient invasion. 
5. Future Challenges for Clinical Application 
Myogenic progenitors made from iPSCs seem to be a promising candidate for stem cell therapy to 
regenerate skeletal muscle since they can be produced in large quantities and present more  
embryonic-like features, so are probably more motile and proliferative compared to adult myoblasts. 
However, even though results in animal models show an improvement from previous work with 
isolated myoblasts, in terms of fiber contribution and functional recovery [39,41], a clinically 
relevant transplantation protocol still needs to be designed. 
5.1. In Vivo Survival, Engraftment and Migration 
One of the major caveats of myoblast therapy was the massive death after transplantation.  
The inflammatory and immunological response to allogenic transplants probably played a role in the 
survival of the cells and also engraftment, migration, and differentiation [48]. However, myoblast 
death is seen before the onset of the immunological response and in the presence of immunosuppressors 
or for autologous transplantation, where there should be no immune response [21,23]. Also, anoikis and 
the toxic environment from the high oxidant stress that characterizes dystrophic muscles may play a 
role in the survival of cells. These challenges to survival will be encountered by hiPSCs-MP in the 
same ways as purified adult myoblasts. Regarding engraftment, all the published work on 
hiPSCs-MP in animal models shows in vivo engraftment and fusion with host cells, but greater extent 
is needed for a clinically relevant cell therapy protocol. Limited migration from the injection site, in 
part due to high mortality, but also to intrinsic capacity, is another major limitation that iPSC-derived 
cells must overcome to outperform myoblast therapy. Some authors describe iPSC-MP as resembling 
embryonic more than adult myoblasts [31]. The use of two markers expressed during embryogenesis 
by hypaxial migratory myogenic precursors, C-MET and CXCR4, has been proposed to isolate the 
most migratory fraction of hiPSC-MD [49]. Also, beta 1 integrin, expressed in satellite cells, is 
essential for engraftment [11] and can be another migratory phenotype selection marker. 
5.2. Fibrosis 
Another major limitation to regeneration is dense fibrotic tissue. TGF- 1 induces collagen I 
deposition from myogenic cells with subsequent fibrotic tissue formation. Fibrosis limits myoblast 
engraftment as well as motility and this prevents axons from arriving to myofibers. Unfortunately, 
there are no drugs on the market that can overcome fibrosis in MD patients. However, there is a 




reduced fibrosis due to paracrine effects [50]. This inhibitory effect should be studied in hiPSCs-MP 
if they are to be a candidate for use in a clinical setting.  
5.3. Creating the Perfect Niche 
Tissue engineering can also be of great help for the survival of transplanted myogenic progenitors 
in the hostile environment of a damaged tissue. Creating a three-dimensional niche for the 
transplanted myogenic progenitors that resembles satellite cells’ natural niche in vivo by using 
biomaterials (alginate, collagen, and hyaluran) will conserve the engrafted cells’ homeostasis and 
allow asymmetric division and myogenic commitment [51]. The cells to be transplanted would be 
seeded in the 3D scaffold and a graft generated in vitro. To complete the niche, extracellular matrix 
components and signaling molecules to stimulate proliferation, migration, and angiogenesis should 
be included. Muscle flaps made with decellularized devices from large mammals and synthetic 
scaffolds complemented with an in vitro-produced extracellular matrix from cell cultures derived 
from the host provide suitable tools for translation to the clinic [52]. From the complex set of 
requirements for skeletal muscle tissue engineered implants to function and integrate in vivo, some 
issues have already been addressed, such as restoration of the muscular-tendon junction or 
vascularization, while others like reinnervation still need further work [49]. 
5.4. Genetic Correction vs. Immunocompatible Transplantation 
When addressing genetic origin myopathies, the transplanted cells should contain the correct 
version of the gene. This can be achieved in two ways: by genetic correction of patient-derived cells or 
by allogenic transplantation of immunocompatible donor cells. One of the major features of iPSCs is 
the possibility of generating patient-derived tissues with minor invasion. Several groups have 
performed gene correction on patient iPSCs. iPSC-derived mesangioblasts, from a Limb-Girdle MD 
patient, in which the wild-type alpha-sarcoglycan gene had been restored by lentiviral delivery, 
engrafted, and fused with host fibers when transplanted in nude mice [46]. Lamin A/C (LMNA) has 
also been corrected in laminopathy patient-derived iPSCs using a helper-dependent adenoviral 
vector, which is safer than other viral vector approaches [53]. Duchenne MD iPSCs have also been 
corrected with -utrophin using a sleeping beauty transposon system [39]. In any case, gene therapy 
is still under development and a totally safe way of gene correction has still not been demonstrated. 
Another approach is to transplant cells created from a healthy donor that are matched for the main 
antigens in the host immunological rejection, the HLA antigens. An HLA-typed bank of iPSCs could  
be created to provide a source of compatible donor cells for the individual patients. A relatively small 
number of donors can provide an acceptable match to a high percentage of the population [54].  
This approach would also be more feasible as a therapeutic approach than the expensive and  
time-consuming generation of personalized iPSC-MP. 
It is necessary to take into account that in the case of genetic diseases that lack the native protein, 
its expression from the grafted tissue will most likely induce a considerable immune response that 





5.5. Delivery Route 
Moreover, the desirable myogenic progenitor should be able to cross the blood barrier to allow  
for systemic delivery. Treatment of local damage could be done by local intramuscular injections  
or bio-engineered grafts, but for a cell therapy for MD, SMA, and ALS, in which all muscles in the 
body are affected, a systemic delivery is necessary. Very few reports show successful engraftment 
after intra-arterial delivery [38,39,46]. The adequate dosage and regime of injections still needs  
further study. 
5.6. Safety 
For all the reported work in humans and animals models using muscle stem cells, neither adverse 
side effect has been described, nor colonization in other organs when systemically delivered [39]. 
Also, for iPSC-MP no teratoma formation has been detected [37,39]. However, the double 
reprogramming process—first to pluripotency and then to myogenic lineage—bring along the risk of 
chromosomal abnormalities and genetic instability [55]. Darabi et al. described how, from several 
clones tested for in vivo engraftment and fiber contribution, those that performed better were the ones 
with a normal karyotype [38]. In this sense, chromosomal, genetic, and epigenetic studies must be 
performed on the cells to be transplanted before taking them to the clinic application. Also, 
reprogramming and differentiation methods should not include exogenous DNA but use, for 
example, mRNA transfection; the use of the oncogene c-Myc should be avoided when 
reprogramming for clinical applications. Genes involved in epigenetic remodeling [56] and cell cycle 
regulation [57] have been proposed as alternatives to c-Myc in reprogramming. In this regard, 
variants of c-Myc with no oncogenic potential such as L-Myc or the W136E c-Myc mutant are also 
able to induce reprogramming to pluripotency with less tumorigenic potential [58]. 
5.7. Clinical Grade Protocols 
Whatever the method of choice is for generating the myogenic progenitors, a clinical grade 
protocol must be designed for the cells to be used in patients. The generation process should not 
include any viral vector or exogenous DNA, should be free of animal products, and should use as far 
as possible defined media to increase reproducibility and comply with good manufacturing 
procedures. Such a protocol has not yet been described for either iPSC generation or the derivation  
of MP. 
6. Conclusions 
The use of hiPSCs as a source of myogenic progenitors for cell therapy for the treatment of 
muscle degenerative diseases overcomes several of the limitations encountered in adult myoblast 
therapy: (i) easy non-invasive source of donor cells; (ii) unlimited proliferative capacity in vitro, and 
(iii) better performance when tested in mouse models in vivo—possibly because of more 
embryonic-like features. In recent years, several protocols of derivation of myogenic progenitors 




transcription factors (Pax7, MyoD1) overexpression or GSK3  inhibitors has contributed greatly in 
this direction. However, a clinical grade protocol still needs to be described, including the definition 
of safety and genetic stability requirements for clinical applications. Also, isolation of the MP 
presenting the most promising features for successful regeneration in vivo could improve the 
performance of the cell therapy, such as selecting cells that are more migratory and proliferative or 
with the possibility of systemic delivery. Other limitations relating to the host—for example, the 
inflammatory and immune response and the appearance of fibrotic tissue—present a major hurdle to 
a cell therapy approach. More research with selective inhibitors or modulators of these processes is 
needed, and the use of bioengineering to create a 3D protective niche for the transplanted cells would 
contribute to the long-term success of a muscle stem cell therapy strategy. 
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The Use of Patient-Specific Induced Pluripotent Stem Cells 
(iPSCs) to Identify Osteoclast Defects in Rare Genetic  
Bone Disorders 
I-Ping Chen 
Abstract: More than 500 rare genetic bone disorders have been described, but for many of them only 
limited treatment options are available. Challenges for studying these bone diseases come from a 
lack of suitable animal models and unavailability of skeletal tissues for studies. Effectors for skeletal 
abnormalities of bone disorders may be abnormal bone formation directed by osteoblasts or 
anomalous bone resorption by osteoclasts, or both. Patient-specific induced pluripotent stem cells 
(iPSCs) can be generated from somatic cells of various tissue sources and in theory can be differentiated 
into any desired cell type. However, successful differentiation of hiPSCs into functional bone cells is 
still a challenge. Our group focuses on the use of human iPSCs (hiPSCs) to identify osteoclast 
defects in craniometaphyseal dysplasia. In this review, we describe the impact of stem cell 
technology on research for better treatment of such disorders, the generation of hiPSCs from patients 
with rare genetic bone disorders and current protocols for differentiating hiPSCs into osteoclasts. 
Reprinted from J. Clin. Med. Cite as: Chen, I.-P. The Use of Patient-Specific Induced Pluripotent 
Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders. J. Clin. Med. 
2014, 3, 1490–1510. 
1. Introduction 
Studying rare genetic bone disorders is clinically highly relevant. Although individual diseases 
only affect a small percentage of the population (less than 200,000 people or about 1 in 1500 people 
in the United States), overall, a large number of people suffer from these skeletal disorders due to 
their frequency (almost 500 rare genetic bone disorders listed by NIH Office of Rare Disease 
Research). Many of these diseases become apparent early in life and are present throughout the 
patient’s entire life. The diverse expressivities of clinical manifestations, from lethality of newborns 
to mild skeletal abnormalities, make the diagnosis of some of these disorders challenging. Moreover, 
most of these rare bone diseases are understudied due to the rarity of human specimens and 
unavailable animal models, and therefore treatment options are often limited or lacking. It is thus 
important to establish better models for studying such disorders. 
Research focusing on genetic disorders of the skeleton is not only beneficial for future treatment 
of patients, but has significantly contributed to our knowledge on key concepts of bone biology.  
Rare genetic bone disorders have been linked to abnormal bone development and/or bone 
remodeling. Pathologically and embryologically these diseases can be subdivided into four major 
groups: (1) disorders affecting skeletal patterning; (2) disorders of condensation/differentiation of 
skeletal precursor structures; (3) disorders affecting growth and (4) disorders of bone homeostasis 
caused by perturbation of interaction between the bone forming osteoblasts and the bone resorbing 




dysplasia (CMD) characterized by progressive thickening of craniofacial bones and widening of 
metaphyses in long bones, utilizing a knock-in mouse model [2]. We have identified defects of 
osteoblasts and osteoclasts in mice with a CMD mutation [3]. We currently study CMD in a human 
system using patient-specific induced pluripotent stem cells (hiPSCs) to identify osteoclast defects 
and we believe this strategy can be applied widely for studying other rare genetic disorders. 
In this article, we review some of the rare genetic bone disorders with osteoclast defects, the 
generation of hiPSCs from patients with rare genetic bone disorders and the protocols for 
differentiating hiPSC into osteoclasts. 
2. Rare Genetic Bone Disorders with Osteoclast Defects 
Osteoclasts are cells responsible for resorbing bone and work in close concert with osteoblasts to 
model the skeleton during growth/development and to remodel the bone throughout life. Osteoclasts 
are derived from the monocyte/macrophage lineage of hematopoietic stem cells and are 
multinucleated giant cells expressing marker genes, such as tartrate-resistant acid phosphatase 
(Trap), Cathepsin K, calcitonin receptor, nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1). 
Development of osteoclasts (osteoclastogenesis) involves (1) the commitment of hematopoietic stem 
cells into osteoclast precursors; (2) the fusion of mononucleated osteoclast precursors into 
multinucleated osteoclast syncytia; (3) the differentiation/maturation to functional osteoclasts. 
During stage 1, transcription factors PU.1, MITF and c-FOS are important determinants of lineage 
specification [4–6]. In addition, M-CSF signaling is necessary for proliferation and survival of 
osteoclast progenitors as first became obvious by the osteopetrotic phenotype of mice lacking the 
M-CSF gene (op/op mice) [7]. Interaction of RANKL, a member of TNF family and strongly 
expressed by osteoblasts, with its receptor RANK on osteoclast progenitors is necessary for the 
fusion of osteoclast precursors. The activation of RANK/RANKL signaling initiates a cascade of 
gene expression, including the expression of chemokines such as Mcp-1 to attract RANK+ 
mononuclear osteoclast precursors and molecules important for osteoclast fusion such as Atp6v0d2 
and DC-Stamp [8,9]. The final step in differentiation to mature and functional osteoclasts involves 
the formation of a ruffled border and sealing zone. Lack of functional osteoclasts by disruption of 
these processes or failure of polarization and cytokine organization can lead to osteopetrosis [10]. 
Many rare genetic bone disorders are partially or primarily caused by osteoclast defects. 
Dysfunctional osteoclasts can result in too much bone while increased bone resorption can lead to 
decreased bone mass. Some diseases present a combination of osteosclerosis with osteolytic lesions. 
Studies on these disorders highlight the important roles of some specific proteins or signaling 





2.1. Diseases of Decreased Osteoclast Resorption 
Osteopetrosis: Three main forms of hereditary osteopetrosis are autosomal recessive osteopetrosis 
(ARO), intermediate autosomal recessive osteopetrosis (IARO) and adult dominant osteopetrosis 
(ADO), the most severe form being ARO. Mutations causing these diseases generally lead to lack of 
acid secretion in osteoclasts. ARO presents in infants with severe sclerosis of bone, an increased rate 
of fracture, extreme reduction of bone marrow space, hepatosplenomegaly, anemia, compression of 
cranial nerves and growth failure [11]. Infantile malignant osteopetrosis is generally lethal and can 
only be treated by early bone-marrow transplantation. IARO is a recessive form of osteopetrosis with 
renal tubular acidosis. The affected protein, carbonic anhydrase type II is highly abundant in 
osteoclasts, cerebral neurons and in renal intercalated cells. Clinical features of IARO patients 
include the milder form of osteopetrosis, mental retardation due to cerebral calcification and renal  
dysfunction [12]. Two distinct types of ADO are known [13]. ADO is characterized by a generalized 
diffuse osteosclerosis with the most pronounced thickening at the cranial vault in its type I form and 
the most pronounced abnormalities in vertebrae in type II (Albers Schonberg disease). 
Pycnodysostosis: This is an autosomal recessive disorder and can be diagnosed during early 
infancy. The phenotype is milder than ARO with short stature, recurrent bone fracture, skull 
deformity and hypoplasia of facial bones, sinuses and clavicles. Long bones are hyperostotic with 
narrow medullary canals. The calvarium and base of the skull are sclerotic. The genetic defect for 
pycnodysostosis has been identified in Cathepsin K, a lysosomal cysteine protease required to 
degrade collagen in resorption lacunae of osteoclasts [14]. 
2.2. Diseases of Increased Osteoclast Resorption 
Paget’s disease of bone (PDB): PDB is a late onset bone disease starting at mid-life or later.  
Genetic predisposition together with environmental risks and other risk factors such as trauma or 
surgery contribute to its etiology. PDB affects single or multiple locations of the skeleton where focal 
bone resorption occurs and bone is replaced with soft, fibrous expansile tissue that result in 
characteristic enlarged and softened bone tissue. Clinical symptoms include bone pain, bone 
deformity, deafness, pathological fractures and osteoarthritis [15,16]. Although increased osteoclast 
activity is primarily the cause of PDB, excessive osteoblast activity reflected in elevated serum 
alkaline phosphatase has been reported [17], which could be a sign of increased bone turnover. 
Juvenile PDB (JPDB): Different from Paget’s disease of bone, JPDB usually occurs in infancy or 
early childhood, characterized by massive thickening of calvaria, widened diaphyses, and 
deformities of extremities and vertebrae [18]. Autosomal recessive mutations in TNFRSF11B result 
in a less efficient form of osteoprotegerin (OPG) with reduced affinity for RANKL or in a failure to 
express OPG protein. OPG is a decoy receptor for RANKL, thus regulating osteoclast formation.  
As a consequence, increased bone resorption coupled with increased bone formation, are seen in  
JPDB [19,20]. 
Familial expansile osteolysis (FEO): FEO is an autosomal dominant rare bone disorder 
characterized by osteolytic lesions in major bones of the appendicular skeleton during early 




ear and jaw [21,22]. Mutations identified in TNFRSF11A cause enhanced RANK-mediated nuclear 
factor- B (NF- B) signaling and increased bone remodeling [23]. 
Expansile skeletal hyperphosphatasia (ESH): ESH is characterized by expanding hyperostotic  
long bones, early onset deafness, premature tooth loss, episodic hypercalcemia and increased  
alkaline phosphatase activity; the skull and appendicular skeleton display hyperostosis and/or 
osteosclerosis [24]. 
Mutations responsible for these rare disorders affecting osteoclast activity are summarized in  
Table 1. Research of disorders mentioned above would be greatly enhanced if elaborate models for 
studying osteoclastogenesis and osteoclast function would be available. Induced pluripotent stem 
cells (iPSCs) could be one worthwhile avenue to study such disorders in humans. iPS cell approaches 
have been published for certain bone remodeling disorders described below. 
Table 1. Mutations in rare genetic bone disorders with osteoclast defects. 
Diseases with Decreased Bone Resorption 
Disease OMIM Gene Affected Protein Affected Reference(s) 
ARO 259,700 TCIRG1 3 Subunit of vacuolar proton pump H+ ATPase [1,25] 
ARO 259,700 CLCN7 Chloride channel [26] 
ARO 259,700 OSTM1 GL [27] 
IARO 259,730 CAII Carbonic anhydrase II [12] 
ADOI 166,600 Lrp5 Lrp5 [28] 
ADOII 166,600 CLCN7 Chloride channel [29] 
Pycnodysostosis 265,800 CTSK Cathepsin K [14] 
PDB 6,002,080 SQSTM1 P62 [30,31] 
JPDB 239,000 TNFRSF11B Osteoprotegerin (OPG) [19] 
FEO 174,810 TNFRSF11A RANK [23] 
ESH N/A TNFRSF11A RANK [32] 
ARO: autosomal recessive osteopetrosis; IARO: intermediate autosomal recessive osteopetrosis; ADOI: 
adult dominant osteopetrosis, type I; ADOII: adult dominant osteopetrosis type II; PDB: Paget’s disease of 
bone; JPDB: Juvenile Paget’s disease of bone; FEO: familial expansile osteolysis; ESH: expansile skeletal 
hyperphosphatasia; OMIM: Online Mendelian Inheritance in Man; GL: Grey lethal; N/A: not available. 
3. Generation of hiPSCs from Rare Genetic Bone Disorders 
hiPSCs, similar to human embryonic stem cells (hESCs), have the ability to self-renew 
indefinitely and in theory differentiate to any cell type when induced under appropriate conditions. 
The advances in hiPSCs technology opened new opportunities for medical research in disease 
modeling, drug screening, gene therapy and genome editing [33–35]. Generation of hiPSCs can, for 
example, be achieved by introduction of reprogramming factors, OCT3/4, SOX2, KLF4 and c-MYC 
or OCT3/4, SOX2, NANOG, and LIN28 [36–38]. Methods successfully delivering these reprogramming 
factors into somatic cells include transduction with retroviruses, lentiviruses, adenoviruses, 
piggyBac transposons, episomal vectors, RNA, or protein [37,39–44]. Many types of somatic cells 
have been reprogrammed into hiPSCs, including fibroblasts, keratinocytes, peripheral blood 




follicles and urinary cells [37,45–49]. Patient-specific hiPSCs provide unique opportunities for 
researchers to dissect the pathogeneses and identify potential treatment strategies for the rare genetic 
bone disorders by providing a virtually unlimited source of cells carrying the disease-causing 
mutations. hiPSCs can be differentiated into functional cells of interest in the skeletal system, 
including osteoclasts. hiPSC disease modeling has been established for several non-skeletal 
disorders including type I and type II diabetes, muscular dystrophy, amyotrophic lateral sclerosis, 
Parkinson’s disease, glioblastoma, familial platelet disorder with predisposition to acute myeloid 
leukemia (FPD) [36,50–55]. There have been only few attempts to establish hiPSCs from patients 
with rare genetic bone disorders (see also Table 2). 
Table 2. iPSCs generated from patients with rare genetic bone disorders. 
Disease 









MSC derived from 
bone fragments 
(1) lentivirus 
(1) OCT4, SOX2,  
LIN28 or NANOG 
6 [56] 
(2) floxed, polycystronic 
foamy virus 
(2) OCT4, SOX2,  
KLF4 and c-MYC 
  
CMD 
5–7 mL  
peripheral blood 
Sendai virus 
OCT3/4, SOX2,  
KLF4 and c-MYC 
8 [57] 
FOP Dermal fibroblasts 
(1) retrovirus 
(1) OCT4, SOX2,  
KLF4 and c-MYC 
5 [58] 
(2) episomal vectors 
(2) SOX2, KLF4, 
OCT4,  
L-MYC, LIN28, p53 
  
MFS Dermal fibroblasts retrovirus 
OCT4, SOX2, KLF4 
and c-MYC 
2 [59] 
OI: osteogenesis imperfecta; CMD: craniometaphyseal dysplasia; FOP: Fibrodysplasia ossificans 
progressiva; MFS: Marfan syndrome; MSC: mesenchymal stem cells. 
Osteogenesis Imperfecta (OI): OI, also known as brittle bone disease, is characterized by brittle 
bones that are prone to fracture and are caused by mutations in the COL1A1 or COL1A2 genes in the 
majority of cases. Misfolded collagen overwhelms the protein degradation machinery of cells and 
leads to abnormal bone matrix deposition by osteoblasts. 8 Types of OI have been identified. There is 
currently no cure for OI and treatment focuses on the prevention of fractures and the maintenance of 
mobility [60]. Deyle et al. established mesenchymal cell cultures from discarded bone fragments of 
OI patients undergoing surgery and further inactivated mutant collagen genes by adeno-associated 
virus (AAV)-mediated gene targeting, thus preventing the expression of misfolded collagen protein. 
OI and gene-targeted OI mesenchymal cells have been reprogrammed to hiPSCs [56]. 
Craniometaphyseal dysplasia (CMD): CMD is characterized by progressive hyperostosis of 
craniofacial bones and widened metaphyses of long bones. Patients often suffer from blindness, 
deafness, facial paralysis and severe headache due to hyperostosis and compression of the brain and 
nerves. Mutations for the autosomal dominant form of CMD have been identified in of progressive 




identified dysfunctional osteoclasts in knock-in (KI) mice carrying a Phe377del mutation and in 
human osteoclast cultures [2,3]. The increased bone mass phenotype in CMD mice (AnkKI/KI mice) 
can partially be rescued by bone marrow transplantation. We have established a simple and efficient 
method to generate integration-free hiPSCs from peripheral blood of CMD patients and healthy 
controls using the Sendai virus, a cytoplasmic RNA viral vector [57], that can easily be removed 
from cells after reprogramming to iPSCs. 
Fibrodysplasia ossificans progressiva (FOP): FOP is a rare genetic disorder caused by hyperactive 
mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 [64]. It is characterized 
by progressive ossification of soft tissues. The mechanism of heterotopic ossification is endochondral 
bone formation which involves pre-cartilaginous, fibro-proliferative and mineralization stages. 
Matsumoto et al. generated hiPSCs from skin fibroblasts of FOP patients and controls and showed 
increased in vitro chondrogenic differentiation and mineralization in FOP hiPSCs compared to wild 
type hiPSCs [58]. 
Marfan syndrome (MFS): MFS is a life-threatening, autosomal dominant disease with mutations 
identified in FIBRILLIN-1 (FBN1) [65]. It is a disorder of fibrous connective tissue involving three 
systems: skeletal, cardiovascular and ocular. Skeletal features include long limbs and digits, 
deformities of vertebrae (scoliosis, thoracic lordosis) and anterior chest, increased height, and mild to 
moderate joint laxity. Quarto et al. generated hiPSCs from MFS patients and studied the pathogenic 
skeletogenesis in vitro [59]. They show that MFS-hiPSC faithfully represent the impaired osteogenic 
differentiation as a consequence of activation of TGF-  signaling and revealed a crosstalk between 
BMP and TGF-  signaling in MFS [66]. 
4. Differentiating hiPSCs into Osteoclasts 
4.1. Differentiating Mouse Embryonic Stem Cells (mESCs) into Osteoclasts 
Several studies have reported the generation of osteoclasts from mESC lines by culturing mESCs 
directly on a culture plate or by co-culturing mESCs with mouse bone marrow-derived stromal cells 
(ST2) or with the newborn calvaria-derived stromal cell line (OP9) from mice deficient in 
macrophage colony-stimulating factor (M-CSF) or through EB formation (for details see Table 3). 
Information gained from these mouse ESCs/iPSCs studies provided the fundamentals for 





4.2. Commitment of Human ESCs/hiPSCs into Hematopoietic Lineages/OC Precursors 
Consistent and adequate hematopoietic differentiation of hiPSCs is a prerequisite step for 
differentiating hiPSCs into osteoclasts. Hematopoiesis during embryogenesis starts with the 
formation of the primitive streak, mesoderm differentiation and hematopoietic specification. In vitro 
studies have shown that hiPSCs can be differentiated into different hematopoietic lineages through 
similar processes. Inducing hematopoiesis from human embryonic stem cells (hESCs) or hiPSCs has 
been reported by several extensive studies using three systems: (1) differentiation by coculturing  
hESC/hiPSCs with stromal cells; (2) differentiation through formation of embryoid bodies (EB), 
which can be differentiated into the three germ layers including mesoderm; (3) differentiation by 
monolayer culture of hESCs/hiPSCs on extracellular matrix protein coated-plates, such as collagen 
IV. We summarize culture conditions of these protocols in Table 4. 
There are advantages and disadvantages inherent to these protocols. Differentiation efficiency of  
co-culture methods relies largely on optimized cell densities of hESCs/hiPSCs and the mouse 
stromal cell lines. It can be challenging to have both cell culture systems ready for co-culture at the 
same time. On the other hand, co-culture method requires less hematopoietic cytokines and is 
therefore relatively inexpensive compared to protocols involving EB and monolayer cultures. 
Concentrations of cytokines used are critical in those cultures. Stimulatory or inhibitory effects of 
cytokines towards hematopoiesis can be observed depending on the concentrations used. It is 
difficult to directly compare the lengths of cell culture time or hematopoietic differentiation 
efficiencies among the approaches described in Table 4. Variability of culture conditions used for the 
experiments among these protocols is discussed below. 
4.3. Marker Genes for Mesodermal Formation and Hematopoietic Differentiation 
Marker genes for mesodermal and hematopoietic lineages have been used to determine the 
efficiency of hematopoietic differentiation protocols during in vitro differentiation. Temporal 
expression patterns of certain marker genes are reliable indicators of mesoderm and hematopoietic 




the expression of marker genes such as Brachyury (T), Mix paired-like homeobox (Mixl1), 
Goosecoid homeobox (GSC), and silencing of the pluripotency genes [74,75]. While kinase insert 
domain receptor (a type III receptor tyrosine kinase, KDR), also known as endothelial growth factor 
receptor 2 (VEGFR-2) or fetal liver kinase 1 (Flk1), is already detected in hESC/hiPSCs, its 
expression increases during the transition from mesoderm to hematopoietic lineage [76]. In addition, 
transcription factors stem cell leukemia (Scl/Tal-1), runt-related transcription factor 1 (Runx1), 
globin transcription factor 1 (GATA-1) and GATA-2 play important roles in hematopoietic commitment 
during embryogenesis [77–79]. Combinations of surface marker expression are used to detect  
the hematopoietic stem cells (HSC) or the maturation of HSCs into specific hematopoietic cells. 
CD34, CD31 and VE-cadherin are expressed in early hematopoietic cells and vascular associated 
tissues [76]. CD45 is a pan-leukocyte marker [80]. Lin CD34+CD43+CD45+ cells represent a 






4.4. Factors and Cytokines to Promote Hematopoiesis 
Defined factors/cytokines can be added to support hematopoietic cell proliferation or differentiation 
under controlled conditions. BMP4 alone can induce primitive streak and early hematopoietic gene 
expression, including Mixl1, Brachyury, Goosecoid, KDR, Runx1 and Gata2 while BMP4 together 
with VEGF can increase expression of Scl and CD34 [91]. The addition of FGF2 during 
hematopoietic differentiation of hESCs increases total cell number by improving cell proliferation 
but not cell survival [91]. A mixture of cytokines including stem cell factor (SCF), fms-like tyrosine 
kinase receptor-3 ligand (Flt-3), interleukin-3 (IL-3), interleukin-6 (IL-6) and granulocyte 
colony-stimulating factor (G-CSF) and thrombopoietin (TPO) is commonly used in hematopoietic 
differentiation protocols for hESCs. These cytokines have been shown to play important roles in 
maintenance of human hematopoietic cells [92,93]. Addition of SCF in the presence of BMP4, 
VEGF and FGF can significantly increase the yields of hematopoietic progenitors and mature cells  
in vitro [91]. When added to IL-3 and GM-CSF, SCF has profound effects on in vitro proliferation of 
primitive hematopoietic progenitors [94]. 
4.5. Variability among Hematopoietic Differentiation Protocols 
Some studies showed variable efficiencies for deriving hematopoietic cell populations from 
hESCs/hiPSCs. Many factors contribute to this variability including the somatic cell type used for 
hiPSC reprogramming; the method of deriving hiPSCs; incomplete removal of reprogramming 
transgenes in hiPSCs; the culture conditions for maintaining hiPSCs; the type of differentiating 
medium, growth factors and hematopoietic cytokines added in the differentiation protocol; the 




hypoxia); and the size of EBs or the densities of stromal cell lines [95]. It has been suggested that 
epigenetic memory exists in hiPSCs and the differentiation phenotype may be influenced by their 
cells of origin [96]. Transgenes remaining in hiPSCs can have a negative impact on hiPSC 
differentiation [97]. Multiple concentrations of BMP4 (5, 10, 25, 50 ng/mL) were tested and showed 
no differences in promoting CD34+CD45+ populations [85] while Pick et al. showed BMP4 
increases primitive streak and hematopoietic gene expressions in a dose-dependent manner [91]. It is 
therefore important to develop a method that eliminates as many variable factors as possible and that 
aims to obtain hematopoietic cells from hiPSCs by a reproducible and efficient protocol. 
4.6. Differentiating hiPSCs-Derived Osteoclast Progenitors into Osteoclasts 
Two publications describe the successful differentiation of hiPSCs to hematopoietic cell stage and 
further to mature OC progenitors and into functional osteoclasts. Choi et al. cultured a 
Lin CD34+CD43+Cd45+ population in the presence of GM-CSF and vitamin D3 on poly  
(2-hydroxyethyl methacrylate)-coated plates for 2 days to expand osteoclast progenitors and then 
induced osteoclast maturation in cultures with -MEM, 10% FBS, and MTG solution supplemented 
with GM-CSF (50 ng/mL), Vitamin D3 (200 nM) and RANKL (10 ng/mL) [81]. Grigoriadis et al. 
cultured myeloid precursors derived from hiPSCs in IMDM containing 10% FCS, M-CSF (10 ng/mL) 
and RANKL (10 ng/mL). Osteoclasts were defined as multinucleated cells ( 3 nuclei) by TRAP 
positive staining and the capability of resorbing bone/dentin chips. Expressions of OC marker genes 
such as Cathepsin K, calcitonin receptor, NFATc1 are increased in these functional OCs [87]. 
Studies summarized in Tables 3 and 4 demonstrate that osteoclasts can be generated from both, 
human and mouse ES/iPSCs. In general, differentiation of osteoclasts from hESCs/hiPSCs systems 
is more challenging than differentiation from mouse ESCs/iPSCs. Differentiation of hESCs/hiPSCs 
requires more hematopoietic cytokines, longer culture periods and generally results in less efficient 
osteoclast formation. However, the mechanisms behind differences between human and mouse 
osteoclastogenesis are still unclear. 
4.7. Strategies of Using hiPSC-Osteoclasts to Study Rare Genetic Bone Diseases 
hiPSC technology in general enables researchers to reprogram somatic cells into an ES-like state 
followed by differentiation into desired cell type. While human osteoclasts can be differentiated 
directly from peripheral blood, the big advantage of hiPSC technology is that osteoclasts can be 
generated without repeated sampling of patients. hiPSCs provide a virtually unlimited cell source to 
study molecular mechanisms of osteoclastogenesis with the potential to develop therapies, which is 
especially important when studying rare genetic bone diseases. Because of potential species-specific 
differences, studying abnormal osteoclastogenesis in the human system may be closer to clinical 
reality than using animal models. 
A preferred strategy for studying defective osteoclastogenesis in rare genetic bone disorders using 
patient-specific hiPSCs is summarized in Figure 1. One challenge of hiPSC disease modeling in vitro 
is the lack of genetically matched controls. Using healthy subjects as controls may not be the best 




efficiency because of biological variability [98]. Distinguishing mutation-relevant disease 
phenotypes from genetic/epigenetic variations becomes easier in isogenic hiPSCs, which only differ 
at disease-causing mutations. Correction or introduction of specific mutations into a cell can be 
achieved by genome editing using zinc-finger nucleases (ZFNs), transcription activator-like effector  
nucleases (TALENs) or the clustered regulatory interspaced short palindromic repeats/Cas9 system 
(CRISPR) [99–102]. Using step-wise OC differentiation protocols for differentiating hESCs or 
hiPSCs may allow researchers to identify which step of osteoclastogenesis is disrupted by a disease 
causing mutation. Analysis tools are available to study each step (lineage determination of 
precursors, precursor proliferation, fusion to multinucleated syncytia, maturation to functional 
osteoclasts) such as expression of marker genes, numbers of TRAP+ mono/multinucleated cells, 
resorption efficiency, live-image migration assays and nuclear localization of NFATc1. Therapeutic 
strategies can be investigated once the pathologic mechanisms are understood. 
Figure 1. Summary of generating osteoclasts from human iPSCs. 
 
5. Conclusions 
Osteoclast defects are involved in many rare genetic bone diseases as well as in some common 
bone diseases such as osteoporosis. Although human OC can be cultured from peripheral blood, 
being able to differentiate OCs from hiPSCs has at least two additional advantages: (1) eliminating 
the need to repeatedly obtain blood from study subjects; (2) serving as an in vitro model for studying 
hematopoiesis during embryogenesis. Lessons learned from embryology and differentiation studies 
are expected to improve protocols for consistent and efficient differentiation of hiPSCs into 
hematopoietic cells and further into osteoclasts. Similar concepts can be applied to differentiate 
hiPSCs to other bone cells such as osteoblasts. We believe this model will have great impact on a 
better understanding of bone diseases and to establish the bases for potential therapies. 
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Human iPS Cell-Derived Germ Cells: Current Status and 
Clinical Potential 
Tetsuya Ishii 
Abstract: Recently, fertile spermatozoa and oocytes were generated from mouse induced 
pluripotent (iPS) cells using a combined in vitro and in vivo induction system. With regard to germ 
cell induction from human iPS cells, progress has been made particularly in the male germline, 
demonstrating in vitro generation of haploid, round spermatids. Although iPS-derived germ cells are 
expected to be developed to yield a form of assisted reproductive technology (ART) that can address 
unmet reproductive needs, genetic and/or epigenetic instabilities abound in iPS cell generation and 
germ cell induction. In addition, there is still room to improve the induction protocol in the female 
germline. However, rapid advances in stem cell research are likely to make such obstacles 
surmountable, potentially translating induced germ cells into the clinical setting in the immediate 
future. This review examines the current status of the induction of germ cells from human iPS cells 
and discusses the clinical potential, as well as future directions. 
Reprinted from J. Clin. Med. Cite as: Ishii, T. Human iPS Cell-Derived Germ Cells: Current Status 
and Clinical Potential. J. Clin. Med. 2014, 3, 1064–1083. 
1. Introduction 
There are various reasons to generate germ cells from human pluripotent stem cells in the 
laboratory. First, in vitro recapitulation of gametogenesis and early embryogenesis using such 
induced germ cells is expected to enhance our understanding of the basis of human reproduction 
because the inaccessibility to human eggs (oocytes) and embryos has hampered relevant research. 
Second, human germ cell induction research will establish a precious platform for modeling 
infertility and congenital anomalies that have been difficult to study using animals. Third,  
the in vitro induction of germ cells from autologous pluripotent stem cells should lead to a new  
form of assisted reproductive technology (ART) for infertile patients who wish to have 
genetically-related children. 
Recent advances in stem cell research have made it conceivable that human sperm (spermatozoon) 
and oocytes will be induced from pluripotent stem cells in the near future. Notably, a Japanese group 
reported that mouse embryonic stem (ES) cells and induced pluripotent (iPS) cells could be 
differentiated into fertile spermatozoa and oocytes via primordial germ cell (PGC)—like cells, and 
demonstrated that viable offspring could be derived from pluripotent stem cells [1,2]. Although their 
protocols used gonadal tissues and an in vivo induction system, their work established an important 
step on the path to the in vitro recapitulation of gametogenesis. Significant progress has also been 
made in the differentiation from both human ES cells [3–8] and iPS cells [8–13] into human germ 
cells over the last decade. A recent report demonstrated that human iPS cells can be indirectly  




cells [10,12,13]. Rapid advances in stem cell research would help to overcome the current technical 
issues and lead to the in vitro formation of bona fide human spermatozoa and oocytes.  
If functional oocytes and spermatozoa can be differentiated from human iPS cells, the use of 
such cells for research will contribute to the molecular elucidation of gametogenesis, as well as the 
onset and progression of various diseases in obstetrics, gynecology, and neonatology/pediatrics. 
However, with regard to the reproductive use of such germ cells induced from autologous iPS cells, 
sufficient preclinical research will need to be performed to confirm the safety of the offspring. 
Remarkably, the overview of ART (Appendix) using induced germ cells appears to occur against the 
Weismann barrier, wherein hereditary information moves only from germ cells to somatic cells [14]. 
Such germ cells are likely to be subject to genetic and/or epigenetic instabilities during iPS cell 
generation and germ cell induction. Moreover, although assessing the biological function of 
induced germ cells involves the creation of embryos and subsequent culture for a short period, 
human embryo research is strictly regulated in most countries [15]. In this review article, the 
current status of germ cell induction from human iPS cells is examined and discussed in light of 
clinical potential and future directions. 
2. Clinical Implications of Germ Cell Induction in Vitro 
Two fundamental cell types constitute multicellular eukaryotes. Somatic cells proliferate by 
mitosis and form the tissues and organs comprising the body. Germ cells undergo meiosis as well 
as mitosis, resulting in the generation of gametes that can transfer half the genetic material to the 
next generation. The lineage of germ cells is referred to as the germline. 
If germ cells can be efficiently induced from human iPS cells, the availability of such germ cells 
could contribute to various biomedical fields. First of all, the research use of human female germ 
cells and embryos is largely difficult owing to ethical reasons and the scarcity of oocytes and 
embryos for research. In contrast, patient-specific induced germ cells can model diseases that are 
derived from aberrant germ cells or that occur during embryogenesis. A wide variety of somatic 
cells which are differentiated from patient-specific iPS cells have already been used for 
disease-modeling to enhance the understanding of the pathogenesis of diseases [16]. Currently, the 
low efficiency of the differentiation of human iPS cells into germ cells has hampered the unveiling 
of the molecular pathogenesis of various diseases, including germ cell tumors [17], aneuploidy, sex 
chromosome abnormalities [11], and female and male infertilities. 
If functional germ cells are induced from iPS cells, such germ cells are also expected to impact 
ART treatment (Figure 1). Although ART has helped many infertile patients to produce offspring, 
the current ART procedures are based on the premise that an infertile couple can produce fertile 
gametes in order to perform intrauterine insemination (IUI), in vitro fertilization (IVF), or 
intracytoplasmic sperm injection (ICSI) (Appendix). Otherwise, the couple must use donor 
gametes. This option has raised ethical issues and social confusion. ART using donor gametes 
results in the birth of genetically-unrelated children. Such children born of donor gametes 
frequently confront stigma that stems from being uninformed about their genetic parents or due to 
their lack of resemblance to their parents in shape and appearance [18]. In addition, some sperm 




social problems [19]. Such cases frequently occur because there are many prospective parents who 
have no viable gametes due to congenital anomalies, or because they have been rendered sterile by 
receiving chemotherapy and radiation therapy for cancer treatment [20–22], or because the females 
have undergone age-related oocyte senescence [23]. 
Recent progress in germ cell induction research is increasing the possibility of a new form of 
ART using germ cells induced from autologous iPS cells for patients with no viable gametes 
(Figure 1). If fertile spermatozoa can be induced from a male patient’s iPS cells, performing IVF or 
ICSI will be possible using the generated spermatozoa. Similar approaches can be performed when 
fertile oocytes are generated from iPS cells. Even if no mature spermatozoa are obtained from the 
induction, in vivo spermatogenesis could be restored by transplanting spermatogonial stem cells 
(SSCs) derived from autologous iPS cells into the testis of a male patient [24–26]. In 1997, 
infusions of oocyte cytoplasm including mitochondria from donor oocytes was conducted in order 
to enhance the fertility of quality-compromised oocyte with mitochondrial defects [23], resulting in 
the birth of over 30 children [27]. However, the U.S. Food and Drug Administration concluded that 
further research was required for the use of this procedure in humans due to potential health risks to 
the progeny [28]. If this ooplasmic transfer procedure is sufficiently improved and induced female 
germ cells which genetically match the patient’s oocytes can be obtained from iPS cells, such germ 
cells could be used as a resource for ooplasmic transfer. Following such ART procedures, the 
resulting embryos can be carefully examined for three to five days post-conception, and one or 
more viable embryo(s) can then be selected for embryo transfer. Thus, autologous iPS-derived 
germ cells are expected to meet the reproductive needs of infertile couples who have lost viable 





Figure 1. The potential reproductive uses of iPS cell-based germ cells. Autologous iPS 
cells can be generated from somatic cells biopsied from infertile patients who have lost 
viable oocytes or spermatozoa. Subsequently, germ cells are induced from the iPS cells. 
The regenerated germ cells can be used for in vitro fertilization or intracytoplasmic sperm 
injection to create embryos for transfer. In cases of male infertility, spermatogonial  
stem cells (SSCs) could be transplanted into patients to restore spermatogenesis potential.  
In cases of female infertility, ooplasmic transfer to enhance the viability of 
quality-compromised oocytes is conceivable if female germ cells with a sufficient number 
of mitochondria can be induced from iPS cells. 
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3. The Induction of Germ Cells from iPS Cells 
Human iPS cells were initially generated from somatic cells by the ectopic expression of four 
transcription factor genes (OCT4, SOX2, KLF4, and c-MYC) in 2007 [29]. The current iPS cell 
generation methods vary in the choice of somatic origin, the set of reprogramming factors, and the 
transduction methodology [30]. The new pluripotent stem cells have become the starting material for 
germ cell induction, in which ES cells had been used (Table 1). Clinical applications of iPS-derived 
germ cells require scientific scrutiny in terms of meiosis, epigenetic programming, and the organization 
of the nucleus and mitochondria. Based on lessons learned from previous research on human ES  
cells [3–8] (Table 1), non-human primate ES cells [31], and mouse pluripotent stem cells [1,2,32–35], 
the current primary differentiation strategy involves differentiating human iPS cells into PGCs, and 
subsequently directing the PGCs to undergo meiosis, with some variations (Table 1). The PGC 
formation has been verified by the expression of marker genes or immunostaining for marker proteins 




assessing the haploidy of differentiated cells as well as detecting meiosis-associated markers, such as 







Figure 2. Differentiation pathway from human iPS cells to germ cells. Human iPS cells 
are differentiated into primordial germ cells (PGCs), and further differentiated into 
meiotic cells. Indicated information regarding confirmed markers is derived from 
research reports regarding germ cell induction using human iPS cells. PGCs: primordial 











































































































3.1. Induction of the Male Germline 
The differentiation of human male iPS cells has so far produced PGCs [8–10], gonocytes [11],  
SSCs [12], spermatocytes [12,13], and haploid, round spermatid-like cells [10,12,13] (Figure 2,  
Table 1). As early as 2009, Park et al. [8] reported PGC induction from human iPS and ES cells. 
They used a triple biomarker (cKIT, SSEA1, VASA) assay to identify and isolate the PGCs, and 
demonstrated that culturing such human pluripotent stem cells on human fetal gonadal stromal 
cells, which were derived from a 10-week-old human fetus, significantly improved the efficiency 
of PGC formation. Moreover, the efficiency was comparable among various ES cell and iPS cell 
lines. Utilizing bisulfite sequencing, they showed that the PGCs initiate imprint erasure from 
differentially methylated imprinted regions (H19, PEG1, and SNRPN DMRs) by day seven of 
differentiation. However, PGCs derived from iPS cells did not initiate imprint erasure as 
efficiently, suggesting that further investigation is needed on the epigenetic status during germ cell 
induction from iPS cells.  
In 2011, Panula et al. compared the potential of human iPS cells, derived from adult and fetal 
somatic cells to form primordial and meiotic germ cells [10]. As a consequence, approximately 5% 




morphogenetic proteins (BMPs). In addition, by overexpressing intrinsic regulator genes, including 
DAZ, DAZL, and BOULE, iPS cells formed meiotic cells with extensive synaptonemal complexes 
and post-meiotic haploid spermatid-like cells. These results show that human iPS cells generated 
from adult somatic cells can form germline cells other than PGCs. More recently, similar results 
using the overexpression of VASA and/or DAZL was reported, demonstrating that both human ES 
cells and iPS cells differentiated into PGCs, and the maturation and progression of these cells 
through meiosis was enhanced [9]. Again, post-meiotic male haploid cells were induced in 14 days 
following the overexpression of the two regulators. Moreover, the methylation pattern of the H19 
locus, similar to that of normal germ cells, was observed following the expression of VASA alone. 
Therefore, such RNA-binding proteins appear to promote the meiotic progression of human iPS 
cell-derived germ cells in vitro.  
In contrast to these studies, Eguizabal et al. demonstrated that without the overexpression of 
germline related factors, postmeiotic haploid cells were consistently obtained from human iPS cells 
of different origins (keratinocytes and cord blood), generated with a different number of 
transcription factors [13]. Their two-step differentiation protocol begins with iPS cell culture for 
three weeks with human ES cell media in the absence of bFGF. Subsequently, retinoic acid (RA) is 
added to the medium, and the culture continues for three more weeks. Then, the cells are sorted and 
reseeded onto culture plates in the presence of forskolin (FRSK), human recombinant leukemia 
inhibiting factor (rLIF), bFGF, and the CYP26 inhibitor, R115866, for at least two weeks. 
Consequently, the post-meiotic spermatid-like cells with acrosin-staining were identified. 
Moreover, Easley et al. also reported a similar direct differentiation approach without the 
overexpression of genes [12]. They adopted standardized mouse SSC culture conditions [36] and 
demonstrated that human ES cells and iPS cells differentiated directly into advanced male germ 
cell lineages, without genetic manipulation. They observed spermatogenesis in vivo by differentiating 
these pluripotent stem cells into UTF1-, PLZF-, and CDH1-positive spermatogonia-like cells;  
HIWI- and HILI positive spermatocyte-like cells; and haploid, round spermatid-like cells 
expressing acrosin, TP1, and Prot1. Such spermatids had uniparental genomic imprints similar to 
those of human sperm on two loci: H19 and IGF2. These results demonstrate that male iPS cells 
have the ability to differentiate directly into haploid, round spermatids in vitro. 
Therefore, male germ cell induction from iPS cells has rapidly advanced since 2009. Although 
transplantation of autologous SSCs to restore spermatogenesis has already succeeded in infertile 
monkeys [37], clinical use of SSCs induced from iPS cells requires considerable caution. Notably, 
Amariglio et al. warned that transplantation of stem cells, not differentiated cells, in a patient could 
cause an adverse event [38]. They reported that a boy with ataxia telangiectasia treated with the 
intracerebellar and intrathecal injection of human fetal neural stem cells was diagnosed with a 
multifocal brain tumor four years after the first injection. One might consider using iPS  
cell-derived spermatids in the clinical setting. However, although oocytes have been fertilized with 
elongated spermatids [39,40], they were insufficiently fertilized with premature, round spermatids, 
resulting in poor embryonic development [41–43]. Successful fertilization of oocytes with more 




Based on the recent mouse work by Hayashi et al. [1], primordial germ cell-like cells (PGCLCs) 
were generated from ES cells and iPS cells through epiblast-like cells (EpiLCs), a cellular state 
highly similar to pregastrulating epiblasts but distinct from epiblast stem cells (EpiSCs). To examine 
whether such PGCLCs undergo proper spermatogenesis, PGCLCs were transplanted into the 
seminiferous tubules neonatal mice lacking endogenous germ cells. As a result, fertile spermatozoa 
were produced in the thick tubules. The global transcription profiles, epigenetic reprogramming, 
such as imprinted genes (Igf2r, Snrpn, H19, and Kcnq1ot1), and cellular dynamics during PGCLC 
induction from EpiLCs resembled those associated with PGC specification from the epiblasts. 
Remarkably, they identified Integrin-b3 and SSEA1 as markers that could be used to isolate 
PGCLCs from differentiated cells. More recently, Ramathal et al. demonstrated that human iPS cells 
transplanted directly into mouse seminiferous tubules differentiated extensively to form germ 
cell-like cells with morphology indistinguishable from that of fetal germ cells, and these cells 
expressed PGC-specific proteins including VASA, DAZL, and STELLA [11].  
These findings revealed the significance of differentiation pathway from iPS cells to germ cells 
and elaborated the need for culture conditions that mimic the stem cell niche in the testis to 
efficiently and effectively direct human iPS cells to form more advanced germ cells in vitro.  
3.2. The Induction of Female Germline 
In contrast to male germline induction, the differentiation of iPS cells or ES cells into female 
germ cells has been insufficiently studied (Table 1, Figure 2). Eguizabal et al. consistently 
observed between 1.0%–2.0% haploid cells per human female iPS cell line (derived from 
keratinocytes or cord blood) in their two-step differentiation protocol [13]. Their female iPS cells 
were differentiated into haploid cells following the detection of the SCP3 and H2AX proteins 
(indicators of meiotic competence). However, they observed that most of the iPS cell lines, 
including female cells, increased their methylation status of H19 (the maternally expressed, 
paternally imprinted gene), displaying a clear tendency toward paternal imprinting. Therefore, it 
appears that the germ cells induced from female iPS cells are certainly haploid, but are incomplete 
as mature female germ cells because oocytes only extrude the last polar body after fertilization. 
Panula et al. also reported a similar result regarding the differentiation of female iPS and ES  
cells into meiotic germ cells by the overexpression of the intrinsic regulators [10]. Moreover, 
Bucay et al. showed that germ cells differentiated from human ES cells in vitro express both male 
and female genetic programs regardless of their karyotype [7]. 
With regard to mouse systems, there have been attempts to induce female germ cells from ES 
cells since 2003 [44–48]. Although a follicle-like structure with oocyte-like cells was spontaneously 
observed, entrance into meiosis was not confirmed in those reports. Nicholas et al. clearly noted 
that mouse ES cell-derived oocyte maturation ultimately fails in vitro [48]. They transplanted ES 
cell-derived oocyte-like cells into an ovarian niche to direct their functional maturation and showed 
that the physiological niche of the ovary is required for their differentiation. Notably, Hayashi et al. 
showed that mouse female ES cells and iPS cells were differentiated into fertile oocytes via EpiLCs 
and PGCLCs [2], using a combined in vitro and in vivo system which led to the successful 




gonadal somatic cells as reconstituted ovaries, they underwent X-reactivation, imprint erasure,  
and cyst formation, and exhibited meiotic potential. After PGCLCs in the reconstituted  
ovaries were transplanted under the mouse ovarian bursa, such cells matured into germinal 
vesicle-stage oocytes, and contributed to fertile offspring after in vitro maturation and fertilization. 
Therefore, the differentiation of female iPS cells into germ cells largely depends on the use of an  
in vivo system. 
The difficulty in female germ cell induction from pluripotent stem cells is more likely to reflect  
in vivo oogenesis. Human gametogenesis initiates around the 23–26th day post-conception [49]. 
The precursors of gametes, the PGCs, appear in the dorsal wall of the yolk sac near the developing 
allantois. The PGCs proliferate and migrate through the dorsal mesentery into the gonadal ridges. 
The PGCs are found in the gonads by the fourth week post-conception. Thereafter, female and 
male PGCs differentiate into oogonia (subsequently, oocytes) or gonocytes (subsequently, 
spermatozoa), respectively. The male germ cells undergo mitotic arrest until birth, whereas the 
female germ cells further enter meiotic arrest (Figure 2). Following birth, such germ cells are 
reactivated and resume meiosis, resulting in the beginning of the production of mature oocytes and 
spermatozoa after puberty. Therefore, human gametogenesis proceeds on a long-term basis with 
gender differences in meiotic progression. 
In males, SSCs are maintained, and contribute to spermatogenesis by self-renewal in vivo for a 
long time. In addition, human SSCs can be maintained in vitro for a long term. Sadri-Ardekani et al. 
demonstrated that the human SSC numbers increased 53-fold within 19 days in testicular cell 
culture and increased 18,450-fold within 64 days in a germline stem cell subculture [50]. 
Conversely, it has generally been considered that most female germ cells enter meiosis I until birth, 
do not proliferate after birth, and that the number of the germ cells gradually declines until 
menopause (at approximately 40 years) [51]. The significant differences in the proceedings 
between spermatogenesis and oogenesis appear to impact the differentiation of human iPS cells 
into germ cells in the laboratory. However, there have been several unique reports regarding 
mammalian oogenesis. Some groups have reported the isolation of oogonial stem cell-like cells in 
mice and humans [52–55]. However, there are counterarguments about the existence of oogonial 
stem cells [56–58]. If the mitotically active oogonial cells can be isolated in a reproducible manner, 
the findings are expected to contribute to enhancing female germ cell induction as well as 
providing a mitochondrial resource for ooplasmic transfer. 
4. Future Directions 
In order to improve the induction efficiency and functional completeness of germ cell induction 
from human iPS cells, deeper insight into iPS cell generation and gametogenesis in vivo is vital. In 
addition, creating human embryos is likely to require the assessment of the developmental potential 
of induced germ cells. The conditions to permit the creation of human embryos for these functional 
assays should be discussed, because such experiments are frequently associated with ethical 





4.1. Genetic and Epigenetic Stability of Human iPS Cells 
As mentioned in the Introduction, the ART using induced germ cells appears to be against the 
Weismann barrier. Induced germ cells are likely to be subject to genetic and/or epigenetic 
instabilities during iPS cell generation and germ cell induction. The genetic stability of iPS cells 
significantly impacts their research use, in addition to their safe medical use. Some cytogenetic 
analyses have suggested that human iPS cells and ES cells are likely to acquire trisomies in 
chromosome 12, and 17, indicating an underlying mechanism of growth advantage associated with 
culture adaptation [59–61]. Moreover, the tendency for large-scale chromosomal aberrations 
appears to have no dependence on the cell origin or iPS generation methods, although some of the 
chromosomal aberrations observed in PS cells were derived from the original somatic cells [59,60,62]. 
In addition, human iPS cell cultures are likely to undergo chromosomal changes at both early and 
late passages. A close examination of the genetic changes during culture indicated that the 
observed peak in occurrence of chromosomal aberrations is at around passage eight in iPS cells, 
while that in ES cells is at around passage 36 [59]. Moreover, smaller copy number variations 
(CNVs) in human iPS cell culture are present across chromosome 12, 17, and 20 [63]. Compared 
with human ES cells, iPS cells showed increased CNVs, and had more CNVs at low passages 
(18%) than at late passages (9%) [62,64]. Therefore, human iPS cells seem to be subject to genetic 
changes at earlier culture stage, mostly resulting from somatic cell reprogramming. 
The genetic instabilities might occur not only in nuclear DNA, but also in mitochondrial DNA 
(mtDNA). The copy number of mtDNA, which encodes proteins required to produce ATP for 
motility of spermatozoon ranges from 2.8 to 226 copies of mtDNA [65]. In contrast, in oocytes, the 
mtDNA copy number ranges from 20,000 to 598,000 [66–69], significantly impacting the outcome 
of fertility in ART. Since proper ATP production by mitochondria is essential for accurate meiosis 
in oogenesis as well as normal embryonic development [66–69], the mtDNA integrity of human 
iPS cells needs to be addressed. Relative to the founder fibroblasts, a higher rate of heteroplasmic 
variation was observed in human iPS cells [70]. Although this phenomenon may imply an 
increased mutation load in the iPS cells, such iPS cell lines showed no significant metabolic 
differences. Van Haute et al. tested 16 human ES cell lines and showed that they carry a plethora of 
diverse mtDNA deletions [71]. The mtDNA mutations did not seem to correlate with the time in 
culture, and were detected in the early passage cells. Such deletions did not appear to impact the 
differentiation potential, and were still present in terminally differentiated cells. Conversely, 
Wahlestedt et al. reported a unique result using a mutator mouse model with an error-prone 
mtDNA polymerase [72]. They investigated the impact of an established mtDNA mutational load 
regarding the differentiation properties of mouse iPS cells. As a consequence, the mutator iPS cells 
displayed delayed proliferation kinetics and harbored extensive differentiation defects, although 
somatic cells with a heavy mtDNA mutation burden were amenable to reprogramming into iPS 
cells. These findings suggest the need for careful analyses of the nuclear DNA and mtDNA in 
human iPS cells prior to germ cell induction. 
In addition, epigenetic aberrations in human iPS cells have been pointed out, indicating defects in 




methylation profiles suggested that some iPS cell lines possess somatic memory [74,75]. Although 
iPS cell lines with such memory might readily differentiate into germ cells, careful assessment of 
the epigenetic status of human iPS cells is required to avoid a low efficiency differentiation or 
aberrant epigenetics in the resulting germ cells. 
4.2. The Pluripotency State of Human iPS Cells 
Human ES and iPS cells are more similar to mouse EpiSCs that were derived from epiblasts in 
postimplantation embryos than mouse naive, ground state ES cells [76,77]. The features of the 
ground state pluripotency include driving Oct4 (also known as Pou5f1) transcription by its distal 
enhancer, globally reduced DNA methylation, prominent deposition of the repressive histone 
modification H3K27me3, and bivalent domain acquisition on lineage regulatory genes [78]. 
Moreover, human female ES and iPS cells frequently show a pronounced tendency for X 
chromosome inactivation. These lines of evidence suggest that human iPS cells represent a primed 
state of pluripotency that is distinct from the naive pluripotent ground state of mouse ES and iPS 
cells. Recently, some new methods to establish human iPS cells have been proposed [79–81]. These 
methods, which are based on 2i/LIF conditions (exogenous stimulation with leukemia inhibitory 
factor and small molecule inhibition of ERK1/ERK2 and GSK3  signaling) with additional 
components, demonstrated the establishment of human iPS cells in the naive ground state [79,81], or 
in the preimplantation epiblast state [80]. The use of human iPS cells generated by such methods are 
likely to facilitate the subsequent appropriate differentiation pathway to germ cells, as demonstrated 
by the two mouse experiments in which mouse pluripotent stem cells were differentiated into germ 
cells via EpiLCs [1,2]. 
4.3. Spatio-Temporal Factors in Gametogenesis 
Currently, germ cell induction from human iPS cells is advancing primarily in the male 
germline. A better understanding of gametogenesis would facilitate the induction of female germ 
cells, as well as the terminal differentiation into spermatozoa. Following puberty, spermatogenesis 
occurs at the seminiferous tubules in the testis in which Sertoli cells co-exist with Leydig cells.  
In inducing male germ cells, co-culture with Sertoli cells that foster and differentiate spermatocytes 
in vivo has already been introduced to induce spermatogenesis in vitro. Park et al. improved PGC 
generation using a co-culture system with human fetal gonadal cells [8]. Moreover, Bucay et al. 
reported that PGC generation from human ES cells was accompanied by the development of 
Sertoli-like support cells [7]. Moreover, another article reported that testosterone, which the Leydig 
cells of the testes produce, was added to the culture medium in order to promote differentiation of 
mouse iPS cells into male germ cells in vitro [82]. More elaborate culture systems including Sertoli 
cells and Leydig cells may be effective to induce terminally differentiated male germ cells. 
However, fetal and adult populations of Leydig cells are distinct cells in terms of their physiology 
and function [83]. A recent report suggested that Sertoli cells support adult Leydig cell 
development in the prepubertal testis [84]. Regarding female germ cell development, oocytes  




When stimulated at puberty, the oocyte enlarges, and the follicular cells continue to proliferate to 
form many layers surrounding the oocyte. These cells eventually become known as granulosa cells 
that secrete progesterone after ovulation. Qing et al. have used co-culture with ovarian granulosa 
cells in the induction of oocyte-like cells expressing oocyte-specific genes including Figalpha, 
GDF-9, and ZP1-3 from mouse ES cells [47]. Interestingly, when they were co-cultured with 
Chinese hamster ovary (CHO) cells or cultured in CHO cell-conditioned medium, these cells did 
not express all of these oocyte-specific markers during the germ cell induction. Moreover, Nicholas 
et al. differentiated mouse Oct4-GFP ES cells in vitro, isolated GFP positive germ cells by FACS 
and co-aggregated the cells with dissociated mouse newborn ovarian tissue [48]. Subsequently, 
they transplanted the co-aggregates under the kidney capsule of recipient mice. They observed ES 
cell-derived Oct4-GFP positive oocytes in the graft despite the efficiency being low. Furthermore, 
in a recent work [2], Hayashi et al. differentiated PGCLCs, which were induced from mouse ES 
and iPS cells into fertile oocytes, by using in vitro aggregation with female gonadal somatic cells 
and transplantation of germ cells under the mouse ovarian bursa. The spatio-temporal factors 
associated with human gametogenesis in vivo should be further considered to develop more 
elaborate culture or differentiation systems in order to increase the possibility of inducing more 
mature germ cells from human iPS cells.  
4.4. Assessing the Developmental Potential of Induced Germ Cells 
In order to confirm whether induced human germ cells possess the correct biological functions, 
creating embryos and culturing them for a short term is indispensable prior to considering the use 
for clinical applications. In doing so, a subsequent biological analysis would necessitate the 
establishment of ES cells from the embryos. Nonetheless, these experiments are likely to raise 
ethical concerns owing to the fact that such embryos are created and destroyed for research 
purposes, not for reproduction. In some countries, creating a human embryo and monitoring the 
development of human embryos until the 14th day post-conception or until the beginning of the 
formation of the primitive streak may be permitted with approval of an institutional review board 
(IRB) and/or national authorities [15]. However, such human embryo experiments require 
sufficient data to support their use based on animal experiments to confirm scientific or medical 
rationality. Since non-human primate (NHP) experiments are more scientifically comparable with 
the human conditions than experiments in lower animals such as rodents, the data obtained from 
NHP experiments are likely to be required by IRB or other bodies with regard to granting 
permission for human embryo research. 
5. Conclusions 
As discussed above, human germ cell induction has advanced primarily in the male germline, 
progressively reaching to a final differentiation stage. Meticulously selecting human iPS cell lines 
with higher pluripotency and genetic integrity is expected to improve the efficiency of the formation 
of PGCs and entrance into meiosis. Moreover, placing the differentiated cells in culture systems 




female germ cells that are more similar to oocytes. Further considerations of the intrinsic regulators 
that could be overexpressed are also likely to advance meiotic progression, complete meiosis, and 
functionally mature these germ cells. 
Rapid advances in stem cell research will likely enable human iPS cells to differentiate into 
elongated spermatids or bona fide spermatozoa within the next decade or less. Recently, perplexing 
ethical and social concerns associated with the careless use of induced germ cells have been  
raised [15]. The use of ART with induced germ cells might facilitate posthumous conception, the 
birth of many siblings in a region without their knowing their genetic relationships, and facilitating 
the birth of a “savior sibling” to provide HLA-matched transplantation therapy for a relative. The 
uncontrolled or unethical use of induced germ cells would make the current problems associated 
with ART more complicated. As human germ cell induction from human iPS cells proceeds, 
appropriate deployment of this stem cell technology in ART will become an urgent matter that will 
need to be addressed by both researchers and the general public, including prospective parents.  
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Appendix 
Assisted Reproductive Technology (ART) 
ART involves several types of medical procedures to achieve pregnancy. Types of ART include 
IUI, oocyte retrieval, IVF, and ICSI.  
Intrauterine Insemination (IUI) 
At the early stage of ART, IUI is performed by placing spermatozoa inside a woman’s uterus in 
order to facilitate fertilization. 
In Vitro Fertilization (IVF) 
IVF begins with the induction of ovulation via hormonal stimulation, followed by oocyte 
retrieval. Subsequently, the retrieved oocytes are fertilized with spermatozoa in a petri dish. The 
resulting embryos are cultured for three to five days following fertilization, and one or more viable 
embryo is transferred to the uterus. 
Intracytoplasmic Sperm Injection (ICSI) 
In cases of male infertility, one spermatozoon is generally injected into an oocyte to facilitate 





Ooplasmic Transfer [23,27,28] 
In cases of female infertility, ooplasm, including mitochondria from fresh, mature or immature, 
or cryopreserved-thawed donor oocytes are directly injected into recipient oocytes via a modified 
ICSI technique to enhance the viability of the oocytes. Currently, there is a moratorium on this 
procedure in the U.S. and Canada due to the potential health risks to the progeny. 
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Comparing ESC and iPSC—Based Models for Human  
Genetic Disorders 
Tomer Halevy and Achia Urbach 
Abstract: Traditionally, human disorders were studied using animal models or somatic  
cells taken from patients. Such studies enabled the analysis of the molecular mechanisms  
of numerous disorders, and led to the discovery of new treatments. Yet, these systems are limited or 
even irrelevant in modeling multiple genetic diseases. The isolation of human embryonic stem cells 
(ESCs) from diseased blastocysts, the derivation of induced pluripotent stem cells (iPSCs) from 
patients’ somatic cells, and the new technologies for genome editing of pluripotent stem cells have 
opened a new window of opportunities in the field of disease modeling, and enabled studying 
diseases that couldn’t be modeled in the past. Importantly, despite the high similarity between ESCs 
and iPSCs, there are several fundamental differences between these cells, which have important 
implications regarding disease modeling. In this review we compare ESC-based models to 
iPSC-based models, and highlight the advantages and disadvantages of each system. We further 
suggest a roadmap for how to choose the optimal strategy to model each specific disorder. 
Reprinted from J. Clin. Med. Cite as: Halevy, T.; Urbach, A. Comparing ESC and iPSC—Based 
Models for Human Genetic Disorders. J. Clin. Med. 2014, 3, 1146–1162. 
1. Introduction 
Pluripotent stem cells have an unlimited self-renewal capacity and can differentiate into virtually  
any adult cell type [1] and even some extra-embryonic tissues [2,3]. These features make human 
pluripotent stem cells (hPSCs) a useful tool for disease modeling, which overcomes limitations 
observed in animal and adult human cellular models. While the use of animal models proved to be 
extremely valuable and successful in many cases [4], there are numerous diseases, such as 
Lesch-Nyhan syndrome [5], Turner syndrome [6] and Fragile X syndrome [7], that cannot be studied 
using animal models due to species-specific differences. The use of mature cells from patients can 
solve the species-specificity issue but this strategy is limited by the fact that it enables studying only 
a few types of cells at a specific developmental stage, and in many cases requires also transformation 
of the cells to enable their proliferation in culture. By contrast, due to their unique properties, hPSCs 
enable exploration of different types of cells, to study the effect of a specific mutation on 
differentiation or development and can proliferate in vitro without additional transformation. Indeed, 
since the generation of the first human embryonic stem cells (ESCs) based model (a model for 
Lesch-Nyhan syndrome by targeting of the HPRT gene in human ESCs) [5] dozens of disease 
models were generated by reprogramming of somatic cells from patients [1], by derivation of mutant 
ESCs from affected embryos diagnosed by pre-implantation genetic diagnosis (PGD) or by genetic 
manipulation of normal ESCs [8] (see Figure 1). While some models were used as a “proof of concept” 
to demonstrate that hPSCs can be derived from a wide range of disorders [9–11] or to show the 




were further used to obtain novel mechanistic or physiological insights regarding the disorders.  
One example is a model for Amyotrophic Lateral Sclerosis (ALS) by Kiskinis et al. [13]. 
Figure 1. Human pluripotent stem cell-based models for genetic disorders can be 
generated by different techniques. Mutated human pluripotent stem cells can be derived 
by genetic manipulation of normal pluripotent stem cells, from affected embryos 
(identified by PGD), or from adult patients (by reprogramming of somatic cells). 
 
The general differences between ESCs and induced pluripotent stem cells (iPSCs) and the 
utilization of hPSCs for disease modeling has been discussed extensively in the literature [1,14–16].  
In this review we will focus on the differences between ESC-based models and iPSC-based models, 
and discuss the effect of genome editing technologies on the field of disease modeling. 
2. ESCs vs. iPSCs in Disease Modeling 
Theoretically, a given disorder can be equally modeled by iPSCs and by ESCs, as both are 
pluripotent stem cells. However, several reasons have made iPSCs derived from patients the system 
of choice: 
(1) The use of normal human ESCs to model a genetic disorder requires genetic manipulation to 
induce the specific mutation that one would like to study. The way to obtain a mutation that will be 
identical to the natural occurring mutation, seen in patients, is by genome editing. However, the 
efficiency of genome editing in human ESCs, before the establishment of gene targeting technologies 
as discussed below, was extremely low (especially in cases where a homozygous mutation was 
required) [17] and derivation of iPSCs that already contain the specific mutation obviates the needs 
for this inefficient process. 
(2) While the above mentioned limitation can be overcome by derivation of mutant ESCs from 
affected embryos identified by Preimplantation Genetic Diagnosis (PGD), this procedure is limited 
to a small number of diseases in which PGD is normally preformed, and can be done only in labs that 
are associated with in vitro fertilization (IVF) units. 













(3) By contrast to iPSCs from affected individuals, in the case of ESCs based models, the 
correlation between the genotype and the phenotype is not obvious, and the penetrance of the 
mutation might be low as a results of specific “protective” genetic background [18]. 
(4) Lastly, in some countries the use of human ESCs is limited or banned due to ethical and  
religious concerns regarding the use of human embryos for research purposes as was discussed  
by others [19,20]. 
Nevertheless, possible drawbacks in modeling genetic disorders by iPSCs suggest that some 
disorders or specific aspects within a given disease might be better modeled in ESCs than iPSCs.  
The generation of a faithful iPSC-based model might be disrupted due to the following reasons  
(see Figure 2): (1) Incomplete reprogramming as a result of “Epigenetic memory” of the original 
somatic cells [21–23]; (2) Mutations accumulated during the reprogramming process [24] and 
deleterious effects (such as chromosomal instability, [25]) of the reprogramming process on the 
genome integrity of iPSCs; (3) Genetic aberrations that significantly decrease the reprogramming 
efficiency [26]; (4) The absence of appropriate sources of somatic cells such as in the cases of genetic 
aberration and aneuploidies that lead to very early embryonic lethality [6]. 
To demonstrate the commonalities and differences between ESC- and iPSC-based models, we 
compared models for X-linked, autosomal recessive and autosomal dominant disorders in which 
disease-related phenotypes were observed in both models (Table 1). As expected, in some cases the 
ESC-based models and the iPSC-based models were similar (spinal muscular atrophy [27,28], 
Shwachman-Dimond syndrome [29], long QT syndrome [30], and some aspects of myotonic 
dystrophy [31,32]). However, in other cases the iPSCs were limited in their capacity to model the 
disorder or specific aspects within the disorders. To demonstrate some of these cases, and to discuss 
the principles behind them, we will focus on the following disorders: Turner syndrome, Fanconi 





Figure 2. Limitations in the generation of iPSC-based disease models. The “X-axis” in 
this scheme depicts the specific stages during the formation of iPSC-based models that 
might be affected by the different factors that discussed in the main text. 
 
3. Turner Syndrome 
X chromosome monosomy (XO) is one of the most common chromosomal abnormalities, as 3%  
of all pregnancies start with XO embryos [33]. Yet, approximately 99% of the XO embryos undergo 
miscarriage during the first trimester [33,34]. The 1% that survive to term are born with Turner 
syndrome which is characterized by several phenotypes; the most common among them are growth 
failure, gonadal dysgensis and webbed neck [34]. While Turner syndrome derived iPSCs can be used 
in order to study the phenotypes of the patient (pending the availability of the required differentiation 
protocols), they might be problematic in modeling the early lethality of XO embryos, as they 
represent the exceptional 1% of the cases that survived to term. 
In agreement with this notion, gene expression analysis of XO ESCs (derived by screening for  
ESCs with normal karyotype that lost one of their X chromosomes) revealed a significant effect of  
X chromosome monosomy on the expression of placental genes and suggests that the reason for the 
early lethality is abnormal placental development [6]. By contrast, there was almost no effect of X 
chromosome monosomy on placental gene expression in iPSCs derived from Turner syndrome 
patients, and even from amniotes of a 20 weeks old embryo [35]. The results suggest that Turner 
syndrome iPSCs represent the rare cases in which the embryo survived despite the XO karyotype. 
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4. Fanconi Anemia 
Fanconi Anemia (FA) is an autosomal recessive disorder caused by a mutation in any of the 16 
FANC genes and characterized by congenital abnormalities, cancer predisposition and progressive 
bone marrow failure [44]. Initial attempts to reprogram somatic cells from FA patients into iPSCs 
failed unless using fibroblasts that were first genetically corrected [45]. These results suggested that 
the FA pathway is essential for the reprogramming pathway (probably due to defective DNA repair 
and genomic instability of FA cells) and therefore that FA can’t be easily modeled by iPSCs. 
However, further attempts to reprogram “uncorrected” somatic cells from FA patients under hypoxic 
conditions [26], and even under normoxic conditions [25], showed that iPSCs can be derived from 
FA somatic cells, albeit in a very low efficiency and revealed that “…somatic cells harboring 
mutations that render the FA pathway defective are resistant but not refractory to reprogramming” [26]. 
Nevertheless, significant chromosomal aberration in uncorrected FA-iPSCs [25], but not in FA-iPSCs 
derived from “corrected” somatic cells [26] or in human ESCs with stable knockdown of FANCC [25] 
suggests that the FA pathway is required to prevent DNA damage and chromosomal instabilities 
associated with the reprogramming process. The severe aneuploidy in the uncorrected FA-iPSCs but 
not in the ESC-based model for Fanconi anemia suggests that ESCs and not iPSCs should be used to 
study FA. Surprisingly though, it has been recently shown [41] that FA-iPSCs with a normal 
karyotype can be derived from FA somatic cells upon episomal reprogramming. Moreover, the 
FA-iPSCs were very similar to FA-ESCs that were generated by gene targeting of the FANCA gene 
using the TALEN mediated gene targeting [38]. The FA-iPSCs and the FA-ESCs were extensively 
studied and compared to isogenic control cells (the original ESCs and target corrected FA-iPSCs) 
and proved to be a very useful model for different aspects of Fanconi anemia. While the reasons for 
the differences in the chromosomal stability between the viruses mediated reprogramming and the 
integration-free episomal mediated reprogramming are still not clear, these results indicate that in 
some cases, the reprogramming method itself might have a dramatic effect on the quality of the 
iPSCs and thus, should be taken under consideration when choosing to generate a disease model by 
reprogramming of somatic cells from patients. 
5. Fragile X Syndrome 
Fragile X syndrome (FXS) is a trinucleotide repeat disorder and is the leading cause of inherited 
intellectual disability in males, affecting approximately one in every four thousand boys and one in  
eight thousand girls worldwide [46–49]. The mutation leading to the syndrome is a trinucleotide 
CGG expansion at the 5  untranslated region of the fragile X mental retardation 1 (FMR1) gene, 
which is accompanied by epigenetic changes, resulting in the silencing of the gene [49,50]. The 
product of the FMR1 gene is the fragile X mental retardation protein (FMRP) which is most abundant 
in the brain and testis and plays a major role in synaptic plasticity [51]. 
In 2007 human ESCs from FXS affected embryos (FXS-ESCs) were derived for the first time 
through PGD and enabled the study of the development of the disease [7]. Interestingly, although 
carrying the full mutation, FXS-ESCs showed both FMR1 mRNA expression and the presence of 




regulated process. Moreover, the study indicated that FMR1 is silenced in FXS embryos only during 
development and that the inactivation is initiated by chromatin modifications prior to DNA 
methylation [7]. Other studies on FXS-ESCs supported the finding that FMR1 is expressed in full 
mutation embryos and is silenced only during differentiation and further demonstrated that FMR1 
plays an important role in early stages of neurogenesis and synaptic function [52,53]. Therefore, 
FX-ESCs are invaluable to study many aspects of FXS, first and foremost the epigenetic silencing 
mechanism. However, there are also limitations in the FX-ESCs model: FXS is represented by 
profound variability in patients, ranging from the varying length of the repeats, through the 
methylation levels, and to the neurological phenotype itself. The degree of intellectual impairment 
also varies between different individuals, as only about 30% of full mutation carriers display autistic 
behavior [54,55]. Additionally, some carriers of the full mutation allele do not display any of the 
syndrome’s phenotypes [56,57]. As this variability is not inherited from the parents and is detected 
only after PGD analysis, the probability of acquiring numerous human embryonic stem cells 
displaying the entire spectrum of genetic and epigenetic differences is quite small and may take 
several years. 
In contrast to the FMR1 expression seen in FXS-ESCs, it seems that in FXS derived iPSCs  
(FXS-iPSCs), despite successful reprogramming of patients derived fibroblasts, the FMR1 gene is 
resistant to the process and remains methylated and silent [36,58,59]. Thus, while the FXS model in 
human ESCs demonstrated the temporal silencing of FMR1, in FXS-iPSCs FMR1 was already 
inactive in the undifferentiated state. This fundamental difference between FXS-ESCs and 
FXS-iPSCs controls the choice of model according to the question being asked. In order to better 
understand the different aspects of the initiating steps of the FMR1 silencing such as CGG methylation 
and the epigenetic silencing, one should use the FXS-ESC model. On the other hand, if one wishes to 
model neural development, screen for new drugs or understand the CGG expansion mechanism it is 
preferential to use the FXS-iPSC model to understand the effects of lack of FMRP on developing 
neurons, as we do not fully understand at which time point during the differentiation process FMR1 
is silenced in ESCs in vitro. One example using FX-iPSCs to model Fragile X syndrome is a study 
aimed to evaluate the reactivation of FMR1 in FXS-iPSCs and their neuronal derivatives through 
epigenetic modulation drugs. This study showed not only that reactivation is possible but also 
uncovered additional layers of epigenetic control on FMR1 [60]. 
6. Huntington’s Disease 
Huntington’s disease (HD) is an autosomal dominant neurological disorder caused by a 
trinucleotide repeat expansion and characterized by a late onset progressive neurodegeneration 
ending with death [61,62]. In HD, an expansion of a CAG repeat in the first exon of the Huntingtin 
(HTT) gene leads to a toxic gain of function activity of the mutant Huntingtin protein (mHTT), 
containing an increased number of polyglutamines at the N terminus [62]. These polyglutamine tails 
are then cleaved and accumulate as aggregates in the nuclei of neurons [63]. 
During the past few years, several groups have successfully created iPSC models for HD  
(HD-iPSCs) [11,43,64,65]. Some have further differentiated HD-iPSCs to neurons and showed 




lysosomal activity in both HD-iPSCs and derived neurons [65]. The most comprehensive work done 
with the HD-iPSCs model system was performed by the HD-iPSC Consortium, in which several 
HD-iPSC lines were created and analyzed by a group of different labs [43]. In this work, HD-iPSCs 
were also differentiated into neural stem cells (NSCs) and neurons. HD-derived NSCs showed 
differential gene expression accompanied with changes at the protein level as well. Other changes 
observed were compromised energy metabolism, inability to fire action potential and increased cell 
death. Neurons also display increased death under different stress conditions most notably in lines 
containing longer repeats. 
HD-iPSCs provide a useful model, however, it was never shown that they accumulate any 
insoluble aggregates, and thus cannot be used to study the formation and pathological contribution of 
this aggregates to the development of the disease. In order to study this aspect of the syndrome, 
normal ESCs were genetically engineered to express the polyglutamine repeats [42]. Neurons derived 
from these HD-ESCs matured over a period of several months and showed the polyglutamine 
aggregates. Similar to HD-iPSCs, HD-ESCs derived neurons exhibited progressive death under stress 
conditions. It was also shown using this model that reduction of mHTT by just 10% is sufficient to 
prevent toxicity and lowering the expression levels of HTT by up to 90% had no effect on neurons, 
opening the possibility to screen for new drugs to control the levels of mHTT. Thus, HD-ESCs may 
provide a stronger tool than HD-iPSCs in our understanding of the initiation and progression of the 
pathology of HD. However, work done on ESCs derived directly from an embryo with HD did not 
show the formation of polyglutamine aggregates [66]. Furthermore, HD embryos from PGD are not 
readily available, and due to the fact that HD is a late onset disease, we do not know the ultimate 
phenotype of these never developed embryos. In this case, more work should be done on both 
HD-ESCs and HD-iPSCs in an attempt to obtain more of the molecular phenotypes characteristic of 
the disease to create a better model system. 
7. Disease Modeling by Gene Targeting of hPSCs 
As mentioned above, hPSCs based models can be generated by the derivation of ESCs from 
affected embryos diagnosed by PGD or by genetic manipulation of normal hPSC cells. 
Down-regulation or over-expression of specific genes can be easily achieved by RNAi technologies 
(for down regulation) or by introduction of exogenous genes into the genome (for over-expression). 
While these methods proved to be very informative in some cases, they can’t mimic the natural 
occurring mutation in the patients and therefore the relevance of the finding to the disease might be 
questionable in other cases. To overcome this problem, one has to induce a specific mutation that is 
identical to the mutation occurring in patients. However, until lately, genome editing in mammalian 
cells was an extremely inefficient process [17], and therefore it was challenging to generate 
homozygous mutations in human cells using the traditional methods for gene targeting. The 
development of new technologies for gene targeting, (reviewed in details in [17]) especially the 
TALEN technology and the Cas/CRISPER technology have dramatically increased the efficiency of 
gene targeting in mammalian cells and enabled to correct specific mutations or to obtained 




These methods enable, for the first time, the comparison between isogenic cells that differ only in 
the specific mutation under investigation. This can be achieved by induction of a specific mutation in 
otherwise normal ESCs, by correction of a specific mutation in iPSCs or by combination of both 
methods [30,41] One possible drawback in these methods is the possible off-target effect that might 
result in additional unplanned genetic aberrations [17]. To overcome this possibility it is important to 
design the targeting sequence in a way that will decrease the off-target effects and to target different 
sequences of the same gene. Among these methods, the CRISPR technique will probably become the 
first choice for most labs due to the combination of accuracy, efficiency and accessibility. 
8. “Guidelines” for Choosing the Optimal Model System for a Given Disease 
The choice between modeling disorders with ESCs or iPSCs is dependent on several factors.  
We propose that the optimal model that probably overcomes most if not all the drawbacks mentioned 
above, is a model that combines both ESCs (that were genetically modified to carry a specific 
mutation) and iPSCs from patients (with an isogenic control of iPSCs from the same patient in which 
the mutation was corrected by genomic engineering). Such “combined methods” have been recently 
generated for long QT syndrome [30] and for Fanconi anemia [41]. However, as was discussed 
above, in some cases only one of the two methods is doable/informative. In Figure 3 we suggest 
general guidelines that should assist in choosing the right system for a given disorder. We generated 
this scheme based on the following assumptions: 
Figure 3. Scheme depicting the steps in choosing the appropriate system for disease 
modeling. While in some cases there is only one possible option (either ESCs or iPSCs), 
in other cases both ESCs or iPSCs can be used and the decision between the two methods 
should be done after the consideration of the advantageous and disadvantageous of each 
one of the options (some of them are described in the scheme). 
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Multifactorial disorders in which there is a major contribution to factors other than genetic factors  
on the disease etiology can be modeled exclusively by iPSCs from patients that already manifested  
the disease and can’t be modeled by ESCs. Similarly, iPSCs but not ESCs should be used to model 
multigenic disorders in which the genetic factor cannot be narrowed down into a single gene,  
(the discussion regarding the use of hPSCs to model these type of disorders is out of the scope of this 
review). Other than these two groups of disorders, “monogeneic” disorders can be modeled 
theoretically using both systems but under the following notions: (1) Genetic aberrations that lead to 
early lethality should not be modeled by iPSCs that derived from individuals that survived to term as 
they represent the exceptional cases (these rare cases however, can be used to study the effect of the 
genetic aberration on the phenotype of the exceptional embryos that survived to term and the genetic 
backgrounds that enable them to escape the early lethality); (2) Possible epigenetic memory in iPSCs 
has to be taken under consideration. While in general the epigenetic memory is considered to have a 
negative effect on iPSCs (as the pluripotent cells retain some of their previous identity of adult cells 
and therefore might not be equivalent to normal pluripotent cells), one can also utilize these 
phenomena in a positive manner. For example, in cases of hematopoietic disorders, iPSCs that were 
derived from blood cells might undergo hematopoietic differentiation in a greater efficiency than 
ESCs or iPSCs derived from other somatic cells [16]; (3) In cases in which no epigenetic effect is 
predicted, the best choice is to combine both model systems. When only one of the two systems will 
be used it is important to keep in mind the following limitations of each one of the methods: (a)  
The reprogramming process itself might results in accumulation of genetic aberrations that under 
some circumstances might affect the reliability of the model; (b) The penetrance of the mutation in the 
ESCs based model might not be completed (as a result of “protective” genetic background).  
By contrast, iPSCs are derived from patients that already manifested the phenotype and therefore one 
should not be concerned about “protective” genetic background; (c) In the case of PGD-based models 
the number of available samples (affected embryos) might be limited; (d) Gene targeting by the 
TALEN or CRISPER systems might lead to off-target effects. 
9. Conclusions 
Reprogramming of somatic cells from patients is a relatively easy procedure that doesn’t involve 
the usage of human embryos, nor ethical issues, and results in the formation of iPSCs with the naturally 
occurring mutation. Therefore, since the first derivation of human iPSCs from normal donors [67–69] 
and from patients [11], this method was considered by many to be the optimal methodology for 
disease modeling by human pluripotent cells (due to scientific reasons as well as other reasons). 
Indeed, during the last several years numerous models for genetic disorders were generated by 
reprogramming of somatic cells from patients. Yet, in many cases the mutant cell lines were not 
further analyzed to study their relevance to the actual disorders. In this review we focused on  
iPSCs based models and ESCs based models that have been shown to have a phenotype related to  
the disease. 
To demonstrate that iPSCs can’t always replace ESCs in disease modeling, we focused on  
four models, each one emphasizes a specific aspect of the differences between ESC-based models 




might result in the generation of de-novo mutations [24] that might add “noise” to the system.  
On the other hand one general advantage of iPSC-based models compared to ESCs-based models is 
the fact that the patient chosen already manifested the phenotype associated with the mutation.  
This assures that there is no effect to the specific genetic background on the penetrance of the mutation. 
Based on the comparison between ESC-based models and iPSC-based models we suggested in  
Figure 3 a general guidelines to assist in choosing the appropriate model for a given disorder. 
Lastly, the development of the “iPSCs technology” by Takahashi and Yamanaka some eight years 
ago [70], dramatically changed the entire field of pluripotent stem cells biology. While the most 
desirable application of this technology is probably for cell therapy, there is no doubt that currently 
the most common application of iPSCs is for disease modeling. In this review we highlighted some 
of the pros and cons of iPSCs compared to ESCs in regards to disease modeling and discussed the 
effect of advanced technologies for genome editing on the field. We believe that the field of disease 
modeling by hPSCs has reached a point wherein the challenge is not to derive pluripotent cells  
(ESCs or iPSCs) with a specific mutation but rather to better understand the pathophysiology of the 
disease and finding effective therapies. 
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Design of a Tumorigenicity Test for Induced Pluripotent Stem 
Cell (iPSC)-Derived Cell Products 
Shin Kawamata, Hoshimi Kanemura, Noriko Sakai, Masayo Takahashi and Masahiro J. Go 
Abstract: Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because 
of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. 
However, these features of PSC-derived cell products are associated with concerns regarding the 
generation of iatrogenic teratomas or tumors from residual immature or non-terminally differentiated 
cells in the final cell product. This concern has become a major hurdle to the introduction of this 
therapy into the clinic. Tumorigenicity testing is therefore a key preclinical safety test in 
PSC-derived cell therapy. Tumorigenicity testing becomes particularly important when autologous 
human induced Pluripotent Stem Cell (iPSC)-derived cell products with no immuno-barrier are 
considered for transplantation. There has been, however, no internationally recognized guideline 
for tumorigenicity testing of PSC-derived cell products for cell therapy. In this review, we outline 
the points to be considered in the design and execution of tumorigenicity tests, referring to the tests 
and laboratory work that we have conducted for an iPSC-derived retinal pigment epithelium (RPE) 
cell product prior to its clinical use. 
Reprinted from J. Clin. Med. Cite as: Kawamata, S.; Kanemura, H.; Sakai, N.; Takahashi, M.;  
Go, M.J. Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell 
Products. J. Clin. Med. 2015, 4, 159–171. 
1. Introduction 
Several notable clinical trials using human Pluripotent Stem Cell (PSC)-derived cell products 
have been conducted recently. In the first, Geron used embryonic stem cell (ESC)-derived 
oligodendrocyte progenitor cells (GRNOPC1) for treatment of acute spinal cord injury [1]. 
Advanced Cell Technology initiated a study in which ESC-derived retinal pigment epithelium (RPE) 
was used for treatment of Stargardt’s disease and dry type Age-related Macular Degeneration 
(AMD) [2]. More recently, a clinical study for wet type AMD using induced Pluripotent Stem Cell 
(iPSC)-derived RPE was started at Riken CDB [3–5]. 
While clinical applications are moving forward, there are concerns that transplantation of 
differentiated PSC might lead to the formation of tumors in the recipient. Thus, examination of this 
possible outcome of transplantation is critically important. Cell transplantation or infusion therapy is 
distinctly different from drug administration. One must consider that transplanted or infused cells 
can survive for long periods in the host and may form tumors at the site of transplantation or at distal 
sites. The extent of tumor formation can be influenced by the microenvironment at the 
transplantation site or the ultimate homing site of the host. Furthermore, once a tumor has formed, it 
may influence the physical condition of the host through secreted factor(s) [6]. 
The aforementioned aspects of cell therapy must be addressed with animal transplantation studies 




cells are particularly important in the case of PSC-based cell therapies. As PSC have “unlimited” 
proliferation potential as undifferentiated stem cells, they can generate teratomas if they remain in 
the final product. The chance of generating a teratoma will increase if the procedure uses an 
autologous iPSC-derived cell product that presents no immunologic barrier. PSC might accumulate 
chromosomal abnormalities by selecting cells with unusual proliferative advantages over a long 
culture period. Lund et al. reported that some 13% of ESC and iPSC maintained in research labs 
worldwide demonstrated some type of genetic abnormality [7]. For that reason, the timely 
assessment of the genetic stability of PSC is of major interest for both research labs and clinical PSC 
banks. In addition, it is important to assess the potential for differentiation resistance due to 
incomplete reprogramming or a differentiation bias due to epigenetic memory when iPSC-based 
therapy is considered. In this context, it is necessary to assess the tumor-forming potential of 
non-terminally differentiated cells as well. 
Information regarding genetic stability, gene expression, differentiation marker expression, cell 
growth rate and how cells were generated must be collected and evaluated prior to commencement of 
tumorigenicity testing. Next, it is necessary to have a clear idea about the scope and objective of  
related safety parameters: toxicology tests, Proof of Concept (POC) tests, biodistribution tests and 
tumorigenicity tests that can be conducted concurrently. 
Toxicology tests can be designed depending on the properties of testing reagents and the purpose 
of the tests. The Organisation for Economic Cooperation and Development (OECD) Guideline for 
the Testing of Chemicals [8] is an internationally recognized test guideline for toxicology testing. 
They should be conducted in a blinded fashion to minimize the bias of measurement and observation 
by operators. Short-term and long-term end points are to be defined. Toxicology tests should be 
conducted by using clinically relevant methods of administration so that they can provide insights 
into a safe range of therapeutic cell doses. Acute (early) and late phase end points should be 
established in this test. 
POC tests often employ a genetically modified animal that offers a model of the disease in 
question (e.g., Tg, KI, KO or KD mice) or injured animals to address the potential benefit or efficacy 
of the investigational therapy and to define the range of the effective dose used in clinical application 
by escalating the doses. The administration route and the method should be as close as possible to the 
intended clinical use. Positive and negative events should be clearly defined. In such a POC study, 
indices such as physiological recovery of lost function or overall survival of transplanted cells that 
could underlie intended therapeutic use are examined. Measurement of indices should be conducted 
in a blinded fashion to minimize bias during data acquisition. The size of the test group should be 
large enough to permit meaningful statistical analysis. 
Biodistribution tests should be conducted to address tumorigenic proliferation of transplanted 
cells at the ectopic site. Alu sequence PCR is commonly used to detect human cells in host tissues or 
organs. While this PCR test detects human cells over a 0.1% frequency in host tissue by DNA  
ratio [9], greater sensitivity is needed to detect small metastatic colonies. In PET technology, 
proliferative cell mass is labelled by taking in a metabolic probe such as 18F FLT, providing a 
distribution of tumorigenic cell proliferation in the animal’s body. However to trace the behavior of 




marker genes by retrovirus or lentivirus that can emit a signal with a high S/N ratio. These 
approaches are currently under development. 
2. Guidelines for Tumorigenicity Tests 
Somatic cells with a normal chromosomal structure show limited proliferation potential. 
Tumorigenicity testing of mesenchymal stem cells may not reveal a serious problem [10]. However, 
in the case of PSC-derived cell products, the tumor-forming potential should be examined 
thoroughly because of the “unlimited” proliferation capacity of PSC and their genetic instability. 
However, there is no internationally recognized guideline for tumorigenicity testing of cells used for 
cell therapy. WHO TRS 878, “Recommendation for the evaluation of animal cell cultures as 
substrates for the manufacture of cell banks” [11,12] provides a guideline for animal cell substrates 
used for the production of biological medicinal products, but not for cells used for therapeutic 
transplantation into patients. Recently, FDA/CBER commented on the issues to be considered for 
cell-based products and associated challenges for preclinical animal study [13]. The report stated that 
when tumorigenicity testing of ESC-derived cellular products is undertaken, the tumorigenicity tests 
should be designed considering the nature of cell products to be transplanted and the anatomical 
location or microenvironment of the host animal. Tumorigenic test results from the administration of 
cells through nonclinical routes are not considered relevant as they would not assess the behavior of 
transplanted cells in the intended microenvironment to which the cells would be exposed. The study 
design should include groups of animals that have received undifferentiated ESCs, serial dilutions of 
undifferentiated ESCs combined with ESC-derived final products to infer the contamination of 
undifferentiated ESCs in the final product. 
The aforementioned summarizes current discussions of tumorigenicity testing. However, we still 
need to answer a fundamental question: “How can we extrapolate animal tumorigenicity testing to 
humans?” The design of tumorigenicity tests should attempt to answer this question. For this,  
we must first estimate the risk that we will underestimate the incidence of tumor-forming events in 
humans by conducting an improper or non-informative animal study. So, how do we define such 
risk? For example, there is a risk that a study is unable to link unexpected tumor formation to genetic 
abnormalities of test cells presented before transplantation due to inadequate genetic information 
regarding test cells. In addition, there is a risk of obtaining “false” negative results by transplanting 
an insufficient dose, using an inadequate monitoring period, using an improper immunodeficient 
animal model that is insufficient to detect tumor, not transplanting into the right anatomical position, 
failure of transplantation itself or unexpected early death of transplanted cells in host tissue. We can 
address the risks by conducting quality control tests of test cells prior to transplantation and small 
scale pilot studies to determine the design of tumorigenicity tests. The following points should be 
considered in designing tumorigenicity tests. 
1. The history of cell production (cultured in a research lab or Good Manufacturing Practice 
(GMP) grade cell processing facility). 
2. Quality control records of test cells (e.g., phenotype, gene expression, sterility tests, genetic 




3. The type of immunodeficient animal model used and the route of administration (clinical 
route or subcutaneous route). 
4. The method of transplantation (e.g., embedded with Matrigel or in sheets or in cell 
suspension). 
5. Gender and number of animals to be used. 
6. Information about the microenvironment at the transplanting site. 
7. Dose of cells to be transplanted. 
8. Selection of a positive control cell and definition of positive tumor-forming event. 
9. Monitoring periods. 
10. Protocol for immunohistochemistry (IHC) to detect transplanted cells in host tissue. 
11. Method to detect ectopic tumor formation. 
3. Specification of Test Cells 
Cells used in tumorigenic tests should be generated in a manner as close as possible to that 
intended for clinical use. In this context, it is preferable that cells used for all preclinical tests should 
be generated in a GMP-grade cell processing facility for clinical use. This approach would minimize 
bias originating from differences in cell production quality. Several types of data, including gene 
expression profiles obtained from gene chips or qRT-PCR to assess stem cell-like markers and 
differentiation markers, phenotypic analysis by flow cytometry, sterility tests, mycoplasma tests, 
exome sequencing, chromosomal stability tests with comparative genomic hybridization (CGH) 
array and karyotyping by multi-color banding (mBAND) or fluorescent in situ hybridization (FISH) 
would be valuable. For iPSC-derived cell products, EB formation assays would provide insights into 
differentiation potential. The results could be used to select “good” clones that demonstrate no 
differentiation bias or no differentiation resistance. These quality control tests and cell characterization 
tests are not a part of tumorigenicity testing per se. However, the information on starting material 
should be linked to the results of tumorigenicity testing to render the test results more informative. 
In tumorigenicity testing of PSC-derived cell products, one can anticipate several tumor-forming 
events that include teratoma formation from residual “differentiation-resistant” PSC with normal 
karyotype, cancer-like progressive tumor formation from cells with abnormal karyotype or acquired 
genetic variation during culture and tumors with differentiation bias generated from imperfectly 
reprogrammed cells. To understand the nature of tumor-forming events, the link with results of these 
quality control tests is indispensable. 
4. Selection of an Animal Model 
In general, if one were to use “non-immunodeficient” healthy animals or “non-immunodeficient” 
disease model animals for tumorigenicity testing, one would have to administer a large amount of 
immunosuppressant for long-term monitoring. However, this approach will not always guarantee 
satisfactory engraftment of xeno-transplants. Primates can be used for tumorigenicity testing as 
models representative of humans, but this model is more useful for POC tests, not for tumorigenicity 




human cells (final product) are to be used in the test. Large immunodeficient animals like the SCID 
pig [14] are also available. However, again, the SCID pig model would be useful to address 
transplantation efficiency of human cells, such as xeno-bone marrow transplantation of human 
hematopoietic stem cells as a part of a POC study in large animals. They are not cost-effective large 
scale statistical studies. To conduct tumorigenicity tests with a sufficient number of immunodeficient 
animals, a rodent model is a reasonable option for the preparation of test cells. Immunodeficient mice 
such as nude mice (BALB/cA, JCl-nu/nu), SCID mice (C.B-17/Icr-scid/scid), NOD-SCID mice 
(NOD/ShiJic-scid) and NOG mice (NOD/ShiJic-scid, IL-2R  KO) have been widely used for human 
cell transplantation studies. Prior to the design of tumorigenicity tests, one needs to evaluate the 
tumor-generating potential of these immunodeficient mouse strains by transplanting various dose of 
tumorigenic cell lines subcutaneously. 
Another well-known transplantation site in rodents is beneath the testicular capsule space. This 
transplantation model is mainly used to test for satisfactory engraftment of test cells for POC tests, 
not for tumorigenicity tests. In our hands, it requires elaborate surgical skills and needs at least 104 
iPSCs to generate tumors in NOG mice. In addition, tumor formation in the intraperitoneal space is 
hard to detect from the appearance of mice, thereby preventing statistical studies for tumor-forming 
events in a timely manner. In our case, the tumorigenic potential of immunodeficient mice was 
assessed by transplanting various doses of HeLa cells subcutaneously, following recommended 
procedure stated in WHO TRS 878 [11,12]. The mice were monitored over 12 months, and the 
TPD50 (minimum dose that can generate a tumor in 50% of transplanted mice) was calculated by the 
Trimmed Spearman-Karber method for each strain [9]. HeLa cells were used as a representative line 
of somatic tumorigenic cells with a genetic abnormality. For transplantation, a collagen-based gel 
lacking nutrients is sometime used to embed cells and to retain them at the designated transplantation 
site. Importantly, the gel per se does not support growth of the transplanted cells at the site. We have 
used Matrigel® (BD Biosciences, San Jose, CA, USA) to embed cells and to increase their 
tumor-forming potential [15]. We obtained the following values for the TPD50 for HeLa cells with 
Matrigel® via a subcutaneous route: Nude, 103.5 (n = 120); SCID, 102.5 (n = 24); NOD-SCID, 102.17  
(n = 24); NOG, 101.1 (n = 75). It is notable that during the course of experiments covering 9 months of 
observation, we also observed spontaneous thymomas with a frequency of some 14% in NOD-SCID 
mice in agreement with previous reports [16], which makes interpretation of tumorigenicity tests 
with NOD-SCID mice complicated. 
Based on the preceding data, we chose NOG mice for subcutaneous tumorigenicity testing of  
iPSC-derived RPE, assuming that NOG mice could generate tumors from the lowest number of 
residual PSC or tumorigenic non-terminally differentiated PSC-derived cells. We then subcutaneously 
transplanted various doses of iPSC (201B7, Riken CDB) with Matrigel® into NOG mice to determine 
TPD50 for iPSC. The TPD50 value for iPSC (201B7) via the subcutaneous route was 102.12 (n = 20) 
over 84 weeks of observation [9] (Figure 1). Tumorigenicity tests via a subcutaneous route with 
NOG mice is a sensitive quality control test to detect a small number of remaining PSC in 
PSC-derived investigational product regardless of cell type. Of course, the TPD50 for iPSC 
transplanted via a clinical route can be checked independently. In our case, we used nude rats for 




transplanting cells via a clinical route requires outstanding technique by a skilled operator. Thus,  
we needed larger animals to avoid “false” negative results due to failure of transplantation, to 
transplant a clinically relevant dose of GMP-grade iPSC-derived RPE (without Matrigel) and to 
confirm that the transplantation of brown colored RPE was in the right position in the albino eye ball 
of nude rats [9]. We did not use any “AMD” disease model animals [17,18] because they will not 
recapitulate all the features of human AMD. In human AMD, the macular region is focally affected 
and the rest of the retinal area is intact. Treatment of human wet-type AMD with an iPSC-derived 
RPE sheet is conducted by transplanting the RPE sheet into the affected lesion after removal of 
choroidal neovascularization. Thus, we assumed that a transplanted RPE sheet would receive a 
trans-effect from the intact retina. For that reason, we transplanted the RPE sheets into nude rats 
with intact retinal function rather the recapitulate the microenvironment of the clinical setting. 
Thus, the choice of animal should be made depending on the degree of immunodeficiency, 
anatomical demands and planned clinical manipulation. The TPD50 value for iPSC or HeLa cells via 
the clinical route was 104.74 (n = 26) or 101.32 (n = 37) respectively (Figure 2). The large discrepancy 
between the TPD50 values for iPSC and that of HeLa prompted us to examine the effect of the 
microenvironment on iPSC-derived products to better design tumorigenicity tests via the clinical 
route (see below). 
 
Figure 1. Subcutaneous tumorigenicity test with NOG mice. A table in above showed 
type of cells used as a positive control for tumorigenicity test (iPSC cell line 201B7 and 
tumor cell line HeLa), minimum dose for tumor formation and Log10 TPD50 for them 
when transplanted subcutaneously with  Matrigel®. A line graph showed value for 
Log10 TPD50 for iPSC or HeLa at respective monitoring point (0–55 weeks). Photos 
(clock-wise); NOG mouse with tumor, teraoma from NOG mouse, Slice section of 
teratoma after HE staining; cartilage (mesoderm), intestinal tissue-like (endoderm) or 





Figure 2. Tumorigenicity test via clinical route with Nude rats. A table in above 
showed type of cells used as a positive control for tumorigenicity test (iPSC cell line 
201B7 and tumor cell line HeLa), minimum dose for tumor formation and Log10 TPD50 
for them when transplanted via clinical route. A line graph showed value for Log10 
TPD50 for iPSC or HeLa at respective monitoring point (0–55 or 64 weeks).  Photos 
(left from top to bottom); NC: non-transplanted control, iPSC: iPSC transplanted 
mouse. iPSC-transplanted (iPSC) or non-treated control (NC) eye ball. HE staining of 
slice section of iPSC-transplanted eye ball. Photos (right top to bottom) histology of 
teratoma formed; cartilage (mesoderm), intestinal tissue-like (endoderm) or neuron-like 
(ectoderm) tissue. 
Another option to address the tumorigenic potential of autologous iPSC-derived products is to 
transplant rodent cells into a rodent with same genetic background to evade immune rejection 
associated with xeno-transplantation. Of course, it will be necessary to accumulate sufficient data to 
demonstrate that rodent cells used in this test are equivalent to human investigational cell products 
before starting the test. 
5. Administration Route and Microenvironment at the Transplantation Site 
The administration route should mimic the clinical route as closely as possible to address the 
tumorigenic potential of investigational cells in the context of the microenvironment at the 




including trans-effects from the microenvironment on investigational cells should be assessed prior 
to the commencement of large scale tumorigenicity testing. In the event of teratoma formation by 
residual undifferentiated PSCs, trans-effects of host tissue on PSC should be examined. Towards this 
end, we have established an in vitro co-culture system by placing PSC in culture inserts and culturing 
host or human primary tissue on the bottom of the dish. When iPSCs in culture inserts were 
co-cultured with cardiomyocytes or neural cells in the bottom of the dish, the growth of iPSC was not 
affected, but when they were co-cultured with RPE, the number of iPSCs was reduced drastically [19]. 
We found that RPE secreted Pigment Epithelium-derived Factor (PEDF). Addition of anti-PEDF 
antibody into the co-culture system blocked the reduction of iPSC cell number. Further addition of 
recombinant human PEDF (hrPEDF) induced apoptotic cell death and dramatically reduced ESC and 
iPSC cell number. hrPEDF did not show any reduction in the number of HeLa cells. Indeed, the 
TPD50 for iPSC was 104.75 when transplanting into the subretinal space (clinical route), while that 
for HeLa was 101.32. That means that approximately 20 HeLa cells could generate a tumor in the 
subretinal space in half of the rats transplanted, but more than 5 × 104 iPSCs were required to 
generate teratomas in the subretinal space in half of the rats transplanted. As we transplanted  
0.8–1.5 × 104 iPSC-derived RPE cells in sheets via the clinical route in tumorigenicity tests, it is 
unlikely that we could observe teratomas from tumorigenicity tests via the clinical route. Further 
tests, such as transplanting serial dilutions of iPSC in the final product in the subretinal space would 
not be informative and cannot be justified if tried. However, tumorigenicity tests via the clinical 
route could be useful to address the tumorigenic potential of non-terminally differentiated 
tumorigenic cells in iPSC-derived RPE products. This test would be sensitive enough to detect 
tumors in half the rats transplanted with 20 HeLa cells. We conducted this test for this reason and 
observed no tumor-forming event (n = 36) during a 10–20 months monitoring period. The lack of 
tumor-forming events was eventually confirmed by IHC of transplanted cells in host tissue section. 
We point out that the risk of teratoma formation by a small number of residual iPSC in  
iPSC-derived RPE in a clinical setting should be thoroughly addressed especially for autologous cell 
transplantation. Towards this end, subcutaneous tumorigenicity tests are being conducted 
concurrently with NOG mice wherein we transplant 1 × 106 cells embedded in Matrigel. This test is 
sensitive enough to detect as few as 10 iPSCs [8]. We have conducted this test with 71 animals that 
were monitored for 9 to 21 months and obtained negative result after examination of tissue sections 
by IHC. 
In addition, we reported a highly sensitive residual hiPSC detection method based upon qRT-PCR 
using primers for the LIN28A transcript [20] in hiPSC-derived RPE. This method enabled us to detect 
residual hiPSCs down to 0.002% of differentiated RPE cells. These assays were effective quality 
control tests and test cells with negative results with this qRT-PCR test could be used for 
tumorigenicity testing and therapy. We conclude that even if a few (less than 10) autologous iPSCs 
are present in an iPSC-derived cell product, the chance of developing a teratoma is negligible when 





6. Monitoring Period 
We subcutaneously transplanted various doses of HeLa cells with or without Matrigel® into Nude, 
SCID, NDO-SCID and NOG mice and into the subretinal space of nude rats. We also subcutaneously 
transplanted various doses of iPSC with or without Matrigel® into NOG mice or into the subretinal 
space of NOG mice. As HeLa cells and iPSC can generate tumors in NOG mice with a relatively 
small number of cells, a long observation period can be required so that a tumorigenic event 
originating from a small number of transplanted cells is not overlooked. Ten HeLa cells needed  
18 weeks and 10 iPSCs needed 40 weeks to generate tumors in NOG mice in the longest cases.  
Ten HeLa cells needed 33 weeks and 1 × 104 iPSCs required 33 weeks to generate tumors in the 
subretinal space of nude rats in the most protracted cases. Overall, it is recommended that the 
immunodeficient rodents be monitored up to 12 months so that a tumor formation event is not missed 
and to conduct satisfactory statistical analyses. 
7. Detection of Transplanted Cells 
Tumor formation by transplanted human cells can be detected regardless of cell type (teratoma or 
tumor) by staining tissue sections of the transplant site in host animal with human-specific antibody 
and Ki67. Nuclear staining with DAPI or Hoechst will not demonstrate that the cells in the tissue 
section were viable at the time of sacrifice, but sharp margins of the nuclear membrane will suggest 
that cells were alive and free from autophagy or necrotic events. Human-specific antibodies such as 
STEM121 (StemCells, AB-121-U-050), Lamin A + C (Abcam, AB108595), and HNA clone 3E1.3 
Millipore MAB4383) can be used to identify human cells in host tissue. In situ hybridization with a 
species-specific (human, mouse, rat, etc.) probe may generate clear signals, but it may require 
elaborate sample preparation steps when a paraffin section is used. Tumor-forming cells with 
proliferation potentials were clearly distinguished by positive staining with Ki67 (MIB-1, Dako 
M7240) [9]. Further staining of human cells with antibodies specific for human differentiation 
markers will clearly identify the transplanted human cells. 
8. Dose, Number and Sex of Immune Deficient Animals 
The dose used in tumorigenicity tests should be determined in the context of the intended clinical 
use. In general, toxicology tests or POC tests require an escalation of doses to define the safety 
margin or the effective therapeutic margin. However, this may not be the case with tumorigenicity 
tests as they aim to address the tumorigenic potential of the maximum dose of the cell product that 
will be used in therapy. Considering the body size of the animal and anatomical space of the 
receptive transplant site in the animal, a relevant dose should be administered via the clinically route. 
In our case, we transplanted 0.8–1.5 × 104 iPSC-derived RPE cells into the subretinal space of nude 
rats and 1 × 106 iPSC-derived RPE cells with Matrigel® subcutaneously, based on the fact that  
we intended to transplant 4–8 × 104 iPSC-derived RPE in the clinic. We transplanted a maximum  





The number of rodents in each group should be more than 6 for statistical analysis to obtain 
significant results using the Clopper-Pearson method. If the cell therapy focuses on a single gender, 
the sex of mice should be matched in the tumorigenicity test. If not, female mice should be chosen to 
conduct the tests as stated in WHO TRS 878. Male mice attack cage mates, which leads to a 
reduction of animal number during long-term monitoring. 
9. Conclusions 
It is important to design animal tumorigenicity tests so that they do not underestimate the 
frequency of tumorigenic events in a clinical setting, based on risk assessment of the respective 
test. In this review, we have highlighted points to be considered by emphasizing the possible risks 
and the countermeasures we have taken against them. It is important to gather genetic information 
from the PSC-derived cell product by CGH array, mBAND and FISH analysis in a timely manner. 
We need to evaluate the effect of the microenvironment on test cells at the transplant site and the 
tumor-forming potential of test animals via both the clinical route and via the subcutaneous route. 
The latter would serve as a sensitive quality control test. This analysis must be mindful of the 
required dose, type and duration of monitoring and application of an effective IHC method to 
detect and evaluate the transplanted cells. Conducting pilot studies will help to obtain some of the 
information and design informative pivotal tests. Clinical researchers need to fully understand the 
scope and limit of each preclinical test to predict adverse events in the clinic. 
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Concise Review: Methods and Cell Types Used to Generate 
Down Syndrome Induced Pluripotent Stem Cells 
Youssef Hibaoui and Anis Feki 
Abstract: Down syndrome (DS, trisomy 21), is the most common viable chromosomal disorder, with 
an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment and 
several other developmental abnormalities, for the majority of which the pathogenetic mechanisms 
remain unknown. Several models have been used to investigate the mechanisms by which the extra 
copy of chromosome 21 leads to the DS phenotype. In the last five years, several laboratories have 
been successful in reprogramming patient cells carrying the trisomy 21 anomaly into induced 
pluripotent stem cells, i.e., T21-iPSCs. In this review, we summarize the different T21-iPSCs that 
have been generated with a particular interest in the technical procedures and the somatic cell types 
used for the reprogramming. 
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1. Introduction 
Down syndrome (DS), caused by a trisomy of chromosome 21 (HSA21), is the most common 
genetic developmental disorder, with an incidence of 1 in 800 live births. DS individuals show 
cognitive impairment, learning and memory deficits, arrest of neurogenesis and synaptogenesis, and 
early onset of Alzheimer’s disease [1,2]. They are also at greater risk of developing acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The incidence of ALL, the most 
common leukemia in childhood, is approximately 20-fold higher in children with DS than in the 
general population. The incidence of AML is between 46- to 83-fold higher, with a particular 
susceptibility to acute megakaryoblastic leukemia [3]. The detailed pathogenetic mechanisms by 
which the extra copy of HSA21 leads to the DS phenotype remain unknown. However, there is 
evidence that several regions exist on HSA21 with various “dosage sensitive” genes contributing to a 
given phenotype, which could also be modified by other genes on HSA21 and in the rest of the  
genome [4,5]. 
Several models have been used to recapitulate the DS phenotype, such as mouse models [6]. 
However, they do not accurately recapitulate the specificities of the human phenotype. A new 
finding indicating that induced pluripotent stem cells (iPSCs) can be reprogrammed through the 
introduction of a few factors [7,8] has opened a new avenue for the investigation of neurological 
diseases (reviewed in [9]). The first application of this technology appeared only one year after the 
release of these articles, with the derivation of iPSC lines from patients affected by several diseases 
including trisomy 21 [10]. Since that research paper, a dozen other studies reporting the generation of 




summarize the T21-iPSCs that have been reported up to now with a particular focus on the origin of 
the somatic cells and the procedures used for the reprogramming. 
2. Procedures Used for the Reprogramming of T21-iPSCs 
Direct reprogramming into iPSCs involves the ectopic introduction of a set of core 
pluripotency-related transcription factors in a somatic cell. In the vast majority of iPSC studies, OCT4 
(also known as POU5F1), SOX2, KLF4 and MYC (also known as c-MYC) are used for the 
reprogramming into pluripotency as in the original study by Yamanaka’s team [7]. In addition to this 
so-called OSKM cocktail, Thomson and colleagues also proposed another reprogramming cocktail 
that comprises OCT4 and SOX2 but NANOG and LIN28 instead of KLF4 and c-MYC: the so-called 
OSNL cocktail [8]. When this process is successful, compacted colonies appeared in the culture dish 
that showed marked similarities to embryonic stem cells (ESCs) with respect to morphology, growth 
properties, expression of pluripotency factors, self-renewal and developmental potential [7,8,11]. The 
current published T21-iPSC lines have been all generated with the OSKM cocktail, except for one 
study where T21-iPSCs were derived with the OSNL cocktail [12]. Thus, these T21-iPSC lines were 
derived predominantly through integrative delivery systems and, to a lesser extent, through 
non-integrative delivery systems (Table 1). 
Table 1. The different T21-iPSCs reprogrammed. 
Type and Age of Donor Cells 
Reprogramming 
Method 





Fibroblasts from patients  
(1 year, 1 month) with 
unrelated controls 
Retrovirus with OSKM 
The first  
T21-iPSCs generated 
 [10] 
Fibroblasts from a DS patient  
(1 year) with unrelated controls 
Retrovirus with OSKM  
Neurons and AD 
associated phenotype 
[10,13,14] 
Skin fibroblasts from DS 
patients (childs) with no control 
Lentivirus with OSKM 
T21-iPSCs with different 
karyotypes for DS 
 [15] 
Amniotic fluid cells  
(second trimester) with age 
match control 
Lentivirus with OSKM  
Reduced number  
of neurons 
[16] 
Fibroblasts from DS individuals Retrovirus with OSKM Isogenic iPSCs Myeloid Leukemia [10,17] 
Neonatal fibroblasts  
Fetal stromal cells  
Fetal mononuclear cells 
Doxycycline-induced 
Lentivirus with OSKM, 
Retrovirus with OSKM 
 Myeloid Leukemia [18] 
Fibroblasts from DS individuals Lentivirus with OSNL 









Table 1. Cont. 
Type and Age of Donor Cells 
Reprogramming 
Method 





Fibroblasts from  
unrelated patients and  
controls Fibroblasts from a 
mosaic DS patient. 
Episomal vectors  
with OSK or OSNLM 
Non integrating  





Fibroblasts from unrelated 
patients and controls  
Fibroblasts from a  
mosaic DS patient 
Retrovirus with OSKM 
Sendai virus with OSKM 
Isogenic iPSCs Neuron deficit [20] 
Fibroblasts from a DS  
patient (1 year) 
Retrovirus with OSKM 
Sendai virus with OSKM 





Fetal skin fibroblasts from 
monozygotic twins discordant 
for trisomy 21 
Lentivirus with OSKM 
Monozygotic twins 
discordant for trisomy 21 
Neurogenesis, 
gliogenic shift, 
rescue of the 
phenotype 
[22–24] 






DS: Down syndrome; iPSCs: induced pluripotent stem cells; reprogramming cocktails: O for OCT4, S for 
SOX2, K for KLF4, M for c-MYC, N for NANOG, L for LIN28. 
2.1. Integrative Procedures Used for the Derivation of T21-iPSCs 
The first T21-iPSC lines were generated with the OSKM cocktail using the Maloney murine 
leukemia virus (MMLV)-derived retroviruses pMXs [10]. MMLV-derived retroviruses have been 
used in more than half of the studies reporting the generation of T21-iPSCs (Table 1). In this respect, 
MMLV-derived retroviruses allow the delivery of genes into the genomes of dividing cells, and  
the efficiency of iPSC generation from human fibroblasts using MMLV-derived retroviruses is 
approximately 0.01%. 
Lentiviral vectors have also been successfully used to reprogram T21-iPSCs (Table 1). They are 
generally derived from HIV. They exhibit higher infection efficiency than MMLV-derived 
retroviruses and allow the delivery of genes into the genome of dividing and non-dividing cells.  
The efficiency of iPSC generation from human fibroblasts using lentiviral vectors is comparable to 
those of MMLV-derived retroviruses (~0.01%). However, compared to MMLV-derived retroviruses, 
lentiviruses are less repressed in human pluripotent stem cells (hPSCs) [26]. In this respect, a major 
improvement has been seen in the method with the development of single polycistronic vectors 
containing all the reprogramming factors, which reduce multiple transgene insertion into the  
genome [27]. Moreover, in one study, T21-iPSCs were derived through doxycycline-induced 
lentiviral vectors with an OSKM cocktail [18]. The main advantage of this method is that it allows 
greater control over transgene expression; compared with constitutive lentivirus, in which the vector 
is integrated and then may or may not be silenced, the doxycycline-induced lentivirus is integrated 




introduction of lentiviral vectors that incorporate loxP sites allowing their excision via Cre 
recombinase when pluripotency is achieved [28]. However, viral elements flanking the loxP sites 
still remain after excision. 
The use of integrating vectors offers a more efficient means of reprogramming but also raises 
major drawbacks with the risk of (i) genetic and epigenetic aberrations; (ii) overexpression of 
potentially tumorigenic genes such as c-MYC; and (iii) incomplete silencing of reprogramming 
factors following differentiation. Also, the use of integrative approaches has been associated with 
genomic instability of the generated iPSCs. Genomic instability in iPSCs could come from various 
sources, which means karyotype analysis is one of the first verifications that has to be done when 
establishing an iPSC-based disease model. Mutations can originate from the parental somatic cells 
from which the iPSCs are derived or can be generated during the reprogramming process [29]. 
However, this is still debated, as growing evidence supports a similar frequency of genetic 
aberrations in iPSCs, independently of the reprogramming method (integrative or non-integrative) or 
the cell type used for the reprogramming [29–33]. Alternatively, it could be acquired after culture 
adaptation and passaging over time [34,35]. For example, mechanical passaging appears to produce 
more stable cells with a normal karyotype than enzymatic harvesting methods [36–38]. This genomic 
instability is not restricted to long-term culture, but can appear very rapidly, within five passages 
after switching human ESCs to enzymatic dissociation [39]. 
Another major concern of integrative delivery systems is related to a possible transgene 
reactivation that could lead to the overexpression of potentially tumorigenic genes such as c-MYC or 
KLF4. For instance, the presence of c-MYC is a major limitation, as chimeras derived from iPSCs 
frequently develop tumours due to the reactivation of c-MYC [40,41]. Therefore, transgene silencing 
has to be investigated after initial expansion of a few passages of the newly generated  
iPSCs. Moreover, early reports have proposed that residual transgene expression (of c-MYC or KLF4 
in particular), after using integrating viral approaches may affect pluripotency and differentiation 
states [8,11]. It is important to note, however, that reprogramming approaches that exclude c-MYC  
are more labor-intensive and less efficient. In fact, c-MYC is an important inducer of  
reprogramming [42–45], activating pluripotent genes and maintaining the pluripotent state of  
PSCs [46–48]. It is considered the driver of the first transcriptional wave during cellular 
reprogramming into iPSCs [49]. This could explain, at least in part, why the vast majority of the 
reported iPSC lines are achieved using c-MYC. Of note, other potential contributors of 
tumorigenicity of iPSCs have been reported; in particular, we highlighted the crucial role of NANOG 
during reprogramming into iPSCs with respect to germ cell tumor formation [50]. 
Regarding the impact of these methods on the differentiation potential of iPSC lines, Hu et al. 
reported variable potency of iPSCs to differentiate into neural cells independently of the set of 
reprogramming transgenes used to derive iPSCs as well as the presence or absence of the 
reprogramming transgenes in the generated iPSCs [51]. In line with this, in a study comparing the 
differentiation potential of iPSC lines derived from a single parental fibroblast line via several 
reprogramming strategies (+/  c-MYC, excised or non-excised transgene), neither the presence of  
c-MYC nor the presence of the transgene removed the in vitro potential of these iPSCs to differentiate 




that omission in iPSCs of reprogramming factors, and of c-MYC in particular, compromises the 
efficiency of their subsequent differentiation into neuroprogenitor cells and neurons [53]. 
2.2. Non-Integrative Procedures Used for the Derivation of T21-iPSCs 
Two non-integrative approaches have been used for the generation of T21-iPSCs: episomal  
vectors [19] and Sendai virus vectors [20]. Briggs et al. reported the first generation of T21-iPSCs 
free of vectors and transgenes [19]. This reprogramming was achieved by transfection with 
oriP/Epstein-Barr nuclear antigen-1 (oriP/EBNA1)-based episomal vectors [54]. These plasmids can 
be transfected without the need for viral delivery and can be removed from cells by culturing in the 
absence of selection. In other terms, the exogenous DNA is not integrated into the iPSC genome. 
However, the reprogramming efficiency of this approach for human fibroblasts is extremely low, 
~0.0006% [54]. 
An alternative non-integrative method has been used for the generation of T21-iPSCs by the mean 
of Sendai virus [20]. Sendai virus, a member of the Paramyxovirus family is an enveloped virus with 
a nonsegmented negative-strand RNA genome. Modified Sendai virus (through the deletion in one of 
the two envelope glycoproteins) has emerged as an efficient and robust RNA-based gene delivery 
system. Since Sendai virus RNA replication occurs in cytoplasm of the infected cells without a DNA 
phase, there is no risk of vector genome integration into host genome [55]. Thus, the efficiency 
reached by this method is much higher than that achieved with episomal vectors for the 
reprogramming of human fibroblasts to iPSCs: ~1% [55]. 
3. Age and Type of the Donor Cells Used for the Reprogramming 
Reprogramming into iPSCs requires the delivery of pluripotency factors into a somatic cell. This 
is achieved with different efficiencies and kinetics depending on the donor cell type. Therefore, the 
choice of the type of the donor cells is an important aspect to consider before the generation of  
disease-specific iPSCs. As for 80% of the studies reporting the derivation of human iPSCs, 
fibroblasts remain the cell type the most commonly used for the derivation of T21-iPSCs (Table 1). 
There are many reasons for this. Even though dermal fibroblasts are obtained from skin biopsies or 
neonatal foreskin biopsies, which require invasive procedures, they present several advantages. First, 
the culture of fibroblasts is relatively easy and cheap. In culture, fibroblasts also exhibit a high 
proliferation rate, viability and stability (at least in low passages, as the risk of accumulated genomic 
alteration increases with passaging). Moreover, the discovery of iPSC technology has been done 
initially in mouse fibroblasts [56] and subsequently adapted in human fibroblasts [7,8]. Then, most 
of the data available on the relative kinetics and efficiencies of the different methods used for the 
reprogramming have been characterized using fibroblasts as donor’s cells (reviewed in [57]). In line 
with this, most of the iPSCs banked have been generated with fibroblasts as a starting material. All 
these considerations make fibroblasts as the main cell type used for the reprogramming in general as 
well as in DS research. However, other cell type has been used for the generation of T21-iPSCs such 
as cells from amniotic fluids which are more easily obtained and reprogrammed into iPSCs [16]. 




screening. Also, compared with fibroblasts, cells from amniotic fluids transduced with OSKM 
exhibited higher efficiency (100 times more) and are reprogrammed into pluripotency more  
than twofold faster [58]. This makes cells from amniotic fluids as easy to reprogram as  
keratinocytes [59]. Similarly, fetal stromal cells and mononuclear cells have been used for the 
generation of T21-iPSCs [18]. 
During the reprogramming process, the epigenetic state of the donor’s cells has to be reset to  
obtain a pluripotent state; this includes modification of the DNA methylation profile, and chromatine 
marks [60,61]. However, genome wide DNA methylation studies showed that iPSCs retain the DNA 
methylation signature of the donor’s cells [60,62]. This so-called “epigenetic memory” consists of 
residual specific marks of the parental somatic cells that escape the reprogramming process, leading 
to a preferential differentiation potential of the generated iPSCs into the tissue of origin rather than  
other lineages [60,61]. For instance, iPSCs derived from cord blood display a higher capacity for 
hematopoietic differentiation than iPSCs derived from keratinocyte, and reciprocally [60]. However,  
it is important to note that studies investigating donor epigenetic memory of iPSCs have confounded 
the donor’s cell type and the donor genetic background due to the practical difficulty of collecting 
various primary tissues from the same donor. Also, it has been reported that donor epigenetic 
memory appears to be gradually lost after prolonged iPSC culture [60,62,63], which supports the 
idea that the preferential differentiation potential due to epigenetic memory can be overcome. 
Moreover, there are some indications that non-coding RNAs such as miRNAs play a role in 
maintaining residual memory of donor cells in iPSC-derived cells [64,65]. For instance, miR-155 
have been identified as a key player in somatic donor memory of iPSCs in the context of iPSC 
differentiation toward hematopoietic progenitors [64]. 
Another important factor that should be considered when deriving disease specific iPSCs is the 
age of the donor’s cells. T21-iPSCs have been generated from DS tissue from fetal, neonatal and 
adult stages (Table 1). In this respect, embryonic tissue appears to be more prone to reprogramming 
into pluripotency than adult tissue. Barriers such as the age and the differentiation status of the 
donor’s cells could explain this property [66–68]. For instance, it has been shown that the increased 
levels of the age-related genes p16 (INK4A), p19 (ARF) and p15 (INK4B), which encodes two tumor 
suppressors, limit the efficiency and the fidelity of the reprogramming [67]. Also, the differentiation 
stage of the starting cell used for the reprogramming has a critical impact on the efficiency of 
reprogramming into iPSCs. Blood progenitors reprogram into iPSCs up to 300 times more efficiently 
than terminally differentiated blood cells [68]. Similarly, neural progenitor cells which express  
SOX2 endogenously have only been successfully reprogrammed into iPSCs with OCT4 [69]. 
Considering that donor cell type and age may affect the differentiation potential of the iPSCs, it is 
crucial to establish D21-iPSCs and T21-iPSCs from the same parental somatic cells at the same 
developmental age. 
4. Isogenic D21-iPSCs and T21-iPSCs 
Among the potential variables that must be considered when establishing an hPSC-based disease 
model, the definition of a non-disease control is of crucial importance [70,71]. The genetic 




the differences observed in the studies are due only to the disease and not to the choice of either the 
control or the affected samples. Traditionally, iPSCs from unrelated healthy individuals together 
with ones from age-matched, unrelated affected patients are often used to decrease the variability of 
individual genetic background and the variability among the iPSC lines regarding their in vitro 
differentiation potential. To overcome these problems, several approaches have been developed to 
obtain isogenic D21-iPSCs and T21-iPSCs. This is particularly important as isogenic D21-iPSCs and 
T21-iPSCs represent an ideal situation for the investigation of the effect of the supernumerary 
HSA21 on the DS phenotype, since the rest of the genome is theoretically identical. It could also 
limit the need to generate several iPSC lines. 
Chromosomal aberrations have been often observed after culture adaptation over time in  
hPSCs [34]. In particular, stable genomic aberrations that confer growth, self-renewal, and 
differentiation advantages for hPSCs are often selected over time [29,34,72]. In the study by 
MacLean et al., one clone of T21-iPSCs lost one copy of HSA21 with culture passages leading to a 
mixed culture of isogenic D21-iPSCs and T21-iPSCs. Then, they succeeded in isolating isogenic  
D21-iPSCs and T21-iPSCs from this mixed culture by cultivating them as single cells and 
discriminating D21-iPSCs from T21-iPSCs by FISH analysis (Figure 1A) [17]. This event seemed to 
occur also for one clone of T21-iPSCs generated by Chen et al. [25]. 
In another study, Li et al. succeeded in deriving isogenic D21-iPSCs from T21-iPSCs.  
For this, they used an adeno-associated virus to introduce a TKNEO transgene into one copy of 
HSA21 of T21-iPSCs. When the T21-iPSCs were grown in a medium that selected against TKNEO, 
the only cells that survived were the ones that spontaneously lost the extra HSA21 (Figure 1B) [12]. 
In an elegant study, Lawrence et al. have shown that the extra copy of HSA21 in  
T21-iPSCs can be silenced through the insertion of the RNA gene called XIST, a gene responsible for 
the silencing of one of the two X-chromosomes in female cells. Interestingly, they demonstrated that 
the insertion of XIST gene at a specified location in the HSA21 using zinc finger nuclease technology 
effectively repressed genes across the supernumerary HSA21 in T21-iPSCs, leading to the 
generation of isogenic D21-iPSCs and T21-iPSCs (Figure 1B) [21]. 
It is well known that varying degrees of mosaicism for trisomy 21 may exist in the generation 
population; it represents 1%–3% of DS cases [73]. This leads to a combination of euploid cells and 
cells carrying trisomy 21 anomaly within individual tissues (reviewed in [74]). Taking advantage of 
this rare situation, two recent studies reported the derivation of isogenic D21-iPSCs and T21-iPSCs 





Figure 1. Isogenic iPSCs obtained through spontaneous or induced loss of trisomy 21. 
Isogenic D21-iPSCs and T21-iPSCs have been obtained either via spontaneous or 
induced loss of one copy of HSA21. (A) T21-iPSCs can lose one copy of HSA21 after 
culture adaptation and passaging over time [17,25]; (B) The loss of one copy of HSA21 
in T21-iPSCs has been induced through the insertion of a foreign gene called TKNEO 
into one copy of HSA21 (within the APP gene) of T21-iPSCs. When these T21-iPSCs 
were grown in a medium that selected against TKNEO, the most common reason for the 
cells to survive was the loss of one copy of HSA21 [12]. The silencing of one copy  
of HSA21 in T21-iPSCs has been induced through the insertion of XIST into one copy  
of HSA21 of T21-iPSCs. This leads ultimately to the generation of isogenic  
D21-iPSCs [21]. 
Most monozygotic twins are “genetically identical” and are in general expected to be concordant  
for health, chromosomal abnormalities, and Mendelian disorders. However, in very rare cases, 
monozygotic twins can be discordant for the disease (reviewed in [75]). One example of this is 
monozygotic twins discordant for trisomy 21 [76]. We exploited this rare and unique situation by 
deriving iPSCs from fetal fibroblasts of monozygotic twins discordant for trisomy 21 [22–24] and 





Figure 2. Isogenic iPSCs from individual mosaic for trisomy 21 or from monozygotic 
twins discordant for trisomy 21. (A) Isogenic D21-iPSCs and T21-iPSCs have  
been derived from mosaic patients for trisomy 21 [19,20]; (B) Isogenic D21-iPSCs  
and T21-iPSCs have been generated from monozygotic twins discordant for trisomy  
21 [22–24]. 
5. Down Syndrome Phenotype Investigated 
Among the phenotypes observed in DS individuals, only two have been explored using 
T21-iPSCs, namely brain-related defects and myeloid leukemia. 
5.1. Brain-Related Defects 
Five groups, including our own, have reported the recapitulation of the relevant DS phenotype 
using neurons derived from T21-iPSCs. Consistent with a DS post-mortem human brain, T21-iPSCs 
showed reduced neurogenesis when induced to differentiate into neuroprogenitor cells (NPCs) and 
further mature into neurons [19,21,23]. This effect was associated with a proliferation deficit and 
increased apoptosis of NPCs derived from T21-iPSCs [23]. Thus, together with the reduced 




oligodendroglial cells [23] upon neural induction and differentiation. This gliogenic shift appeared 
early in development as it starts at the NPC level [23]. Moreover, neurons derived from T21-iPSCs 
exhibited not only a reduction of their population but also structural alterations compared to those 
derived from D21-iPSCs. They exhibited in particular reduced dendritic development [23] and 
reduced expression of synaptic proteins such as synapsin or SNAP25 [20,23]. In line with this, we 
found a lower proportion of excitatory glutamatergic synapses whereas the proportion of inhibitory 
GABA-ergic synapses was not substantially altered in neurons derived from T21-iPSCs [23]. 
Regarding the electrophysiological properties, neurons derived from T21-iPSCs displayed a 
significant synaptic deficit that affects excitatory glutamatergic synapses and inhibitory GABA-ergic 
synapses equally [20]. 
Furthermore, the increased proportion of astroglial cells at the expense of neurons upon neural 
induction and differentiation of T21-iPSCs [19,23] is of special interest as it has been shown that 
astrocytes derived from T21-iPSCs exhibited higher levels of reactive oxygen species (ROS) and 
lower levels of synaptogenic molecules than astrocytes derived from D21-iPSCs. This ultimately 
contributes to oxidative stress-mediated cell death and abnormal maturation of neurons derived  
from T21-iPSCs [25]. 
Finally, Shi et al. used T21-iPSCs as a PSC model of Alzheimer’s disease pathology, given that DS 
individuals present early onset of Alzheimer’s disease. They showed that cortical neurons derived 
from T21-iPSCs exhibited greater secretion of amyloid peptides, tau protein phosphorylation and 
cell death, supporting the notion that T21-iPSCs are an excellent model for AD study [13]. 
5.2. Myeloid Leukemia 
Two recent studies have explored the potential of T21-iPSCs to model hematopoietic defects 
associated with trisomy 21 [17,18]. Using a differentiation protocol that mainly drives hPSCs 
towards primitive yolk sac-type hematopoietic progenitors, Chou et al. showed that hematopoietic 
progenitors derived from T21-iPSCs exhibit an increased propensity for erythropoiesis [18], similar 
to what it is observed in DS fetal liver hematopoiesis [77,78]. However, in contrast with DS fetal 
liver hematopoiesis, no difference was found between D21-iPSCs and T21-iPSCs in their capacity to 
generate megakaryocytes [18]. In the second study, MacLean and colleagues used a differentiation 
protocol that drives hPSCs towards definitive fetal-liver type progenitors. They found that 
hematopoietic progenitors derived from T21-iPSCs (and from T21-ESCs) exhibit higher multi-lineage 
colony-forming potential [17]. In particular, T21-iPSC-derived hematopoietic progenitors showed a 
greater colony-forming unit for erythroid, myeloid and megakaryocyte lineages [17], consistent with 
DS fetal liver hematopoiesis [77,78]. This indicates that trisomy 21 favours the expansion of 
hematopoietic progenitor cells. Altogether, these two studies point to different defects in primitive 
yolk sac-type hematopoietic progenitors and definitive fetal-liver type progenitors derived from  
T21-iPSCs and further suggest that the effects of trisomy 21 are likely specific to the developmental 
stages of the hematopoietic progenitors. Further studies using this iPSC-based model should provide 





6. Conclusions and Perspectives 
Since the first paper demonstrating that fibroblasts from DS patients can be reprogrammed into 
iPSCs by retroviral delivery of OSKM cocktail [10], several alternative methods and cell types have 
been used to generate T21-iPSCs (Table 1). At the moment, there is no consensus for the cell type 
that should be used for the reprogramming. The choice of the starting material depends not only on 
the availability of the cell type, but also on the ability and efficiency of these cells for 
reprogramming. With respect to the reprogramming method that should be used, this depends mostly 
on the priorities regarding the applications of the generated iPSCs. The priorities are not the same if 
the generated iPSCs aimed at investigating (i) the reprogramming mechanisms; (ii) disease 
modelling and drug screening and (iii) regenerative medicine. For the former aim, as the 
reprogramming approach needs to be efficient, the integrative inducible lentiviruses will meet most 
of the requirements. The safety of the generated iPSCs is a major requirement for clinical 
applications but less crucial for disease modelling and drug screening studies. In this respect, Sendai 
viruses and mRNA methods offer the advantage of generating iPSCs free of vectors and transgenes 
with a high efficiency [79]. 
Another major concern when generating iPSCs is the definition of a non-diseased control. In most 
of the studies reporting disease modelling using iPSCs, iPSC lines from unrelated healthy donors 
have been used as controls since genetically matched non-diseased controls are often difficult to 
obtain. In this respect, isogenic D21-iPSCs and T21-iPSCs offer the unique opportunity to study the 
effect of the supernumerary HSA21 on DS phenotype without the biological “noise” that could result  
from the variability of individual genetic background. These isogenic D21-iPSCs and T21-iPSCs  
has been achieved via several ways: (i) by spontaneous or induced loss of one copy of HSA21 in  
T21-iPSCs [12,17,21,25]; (ii) isogenic D21-iPSCs and T21-iPSCs from an individual mosaic for  
trisomy 21 [19,20]; (iii) isogenic D21-iPSCs and T21-iPSCs from monozygotic twins discordant  
for trisomy 21 [22–24]. Of note is the recent progress in genomic editing technologies such as 
transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN) and 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) (for review [80]) should 
provide opportunities to investigate genotype-phenotype correlations using “gene-edited” iPSC 
lines. For instance, it should allow the study of the contribution of candidate genes on DS phenotype 
by the investigation of the effect of genetic loss-of-function in T21-iPSCs and gain-of-function in 
D21-iPSCs of HSA21 genes in the target cell type of interest for DS. 
A major drawback of iPSC technology is the variability that can appear at each step of the 
reprogramming and the differentiation processes. Reprogramming into iPSCs can give rise to 
unpredictable alterations of the genome such as copy number variants, karyotypic abnormalities,  
point mutations and deletions, epigenetic memory of the parental somatic cells [29–39,60–63]. 
Therefore, it is possible that such genetic and epigenetic alterations can affect the fidelity of the 
results regarding disease modeling and drug screening. Also, there is evidence that iPSC lines 
display variable potency to differentiate into the cell type of interest [51,60]. However, it is unclear 
what factors contribute to this variable efficiency of the iPSC differentiation, as it appears 




generate several iPSC lines from accurately chosen tissue of multiple normal and DS individuals, 
using them in priority non-integrative procedures. Such efforts will improve the identification of the 
pathogenetic mechanisms involved in DS by reducing the noise that could result from the variability 
of individual genetic background and from the experimental artifacts. At the same time, it will reduce 
the discovery of false pathogenetic mechanisms. 
Another aspect that should be taken into account in DS modelling using iPSCs is the presence  
of a broad phenotypic variability among DS individuals. Even though DS individuals share some 
morphogenetic characteristics [1,4,5], trisomy 21 can have differential pathogenicity on individual 
genomes [81]. For example, brain-related defects are common traits in all DS individuals but other 
traits such as congenital heart defects only occur in ~40% of them. In line with this, cases of partial 
trisomy 21 and other HSA21 rearrangements associated with DS features have been  
reported [4,5]. Such cases could serve to link genomic regions of HSA21 with specific phenotypes 
given the possibility of generating the target cell type of interest for DS using T21-iPSCs. 
Regarding the applications of T21-iPSCs, the abundance of studies reporting the generation of  
T21-iPSCs clearly shows that T21-iPSCs are reliable tool for DS modelling, given that the protocols 
for differentiation of iPSCs into neurons or hematopoietic cells are available. These protocols enable 
the production of large quantities of the target cell type for DS modelling. Some of these studies have 
been successful in recapitulating DS phenotypes using iPSCs (see Table 1). In this respect, 
transcriptional profiling of T21-iPSCs has proven extremely informative for the study of the 
pathogenetic mechanisms involved in DS phenotype [17–19,22–24]. For example, T21-iPSCs 
recapitulate the developmental disease transcriptional signature of DS [22–24]. Furthermore,  
T21-iPSCs allow the possibility of linking the genetic data to biological insights by deciphering the 
molecular changes in the target cell type of interest for DS (reviewed [82]). Then, the causal 
involvement of candidate HSA21 genes and pathways can be assayed by studies involving genetic 
loss-of-function in T21-iPSCs and gain-of-function in D21-iPSCs through genomic editing methods 
(for review [80]). Regarding DS modelling, only two phenotypes have been investigated so far:  
brain-related defects and myeloid leukemia (Table 1). However, other phenotypes associated with 
DS deserve investigations (heart defects, lymphoid leukemia and others). Moreover, modelling DS 
using iPSCs offers opportunities for drug screening. In concert with functional genomics, iPSCs form 
a powerful cellular model platform for drug screening assays with direct relevance to the DS phenotype. 
Integrating the genetic findings and the functional insights obtained from T21-iPSC-derived cells 
should provide a path to predict which drug might best counteract DS phenotype. Four studies have 
produced the proof of concept of such an application. Several proteins or pathways have been 
targeted and demonstrated beneficial effects on the DS phenotype, including oxidative 
stress-mediated cell death (with N-acetylcysteine, an antioxidant) [19], neurogenesis impairment 
(with epigallocatechine gallate, a DYRK1A inhibitor) [23], the gliogenic shift (with monocycline, an 
anti-inflammatory drug) [25] and AD-related phenotype (with inhibitors of gamma secretase) [13]. 
Finally, one promising aspect of iPSC technology is the potential use of these cells in cell 
replacement therapy to treat neurological diseases [9]. However, iPSCs have not been used until 
recently for clinical applications due to concerns over the immunogenicity and tumorigenicity of 




replacement therapy with the decision of Takahashi’s team to treat a patient with a degenerative eye 
disease [85]. The possibility to induce the loss of one copy of HSA21 in T21-iPSCs and to produce 
subsequently isogenic D21-cells offers great hope for the treatment of some DS phenotypes (such as 
brain-related defects). However, numerous challenges remain for cell replacement therapy [9,86], 
and further studies are needed to address to which extent cells derived from iPSCs can be used for DS 
therapy. The coming years will tell whether these cells fulfil their potential. 
In conclusion, we believe that T21-iPSC-derived cells are an invaluable resource for medical 
research. They will advance our understanding of the pathogenetic mechanism by which the extra 
copy of HSA21 leads to the DS phenotype. They have already offered the first opportunity to study 
the developmental events in the cell type of interest for DS: brain-related defects using iPSC-derived 
neurons and leukemia using iPSC-derived hematopoietic cells. IPSCs could also serve as a cellular 
platform for the evaluation of potential therapeutics. 
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The Possible Future Roles for iPSC-Derived Therapy for 
Autoimmune Diseases 
Meilyn Hew, Kevin O’Connor, Michael J. Edel and Michaela Lucas 
Abstract: The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their 
use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited 
treatment choices are a potential target for the clinical application of stem cell and iPSC technology. 
IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement 
of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; 
and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of 
systemic, system-specific and organ-specific autoimmunity to explore the potential applications of 
iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in 
auto-immunity to date. 
Reprinted from J. Clin. Med. Cite as: Meilyn Hew, Kevin O’Connor, Michael J. Edel and Michaela 
Lucas. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. J. Clin. 
Med. 2015, 4, 1193–1206. 
1. Introduction 
Pluripotent stem cells have the ability to differentiate into all three of the embryonic germ layers, 
endoderm, mesoderm, or ectoderm. While these pluripotent cells may be of embryonic origin, 
somatic cells can be induced into this pluripotency state by transient ectopic expression of defined 
groups of transcription factors, hence the term “inducible” pluripotent stem cells (iPSCs).  
The advantages of inducing pluripotency includes the potential generation of unlimited numbers of 
required cells, deriving cells from hard-to-source tissues, reproduction of disease models, bypassing 
the ethical concerns regarding the use of embryonic stem cells and importantly provide an 
autologous cell therapy strategy that removes the need for immune suppression drugs. 
2. Background 
Following the seminal paper by Takahashi and Yamanaka [1], which reported using appropriate 
transcription factors, Oct4, Sox2, Klf4, and c-Myc, mouse fibroblasts could be reprogrammed into a 
pluripotent state, it has been demonstrated in human somatic cells. Furthermore, other combinations 
of transcription factors are able to induce pluripotency in human somatic cells as well [1–5]. 
Autoimmune diseases affect individual organs or a combination of organs, including the kidneys, 
brain, bone marrow, joints, or skin, however, the pathogenesis of most autoimmune diseases 
remains, at best, only partially delineated. IPSC technology has the potential to provide key cellular 
subsets which, given to patients, may alter their disease course by providing pure replacement of lost 
cells, may limit damage through immune-modulation of the disease process in vivo, and may provide 
substrates for the purposes of disease modeling in vitro. In this review, systemic lupus erythematosus 




arthritis (RA); diabetes mellitus (DM) as an example of organ specific autoimmunity; and multiple 
sclerosis (MS) as an example of system-specific neurological autoimmunity, to demonstrate the 
promising future research potential towards translational medicine of iPSC-derived treatment in a 
range of different contexts within Clinical Immunology.  
3. Disease Immunomodulation and Potential Cellular Components—SLE and RA  
as Examples 
The loss of tolerance to self is the fundamental basis of autoimmunity, with resultant aberrant 
immune responses of autoantibody formation and/or cellular immunity against self-tissue.  
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease. Usually 
affecting women of childbearing age, it is characterised by the production of multiple auto-antibodies 
directed against double-stranded DNA and other nuclear antigens, which are widely distributed 
throughout the body. The autoantibodies are produced by activated auto-reactive B cells following 
presentation of these self-antigens to self-reactive T cells. Along with autoantibody production are 
reduced populations of regulatory T cells (Tregs), reduced responses to regulation by these cells on 
effector T cells, immunological dysregulation and increased inflammation [6], immune complex 
formation and deposition, and end-organ damage, particularly if the disease affects the kidneys or 
central nervous system.  
Rheumatoid arthritis is a symmetrical, inflammatory disease of synovial joints which also 
manifests extra-articular pathology in about 40% of patients. Affecting other parts of the 
musculoskeletal system, as well as the skin, eye, lung, heart, kidney, and vascular and nervous 
system tissues, it is likely that the inflammatory processes driving the synovial inflammation are also 
responsible for these extra-articular manifestations. RA patients develop autoantibodies to 
post-translationally modified synovial or stress-related proteins, which results in the conversion of 
arginine residues into citrulline (a process known as citrullination). In genetically susceptible 
individuals, preferential binding of these citrullinated self-peptides to MHC molecules may enable 
presentation to peripheral T cells, allowing expansion of potentially self-reactive T-cell populations. 
At the same time, if there is no presentation centrally in the thymus, there is no deletion or negative 
selection of autoreactive T cell populations, which is a possible mechanism for loss of self-tolerance 
in RA.  
The mainstay of treatment, for both SLE and RA, is with immunosuppressive medications, 
however, true immunomodulation in the absence of toxicity is difficult to achieve.  
There are a number of important cell populations that impact on systemic autoimmune disease 
course in which iPSC technology could potentially assist to model their effects and ideally contribute 
to regaining self-tolerance, such as regulatory T cells (Tregs) and dendritic cells. Targeting of 
particular cell lineages, rather than their end products, is also likely to be beneficial in the treatment 





3.1. Regulatory T Cells (Tregs) 
Regulatory T cells (Tregs), have an important role in the state of equilibrium that is immune 
tolerance, and are, therefore, also known as tolerogenic T cells. Tregs are CD4, CD25, and Foxp3 
positive, and act to restrict the extent and duration of T cell mediated immune responses, and 
maintain peripheral tolerance by suppressing auto-reactive T cells that have escaped negative 
selection in the thymus. The mechanisms by which Tregs work continue to be discovered [7]. Most 
Tregs arise centrally in the thymus where cell lineage commitment is determined by T-cell receptor 
(TCR) specificity to self antigen. The transcription factor Foxp3 stabilises gene expression that 
specifies Treg differentiation while other transcription factors, including c-Rel, links TCR 
engagement and Foxp3 expression, within an appropriate cytokine and co-stimulatory molecule milieu, 
for Treg differentiation. 
In the periphery, Tregs can be induced following repeated antigen exposure [8] under the 
influence of TGF-beta, converting Foxp3 negative T cells into Foxp3 positive induced Tregs 
(iTregs). Hence, this replaces T effector populations with regulatory populations, converting harmful 
responses to beneficial regulatory responses. 
The list of potential defects in Tregs leading to autoimmune diseases are many (Table 1). 
Considering this extensive list, however, enables multiple potential targets for iPSC application and 
analysis of disease processes. 
Table 1. Potential defects in regulatory T cells in autoimmune diseases [9,10]. 
Imbalances in peripheral effector and regulatory T cells due to defects in  
thymic selection 
Genetic defects inducing failed Treg function or inadequate Treg activity 
Overwhelming of Treg responses due to epitope spreading in autoimmune diseases, 
Deficient IL-2 (required for Treg development) 
Low CD25 expression (hence reduction of IL-2 signalling)  
Defective conversion of naive T cells to adaptive Tregs (due to IL-10 or  
TGF-beta deficiency) 
APC maturation defects leading to altered T cell activation and altered development 
of tolerogenic phenotype 
Hyper-costimulation by APCs leading to pathogenic T cells rather than  
tolerogenic phenotype 
Aberrant cytokine milieu leading to Treg suppression  
The transfer of autologous Tregs to suppress immune responses has already been demonstrated 
experimentally in SLE and other autoimmune diseases such as diabetes mellitus [11,12]. Regulatory 
T cells are present at locations of inflammation (e.g., synovial fluid, mucosa) [13] though,  
if regulatory T cells are obtained from these sites, there may be inadvertent contamination of 
auto-reactive effector T cells, which could lead to unintended inflammatory consequences from 




regulatory T cells to proliferate exogenously, which places limits on the application of harvested 
Tregs from patients for use in therapeutic treatments. 
The ability to instead induce functional Tregs rather than needing to collect them, has been 
demonstrated from iPSCs in vivo [14]. These cells produced the immunoregulatory cytokines TGF 
beta and IL-10, thus producing a population of presumably functional Tregs. In a promising find, 
both allogeneic and autologous transfers of these iPSC derived Tregs demonstrated clinical efficacy, 
by reducing disease incidence and clinical severity scores in collagen-induced arthritis (CIA), an 
inducible mouse model of RA. 
3.2. Dendritic Cells 
Dendritic cells are highly proficient APCs that are potent in stimulating naive T cells during the 
primary immune response [15]. Numerous abnormalities in dendritic cells have been noted in patients 
with autoimmune diseases, including variations in cells proportions, differences in cytokine  
receptor expression particularly inhibitory receptors, and increased expression of costimulatory  
molecules [16,17].  
Conventional dendritic cells (cDCs, previously known as myeloid DCs) are extremely efficient 
APCs, expressing several Toll-like receptors (TLRs) on their surface and producing TNF-alpha, IL-1, 
IL-6, IL-12, and IL-10 upon stimulation. Under different stimuli, cDCs can demonstrate different 
tolerogenic phenotypes, inducing antigen-specific unresponsiveness in central and peripheral 
lymphoid organs, and, therefore, have a crucial role in the induction of immune tolerance [18].  
These tolerogenic dendritic cells are characteristically able to induce proliferation of Tregs (which  
then modulate immune responses to self-antigens), and to induce anergy in auto-reactive effector  
T cells [18,19]. Depending on the stimuli applied to the cDCs, different tolerogenic phenotypes are 
demonstrated, with functional differences in the Treg responses that are elicited [10]. Thus, 
depending on the desired Treg outcome, there is potential to preferentially select these outcomes by 
altering the particular phenotype of the applied tolerogenic dendritic cell in disease immunotherapy.  
For example, Tregs can be induced in vivo by NFKB or CD40-deficient DCs. Conventional DCs 
require the transcription factor RelB to enable priming of the immune system through CD40 and  
MHC-molecule expression [20,21]. Blocking of RelB and other NFKB family members in cDCs 
results in induction of Tregs through modified cDC activity, therefore RelB activity is thought to 
determine the outcomes of antigen-presentation to cDCs. Methods to block RelB activity, and that of 
other NFKB family members have been developed to produce modified DCs that are consistently 
tolerogenic through the induction of Tregs [20,22,23]. In murine models of antigen-induced arthritis, 
modified DCs have been shown to suppress joint inflammation and erosion [24]. As tolerance 
induction by these DCs has been shown to be dose-dependent and route-independent [22], after 
induction of inflammatory arthritis by joint injection of methylated bovine serum albumin (mBSA), 
the mice were able to be subcutaneously injected with modified DCs exposed to mBSA, resulting in 
a suppression of inflammatory responses in the joints.  
Given proof of concept studies using regulatory DCs in immunotherapy have demonstrated a 




autologous immunotherapy is an exciting focus for possible future therapies [10,16,17], particularly 
in the immunomodulation of the inflammation noted in SLE and RA.  
Plasmacytoid dendritic cells (pDCs) constitutively produce anti-viral Type 1 interferons as part of 
the immune response to viral infections. However, in patients with autoimmune diseases, such as 
SLE, pDCs are thought to instead make interferons following TLR ligation by endogenously derived  
nucleic acids [27]. The immune response is, thus, driven not by exogenous infection, but by activity  
against self-antigens.  
Plasmacytoid dendritic cells that produce Type I interferons are found in the tissues of affected 
organs in SLE and other autoimmune conditions. Type I interferons have activity through several 
down-stream pathways to increase dendritic cell maturation and activation and, hence, antigen 
presentation to immune lymphocytes, and non-haematopoietic cell cytokine and MHC expression [6]. 
This immune activation results in up-regulated inflammation, and a positive-feedback loop with  
further dendritic cell production of interferon, and resultant anti-self T cell activation and B cell  
auto-antibody production. 
In patients with active SLE, polymorphonuclear lymphocytes (PMNLs) have been shown to  
up-regulate interferon genes giving an interferon “signature”, which correlates with disease severity, 
and high dose steroids which abrogate this signature induce clinical remission. Depletion of pDCs 
early in the course of SLE can reduce the clinical and serological evidence for autoimmunity [28]. 
This evidence indicates that the ability to model the interactions of pDCs would be beneficial to 
understanding more of the underlying pathogenesis in SLE. 
The routine use of dendritic cells for research into the generation of immunomodulation, or for 
disease modeling in vitro, in SLE, RA and other autoimmune diseases is limited by the lack of 
plentiful and stable dendritic cells of the appropriate phenotype. Peripheral collection of precursors 
for autologous transfer through plasma exchange is not without morbidity, and the cost and logistics 
for wide-spread collection may not be feasible. Therefore, while able to be generated from 
haematopoietic stem cells, regulatory dendritic cells have recently been generated from murine 
iPSCs [19]. These iPSC-derived regulatory dendritic cells have been shown to have similar 
morphology to bone marrow derived regulatory DCs, and appeared to have similar activity to bone 
marrow derived regulatory DCs in not stimulating allogeneic CD4+ T cells, only weakly stimulating 
allogeneic CD8+ T cells and having similar efficient antigen uptake. What remains is to demonstrate 
stable phenotype and function, which can then enable comparison of results in clinical trials and 
other applications to be explored. 
Once cells are generated from iPSCs, these need to have a valid functional assessment for 
tolerogenic properties. Similarly, as there is a theoretical risk for replication of the disease process 
with autologous transfer of cells, and a demonstrated risk for malignancy with iPSCs, appropriate 





3.3. Disease Modelling in SLE or RA 
Theoretically, the potential for disease modelling could be greatly expanded by generating and 
studying the different tissue lineages from patient-derived iPSCs [3]. While neurological tissue 
collection remains elusive, methods for expansion of renal specific cells into iPSCs through  
non-invasive urinary cell collection has been described [29]. Therefore in vitro examination of 
pathological processes using iPSCs derived from affected patients, and, possibly, regeneration of 
tissue from unaffected patients may both be possible. However, the end-organ damage of SLE is a 
manifestation of systemic immune dysregulation therefore the targets of therapy or investigation 
may be more well-focussed on the interactions between cellular populations and an examination of 
the matrix of effects on tolerance and auto-reactivity. Both SLE and RA are multifactorial in their 
pathogenesis with a complex interaction between environment and genetics, resulting in the loss of 
self-tolerance [30,31]. 
4. Generation of Reparative Tissue in Autoimmunity—Diabetes Mellitus 
Diabetes mellitus is a significant clinical problem with high morbidity and mortality associated 
with microvascular and macrovascular complications of hyperglycaemia. Arising either from beta 
cell dysfunction and insulin resistance, or from autoimmune cell-mediated pancreatic islet cell 
destruction and resultant lack of insulin, treatments are usually aimed at glycaemic control, or 
reducing insulin resistance. Accurately and consistently replacing insulin at an amount appropriate 
for associated oral intake can be difficult for patients, with the risk for unstable sugars and 
hypoglycaemia.  
Replacement of pancreatic tissue through tissue donation is in current use, however limited 
through lack of donors and restrictive through the requirement for life-long immunosuppression.  
It has been previously pointed out therefore, that treatment for diabetes would ideally renew beta cell 
function and, hence, insulin for glycaemic control, prevent repeat autoimmune destruction of the new 
pancreatic tissue, and repair the micro- and macrovascular complications that may have already 
occurred [32]. 
The current state of play with iPSCs and diabetes, also detailing concerns of immunogenicity, 
tumorigenicity, appropriate differentiation, full maturation, stability of function, and successful 
engraftment have recently been reviewed [33] with much work still required for understanding the 
basic biology of reprogrammed cells.  
However, in terms of current research aspirations, there is great interest in attempting to 
recapitulate normal pancreatic development and generate pancreatic cell types from pluripotent  
cells [34]. This would encompass differentiating iPSCs into definitive endoderm, morphogenesis into a 
three-dimensional structure with contact with appropriate mesenchymal supportive cells to provide 
required growth and development signals, and then commitment of the pancreatic endoderm to 
endocrine precursor cells and thence to beta cells that produce the required insulin in a 
glucose-responsive fashion. 
Thereafter, considerations need to be made on prevention of rejection of transplants, potentially 




been generated from patients with type 1 and type 2 diabetes, as well as maturity-onset diabetes of 
the young [36–38]. 
In terms of functional beta cell production, polyhormonal insulin-expressing cells have been 
derived from human embryonic stem cells and transplanted for some years now, though whether 
from insufficient cell volume transfer, or transfer of functionally immature beta cells, while helping 
fasted blood glucose states, they do not yet consistently ameliorate diabetes in non-fasted mice 
subjects, or tend to lose insulin-secretion capacity [39–41]. In an alternative line of investigation, 
when given enough time to develop in vivo (90–140 days post transplant), engraftment of pancreatic 
progenitor cells derived from human embryonic stem cells have been able to secrete insulin,  
and maintain normoglycaemia in a murine model of induced diabetes up until the grafts are  
removed [42]. 
Subsequently, glucose-responsive, insulin-producing cells have been generated from human 
iPSCs and also shown to have the ability in murine models to reverse hypoglycaemia [43], however, 
can lose insulin secretion over time [44]. While it is important to remember that there are differences 
between embryonic stem cells and iPSCs [45], potentially, progenitor pancreatic cells may be 
developed as well from iPSCs for trials in engraftment, but with the advantages inherent over 
requiring embryonic cell sources. 
5. iPSCs in Autoimmune Neurological Disease—Multiple Sclerosis 
Inducible pluripotent stem cells have been studied extensively in neurodegenerative and 
neurogenetic disorders, more so currently than for inflammatory neurological conditions, such as 
multiple sclerosis (MS), however, the final common pathway of neuronal injury and death is better 
understood in MS than for neurodegenerative conditions. IPSC technology allows potential avenues 
for therapeutics by regeneration of specific neuronal populations [46] or for exerting an 
immunomodulatory effect [47], but also allowing more accurate modelling of neurological disease 
than can be obtained through animal studies [46]. 
MS is the archetypal and most common disabling autoimmune condition of the central nervous 
system (CNS), which provides an ideal framework for research and understanding immune 
dysregulation. MS is a chronic condition, characterised by focal or multifocal inflammatory 
demyelinating episodes resulting in neurological disability depending on the area of the CNS 
involved. There are periods of quiescence and recovery in the most common phenotype, known as 
remitting relapsing MS [48]. 
The pathogenesis of MS and its triggers are multi-factorial with a complex interaction between 
genetic predisposition and environmental factors resulting in immune dysregulation. The first risk 
allele to be identified was the human leukocyte antigen (HLA) class II haplotype HLA-DRB*1501 in 
the 1970s [49]. The Genome-wide Association Study (GWAS) has since identified over 50 
susceptibility loci [50], many of which encode for pro-inflammatory IL-2 and IL-7 [51], with others 
encoding for cytokines, such as CXCR5, IL-12A, IL-12 , and IL-12R 1 [48].  
The genetic association alone does not explain fully the development of MS with vitamin D3 and 
Epstein-Barr virus (EBV) both being important environmental factors to consider in MS. Increased 




which corresponds with the higher incidence and prevalence of MS in these high latitude  
countries [48,52] though the effect of vitamin D3 deficiency on adaptive immunity is not yet fully 
understood. What has also been observed, is that individuals who are seronegative for EBV have 
almost no risk of developing MS [53], and it has been hypothesised that, through molecular mimicry, 
EBV may mimic myelin basic protein pathogenic antigens by presentation on HLA-DRB1*1501, 
therefore, providing links to both environmental and genetic risk factors [48,54]. Myelin reactive 
CD4+ T cells secreting interferon gamma are one of many T cell mediators in the pathogenesis of  
MS [55], with the role of other cell types and cell subsets being also involved, with a reduction in 
effector function of Tregs in MS patients [56], and a key role of pro-inflammatory T helper 17 (Th17) 
cells emerging [48,57]. Given the production of oligoclonal bands in CSF, there is a role of B cells in 
MS pathology, and the understanding of the part played by innate immunity by way of NK (natural 
killer) cells and dendritic cells in the pathogenesis is evolving [48].  
Given the significant effects of MS on affected patients, efforts to provide regenerative or 
immunomodulatory therapy are highly sought. 
Oligodendrocyte precursor cells (OPCs) derived from iPSCs, first described by Onorati et al. in  
2010 [58], possibly provide an exogenous way in which to remyelinate axons as soon as possible 
after an episode of acute demyelination, to best protect axons from ongoing inflammation and 
eventual gliosis. Axonal loss is responsible for the most debilitating functional deficits in the more 
progressed stages of MS, with this loss followed by retrograde neuronal degeneration [59]. Axonal 
degeneration not only occurs in chronic lesions, with good evidence now showing axonal injury in 
acute lesions [60]. 
Cell replacement with OPCs derived from iPSCs have been shown to be successful in animal 
studies, with remyelination and amelioration of disability in experimental autoimmune encephalitis 
(EAE), an animal model of MS [61,62]. 
Neural precursor cells (NPCs) derived from iPSCs have also been shown in EAE to not only have a 
regenerative effect, but also an immunomodulatory effect. One study, in which mouse iPSC-derived 
NPCs were intrathecally transplanted in mice with EAE, exerted a neuroprotective effect, not by 
differentiating into myelin producing cells, but by producing the specific neurotrophin, leukaemia 
inhibitory factor (LIF), which supports the in vivo survival and differentiation of native  
oligodendrocytes [63]. LIF has been shown to inhibit the differentiation of Th17 cells through MAP 
kinase suppression of the cytokine signalling 3 (SOCS3) inhibitory signalling cascade, antagonising 
the interleukin 6 (IL-6)-mediated phosphorylation of signal transducer and activator of  
transcription 3 (STAT3) [64], which is essential for the differentiation of Th17 cells, thus limiting 
CNS inflammation and hence subsequent tissue damage.  
Finally, the disease in a dish approach may give unique insights into the study of pathogenesis in 
neuronal disease and in particular to inflammatory diseases of the CNS, given its inaccessibility. 
IPSCs have been successfully derived from a MS patient’s dermal fibroblasts, and differentiated into 
astrocytes, oligodendrocytes and neurons with a normal karyotype. The patient-derived neurons 
showed electrophysiological differences compared with the control cell line, paving the way for a 





Autoimmune diseases are the result of a combination of environmental influences acting on a 
susceptible genetic background. This causes significant aberrations of self-antigen recognition, 
lymphocyte activation and differentiation, production of pro-inflammatory cytokines and 
autoantibodies, and the final end product of tissue and organ damage. Induced pluripotent stem cells 
technology has the potential to create new safe treatment options, as well as better models to study 
disease and therapies in vitro. Here, we review the so far limited literature in this field. In addition to 
organ replacement strategies where iPSC technology has been applied, we propose that complex  
auto-immune diseases require unique immunomodulatory therapy strategies using cellular 
components and that these components could be made by iPSC technology. Importantly, iPSC 
technology enables us to produce, differentiate and genetically modify large numbers of immune 
cells that can be used therapeutically. Prior to the development of such technologies modification of 
small cell populations with limited ex vivo expansion potential was near impossible. Nevertheless, 
these novel approaches will need to have extensive functional and safety assessments prior to their 
use in a clinical setting.  
Finally, iPSC technology allows for modelling of normal and diseased (based on genetic and 
epigenetic modifications) cellular growth and development, influences of mutations onto function 
and clinical phenotype. In the time of personalized medicine iPSC technologies are likely to feature 
as a key therapeutic tool in auto-immune diseases. 
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